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ABSTRACT 
Colorectal cancer (CRC) is the 3rd most common cancer and the 4th highest cause of 
cancer deaths in the world. Genetic factors play a major role in its predisposition, 
initiation and development. Inherited variants in the CASP8 gene, a key regulator of 
apoptosis, have a potential yet controversial association with CRC risk. Sporadic 
CRC develop through different molecular pathways of genomic instabilities and 
mutations in key cancer driver genes. Classification of sporadic CRC into these 
molecular pathways has potential implications for diagnosis and treatment and it is 
an integral part of CRC studies, however, current published research suffers from 
lack of standardisation. Chromosomal Instability (CIN) drives CRC by affecting 
cancer driver genes, many of which are still to be identified.  
 
This project aimed to: (a) further investigate the role of CASP8 inherited variants in 
CRC risk, (b) to molecularly classify sporadic CRC tumour DNA samples using 
standard techniques and definitions, and (c) to identify novel CRC driver genes 
affected by CIN. A CASP8 promoter in/del variant was genotyped in 1193 CRC 
cases and 1388 matching controls. The coding region of the CASP8 gene was 
sequenced in 94 CRC cases to identify potential novel variants and a copy number 
variant was also investigated. A cohort of 53 paired CRC tumour and normal DNA 
samples were molecularly classified using standard techniques and definitions. 
Common aberration analysis was performed on high resolution array comparative 
genome hybridisation data from 45 chromosomally unstable CRC cases to identify 
focal minimal common regions (FMCR).  
 
CASP8 inherited variants did not significantly affect CRC risk in the investigated 
cohort. CRC molecular classification confirmed the heterogeneity of sporadic CRC 
vii 
 
and a novel molecular subtype was proposed. FMCR were shown to target cancer 
related genes and novel CRC driver genes were proposed. Finally, preliminary 
studies supported the tumour suppressor role of NFKBIA, one of the novel candidate 
driver genes affected by a deletion FMCR. 
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1. INTRODUCTION 
1.1 Cancer 
Cancer is a complex group of distinct syndromes characterised by uncontrolled 
growth and spread of malignant cells. Tumours may affect different organs of the 
body and each tumour can be divided into several types and subtypes. More than 
100 distinct types of cancer are currently known (Hanahan and Weinberg 2000, 
Stratton et al. 2009). Worldwide, cancer is responsible for around 1 in 8 deaths, with 
an estimated total of 7.6 million deaths in the year 2008 (Stratton et al. 2009, Jemal 
et al. 2011). This makes cancer the 3rd leading cause of death after cardiovascular 
and infectious diseases (WHO 2008). In general, the overall lifetime risk of 
developing cancer is around 50% for men and 33% for women (based on data from 
the years 2001-2003) (Hayat et al. 2007).  
1.2 The genetics of cancer 
Genetic factors play a primary role in the predisposition, initiation and development of 
cancer (de la Chapelle 2004, Vogelstein and Kinzler 2004, Stratton et al. 2009). The 
familial clustering of cancer cases was firstly described by the French physician Paul 
Broca, who observed that his wife‟s family had multiple cancer cases (mainly of the 
breast) over 4 generations (Steel et al. 1991). Early suggestions for the involvement 
of genomic abnormalities in the development of cancer were made by David von 
Hansemann in the year 1890 and Theodor Boveri in the year 1902 when they noticed 
an “abnormal chromosome constitution” in malignant tumours and cancer cells 
(Marte 2006, Harris 2008).  After the discovery of DNA as the hereditary material in 
chromosomes, these early suggestions of a genetic involvement in tumourigenesis 
were supported by observations that DNA damaging agents can result in the 
development of cancer (Loeb and Harris 2008, Stratton et al. 2009). Currently, 
germline mutations are known to be responsible for hereditary cancer predisposition 
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and germline variants are known to affect both hereditary and sporadic cancer risk 
(Groden et al. 1991, Miki et al. 1994, Amundadottir et al. 2006, Easton et al. 2007, 
Tomlinson et al. 2008). Moreover, acquired genetic and genomic changes are known 
to drive cancer development (Vogelstein et al. 1988, Sjoblom et al. 2006, Wood et al. 
2007, Leary et al. 2008, Beroukhim et al. 2010) 
1.2.1 Germline genetic factors and cancer predisposition 
Cancer predisposing germline genetic factors can be divided into 3 main types; rare, 
highly penetrant mutations, rare, moderate penetrance mutations and common, lower 
penetrance variants (Balmain et al. 2003, de la Chapelle 2004). Highly penetrant 
germline mutations have been mostly identified through linkage studies in affected 
families. They include mutations in tumour suppressor genes (TSG) such as 
adenomatosis polyposis coli (APC), responsible for familial adenomatous polyposis 
(FAP), and the breast cancer associated genes (BRCA1 and BRCA2) responsible for 
familial breast cancer cases (Groden et al. 1991, Miki et al. 1994, Wooster et al. 
1995). These highly penetrant genetic factors are rare, accounting for ~20% of 
familial cancer cases and ~5% of cancer cases in general (Balmain et al. 2003, de la 
Chapelle 2004). Moderate penetrance mutations also occur in TSG and were mainly 
identified by sequencing candidate genes in familial cancer cases or association 
studies (Meijers-Heijboer et al. 2003, Cybulski et al. 2004). CHEK2 mutations, for 
example, confer moderate risk for several cancer types (Cybulski et al. 2004). 
However, they are also rare and account for <5% of cancer cases (Hemminki et al. 
2009a, Hemminki et al. 2009b).  
 
Much of the unknown inheritance can probably be explained by interactions between 
the more common but less penetrant genetic (and environmental) factors, based on a 
common variant common disease model (Balmain et al. 2003, Pasche and Yi 2010). 
These common, low penetrance genetic factors cannot be identified by linkage 
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studies, but instead require large case control association studies (de la Chapelle 
2004). Two different approaches of association studies have helped in the 
identification of several common cancer susceptibility genes with low penetrance; 
candidate gene association studies and genome wide association studies (GWAS) 
(Pasche and Yi 2010, Chung and Chanock 2011). Candidate genes are usually 
selected based on their involvement in cancer related pathways such as cell 
proliferation and apoptosis (Pasche and Yi 2010). On the other hand, GWAS search 
for common susceptibility factors across the whole genome. GWAS are based on 
high throughput technologies, which genotype hundreds of thousands of common 
single nucleotide polymorphisms (SNPs) in large numbers of cancer cases and 
controls (Chung and Chanock 2011). Recently, copy number variants (CNVs) 
became of use in association studies as an alternative for SNPs (Beckmann et al. 
2007, Venkatachalam et al. 2010). 
1.2.2 Genetic instability, somatic changes and cancer development 
Throughout the development of cancer, cancer genomes acquire various somatic 
genetic changes. These changes can occur on several levels, ranging from single 
nucleotide mutations to the deletion or amplification of entire chromosomes (Balmain 
et al. 2003). Some of these somatic changes play an important role in cancer 
development, usually by affecting key cancer driver genes. On the other hand, some 
of the changes do not provide any selective advantage and are termed passenger 
mutations (Greenman et al. 2007). Despite the large number of cancer types and 
subtypes (>100), cancers are known to share a common pathogenesis in which they 
acquire 6-8 capabilities known as the hallmarks of cancer. These hallmarks are 
shared, more or less, by all types of cancer and they enable the progressive 
transformation of cells from normal to malignant (Hanahan and Weinberg 2011). The 
hallmarks include the ability of the cancer cells to: induce and sustain proliferative 
signalling, avoid growth suppression, resist cell death and apoptosis, replicate 
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continually, induce angiogenesis, activate invasion and metastasis, avoid immune 
destruction and deregulate cellular bioenergetics (Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011).  
 
Cancer hallmarks are mainly acquired through multiple steps of somatic genetic and 
epigenetic alterations and mutations affecting cancer driver genes (Loeb 1991, 
Hanahan and Weinberg 2011). Normally, the human genome is stable and is 
maintained by DNA monitoring and repair pathways which ensure that mutations are 
very rare events. If the mutations responsible for tumourigenesis were to occur at 
these normal rates, cancer would be a very rare disease (Loeb 1991). However, 
cancers occur at substantial frequency worldwide. For example, in the year 2008, 
~12.7 million new cancer cases were reported (Jemal et al. 2011). Therefore, in 
order to acquire enough mutations and occur at such high incidence, cancers must 
be genetically unstable. This is why genomic instability is considered one of the main 
driving forces behind cancer development (Loeb 1991, Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011). 
1.3 Colorectal cancer 
Colorectal cancer (CRC) is the third most common cancer in males (Figure 1.1) and 
the second in females (Figure 1.2) (Jemal et al. 2011). More than 1 million new CRC 
cases are diagnosed annually and ~600,000 related deaths were estimated 
worldwide in the year 2008, making CRC the 3rd highest cause of cancer related 
death in both genders (Figure 1.3)  (Parkin et al. 2005, Jemal et al. 2011). CRC is 
multifactorial and several environmental and genetic factors contribute to its aetiology 
(Jong et al. 2002). Environmental factors include diet, smoking and physical activity. 
In general, obesity, smoking and diets rich in red meat are associated with higher risk 
while regular physical exercise and diets rich in folate and calcium are associated 
with lower risk (Jong et al. 2002).  
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Figures 1.1-1.3 were generated based on data from the GLOBOCAN 2008 project available 
from the International Agency for Research on Cancer (IARC) website http://globocan.iarc.fr/ 
(accessed July, 2011).  
C Incidence of the most commonly diagnosed cancers in men worldwide (2008) 
Incidence of the most commonly diagnosed cancers in women worldwide (2008) 
 
Figure 1.1 Worldwide cancer incidence in males 
Figure 1.2 Worldwide cancer incidence in females 
Figure 1.3 Worldwide cancer mortality in males and females 
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1.3.1 Colorectal cancer: pathology and staging 
CRC progresses slowly over years and tumour development occurs through several 
distinct histo-pathological stages. These stages range from single crypt lesions 
through small adenomatous polyps (benign tumours) to malignant carcinomas with 
metastatic potential (Deschoolmeester et al. 2010, Migliore et al. 2011). CRC stages 
are mainly defined by the tumour, node, metastasis (TNM) staging system of the 
American Joint Committee on Cancer (AJCC) and the International Union Against 
Cancer (UICC), or the Dukes staging system (Compton and Greene 2004, Migliore et 
al. 2011). TNM staging is based on the local extent and the depth of invasion of the 
primary tumour (T), the level of lymph node involvement (N) and the presence of 
distant metastatic cancer (M) (Compton and Greene 2004). The Dukes staging 
system, which has undergone several modifications since it was originally described 
by the British pathologist Cuthbert Dukes in 1932, includes the parameters observed 
in TNM staging, but also describes the level of cancer cell differentiation (Jass and 
Morson 1987, Migliore et al. 2011). In general, both staging systems divide CRC into 
4 main stages that reflect the severity and development of CRC (Table 1.1). Although 
this histo-pathological staging of CRC is useful in stratifying patients into distinct 
groups to predict prognosis and survival, the system is limited in predicting treatment 
response or defining the underlying mechanisms of tumourigenesis  (Westra et al. 
2005, Ogino and Goel 2008, Walther et al. 2009).  
Table 1.1 Summary of TNM and modified Duke’s staging systems 
TNM Stages 
Modified  
Duke's 
Survival (%)* 
Stage 0  Tis, N0, M0 - - 
Stage I  
(no nodal involvement, no metastases) 
T1 (submucosa invaded) A 
90-100 
T2 (muscularis propria invaded) B1 
Stage II  
(no nodal involvement, no metastases) 
IIA (T3, subserosa invaded) B2 
75-85 
IIB (T4, visceral peritoneum invaded) B3 
Stage III  
(no metastases) 
IIIA (T1-T2, N1 (1-3 nodes involved)) C1 
30-40 IIIB (T2-T4, N1 (1-3 nodes involved)) C2/C3 
IIIC (T1-T4, N2 (≥4nodes involved)) C1-C3 
Stage IV (distant metastases) T1-T4, N1-N4, M1 D <5 
* 5 year survival estimates 
Table 1.1 was adapted from (Kerr D J 2001, Horton and Tepper 2005).  
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1.3.2 Colorectal cancer: genetics 
CRC is divided into sporadic and hereditary (familial) cases with genetic factors 
playing a significant role in predisposition to the disease (de la Chapelle 2004). 
Around 75% of CRC cases are sporadic and the remaining 25% of cases show 
hereditary or familial CRC characteristics (Migliore et al. 2011). Large cancer 
heritability studies based on 1st degree family members have shown that amongst 
common cancers, CRC has one of the highest genetic contributions towards its risk 
(Goldgar et al. 1994, Dong and Hemminki 2001). Moreover, a large multi-cohort twin 
study has estimated that the genetic contribution in CRC is ~35%, making it the 2nd 
highest (behind prostate cancer) in terms of heritability of the common cancers 
(Lichtenstein et al. 2000, de la Chapelle 2004). Nevertheless, known and highly 
penetrant inherited genetic factors that predispose to familial CRC are rare and 
account for only 5-6% of cases (Migliore et al. 2011). The two main inherited and 
well-characterised forms of CRC are Lynch syndrome and familial adenomatous 
polyposis (FAP) (Lynch and de la Chapelle 2003, de la Chapelle 2004).  
1.3.2.1 Lynch syndrome 
Lynch syndrome or hereditary non-polyposis colorectal cancer (HNPCC) was 
originally described in 1913 by the pathologist Aldred Warthin, who investigated a 
family with a high incidence of cancer (Lynch and de la Chapelle 1999). The study of 
this family, known as family “G” took place over several decades, with the disease 
being described as a cancer family syndrome in the mid 1960‟s (Lynch et al. 1966). 
In 1970, family “G”  (with more than 650 blood relatives and 95 cancer cases) was 
restudied in detail by Henry Lynch and Anne Krush who described an autosomal 
dominant hereditary cancer syndrome (Lynch and Krush 1971). 
 
Lynch syndrome is mainly caused by germline mutations in one of several DNA 
mismatch repair (MMR) genes such as MLH1, MSH2, MSH6 and PMS2 (de la 
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Chapelle 2004, Migliore et al. 2011). Loss of MMR gene function results in 
microsatellite instability (MSI) (Section 1.3.3.2) which occurs in ~90% of Lynch 
syndrome colorectal  tumours (Nussbaum et al. 2001). The syndrome is inherited in 
an autosomal dominant pattern and accounts for ~3% of the total CRC cases 
(Nussbaum et al. 2001, Migliore et al. 2011). People carrying a germline mutation in 
one of the MMR genes will have ~80% risk of developing CRC (de la Chapelle 2004, 
Migliore et al. 2011). In addition to CRC, Lynch syndrome patients are at an 
increased risk of other forms of cancer, including those of the stomach, ovaries, brain 
endometrium and pancreas (Lynch and de la Chapelle 2003, de la Chapelle 2004, 
Migliore et al. 2011). In 60-70% of Lynch syndrome cases, the tumour is proximal to 
the splenic flexure (Lynch and de la Chapelle 1999, Nussbaum et al. 2001). 
1.3.2.2 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is characterised by the formation of hundreds, 
even thousands, of adenomas in the colorectum, usually starting early in life 
(occasionally in the preteen years) (Nussbaum et al. 2001, Lynch and de la Chapelle 
2003). FAP is caused by mutations in a TSG, namely adenomatous polyposis coli 
(APC). FAP is an autosomal dominant syndrome, and accounts for ~1% of CRC 
cases (Migliore et al. 2011). The penetrance of FAP is almost 100% and CRC 
development is inevitable (at the age of 40 to 50 years) if the adenomas are left 
untreated (Lynch and de la Chapelle 2003, Migliore et al. 2011). Therefore, 
individuals who have a first-degree relative with FAP should be screened for APC 
mutations or have flexible sigmoidoscopy early in life (Lynch and de la Chapelle 
2003). Any patients carrying germline APC mutations or who have colonic polyps 
require an annual endoscopy examination (Lynch and de la Chapelle 2003). It is 
worth mentioning that mutations in APC occur in up to 70% of sporadic colorectal 
tumours (Miyaki et al. 1994, Luchtenborg et al. 2004). 
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1.3.2.3 Low penetrance genes and colorectal cancer risk 
As stated earlier, Lynch syndrome and FAP are caused by highly penetrant and well 
characterised mutations. However, these syndromes are rare, and account for <5% 
of all CRC cases and only ~20% of hereditary CRC cases (Jong et al. 2002, de la 
Chapelle 2004). The remaining majority of the hereditary cases, and a proportion of 
the sporadic CRC cases, are likely to be caused by more common but less penetrant 
genetic variants and polymorphisms (SNPs) (Broderick et al. 2007). These are 
generally difficult to identify as linkage analysis studies do not have enough power to 
detect low penetrance variants (de la Chapelle 2004). Nevertheless, genetic 
association studies using both the candidate gene and the genome wide approaches 
have helped to identify some of these less penetrant genetic variants (de la Chapelle 
2004, Migliore et al. 2011). 
 
Some of the genetic variants identified through candidate gene association studies 
occur within the genes of the metabolic enzymes Glutathione S-transferases (GSTs) 
methylenetetrahydrofolate reductase (MTHFR), and DNA repair genes such as 
XRCC2 (Huang et al. 2007, Curtin et al. 2009b, Economopoulos and Sergentanis 
2010).  However, most of these associations are yet to be confirmed in large and 
independent association studies (Migliore et al. 2011). Several of the genetic variants 
identified through GWAS occur within genes and loci that include SMAD7, CRAC1 
(HMPS), 8q23.3, 8q24, 10p14, 1q41, 3q26.2, 12q13.13 and 20q13.33 (Broderick et 
al. 2007, Haiman et al. 2007, Tomlinson et al. 2007, Zanke et al. 2007, Jaeger et al. 
2008, Tenesa et al. 2008, Tomlinson et al. 2008, Houlston et al. 2010). Recently, 
using fine mapping and a candidate gene approach based on GWAS results, genetic 
variants within GREM1, BMP4 and BMP2 were identified as CRC risk factors 
(Tomlinson et al. 2011). In general, all the verified common risk variants account for 
~6% of the unknown CRC heritability (Lascorz et al. 2010). The identification of more 
of these lower penetrance genetic variants will play an important role in increasing 
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the knowledge of the genetic pathways involved in the initiation, development and 
progression of CRC (de la Chapelle 2004). Moreover, this knowledge also has 
possible implications for the prevention, diagnosis and treatment of CRC (de la 
Chapelle 2004, Lerman and Shields 2004).  
1.3.3 Genomic instability and development of colorectal cancer 
As discussed earlier, genomic instability is a primary driving force in cancer 
development. Three main forms of genomic instability occur in CRC; chromosomal 
instability (CIN), microsatellite instability (MSI) and epigenetic instability, known as 
CpG island methylator phenotype (CIMP) (Thibodeau et al. 1993, Toyota et al. 1999, 
Pino and Chung 2010, Migliore et al. 2011). Studying the global genomic status of 
CIN, MSI and CIMP can play an important role in determining the biological and 
clinico-pathological characteristics of CRC (Issa 2008, Ogino and Goel 2008). 
1.3.3.1 Chromosomal instability 
1.3.3.1.1 The basis of chromosomal instability 
CIN is the most common type of genomic instability in CRC and accounts for 65-85% 
of cases (Derks et al. 2008, Issa 2008, Pino and Chung 2010, Migliore et al. 2011). 
Tumours that develop through the CIN pathway are characterised by frequent 
numerical and structural gains and losses of chromosomal fractions or whole 
chromosomes at a significantly increased rate in comparison to normal cells 
(Rajagopalan et al. 2003). CIN is thought to play an important role in tumourigenesis 
through the amplification of oncogenes such as MYC and the deletion of TSG such 
as SMAD4 and TP53 (Kozma et al. 1994, Ozakyol et al. 2006, Tanaka et al. 2006, 
Ogino and Goel 2008, Migliore et al. 2011). The molecular basis of CIN is not well 
understood. However, it can result from defects in the pathways which regulate and 
maintain chromosome segregations including the DNA damage response, the 
spindle assembly checkpoints, DNA double-strand break (DSB) repair and telomere 
regulation (Zhivotovsky and Kroemer 2004, Pino and Chung 2010). Mutations in 
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genes that play a role in regulating these pathways, such as APC, MRE11 and TP53, 
are implicated in CRC development and are associated with CIN (Wang et al. 2004, 
Pino and Chung 2010). Another important cause of CIN, especially with numerical 
chromosomal defects (rather than structural), is abnormal centrosome function. 
AURKA, an important regulator of centrosome function, is overexpressed in several 
cancers and was recently shown to be associated with CIN in CRC (Baba et al. 
2009). 
1.3.3.1.2 Characterisation of chromosomal instability   
Several techniques and approaches are available to characterise and define CIN. 
They include conventional methods such as karyotyping, loss of heterozygousity 
(LOH) analysis using microsatellite markers, DNA ploidy analysis using flow 
cytometry, fluorescent in situ hybridisation (FISH) and conventional comparative 
genome hybridisation (CGH) and high throughput methods such as bacterial artificial 
chromosome (BAC) CGH and oligonucleotide array CGH and SNP arrays (Hermsen 
et al. 2002, Chang et al. 2006, Cheng et al. 2008, Derks et al. 2008, Baba et al. 
2009, Pino and Chung 2010, Poulogiannis et al. 2010a). These diverse approaches 
and techniques provide different criteria to define CIN; making it very difficult to 
compare results between studies or introduce standard definitions for CIN (Pino and 
Chung 2010). Nevertheless, LOH at several microsatellite markers, such as those on 
18q, 8p and 5q, and the so-called cancer associated events (CAE) (losses in 8p21-
pter, 15q11–q21, 17p12–13 and 18q12–21 and gains in 8q23-qter, 13q14–31 and 
20q13) were proposed to represent CIN. However, these markers are not in standard 
use and are prone to underestimating CIN and producing false-negative results 
(Hermsen et al. 2002, Ogino and Goel 2008). High resolution and genome-wide array 
based techniques are currently the methods of choice; however, a standard definition 
of CIN is still lacking (Brosens et al. 2010, Pino and Chung 2010, Dyrso et al. 2011). 
More recently, next generation sequencing platforms are providing even higher 
resolution and accuracy in the detection of chromosomal aberrations in cancer 
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(Wong et al. 2011). However, their use is currently limited due to the higher cost 
involved. 
1.3.3.2 Microsatellite instability  
1.3.3.2.1 Microsatellite instability and CRC 
In 1993, microsatellite instability (MSI), also known as the mutator phenotype, was 
identified in CRC as a molecular subtype with distinct genotypic and phenotypic 
characteristics (Ionov et al. 1993, Thibodeau et al. 1993). MSI is characterised by 
altered lengths of microsatellites in tumour DNA compared to normal DNA 
(Thibodeau et al. 1993). When microsatellites are located in coding regions of genes, 
MSI can result in frameshift mutations and altered protein function (Vilar and Gruber 
2010). Some of the important cancer genes affected by MSI, and also associated 
with CRC include the pro-apoptotic genes BAX, CASP5 and BCL10, the transforming 
growth factor beta receptor type II (TGFBR2), the insulin-like growth factor II receptor 
(IGF2R) the transcription factor E2F, the cell cycle control gene CHEK1 and the DNA 
repair genes MSH3 and MSH6 (Yin et al. 1997, Bertoni et al. 1999, Trojan et al. 
2004, Iacopetta et al. 2010, Yashiro et al. 2010). 
1.3.3.2.2 Microsatellite instability: molecular basis and testing 
MSI is associated with defective DNA mismatch repair machinery resulting from 
mutations or promoter hypermethylation of MMR genes such as MLH1 and MSH2 
(Zhivotovsky and Kroemer 2004, Ogino and Goel 2008). MSI is the main 
characteristic of Lynch syndrome, however, MSI only occurs in ~15% of sporadic 
colorectal tumours (Nussbaum et al. 2001). The global genomic status of MSI is 
assessed through the analysis of specific microsatellite markers. In 1997, the 
National Cancer Institute (NCI) set the guidelines for MSI testing and developed a 
panel of 5 microsatellite markers; 3 dinucleotide markers (D2S123, D5S346 and 
D17S250) and 2 mononucleotide markers (BAT25 and BAT26). These markers, 
called the NCI consensus panel or the Bethesda panel, were considered to be the 
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reference panel for MSI testing (Boland et al. 1998). Based on this panel, tumours 
with instability in 2 or more markers were classified as MSI-high (MSI-H), while those 
with one unstable marker were defined as MSI-low (MSI-L) and tumours without any 
instability were considered microsatellite stable (MSS) (Boland et al. 1998, Bacher et 
al. 2004). However, the NCI consensus panel suffered from several limitations arising 
from the dinucleotide markers, which were shown to be less sensitive and specific for 
MSI testing when compared to mononucleotide markers (Suraweera et al. 2002). 
In 2002, the NCI released the revised guidelines for MSI, and mononucleotide 
markers were recommended as the most sensitive markers for this type of testing 
(Umar et al. 2004). In 2004, a set of 5 mononucleotides markers (BAT25, BAT26, 
NR21, NR24 and MONO27) were developed for MSI testing according to the revised 
NCI criteria (Bacher et al. 2004). The latter panel was shown to be more accurate in 
determining the MSI-H status in comparison to the old panel (Murphy et al. 2006).  
1.3.3.3 The CpG island methylator phenotype 
Transcriptional silencing of TSG by DNA methylation at promoter CpG islands is very 
common in cancer cells (Ogino et al. 2006a). Several TSG, such as CDKN2A and 
MLH1 were shown to be transcriptionally inactivated by DNA methylation in CRC 
(Ahuja et al. 1997, Kambara et al. 2004). In 1999, a CpG island methylator 
phenotype (CIMP) was proposed as a distinct form of epigenetic instability in a 
subset of CRC tumours (Toyota et al. 1999). CRC cases with CIMP were 
characterised by having a higher frequency of methylated TSG promoters in tumour 
DNA compared to DNA from normal colon tissues (Toyota et al. 1999, Toyota et al. 
2000). The existence of CIMP as a unique form of epigenetic instability in CRC has 
now been established and confirmed (Ogino and Goel 2008). 
1.3.3.3.1 CIMP testing 
The global genomic status of CIMP is usually assessed by quantitatively analysing a 
set of CpG island methylation markers (Ogino and Goel 2008). Several marker 
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panels have been proposed for the evaluation of CIMP in CRC. The classical panel 
that was initially used to investigate CIMP in CRC included the following genes: 
CDKN2A, MINT1, MINT2, MINT31 and MLH1 (Rashid et al. 2001, Hawkins et al. 
2002, Frazier et al. 2003, Samowitz et al. 2005). However, other panels were later 
introduced and were proposed to be more robust than this classical group. One of 
these included the genes CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 
(Weisenberger et al. 2006, Cheng et al. 2008) and another included; CACNA1G, 
CDKN2A, CRABP1, MLH1 and NEUROG1 (Ogino et al. 2006a). In 2007, a large 
population study (based on 920 CRC samples) evaluated the performance of both 
panels and proposed the use of 4-8 genes (RUNX3, CACNA1G, IGF2, MLH1, 
NEUROG1, CRABP1, SOCS1 and CDKN2A) as a highly sensitive and specific panel 
for the evaluation of CIMP in CRC (Ogino et al. 2007). However, the panel is still not 
in standard use (Kim et al. 2010, Jover et al. 2011). 
 
Several techniques are also available to determine the methylation status of the CpG 
markers for the evaluation of CIMP. Some of the commonly used techniques include 
methylation specific PCR (MSP) (which are qualitative) and pyrosequencing and real 
time PCR based assays (that are quantitative) (Samowitz et al. 2005, Ogino et al. 
2006a, Jover et al. 2011). In general, it is recommended that a minimum of 4-5 
validated CIMP markers are employed, and avoiding the use of qualitative 
techniques (Ogino et al. 2006a, Ogino et al. 2007, Goel and Shin 2008). Like MSI, 
CIMP can be divided into several subgroups; intense methylation of several markers 
known as CIMP-high (CIMP-H), less extensive marker methylation (compared to 
CIMP-H) known as CIMP-low (CIMP-L) and absence of methylation or CIMP-
negative (CIMP-N). Nevertheless, CIMP-L definition and its distinction from CIMP-
H/N remain controversial (Ogino et al. 2006b, Goel and Shin 2008).  
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1.3.4 Genetic mutations and colorectal cancer 
Germline mutations in genes such as APC and MLH1 are known to predispose to 
hereditary CRC (Sections 1.3.2.1 and 1.3.2.2). On the other hand, somatic mutations 
in cancer related genes play a primary role (alongside genomic instabilities) in driving 
CRC development (Wood et al. 2007, Migliore et al. 2011). Some of the major 
oncogenes and TSG known to be mutated in sporadic CRC include APC, TP53, 
KRAS, PIK3CA, BRAF and SMAD4 (Woodford-Richens et al. 2001, Davies et al. 
2002, Brink et al. 2003, Iacopetta 2003, Luchtenborg et al. 2004, Ikenoue et al. 2005, 
Velho et al. 2005, Oliveira et al. 2007).   
 
A comprehensive and systematic genome wide sequencing analyses of >18000 
genes was recently performed in CRC and breast cancer (Sjoblom et al. 2006, Wood 
et al. 2007). Sequencing results from >100 CRC patients indicated the presence of 
~80 somatic mutations in a typical colorectal tumour (Wood et al. 2007). However, 
statistical analysis predicted that <15 of these mutations were likely to be drivers of 
tumourigenesis (Wood et al. 2007). In total, 140 CRC driver genes were identified, 
and predicted to play an important role in CRC development and progression (Wood 
et al. 2007). Whilst including the well-known CRC driver genes APC, TP53, KRAS, 
FBXW7, PIK3CA and SMAD4, this exercise also identified a large number of genes 
that had never before been implicated in cancer. The results of these sequencing 
studies revealed the scale of somatic mutations in CRC and confirmed their central 
role in driving tumour development (Sjoblom et al. 2006, Wood et al. 2007). 
1.3.5 Molecular classification & characterisation of colorectal cancer 
As stated, CRC develops through a sequential and multistep process of 
accumulating genetic and epigenetic defects. Although these defects occur in a 
mostly random fashion, they tend to accumulate in patterns (Ogino and Goel 2008, 
Stratton et al. 2009). These organised patterns probably arise due to selection 
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pressure created by advantages and/or disadvantages of carrying some of the 
molecular defects (Ogino and Goel 2008, Stratton et al. 2009), with advantageous 
defects providing the tumour cells with one or more of the cancer hallmarks 
explained earlier (Stratton et al. 2009). Molecular classification of CRC helps in 
understanding the patterns which underlie the molecular mechanisms of 
tumourigenesis. This in turn can help to identify molecular biomarkers with the 
potential to be used in the clinic for predicting treatment response and patients‟ 
prognosis or survival (Westra et al. 2005, Ogino and Goel 2008). In this way, 
molecular classification of CRC can complement histo-pathological classification 
(Section 1.3.1) and provide a more comprehensive picture that can be applied 
clinically. 
 
For a long time it was considered that sporadic CRC develops through a uniform and 
linear pathway of molecular defects, starting with APC inactivating mutations and the 
subsequent acquisition of more defects such as KRAS activation and TP53 
inactivation (Fearon and Vogelstein 1990) (Figure 1.4). This homogenous view of 
sporadic CRC genetic development has directed both research and clinical 
management for several decades (Jass 2007, Issa 2008). However, more recently, 
integrated genetic and epigenetic studies on sporadic CRC cases have shown that it 
can no longer be considered as one uniform and homogenous disease (Shen et al. 
2007, Cheng et al. 2008, Derks et al. 2008, Issa 2008). Instead, there are several 
subtypes of sporadic CRC (at least 3) which develop through different pathways of 
genetic and epigenetic instabilities (CIN, MSI and CIMP), and mutations in key driver 
genes such as; APC, TP53, KRAS, BRAF and PIK3CA (Figure 1.5) (Chang et al. 
2006, Shen et al. 2007, Cheng et al. 2008, Derks et al. 2008, Issa 2008, Nosho et al. 
2008). In addition to their distinct molecular characteristics, these molecular 
pathways/CRC subtypes are known to associate with different clinical and 
pathological features (Shen et al. 2007, Issa 2008) (Figure 1.5). 
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Figure 1.4 The classical linear model for sporadic CRC development 
The classical linear model of genetic and epigenetic defects leading to CRC, the model is widely known as the “Vogelgram”. 
Figure adapted from (Fearon and Vogelstein 1990). 
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Recent studies have shown that sporadic CRC cannot be considered as a single homogenous disease. There are at least 3 molecular pathways for CRC 
development. These pathways provide a better understanding of sporadic CRC development with potential applications in clinic (Adapted from (Issa 2008)).
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Figure 1.5 Sporadic CRC molecular pathways 
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1.3.5.1 An overview of CRC molecular pathways 
Several comprehensive molecular classification systems for sporadic CRC have 
recently been proposed, based on genomic instabilities, genetic mutations and clinic-
pathological features (Jass 2007, Issa 2008, Ogino and Goel 2008). The number of 
molecular subtypes ranges from 3-9 depending mainly on the genomic instabilities 
used and their definitions (Ogino and Goel 2008). Some of the proposed 
classification systems do not incorporate CIN (Ogino and Goel 2008). Moreover, 
some of the suggested subtypes are very rare, bearing subtle differences from the 
others which may not have any clinical relevance (Ogino and Goel 2008). The 
following sections (1.3.5.1.1-1.3.5.1.3) describe the 3 main subtypes based on a 
classification system proposed by Jean-Pierre Issa, which incorporates the 3 
genomic instabilities (CIN, MSI and CIMP) (Issa 2008) (Figure 1.5). 
1.3.5.1.1 The classical MSI-high pathway 
The first molecular pathway of CRC development is known as the MSI pathway.  This 
pathway accounts for 10-20% of sporadic CRC cases (Chang et al. 2006, Shen et al. 
2007, Issa 2008). It is characterised by 2 genomic instabilities; high levels of MSI 
(MSI-H) and in most cases, intense methylation of a wide range of genes (CIMP-H) 
(Issa 2008). MSI in sporadic CRC is thought to occur as a result of CIMP affecting 
distinct MMR genes, mainly MLH1 (Weisenberger et al. 2006). In addition to the 
genomic instabilities, this pathway is also characterised by mutations in key CRC 
driver genes. Mutations in BRAF (mainly V600E) occur at a frequency of 5-18% in 
sporadic CRC. However, they cluster within the MSI-H/CIMP-H pathway with a 
frequency of 40-50% (Oliveira et al. 2007, Shen et al. 2007). PIK3CA mutations were 
shown to play an important role in CRC development with an estimated frequency of 
13-30% (Samuels et al. 2004, Ikenoue et al. 2005, Velho et al. 2005). Several studies 
have shown an association between the most common and oncogenic PIK3CA 
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mutations and the MSI-H/CIMP-H sporadic CRC pathway (Abubaker et al. 2008, 
Nosho et al. 2008). 
 
From a clinico-pathological perspective, sporadic colorectal tumours developing 
through the MSI-H/CIMP-H pathway are thought to arise from serrated or mucinous 
adenomas and mainly occur in the proximal colon (Jass 2007, Shen et al. 2007, Issa 
2008). CRC patients with this pathway are more commonly females, and usually 
have good prognosis and survival (Samowitz et al. 2001a, Shen et al. 2007, Ogino 
and Goel 2008, Ogino et al. 2009).  
1.3.5.1.2 The CIN positive/MSS pathway 
The most common molecular pathway in sporadic CRC (50-70%) is mainly 
characterised by frequent CIN, MSS, CIMP-N/L and mutations in APC and TP53 
(Eshleman et al. 1998, Chang et al. 2006, Shen et al. 2007, Issa 2008). Moreover, 
BRAF is largely unmutated, and the most common BRAF mutation (V600E) occurs at 
a frequency of < 5% in these tumours (Chang et al. 2006, Shen et al. 2007, Derks et 
al. 2008). Colorectal tumours developing through the CIN positive/MSS pathway are 
thought to arise from tubular adenomas and occur mainly in the distal colon (Chang 
et al. 2006, Issa 2008). These tumours are associated with an intermediate prognosis 
and do not show any sex bias (Issa 2008, Ogino and Goel 2008).  
1.3.5.1.3 CIMP-Low/MSS 
The 3rd main molecular pathway is poorly defined and accounts of 10-30% of 
sporadic CRC cases (Issa 2008). It is characterised mainly by CIMP-L (lower levels 
compared to MSI-H/CIMP-H pathway) and mutations in KRAS (Ogino et al. 2006b, 
Shen et al. 2007). The BRAF V600E mutation occurs in some of the cases in which 
KRAS is wild type. This pathway is usually MSS with lower levels of CIN compared to 
the MSS/CIN positive pathway (Shen et al. 2007). Colorectal tumours developing 
through this pathway are thought to arise from villous adenomas and mainly occur in 
the proximal colon (Issa 2008). CRC patients with tumours of this type are more 
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commonly males, usually have poor prognosis and their tumours are more resistant 
to chemotherapeutic agents (Ogino et al. 2006b, Shen et al. 2007). 
 
It is worth noting that these 3 molecular pathways/subtypes do not cover all the 
sporadic CRC cases (Issa 2008). Whilst some CRC cases are reported to show one 
or more of the 3 forms of genomic instabilities, others have been reported without 
any type of genomic instability (Cheng et al. 2008). It is still unclear whether these 
cases represent separate CRC molecular subtypes, with distinct clinico-pathological 
features. 
1.3.5.2 Standardisation of CRC molecular classification 
An important limitation of the molecular classification and characterisation of CRC is 
the absence of standard techniques and definitions for the global genomic 
instabilities (Issa 2008, Ogino and Goel 2008). The use of different methods, 
definitions and marker panels have resulted in major differences in estimating the 
frequencies of MSI, CIN and CIMP (Issa 2008). In order for molecular classification to 
generate clinically useful information, standard techniques and definitions must be 
used to identify the genomic instabilities, especially CIMP and CIN. 
1.3.5.3 Sporadic CRC molecular markers and the clinic 
1.3.5.3.1 Prognostic markers 
A more comprehensive understanding of CRC genetics and epigenetics is paving the 
way for personalised CRC care and treatment in the clinic. The prognostic values of 
CIN and MSI were validated in meta-analyses across a wide range of CRC patients 
(Popat et al. 2005, Walther et al. 2008, Guastadisegni et al. 2010). CIN was 
associated with a bad prognosis, and was recommended to be evaluated as a 
prognostic marker in clinical trials (Walther et al. 2008, Pritchard and Grady 2011). 
On the other hand, MSI was associated with a more favourable prognosis (Popat et 
al. 2005, Guastadisegni et al. 2010). The strength of these prognostic value means 
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that both CIN and MSI are likely to become increasingly utilised for the clinical 
evaluation of CRC (Pritchard and Grady 2011). MSI testing is already available for 
sporadic CRC, however, it is not yet widely used (Pritchard and Grady 2011). Other 
genetic markers with potential prognostic values include the chromosome 18q LOH 
and mutations in BRAF (V600E), both of which predict an unfavourable prognosis 
(Popat and Houlston 2005, Roth et al. 2010). 
1.3.5.3.2 Predictive markers 
The most evident example of personalised CRC treatment based on genetic markers 
is the use of KRAS mutational status as a predictive marker for resistance to anti-
epidermal growth factor receptor (EGFR) therapies such as cetuximab and 
panitumumab (Karapetis et al. 2008, Allegra et al. 2009). Detection of KRAS 
mutations, mostly codons 12 and 13, is currently in routine clinical use, and CRC 
patients with KRAS mutations do not receive anti-EGFR antibodies as part of their 
treatment (Allegra et al. 2009, Pritchard and Grady 2011). In addition to KRAS 
mutations, BRAF V600E mutation, PIK3CA mutations and loss of PTEN expression 
are promising predictive markers for resistance to anti-EGFR therapies (particularly 
in resistant cases with WT KRAS) (Figure 1.6) (Di Nicolantonio et al. 2008, Jhawer et 
al. 2008, Sartore-Bianchi et al. 2009, Di Fiore et al. 2010). A combined panel of these 
mutations might prove to be more efficient in predicting resistance to anti-EGFR 
therapies (Bohanes et al. 2011). 
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Figure 1.6 Anti-EGFR therapy molecular determinants 
A) An overview of the EGFR pathway and the main downstream effector molecules B) In 
sensitive cells, EGFR activation (overexpression, genomic amplification) can be counteracted 
by anti-EGFR therapies C) In resistant cells, mutations affecting downstream effector 
molecules make the treatment ineffective (Adapted from (Di Fiore et al. 2010)). 
 
In addition to their prognostic value, MSI and 18q LOH are also promising predictive 
markers for conventional adjuvant chemotherapy (Pritchard and Grady 2011). MSI 
was shown to predict resistance to treatment with fluorouracil (5-FU), however, the 
association is controversial (Ribic et al. 2003, Jo and Carethers 2006, Kim et al. 
2007). A recent meta-analysis of 31 studies has confirmed that the association 
between MSI and 5-FU resistance is controversial and recommended the use of 
combined genomic markers to predict the efficiency of 5-FU therapy (Guastadisegni 
et al. 2010). Nevertheless, MSI-H CRC cell lines were shown to be more sensitive to 
irinotecan treatment (Vilar et al. 2008) and a recent clinical trial has shown improved 
response of MSI patients to adjuvant chemotherapy with irinotecan (Bertagnolli et al. 
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2009). CIMP was also recently shown as a potential predictive marker for resistance 
to 5-FU adjuvant chemotherapy (Jover et al. 2011). 
 
In summary, due to the more comprehensive and detailed understanding of CRC 
genetic and epigenetic characteristics, personalised CRC treatment is becoming 
more of a reality (Choong and Tsafnat 2011, Pritchard and Grady 2011). Whilst the 
use of a single genetic or epigenetic marker is unable to fully predict prognosis or 
direct treatment decisions, the combinations of several markers through standardised 
CRC molecular classification provide scope for the future use of personalised CRC 
treatment (Choong and Tsafnat 2011). Therefore, this demonstrates the need for 
research directed towards identifying panels of novel genetic and epigenetic markers 
that are implicated in CRC tumourigenesis. 
1.4 Apoptosis 
1.4.1 Background 
Cell death usually occurs through three main pathways; necrosis, autophagy or 
apoptosis (Ishimura and Gores 2005). Apoptosis (the Greek word for “falling off”) was 
described for the first time in 1972 as a mechanism of controlled cell deletion that is 
complementary but opposite to mitosis (Kerr et al. 1972). Apoptosis differs from other 
pathways of cell death, particularly necrosis, by being highly regulated and occurring 
via well-defined steps (Okada and Mak 2004). Also referred to as programmed cell 
death, apoptosis is considered a fundamental and highly controlled biochemical 
pathway that plays an important role in normal tissue homeostasis, differentiation, 
immune system function and embryonic development (Ellis et al. 1991, Jacobson et 
al. 1997, Reed 2000, Fadeel and Orrenius 2005). However, the deregulation of 
apoptosis plays a key role in the development of neurodegenerative and autoimmune 
diseases and cancer (Okada and Mak 2004). Apoptosis is a complicated process 
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and involves the activation and inhibition of several signalling pathways (Huerta et al. 
2006) (Figure 1.7).  
1.4.2 Caspases and apoptosis 
The main executioners of apoptosis are a family of proteolytic enzymes called 
cysteinyl aspartate-specific proteases or caspases (Alnemri et al. 1996, Zhao et al. 
2010). The name “Caspase” reflects the catalytic properties of these proteases; “C” 
refers to the cysteine protease mechanism, and “aspase”  refers to their distinctive 
ability to cleave their protein targets after an aspartate residue (Alnemri et al. 1996).  
 
Up to 14 human caspases have been identified, although not all are implicated in 
apoptosis (Zhang et al. 2004). Caspases that function during apoptosis can be 
divided into two main groups; initiator or activator caspases characterised by a long 
N-terminus (Caspases 2, 8, 9 and 10) and executioner caspases characterised by a 
short N-terminus (Caspases 3, 6 and 7). Caspases are synthesised as inactive 
zymogens, termed procaspases (Earnshaw et al. 1999, Zhang et al. 2004). 
Procaspases can be activated by proteolytic cleavage after an aspartic acid residue, 
which allows autocatalytic activation of initiator caspases (Muzio et al. 1998, Shi 
2004). Activated initiator caspases will, in turn, cleave and activate executioner 
procaspases (Shi 2004). The specificity of the caspases is determined by 4 amino 
acid residues located near the cleavage site (Thornberry et al. 1997). In general, the 
initiator caspases can activate executioner caspases through 2 classical pathways: 
the extrinsic death receptor pathway and the intrinsic (mitochondrial) pathway (Figure 
1.7) (Zhang et al. 2004, Fadeel and Orrenius 2005, Huerta et al. 2006). 
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Figure 1.7 Pathways and regulation of Apoptosis 
Extrinsic (death-receptor) pathway and intrinsic (mitochondrial) pathway. Arrows (   ) 
represent stimulatory effect and dashed lines (       ) represent inhibitory effects.  
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1.4.2.1 Pathways of apoptosis 
1.4.2.1.1 The extrinsic pathway 
The extrinsic pathway is activated through the binding of extracellular ligands such as 
tumour necrosis factor (TNF) and Fas ligand to various death receptors. The 
intracellular (cytoplasmic) domains of these death receptors (death domains) 
subsequently recruit an intracellular adaptor protein known as FADD (Fas-associated 
death domain protein, also known as MORT1). FADD contains a death effector 
domain and death domain which binds to the receptor death domain. FADD then 
attracts and binds procaspase 8 (or procaspase 10) through dimerization of death 
effector domains (Zhang et al. 2004, Elmore 2007). This complex is known as the 
death-inducing signalling complex (DISC). Procaspase 8 can then be auto-activated 
through the close proximity of several procaspase 8 molecules (known as the 
induced proximity model) (Muzio et al. 1998, Shi 2004). Active caspase 8 molecules 
released into the cytoplasm can subsequently cleave and activate executioner 
caspases. This then results in apoptosis and cell death (Figure 1.7) (Johnstone et al. 
2002, Huerta et al. 2006).  
 
In some cell types, such as lymphoid cells, caspase 8 activation by DISC is sufficient 
to initiate apoptosis. However, in other cell types, such as hepatocytes, this pathway 
is not sufficient to fully activate apoptosis. In such cases, the mitochondrial (intrinsic) 
pathway is required to amplify the “weaker” extrinsic apoptotic signal (Igney and 
Krammer 2002, Zhang et al. 2004). The activation of the mitochondrial pathway in 
this case is mediated by BID (a pro-apoptotic member of the Bcl-2 family), which is 
be cleaved and activated by caspase 8 (Figure 1.7) (Luo et al. 1998, Yin et al. 1999). 
1.4.2.1.2 The intrinsic pathway 
In the intrinsic pathway, intracellular stress, such as DNA damage, can activate pro-
apoptotic proteins of the Bcl-2 family through P53 (Section 1.4.3.1) (Figure 1.7). Pro-
apoptotic members of the Bcl-2 family, such as BAX and BAK, stimulate 
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mitochondrial outer membrane permeabilisation and the release of cytochrome C 
and SMAC/DIABLO (Section 1.4.3.3) (Shimizu et al. 1999, Huerta et al. 2006). 
SMAC/DIABLO counteract the anti-apoptotic proteins known as IAP (Section 
1.4.3.3), and free cytosolic cytochrome C forms a complex with APAF1 (apoptotic 
protease activating factor-1) (required for the efficient activation of caspase-9), ATP 
(adenosine triphosphate) and the inactive form of procaspase-9 (Rodriguez and 
Lazebnik 1999, Huerta et al. 2006). This complex, known as the apoptosome, 
activates the initiator caspase 9 and results in activation of executioner caspases and 
apoptosis (Figure 1.7) (Igney and Krammer 2002, Huerta et al. 2006). 
 
Following the activation of either the extrinsic or intrinsic pathway, activated 
executioner caspases (mainly caspases 3, 6 and 7) can cleave specific “death 
substrates”, leading to morphological changes including DNA fragmentation, 
chromatin condensation and cytoplasmic shrinkage, apoptosis and cellular death 
(Zhang et al. 2004, Huerta et al. 2006). 
1.4.3 Regulation of apoptosis 
Apoptosis is a highly controlled process, and several protein families including  B cell 
leukaemia/lymphoma 2 (Bcl-2) family proteins, inhibitors of apoptosis proteins (IAP), 
CASP8 and FADD-like apoptosis regulator (CFLAR) and heat shock proteins (HSP) 
play a role in its regulation. Interactions between these proteins and the apoptotic 
machinery determine the activation or the inhibition of apoptosis at different levels 
(Igney and Krammer 2002, Zhang et al. 2004). 
1.4.3.1 Bcl-2  
The Bcl-2 protein family regulate apoptosis at the mitochondrial level (intrinsic 
pathway). They are divided into pro-apoptotic proteins such as Bcl-2–associated X 
protein (BAX), BCL-2 antagonist/killer (BAK) and BH3-interacting domain death 
agonist (BID) and anti-apoptotic proteins such as Bcl-2, Bcl-XL and Bcl-W (Figure 
 29 
1.7). Bcl-2 proteins regulate the intrinsic pathway by altering the permeability of the 
mitochondrial membrane (Igney and Krammer 2002, Huerta et al. 2006).  
1.4.3.2 CFLAR (FLIP) 
By interfering directly with DISC, FLIP inhibits the initiation of apoptosis via the 
extrinsic pathway. There are 2 splice variants of FLIP; long variant (FLIPL) and short 
variant (FLIPS). Both forms bind to DISC and inhibit the activation of caspase 8 and 
the extrinsic pathway (Figure 1.7) (Igney and Krammer 2002). 
1.4.3.3 IAP  
Nine IAP family members, including  XIAP, apollon and survivin, are known to inhibit 
apoptosis by directly interfering with and inhibiting caspases 3, 7 and 9 (Igney and 
Krammer 2002, Zhang et al. 2004). During apoptosis, a protein known as second 
mitochondria-derived activator of caspase/direct IAP binding protein with low pI 
(SMAC/DIABLO), is released from the mitochondria. This binds and inhibits IAPs in 
order to allow the activation of caspases (Figure 1.7) (Igney and Krammer 2002). 
1.4.3.4 HSP 
HSP influence both the intrinsic and extrinsic pathways of apoptosis (Huerta et al. 
2006). Anti-apoptotic HSP such as HSP27 inhibit the release of cytochrome C, while 
HSP70 and HSP90 inhibit the apoptosome through interfering with APAF-1. On the 
other hand, pro-apoptotic HSP such as HSP10 and HSP60 stimulate caspase 3 
(Huerta et al. 2006).  
1.4.4 Apoptosis and colorectal cancer 
Deregulation or inhibition of apoptosis has been shown to play an important role in 
the initiation, development and progression of cancer (Lowe and Lin 2000, Johnstone 
et al. 2002). In order to proliferate indefinitely, tumour cells must be able to avoid 
apoptosis (Hanahan and Weinberg 2000). It was previously shown that apoptosis is 
inhibited or downregulated during the development of CRC (Bedi et al. 1995, 
Kawasaki et al. 1998). The disruption of the apoptotic pathway usually occurs 
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through the abnormal expression of genes that control and regulate apoptosis (Butler 
et al. 1999). This generally arises through loss of function in genes that upregulate or 
activate apoptosis (such as TP53 and BAX) and overexpression of genes that inhibit 
or downregulate apoptosis (such as BCL2, BIRC5 and FLIP) (Kawasaki et al. 1998, 
Butler et al. 1999, Ryu et al. 2001, Huerta et al. 2006). Besides uncontrolled growth, 
defective apoptosis helps tumour cells to circumvent the body‟s immune defences 
(Ishimura and Gores 2005). 
1.4.5 Apoptosis and chemotherapy 
Cancer treatments – including chemotherapy and irradiation – mainly act through the 
induction of apoptosis. Therefore, defects in the apoptotic machinery usually result in 
cancer cells exhibiting resistance to treatment (Ishimura and Gores 2005). For 
example, mutations in the pro-apoptotic BAX gene were shown to render CRC cells 
resistant to treatment with nonsteroidal anti-inflammatory drugs (NSAID) (Geelen et 
al. 2004, Zhang et al. 2004). On the other hand, overexpression of the anti-apoptotic 
protein FLIP resulted in resistance of CRC cell lines to treatment with CRC drugs 
such as 5-FU, OXA (oxaliplatin) and CPT-11 (irinotecan) (Geelen et al. 2004, 
Longley et al. 2006). 
1.4.6 Apoptosis and genomic instability 
Apoptosis and genomic instability are closely linked in tumourigenesis (Zhivotovsky 
and Kroemer 2004). Genomic instabilities usually result in mutations or abnormal 
expression of genes that regulate apoptosis. For example, MSI often results in 
mutations that inactivate the pro-apoptotic genes BAX, CASP5 and BCL10 (Trojan et 
al. 2004, Iacopetta et al. 2010). Moreover, deletion of the short arm of chromosome 
17 (17p), as a result of CIN, usually leads to TP53 inactivation (Zhivotovsky and 
Kroemer 2004, Ozakyol et al. 2006). P53 protein plays a central role in initiating 
apoptosis, keeping the integrity of the genome and thus preventing tumourigenesis 
(Bourdon 2007, Vazquez et al. 2008). In fact, the TP53 gene is inactivated in up to 
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85% of human cancers (Huerta et al. 2006). Simultaneously, defective apoptosis 
enables the survival and division of cells with unstable genomes, which otherwise 
would be eliminated (Zhivotovsky and Kroemer 2004).    
1.4.7 Caspase 8 
As mentioned earlier, caspase 8 is an initiator caspase that plays a key role in the 
activation of the extrinsic pathway. Moreover, through its cleavage of BID, caspase 8 
also plays an important role in the activation of the intrinsic pathway (Igney and 
Krammer 2002). In 1999, the caspase 8 gene (CASP8) was mapped to chr2q33 
downstream of CFLAR and CASP10 and upstream of ALS2CR12. CASP8 is 
approximately 54Kb in size and contains 13 exons (Figure 1.8) (Grenet et al. 1999). 
There are 8 identified isoforms of caspase 8 (a-h), however, only isoforms, a and b 
are predominantly expressed (Scaffidi et al. 1997), and they result in proteins 
containing 496 and 479 amino acids respectively (relative molecular mass of 
55.4KDa  (isoform a) and 53.7KDa (isoform b). 
 
 
Figure 1.8 CASP8 genomic location, gene structure & protein 
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1.4.7.1 Caspase 8 in cancer and CRC 
Deletion of chromosome 2q33, the genomic region containing CASP8, has been 
reported in several cancers including gastric and lung cancer and neuroblastoma 
(Otsuka et al. 1996, Nishizuka et al. 1998, Teitz et al. 2000, Takita et al. 2001, 
Shivapurkar et al. 2002a, Geelen et al. 2004). Moreover, it was reported that CASP8 
was frequently silenced by methylation in small cell lung cancer (SCLC) cell lines, 
neuroblastoma and medulloblastoma (Teitz et al. 2000, Shivapurkar et al. 2002a, 
Zuzak et al. 2002, Pingoud-Meier et al. 2003a, Stupack et al. 2006). Furthermore, 
CASP8 somatic mutations were reported in ~11% of advanced gastric cancers 
(Soung et al. 2005) and >5% of advanced CRC cases (Kim et al. 2003). Loss of 
CASP8 (by inactivating mutations, genomic deletions or methylation) plays a role in 
inducing resistance to chemotherapy, in promoting metastasis and is associated with 
poor prognosis and survival (Hopkins-Donaldson et al. 2000, Kim et al. 2003, 
Pingoud-Meier et al. 2003a, Stupack et al. 2006) 
1.4.7.2 CASP8 polymorphisms and cancer risk 
Common polymorphisms in CASP8 were shown to affect lung cancer risk (Son et al. 
2006). Moreover, a common missense variant (D302H) in exon 12 of CASP8 was 
reported as a low penetrance susceptibility allele for breast cancer (MacPherson et 
al. 2004, Cox et al. 2007, Shephard et al. 2009). In addition, a 6bp insertion-deletion 
(in/del) polymorphism in the promoter region of CASP8 was shown to affect the 
susceptibility of several common cancers including CRC (Sun et al. 2007). However, 
results of the latter association were not confirmed by additional studies (Haiman et 
al. 2008, Pittman et al. 2008). Nevertheless, preliminary data from our laboratory 
have indicated a possible association between CASP8 SNPs and CRC risk (Curtin et 
al. manuscript in preparation).  
 
 33 
1.5 Aims of the project 
Genetic factors (both inherited and somatic) play a key role in the predisposition, 
initiation and development of CRC. Large family based cancer studies involving 1st 
degree relatives and twin siblings have estimated that the genetic contribution 
towards CRC risk is very high (~35%) (Goldgar et al. 1994, Lichtenstein et al. 2000, 
Dong and Hemminki 2001, de la Chapelle 2004). Whilst some of the inherited factors 
are highly penetrant and rare, others are of low penetrance and are more common. 
Highly penetrant CRC genetic factors are well characterised (e.g. Lynch and FAP 
syndromes), however, they account for <20% of hereditary CRC (de la Chapelle 
2004, Migliore et al. 2011). The remaining cases of hereditary CRC are probably due 
to the more common, but less penetrant, genetic polymorphisms. Several low 
penetrant and common CRC risk variants have been identified through genome wide 
and candidate genes association studies, however, so far they only account for ~6% 
of CRC heritability (Lascorz et al. 2010). By identifying more of these common and 
low penetrant genetic factors, further biochemical pathways involved in the 
pathogenesis of CRC might be identified, with the potential of extensive clinical 
implications (de la Chapelle 2004).  
 
Cellular evasion of apoptosis is considered one of the hallmarks of cancer 
development (Hanahan and Weinberg 2011). This is usually achieved by the 
disruption of genes which regulate apoptosis (Butler et al. 1999). Caspase 8 is an 
initiator caspase with an important role in the regulation of apoptosis. The mutation or 
methylation of CASP8 is implicated in several cancers including CRC (Teitz et al. 
2000, Kim et al. 2003, Soung et al. 2005). Moreover, inherited CASP8 variants were 
shown to affect cancer risk, including CRC (Son et al. 2006, Cox et al. 2007, Sun et 
al. 2007). However, the association between CASP8 inherited variants and CRC risk 
is controversial (Haiman et al. 2008, Pittman et al. 2008). The aims of the first part of 
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the project were to further test the hypothesis that CASP8 inherited variants may be 
involved in CRC risk. This included the following: 
 
1. To investigate the controversial association between CASP8 in/del promoter 
variant and CRC risk by genotyping the in/del variant in 1193 CRC cases and 
1388 matching controls.  
2. To identify any novel or rare CASP8 variants with the potential to affect CRC risk 
by the sequencing of the CASP8 promoter region, exons, exon/intron boundaries 
and the 3‟UTR in 94 CRC cases.  
3. To develop an assay for the CASP8 copy number variant CNV23598, located 
close to the D302H (breast cancer risk) variant in a panel of 284 CRC cases and 
controls, and in 47 carefully selected breast cancer cases and controls enriched 
for CASP8 risk and protective haplotypes respectively.   
 
Sporadic CRC develops through different pathways of genetic and epigenetic defects 
and somatic mutations in key genes. Due to its potential clinical implications, there is 
increased recognition and interest in the molecular classification of CRC. However, 
the field is limited by the lack of standardisation in defining global genomic 
instabilities (CIN, MSI and CIMP) (Issa 2008, Ogino and Goel 2008). Therefore, the 
main aim of the 2nd part of the project was to molecularly classify 53 CRC cases 
using standard definitions and technologies. This involved the following: 
 
1. To investigate and define MSI status using a panel of 5 mononucleotide 
microsatellite markers according to the revised NCI criteria for MSI testing. 
2. To investigate CIMP using the latest validated panel of 7 methylation markers 
and the semi-quantitative methylation-specific multiplex ligation probe 
amplification (MS-MLPA) technology. 
3. To investigate CIN using high resolution genome wide array CGH. 
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CIN is considered the most common genomic instability in CRC. CIN plays a major 
role in CRC development through the amplification of oncogenes (such as MYC) and 
the deletion of TSG (such as SMAD4) (Migliore et al. 2011). However, the picture is 
far from complete (Brosens et al. 2010, Pino and Chung 2010). Therefore, the final 
aim of the project was to identify and characterise novel CRC driver genes affected 
by CIN. This involved: 
 
1. The identification of common focal chromosomal aberrations based on 
genome wide high resolution aCGH data. 
2.  Proof of concept experiments to examine the effects of alterations on one of 
the novel candidate driver genes.  
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 General laboratory equipment and consumables 
Table 2.1 Laboratory equipments 
Equipment Supplier 
ABI 7900 Genotyping Platform Applied Biosystems 
Agarose Gel Electrophoresis Unit (Sub-cell GT) Bio-Rad 
AB104-S Balance Mettler, Toledo 
Class II Microbiological Safety Cabinet Envair 
CO2 Incubator MCO175 Sanyo 
Fujifilm LAS3000 Chemiluminescence Imaging system Fujifilm 
GeneAmp® PCR System 2700 (9700) Thermal Cycler 96 well Applied Biosystems 
Heating Block Grant Boekel BBA 
Heated Plate Sealer ALPS
TM
 50 Abgene 
Heraeus Pico 17 Centrifuge Thermo Scientific 
Harrier 15/80-MSE Centrifuge Sanyo 
Ice Machine Scotsman Ice Machines 
Impact 2 Multichannel Electronic Pipette (0.5-10ml) Matrix 
Multichannel Pipette (0.5-10ml) Matrix 
Multiskan FC spoectrophotometer Thermo Scientific 
Nanodrop Thermo Scientific 
P2, P10, P20, P200, P1000 Pipettes Gilson 
Peltier Thermal Cycler (DNA Engine Dyad 
TM
) 384 well MJresearch Inc 
Power Pack Bio-Rad 
Powerpette Plus Pipette Jencons 
QBD4 Incubator for eppendorfs Grant 
Semi-Dry transfer Cell Bio-Rad 
Titramax 1000 Incubator and Shaker Heidolph 
U:Genius Gel Imager Syngene 
UV Sterilisation Cabinet Bigneat 
Vortex Genie 2 Scientific Industries 
Western Gel Mini Protean II Cell Bio-Rad 
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Table 2.2 Laboratory consumables 
Equipment Supplier 
10ml and 25ml Stripettes Corning Inc 
15ml Centrifuge Tubes Sarstedt 
6 and 96 Well Tissue Culture Plates Greiner Bio-One, Corning Inc  
Cell culture petri dishes Greiner Bio-One 
384 Well PCR Plates Applied Biosystems 
50ml Centrifuge Tubes Corning Inc 
500 l, 1.5ml and 2ml Microfuge Tubes Sarstedt 
96 Well PCR Plates Starlab 
Pipette Tips Matrix, Bioscience, Starlab, Axygen 
Gloves Schottlander 
Heat Sealing Foil Thermo Scientific 
Microseal B Adhesive Sealer Bio-Rad 
Pasteur Pipettes Scientific Laboratory Supplies 
Plate Seals Alphalaboratories 
Reservoirs with Dividers Thermo Scientific 
 
 
2.1.2 Laboratory solutions 
 TAE buffer (1 L, 10x, pH8.0): 0.4 M Tris-base, 11 ml glacial acetic acid, 10 
mM EDTA and ddH2O (pH adjusted to 8.0). 
 EDTA (1 L, 0.5 M, pH8.0): 1.861g sodium ethylene diamine tetra-acetate in 1 
L ddH2O (pH adjusted to 8.0). 
 Phosphate Buffered Saline (PBS) (100 ml, 1x): 1 Oxoid PBS tablet in 100 ml 
ddH2O. 
 Transfer buffer (1 L, 10x): 30.3 g (0.25 M) Tris base, 144 g (1.92 M) glycine 
and ddH2O. 
 TBS (1 L, 10x): 87.66 g (1.56 M) NaCl, 24.22 g (0.2 M) Tris and ddH2O. 
 SDS-PAGE running buffer: 30.3 g (0.25 M) Tris base, 144 g (1.92 M) glycine, 
10 g (1%) Sodium Dodecyl Sulphate (SDS) and ddH2O. 
 Tris-Cl (1 L, 1 M, pH6.8 or pH8.8): 121.1 g Tris-Cl in ddH2O (pH adjusted to 
6.8 or 8.8 as needed). 
 
 38 
2.1.3 DNA samples 
2.1.3.1 Sheffield samples 
Peripheral blood DNA samples from Sheffield and the North Trent region were 
available from patients who had colorectal tumour surgery at the Sheffield Royal 
Hallamshire, Sheffield Northern General, Chesterfield Royal Infirmary, Doncaster 
Royal Infirmary and Barnsley District General hospitals (March, 2001 – June, 2005). 
These samples were identified with a 3 digit number prefixed with a “C”. Peripheral 
blood DNA samples were also available from patients who had chemotherapy 
treatment for metastatic CRC at Sheffield Weston Park hospital (March, 2001 – June, 
2005). These samples are referred to as “metastatic” and the samples numbers are 
prefixed with an “M”. Age- and sex- matched controls were recruited through the 
general practice (GP) registers in Sheffield (October, 2001 – December, 2005) and 
DNA samples were also available from their peripheral blood samples. 
2.1.3.2 Leeds and Dundee samples 
Peripheral blood DNA Samples from Leeds and Dundee were available from patients 
taking part in a population-based CRC epidemiological study in the North of England 
(Barrett et al. 2003). In Leeds, the cases were identified and recruited in Leeds 
General Infirmary and St James‟s hospitals. In Dundee, the cases were recruited 
from Ninewells and Perth Royal Infirmary Hospitals (1997 – 2000). Peripheral blood 
DNA samples from age- and sex- matched controls were also available from both 
Leeds and Dundee GP registers.   
2.1.3.3 Utah samples 
In Utah, peripheral blood DNA samples were extracted from CRC cases selected 
from high risk cancer pedigrees listed in the Utah Cancer Registry (UCR) and Utah 
Population DataBase (UPDB). Peripheral blood DNA samples were also available 
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from cancer-free controls recruited for different studies. Controls were matched 
based on sex and year of birth (within a 5 year age range of the cases).  
2.1.3.4 Paired tumour and normal DNA samples 
For 50 patients from the Sheffield population sample, DNA samples were also 
available from freshly frozen tumour tissue in addition to the peripheral blood. These 
DNA samples were extracted from micro-dissected colorectal tumour tissues that 
contained at least 80% cancerous cells. Throughout this thesis, this cohort of 
matching DNA samples will be referred to as the “Sheffield paired cohort” and the 
DNA extracted from the peripheral blood and tumour tissue will be referred to as 
“normal” DNA and “tumour” DNA, respectively. Patients from this cohort will be 
identified with a 3 digit number prefixed with “CA” and the normal and tumour DNA 
samples for each patient will have the same number prefixed with “N” and “T” 
respectively. Clinical data including gender, diagnosis age, tumour location and 
stage, histological type, tumour differentiation and presence of metastasis were 
available. Follow up data on patient survival are available for these patients until 
March 2011. These data were obtained from the Trent cancer registry. 
 
Seventeen additional paired DNA samples were available from the tissue bank in the 
Royal Hallamshire hospital- University of Sheffield. For these samples, normal DNA 
was extracted from freshly frozen normal colon tissues taken at the time of surgery. 
All tumour and normal tissue samples were checked independently by the pathologist 
Jonathan Bury before being included in the study. Clinical data were also available 
for these patients, however, no follow up information was available. These tissue 
bank patients and their DNA samples will have the same numbering identifiers 
explained above for the Sheffield paired cohort.  
 
 40 
All the subjects included in the study have given informed consent for data and 
sample collection and ethical approval of the study was obtained from South 
Yorkshire Research Ethics Committee (Appendix 3).  
 
The above DNA sample sets were previously used in published genetic 
epidemiological studies (Curtin et al. 2009a, Curtin et al. 2009b). 
2.1.4 Cell lines  
The colon adenocarcinoma cell lines (HCT116, SW620, SW480, HT29, CACO2 and 
COLO205), the Glioblastoma Multiforme (GBM) cell lines (U87 and SNB19) and the 
non-tumour derived cell lines HEK293 (human embryonic kidney epithelial) and 
MRC5-SV2 (foetal lung fibroblast) were supplied by the American Type Culture 
Collection (ATCC), (Bethesda, USA).  
2.1.5 PCR and sequencing primers  
Primer design is described in Section 2.2.5. Primer sequences are provided in 
Appendix 1, tables 1-7. Primers used in this project were obtained from Sigma 
Aldrich (Ebersberg, Germany). The primers were supplied lyophilised and were 
reconstituted with deionised water at a stock concentration of 100 pmol/ μl (as per 
supplier‟s recommendations).  
2.1.6 Pyrosequencing primers 
Pyrosequencing primer design is described in Section 2.2.14.1. Primer sequences 
are provided in Appendix 1, table 8. Pyrosequencing primers were ordered from 
Applied Biosystems (Warrington, UK). The primers were supplied lyophilised and 
were reconstituted with deionised water at a stock concentration of 100 pmol/ μl (as 
per supplier‟s recommendations). 
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2.2 Methods 
2.2.1 DNA extraction 
2.2.1.1 Cultured cells 
DNA from cancer cell lines was extracted using QIAamp DNA mini kit (Qiagen, West 
Sussex) according to the manufacturer‟s instructions. Briefly, the cells were split into 
six 1.5ml tubes and centrifuged at 300 xg for 5 min. The supernatant was removed 
and the cell pellet was re-suspended in 200  μl 1x phosphate buffer saline (PBS). 
The cells were then lysed by the addition of 20  μl proteinase K, 200  μl buffer AL, 
and incubation at 56oC for 10 min. The tubes were briefly centrifuged and 200  μl 
ethanol was added. Next, this mixture was transferred to QIAamp mini spin columns 
(provided in the kit) and centrifuged at 6000 xg for 1 min. The pellets were then 
washed twice by adding the provided wash buffers 1 & 2 with centrifugation at 6000 
xg for 1 min each time. An extra centrifugation step (13000 xg, 3 min) was performed 
to remove any remains of wash buffer 2. Finally, the DNA was eluted by the addition 
of 200  μl elution buffer, 1 min incubation at room temperature, followed by 1 min 
centrifugation at 6000 xg. 
2.2.1.2 Frozen tissues 
Frozen tissue DNA was extracted using the QIAamp DNA mini kit (Qiagen) according 
to the manufacturer‟s instructions. Briefly, the colon tissues were cut into small 
pieces using a scalpel. The pieces were then transferred to a 1.5 ml tube and 180 μl 
of buffer ATL and 20 μl of proteinase K were added. The samples were then mixed 
by vortexing and incubated at 56oC for 15 min, followed by manual homogenisation 
and incubation in an orbital shaker at 56oC overnight. The next day, the tubes were 
centrifuged and 4 μl of RNase A (100 mg/ml) were added. After pulse vortexing for 
15 sec, the samples were left at room temperature for 2 min. Next, 200 μl of buffer 
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AL were added, the samples mixed by vortexing and then incubated at 70oC for 10 
min. The remaining steps were carried out as described in Section 2.2.1.1. 
2.2.2 DNA quantification and quality analysis 
DNA samples were quantified using a NanoDrop spectrophotometer (ND-1000) 
(Fisher Scientific UK Ltd., Loughborough). The ND-1000 software was used with the 
nucleic acids module being selected. After cleaning the sensors, the NanoDrop was 
initialised and blanked using appropriate blank (1x Tris EDTA (TE), water or Qiagen 
elution buffer). Then each sample was quantified by pipetting 1.2 μl onto the sensors. 
The sensors were wiped between different measurements. DNA concentration was 
calculated using a modified Beer-Lambert equation (c = (A * e) /b) where c is DNA 
concentration (ng/ μl), A is absorbance at 260nm, e is the absorbance coefficient and 
equals 50ng-cm/ μl and b is the path length in cm. The purity of the DNA samples 
was determined using A260/A280 and A260/A230 ratios. The former indicates the absence 
of contaminating proteins when the ratio is 1.8-2.0 and the latter indicates absence of 
other organic compounds when the ratio is 1.8-2.2. 
2.2.3 Tumour DNA fragmentation 
In order to assess their degree of degradation, tumour DNA samples were 
electrophoresed on 1% Agarose gel (Section 2.2.7). Prior to loading, 1 μl of each 
sample was mixed with 3 μl water and 1 μl DNA loading buffer (6x) (0.25% (w/v) 
bromophenol blue, 30% (v/v) glycerol). 
2.2.4 Sodium acetate/ethanol DNA precipitation 
Some of the DNA samples used in the project had a low 260/230 ratio which 
indicates contamination with organic substances such as phenol. Such contamination 
can inhibit some of the tests applied to the DNA samples. In order to remove the 
contamination, sodium acetate (NaAc) / ethanol purification was performed. The 
procedure involved adding a one tenth volume of 3 M NaAc to the DNA sample 
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followed by the addition of 2 volumes of 100% ice cold ethanol. This mixture was 
then incubated at -20oC for 90 min. The samples were then centrifuged at 14100 
RPM for 15 min at 4oC and the supernatant was removed. The samples were spun 
again and any residual supernatant was removed. Then, 200 μl of 70% ice cold 
ethanol were added to the pellets which were centrifuged at 14100 RPM for 5 min at 
4oC. As much as possible of the supernatant was removed and the remainder was 
left to evaporate in a laminar flowhood for 15 min. DNA was reconstituted by the 
addition of 100 μl of 1x molecular grade TE (Promega, Southampton) and the 
260/230 ratio was checked again using the NanoDrop (Section 2.2.2). 
2.2.5 Primer design 
2.2.5.1 In silico primer design 
Primers used in the amplification of  CASP8, APC, TP53, KRAS, BRAF, PIK3CA and 
CASP8 CNV23598 were designed using the web-based tool Primer 3 
(http://frodo.wi.mit.edu/, accessed October, 2008 – August, 2010) (Rozen and 
Skaletsky 2000). The target sequence for each region was obtained from NCBI 
(www.ncbi.nlm.nih.gov, accessed October 2008 – August, 2010) (Table 2.3). The 
sequences were then imported into the Primer3 web page. The default parameters 
for picking primers were maintained except for the melting temperature (TM); primer 
TM range of 57°C-63°C was used with 60°C selected as the optimal temperature. For 
primer size, a range between 20-24 nucleotides was used with 22 as the optimal size 
and for primer GC%, a range of 45-55% was set with 50% as the optimal GC 
content. Primer3 provided a list of suggested primers according to the parameters 
chosen and indicated the most suitable pair. The “best pair” was chosen in all cases. 
The primer blast search tool provided by NCBI 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/, accessed February, 2009 – August, 
2010) was then used to test whether the primers were primarily/solely specific to their 
targets. Moreover, all the designed primers were tested for the occurrence of SNPs 
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underneath their annealing sites using the diagnostic SNP check online tool provided 
by the National Genetics Reference Laboratories (NGRL) 
(http://ngrl.man.ac.uk/SNPCheck/SNPCheck.html, accessed October, 2008 – 
August, 2010). 
Table 2.3 NCBI accession numbers 
 
2.2.5.2 Manual primer design 
In a few cases, manual primer design was required to target a very specific area. The 
primers were designed manually to meet the following criteria:  
- 20-25 bases in length 
- GC content of 45-55% 
- 3‟ end to terminate with G or C 
-  Single base repeats >3 were avoided 
- Minimum complementarities between pairs of F and R primers 
- TM in the range 59ºC - 61ºC. Primer TM was calculated using the following 
equation (as recommended by MWG Biotech Ltd.): 
TM=69.3 + (GC% x 0.41)-(650/primer length). 
 
M13 tails (Table 2.4) were attached to all the primers used in this project, except for 
long range PCR primers, internal sequencing primers and fluorescently labelled 
primers. M13 primers are universal primers used for DNA sequencing. They were 
Gene Chromosome Accession number Location Genomic Build 
CASP8 2q33-q34 NC_000002.10 201804871-201862219 36.3 
APC 5q21-q22 NC_000005.8 112100455-112210835 36.3 
TP53 17p13.1 NC_000017.9 7532642-7511445 36.3 
KRAS 12p12.1 NG_007524.1 5001-50675 36.3 
BRAF 7q34 NG_007873.1 5001-195753 36.3 
PIK3CA 3q26.3 NG_012113.1 5001-91190 37.1 
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used to facilitate the sequencing procedure, as all the exons can be sequenced using 
a single primer pair. 
Table 2.4 M13 sequences 
 
Primer Sequence (5’-3’) 
M13 Forward dTGTAAAACGACGGCCAGT 
M13 Reverse dCAGGAAACAGCTATGACC 
 
2.2.5.3 DNA sequencing primer design 
Conventional Sanger sequencing techniques are able to analyse PCR products up to 
600-800 nucleotides in length. The long-range PCR products (Section 2.2.6.2) in this 
study ranged between 1000bp up to 3000bp in length. To sequence across these 
regions, sequencing primers were required. These primers were designed ~400 bp 
apart to ensure enough overlap between the sequences to confidently cover the 
region of interest. Primers were designed manually using the same criteria as in 
Section 2.2.5.2. 
2.2.6 Polymerase Chain Reaction 
2.2.6.1 Conventional PCR 
Exons that required mutation screening were amplified using the polymerase chain 
reaction (PCR) (Mullis et al. 1986). Standard 25 μl PCR reactions were used. Each 
reaction contained 25 ng genomic DNA, 100 ng of each specific primer (forward and 
reverse), 1 μl deionised water and 22.5 μl Reddymix® (1.25 U Taq polymerase, 75 
mM Tris-HCl, 20mM (NH4)2SO4, 0.01% (w/v) Tween20, 0.2 mM of each dNTP and 
1.5 mM MgCl2 (Fisher Scientific UK Ltd.). A conventional PCR includes cycles of 3 
essential steps: denaturation, annealing and extension (Figure 2.1). The cycling 
conditions used in this study were; initial denaturation step at 94ºC for 7 min, 
followed by 35 cycles of denaturation at 94ºC for 1 min, annealing at nºC for 1 min 
and extension at 72ºC for 1 min, and a final extension step at 72 ºC for 7 min (Figure 
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2.1). The annealing temperatures varied according to the TM of the primers 
(Appendix 1). Throughout the project, all PCR reactions were carried out using the 
GeneAmp® PCR System 9200 thermocycler (Applied Biosystems). 
 
 
 
35 cycles of: denaturation (at 94ºC), annealing (depends on  primers TMºC), extension (at 
72ºC) 
 
2.2.6.2 Long-range PCR 
Long-range PCR is used to amplify larger fragments of DNA than those achieved 
using conventional PCR protocols (Cheng et al. 1994). Modifications from the 
conventional PCR protocol included the use of thermostable DNA polymerases with 
high 5‟-3‟ polymerase activity and 3‟-5‟ proofreading capability. Additionally, the 
extension step in the long-range PCR protocol was usually longer than in 
conventional protocols to allow the amplification of large fragments. Long-range PCR 
was performed using the Phusion high fidelity PCR kit (New England Biolabs (UK) 
Ltd., Hitchin). Long-range PCR reactions were set up in a total volume of 50 μl and 
consisted of 62.5 ng genomic DNA, 0.5 μM of each primer (forward and reverse), 
32.5 μl deionised water and 10 μl of 5x Phusion HF buffer®, 200 μM of each dNTP 
and 10 ul of the Phusion DNA polymerase. The long-range PCR conditions consisted 
of the following steps;  initial denaturation at 98ºC for 30 sec, followed by 35 cycles of 
denaturation at 98 ºC for 10 sec, annealing at nºC for 30 sec and extension at 72 ºC 
         7min   1min   1min      1min    7min 14 C 
94 C 
 n C 
  72 C 
  35 cycles                                  10min 
Figure 2.1 Conventional PCR thermal profile 
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for x min, and a final extension at 72ºC for 10 min. The annealing temperatures 
varied according to the TM of the primers (Appendix 1) and the extension time varied 
according to the size of the target region (15-30 sec/Kb). The PCR conditions were 
determined according to the Phusion kit recommendations. 
2.2.6.3 GAP PCR 
GAP PCR is a modified PCR that allows the detection of known insertions and 
deletions. It involves the use of 3 primers: a “common” forward primer, which anneals 
to the sequence upstream of the insertion/deletion site and 2 reverse primers. The 
first primer “insertion” anneals to the inserted sequence when present, and the 2nd 
primer “deletion” will anneal downstream of the insertion/deletion sequence (Figure 
2.2). In the case of a homozygous deletion, the “common” and the “deletion” primers 
alone will produce a product as the “insertion” primer will fail to anneal. In the case of 
an insertion, the “common” and the “insertion” primers alone will produce a PCR 
product as the optimised PCR conditions do not allow the amplification of large PCR 
products. The genotype of the sample is determined by gel electrophoresis based on 
the size of the different products (Figure 2.2). In this project GAP PCR was initially 
used for genotyping the CNV23598. Standard conventional PCR reactions and 
conditions were used, however, with 3 primers (Section 2.2.6.1). 
2.2.6.4 Fluorescent GAP PCR 
Fluorescent GAP PCR was used as a higher throughput method for the genotyping 
of CASP8 CNV23598. The principle is the same as described in the previous section. 
However, the “insertion” and the “deletion” primers were labelled with distinct 
fluorescent dyes and instead of gel based analysis, capillary electrophoresis was 
used. The products appear as peaks of different size and fluorescent colour 
according to the different alleles. Fluorescent GAP PCR was performed using the 
Amplitaq Gold® PCR master mix (Applied Biosystems). The reactions were set up in 
a 10 μl volume and consisted of 5 ng DNA, 0.5 μM of the unlabelled common forward 
 48 
primer, 0.5 μM of the “insertion” labelled reverse primer, 0.2 μM of the “deletion” 
labelled reverse primer, 5 μl of the Amplitaq Gold® PCR master mix and 2.8 μl 
deionised water. The PCR conditions consisted of the following steps; initial 
denaturation at 95ºC for 5 min, followed by 32 cycles of denaturation at 95 ºC for 30 
sec, annealing at 59ºC for 30 sec and extension at 72 ºC for 30 sec, and a final 
extension at 72ºC for 7 min. The products were diluted 1 in 10 with deionised water 
and then electrophoresed on ABI PRISMTM 3730 DNA analyser with appropriate size 
standard by the Core Sequencing Facility (School of Medicine and Biomedical 
Sciences, University of Sheffield, Sheffield, UK). The data were analysed using 
genemapper software version 4.0 (Applied Biosystems). 
 
 
 
A schematic presentation of GAP PCR. Arrows represent the primers used. Black is the 
common forward, Red is the insertion reverse and Blue is the deletion reverse A) The target 
sequence with an insertion, the reverse deletion will anneal, however, the PCR conditions will 
not allow the amplification of large amplicons. B) The target sequence with the deletion, the 
insertion reverse will not anneal C) The different genotypes as will appear on agarose gel. 
 
 Homo INS       Heterozygous     Homo DEL
  
Target Insertion 
Target 
A 
B 
C 
Figure 2.2 GAP PCR 
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2.2.7 Agarose gel electrophoresis 
Prior to further analysis, PCR products were separated and identified using agarose 
gel electrophoresis. To prepare an agarose gel, the following procedure was used. 
Depending on the agarose percentage and the volume of gel required (usually 1.5% 
in 100 ml), an appropriate mass of Multi-Purpose Agarose (Bioline Ltd., London) and 
an appropriate volume of 1x TAE were mixed in a conical flask and heated in the 
microwave oven in short bursts. Once the agarose had fully dissolved and the 
solution had cooled down, 5 μl (10 mg/ml) ethidium bromide (Et.Br.) was added. 
Cooling the gel before Et.Br. addition reduces vaporisation of this mutagenic reagent. 
The solution was then poured into a gel casting tray (with combs in position) and left 
to solidify. When ready, the gel was placed in a Mini-Sub® Cell gel tank (Bio-Rad 
Laboratories Ltd., Hemel Hempstead) and overlaid with TAE (1x) as buffering 
system. 5 μl Et.Br. (10 mg/ml) was also added to the running buffer.  
 
To determine the size of the PCR product, a standard size marker was 
electrophoresed alongside the PCR products. According to the expected size of the 
PCR product, two different standard size DNA markers were used, hyperladder I and 
IV supplied by Bioline-London (Appendix 4). 5 μl of the PCR products amplified with 
the Reddy Mix (contains a loading dye) were loaded directly into the wells. 5 μl of the 
long range PCR products were mixed with 1 μl DNA loading buffer (6x) (0.25% (w/v) 
bromophenol blue, 30% (v/v) glycerol) prior to loading. Gels were electrophoresed at 
100 V for 35 min for conventional PCR products and at 120 V for 1 hour for long-
range PCR products. DNA bands were visualised using a UV trans-illuminator 
U:Genius from Syngene (Cambridge). 
2.2.8 Quantitative fluorescent PCR & microsatellite instability analysis 
Quantitative fluorescent PCR (QF-PCR) is based on the PCR amplification of 
polymorphic microsatellites using fluorescently labelled primers. The products are 
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visualised and quantified by capillary electrophoresis on an automated genetic 
analyser. The microsatellite instability (MSI) status of all the tumour and normal DNA 
samples analysed in this study was determined using a commercially available 
QFPCR kit: MSI Analysis System, Version 1.2 Kit (Promega). The kit includes 
fluorescently labelled primers for five quasimonomorphic mononucleotide 
microsatellite markers; BAT-25, BAT-26, NR-21, NR-24 and MONO-27 as 
recommended by the National Cancer Institute (NCI) revised criteria on MSI testing 
(Bacher et al. 2004, Umar et al. 2004). The MSI analysis was performed according to 
the manufacturer‟s protocol: 2 ng DNA was amplified in a 10 μl PCR mix containing; 
5.85 μl nuclease free water, 1.0 μl Gold STAR 10x buffer, 1.0 μl 10x multiplex primer 
mix and 0.15  μl Amplitaq Gold DNA polymerase (5 U/μl) (Applied Biosystems). 
  
The MSI cycling conditions were performed in a GeneAmp® PCR System 9700 
thermocycler (Applied Biosystems) and consisted of the following steps; initial 
denaturation at 95oC for 11 min, followed by another denaturation step at 96oC for 1 
min, then 10 cycles of denaturation (100% ramp) at 94oC for 30 sec, annealing (29% 
ramp) at 58oC for 30 sec and extension (23% ramp) at 70oC for 1 min, followed by 20 
more cycles of denaturation (100% ramp) at 90oC for 30 sec, annealing (29% ramp) 
at 58oC for 30 sec and extension (23% ramp) at 70oC for 1 min, then a final 
incubation step at 60oC for 30 min. The products were then analysed on ABI 
PRISMTM 3730 DNA Analyser with appropriate size standard by the Core 
Sequencing Facility. The results were analysed using genemapper software version 
4.0 (Applied Biosystems). The MSI markers were considered unstable if they exhibit 
a change in size in the tumour DNA compared to the paired normal DNA. Samples 
were classified to have high MSI (MSI-H) if they showed instability in two or more of 
the 5 mononucleotide markers, low MSI (MSI-L) if they showed instability in one of 
the markers, and MSS if none of the markers showed instability (Murphy et al. 2006) 
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2.2.9 TaqMan real time PCR 
TaqMan assays involve the use of dual-labelled oligonucleotide probes 
complimentary to the target DNA sequence as illustrated in Figure 2.3 (Heid et al. 
1996). The probes are fluorescently labelled with a reporter fluorophore at the 5‟ end 
and a „quencher‟ molecule at the 3‟ end. The quencher molecule quenches the 
fluorescent signal emitted by the fluorophore. The quenching process requires close 
proximity between the quencher and the reporter molecules. During PCR, the probe 
will anneal to the target sequence. However, due to the 5‟ exonuclease activity of 
Taq polymerase, the probe, if perfectly annealed, will be hydrolysed resulting in the 
release of the reporter and quencher molecules and consequently the generation of a 
fluorescent signal. Subsequently, the signal is detected and quantified using a 
quantitative PCR machine (Figure 2.3). If the probe is not perfectly matched to the 
target area, it will not be hydrolysed and the fluorescent signal will be minimal as the 
3‟ quencher stays in close proximity to the 5‟ fluorophore. 
2.2.9.1 TaqMan genotyping assays 
TaqMan assays were used for the genotyping of a 6bp insertion-deletion (ins/del) 
polymorphism (rs3834129) in the promoter region of CASP8. Probes specific for 
each allele were used and each probe was labelled with a different reporter 
fluorophore (FAMTM for insertion and VIC® for deletion). Thus, depending on the 
attached probe, the signal differs according to the genotype at that position. PCR 
reactions were performed in 384-well PCR plates with 10 ng genomic DNA in each 
well. Standard 5 μl PCR reactions were used. Each reaction contained 2.5 μl of 2x 
TaqMan Genotyping mastermix (ultrapure hot start AmpliTaq Gold DNA polymerase, 
deoxynucleotide triphosphates with UTP, AmpErase uracyl-N-glycosylase (UNG), 
passive reference dye, and optimised buffer), 0.0625 μl of primers and TaqMan 
probe mix (Applied Biosystems) and 2.4375 μl deionised water. The plates were 
sealed using BioRad PCR microseals (Bio-Rad Laboratories Ltd.). 
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After centrifugation of the PCR plates for 1 min at 2000 RPM, TaqMan PCR reactions 
were performed under the following conditions: initial incubation at 50oC for 2 min, 
initial denaturation at 92oC for 10 min, followed by 40 cycles of denaturation at 92oC 
for 15 sec and combined annealing/extension at 60oC for 1 min. All TaqMan assays 
were carried out in a Dyad Peltier Thermal Cycler (MJ Research, currently supplied 
by Bio-Rad Laboratories Ltd.). TaqMan PCR products were analysed using an ABI 
HT7900 real time PCR machine (Applied Biosystems). The data were analysed using 
the allelic discrimination module of the Sequence Detector Software version 2.2.1 
(Applied Biosystems). 
 
Figure 2.3 TaqMan assay principle 
A schematic presentation of the TaqMan assay principle. For simplicity, the figure is showing 
PCR amplification in the forward direction only. 
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2.2.9.1.1 TaqMan genotyping quality control 
Several measures were taken to ensure good quality genotyping results. For 
example, up to 10% of the DNA samples were duplicated on separate 384-well PCR 
plates. These samples were thus genotyped twice to check the reproducibility of the 
assay. Duplicate samples were considered informative when successfully called in 
both assays and a duplicate concordance rate of ~98% represented high 
reproducibility. Additionally, no-template controls (NTC) were included on each plate 
to check for DNA contamination.  
2.2.9.2 TaqMan copy number assays 
Real Time PCR TaqMan copy number assays were used to validate the accuracy of 
the aCGH data (Section 2.2.15). Three of the common focal aberrations (PARK2, 
KCNMA1 and NFKBIA) identified in this project were chosen for confirmation by 
TaqMan copy number assays. Pre-designed assays were chosen from the ABI 
website (http://www.appliedbiosystems.com) (Table 2.5). Pre-designed TaqMan 
Copy number reference assays (TERT and RPPH1) were also used for the relative 
quantification of the copy numbers of the targets. The assays contain forward and 
reverse primers and a dye-labelled TaqMan probe (FAMTM for the target assays and 
VIC® for the reference assays). These reference assays were chosen to anneal to a 
region in the sample known to have a diploid copy number, based on the aCGH 
results. The target copy number assays were run simultaneously with the copy 
number reference assay in a duplex real time PCR. The number of copies of the 
target sequence is determined by relative quantification (RQ) based on a 
comparative threshold cycle (CT) method (ΔΔCT). Threshold cycle is the fractional 
cycle number at which the emitted fluorescence level passes the detection threshold 
(Figure 2.4). The CT difference (ΔCT) between the target and the reference assays is 
calculated and compared to the ΔCT value of control DNA samples known to have a 
chromosomally stable diploid genome. 
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Table 2.5 TaqMan copy number assays 
Gene Assay Number Cytoband Genomic location Genomic Build 
PARK2 Hs03585570-cn 6q26 chr6:162636459 37.1 
KCNMA1 Hs03760015-cn 10q22.3 chr10:79111001 37.1 
NFKBIA Hs00462687-cn 14q13.2 chr14:35870871 37.1 
 
 
 
 
A TaqMan copy number assay amplification plot showing tumour and normal DNA 
amplification curves. The CT of the tumour DNA is smaller in comparison to the CT of the 
normal DNA indicating an increased copy number in the Tumour DNA. This sample had 
amplification at this genomic location. 
 
PCR reactions were performed in 384-well PCR plates with 2 μl of 5 ng/μl DNA 
samples. Standard 8 μl PCR reactions were used. Each reaction contained 5 μl of 2x 
TaqMan Genotyping mastermix, 0.5 μl of 20x TaqMan copy number target assay, 0.5 
μl of the 20x TaqMan copy number reference assay and 2 μl nuclease free water. 
NTC were also included in all of the experiments to check for contamination. The 
plates were sealed using BioRad PCR microseals (Bio-Rad Laboratories Ltd.). After 
centrifugation of the PCR plates for 1 min at 2000 RPM, they were loaded in an ABI 
HT7900 real time PCR machine (Applied Biosystems) and reactions performed using 
the following conditions; initial denaturation at 95oC for 10 min, followed by 40 cycles 
Figure 2.4 TaqMan copy number assay amplification plot 
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of denaturation at 95oC for 15 sec and combined annealing/extension at 60oC for 1 
min. The results were then initially analysed using the copy number module of the 
Sequence Detector Software version 2.2.1 (Applied Biosystems). Copy numbers for 
the samples were then predicted using the Copy Caller software v1.0 (Applied 
Biosystems). 
2.2.10 DNA sequencing 
During this project, bidirectional automated dye terminator DNA sequencing was 
used to identify any sequence variants in specific target regions. This DNA 
sequencing method is based on dideoxynucleotide (ddNTPs) sequencing chemistry 
developed by Frederick Sanger in the 1970s (Sanger et al. 1977). In the current 
evolved form of Sanger sequencing, 4 different fluorescently labelled ddNTPs (one 
for each of the 4 bases adenine, thymine, cytosine, and guanine) are mixed with non-
labelled dNTPs (A, T, C and G) in a PCR reaction. The ddNTPs incorporation during 
the PCR extension step results in termination of the reaction as a result of the 
absence of a 3‟-OH group. This will happen at all positions in the target DNA 
sequence and result in a series of fluorescently labelled DNA fragments of different 
lengths. Capillary electrophoresis can then be used to separate the DNA fragments 
according to their length and the fluorescent signal will be captured at all positions. 
The last two steps are usually performed in an automated DNA analyser. 
 
DNA sequencing was applied on PCR products for the detection of sequence 
variants. After being amplified and assessed (using agarose gel electrophoresis), 
PCR products were enzymatically purified in preparation for sequencing. This step 
was performed to remove the residual primers and to degrade the remaining dNTPs; 
both of which might interfere with the quality of the sequences obtained. Enzymatic 
purification was carried out using the following protocol: 6 μl PCR product, 4 μl of 
ExoSAP-IT (GE Healthcare UK Ltd., Little Chalfont) (1:4 dilution v/v) and 4 μl 
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deionised H2O were mixed in a 0.5 μl PCR tube. The reaction was then incubated at 
37ºC for 30 minutes and denatured at 80ºC for 15 minutes. ExoSAP-IT is a mixture of 
two enzymes: the first one is Exonuclease I (Exo I) which removes any single-
stranded DNA and primers. The second enzyme is Shrimp Alkaline Phosphatase 
(SAP) which degrades residual dNTPs (Werle et al. 1994; www.usbweb.com).  
 
All sequencing reactions were carried out by the Core Sequencing Facility using an 
ABI PRISMTM BigDye Terminator v3.1 Sequencing standard kit and were performed 
on an ABI PRISMTM 3730 DNA analyser (Applied Biosystems). 
2.2.11 Sequence analysis 
2.2.11.1 Manual analysis 
All sequences were visually checked for double peaks, which might indicate a 
heterozygous position. When necessary, the sequences were checked against the 
published gene sequences and control sequencing results. 
2.2.11.2 Staden sequence checking 
The sequences were also analysed with reference to control sequence traces using 
the Staden sequence analysis package (Bonfield et al. 1998). A blank Staden 
database was set up for CASP8, APC, TP53, KRAS, BRAF and PIK3CA analysis. 
The target sequence was exported and saved from the Ensembl database as a text 
file (www.ensembl.org, accessed September, 2008 – August, 2010). Next, pregap4 
software (v1.4b1) from the Staden package was used to add the target sequence 
and a new database template was created. Subsequently, GAP4 software (v4.8b1) 
was used to edit the target sequence. All the exons were highlighted using the contig 
editor. For sequence analysis, the ab1 files of the generated sequences were placed 
in the Staden databases. The files for the samples and the controls were added 
using pregap 4 and the control was set as the reference sequence. GAP4 was then 
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used to analyse the imported sequences. GAP4 compares the fluorescent traces of 
the target sequence against those of the control sequence. It then subtracts the pairs 
of wild-type and mutant traces to produce new traces that represent the differences; 
those that are significant are highlighted (Bonfield et al. 1998). Each amplicon was 
processed and analysed separately. 
2.2.12 Methylation Specific Multiplex Ligation Probe Amplification 
Multiplex Ligation Probe Amplification (MLPA) is a multiplex fluorescent PCR method 
that is used to detect copy number variation (Schouten et al. 2002) (Figure 2.5). The 
technology involves the use of oligonucleotide probes of variable, but unique, lengths 
complimentary to various DNA targets. Other than the target specific sequence, the 
MLPA probes will also have identical 5‟ or 3‟ end sequences that are then amplified 
by a single fluorescent primer pair. The products are analysed by capillary 
electrophoresis and different product sizes will reflect the different targets. In 
methylation specific MLPA (MS-MLPA), the addition of a digestion step using 
methylation sensitive endonucleases result in the ability to semi-quantify the 
methylation level in DNA samples (Nygren et al. 2005) (Figure 2.5). MS-MLPA has 
several advantages over other methylation analysis technologies; it is not based on 
bisulphite conversion, it requires a small amount of DNA, and it allows the 
multiplexing of several markers in a single reaction (Jeuken et al. 2007). The MS-
MLPA kit ME042-A1 was used in this project to determine the methylation status of 8 
markers (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and 
SOCS1) in paired normal and tumour DNA samples. All the steps were carried 
according to the manufacturer‟s instructions (MRC-Holland, Amsterdam). It is 
noteworthy here that copy number analysis using the MS-MLPA kit was not 
performed, since the reference probes targeted unstable genomic areas in CRC. 
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MS-MLPA probes contain 2 oligonucleotides; one short synthetic and one long M13-derived.  
Up to 50 MS-MLPA probes can be used in a single reaction. Both oligonucleotides contain 
universal primer sites and target specific sequences. Each M13 derived oligonucleotide also 
contains a “stuffer” sequence with a probe specific length. Moreover, MS-MLPA probes also 
contain an HhaI recognition site (only methylation specific probes). When attached to a 
methylated DNA target, methylation sensitive HhaI enzyme will fail to digest the probe, a 
fluorescent signal will be produced, and peaks will be observed through the genemapper 
analysis. When attached to unmethylated DNA target, HhaI will digest the probes and no 
signal will be detected. *Adapted from (Nygren et al. 2005). 
Universal forward primer Universal reverse primer 
Variable size stuffer 
Targets specific sequence 
M 
M 
Methylated target  Unmethylated target 
Target DNA denaturation        and multiplex probe hybridisation 
M 
M 
Simultaneous ligation &      digestion with HhaI 
      PCR amplification        with universal primers 
Capillary electrophoresis  &    methylation analysis 
    Highly methylated DNA   Non-methylated 
Figure 2.5 MS-MLPA technology 
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2.2.12.1 DNA denaturation and MS-MLPA probe hybridisation 
DNA samples (50 ng) were diluted in 5 μl of molecular biology grade 1xTE buffer 
(Promega) in 0.2 ml PCR tubes. The diluted DNA samples were then denatured by 
incubation in the GeneAmp® PCR System 9200 thermocycler (Applied Biosystems) 
at 98oC for 10 min followed by cooling down to 25oC. Following that, 3.0 μl of SALSA 
probe/MLPA buffer (1:1) mix were added to the samples, which were then mixed 
carefully by pipetting up and down and incubated at 95oC for 1 min followed by 60oC 
for 16 hrs. 
2.2.12.2 Ligation and digestion 
Before the end of the 16 hr incubation, the following mixes (per sample) were 
prepared and kept on ice; Ligase buffer A mix: 3 μl of ligase buffer A with 10 μl of 
nuclease free water, ligase-65 mix: 1.5 μl of ligase-65 buffer B, 0.25 μl of ligase-65 
enzyme and 8.25 μl of nuclease free water, ligase-digestion mix: 1.5 μl of ligase-65 
buffer B, 0.25 μl of ligase-65 enzyme, 0.5 μl HhaI enzyme (10 U/ μl) and 8.25 μl of 
nuclease free water. For each sample, a new 0.2 ml PCR tube was labelled and 
prefixed with D (referring to digestion mix). After the end of the 16 hr hybridisation, 13 
μl of ligase buffer A mix were added to each sample tube and mixed by pipetting. 
After that, 10 μl of the sample/ligase buffer A mix were transferred to the D prefixed 
labelled PCR tubes. Both tubes were then incubated at 49oC for at least 1 min (in the 
thermocycler). While at 49oC, 10 μl ligase-65 mix were added to the first tube of each 
sample (ligation reaction), then 10 μl of the ligase-digestion mix were added to the D 
prefixed labelled tubes of each sample (ligation digestion reaction). Both tubes were 
then incubated at 49oC for 30 min followed by 5 min at 98oC. 
2.2.12.3 Amplification and capillary electrophoresis 
For each sample, 2 PCR tubes (0.2 ml) were labelled (with and without the D- prefix). 
The following mixes were prepared and kept on ice; SALSA PCR buffer mix: 2 μl of 
SALSA PCR buffer with 13 μl nuclease free water, polymerase mix: 1 μl SALSA PCR 
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primers, 1 μl SALSA enzyme dilution buffer, 0.25 μl SALSA polymerase and 2.75 μl 
nuclease free water. In the new labelled 0.2 ml PCR tubes, 5 μl of MLPA ligation or 5 
μl of ligation digestion reaction were mixed with 15 μl of SALSA PCR buffer mix. The 
tubes were placed on ice and 5 μl polymerase mix was added to each tube. The 
tubes were then placed in a preheated thermocycler (72oC) and amplified using the 
following PCR conditions; 35 cycles of denaturation at 95oC for 30 sec, annealing at 
60oC for 30 sec and extension at 72oC for 60 sec followed by 20 min incubation at 
72oC. The PCR products were then electrophoresed on an ABI PRISMTM 3730 DNA 
Analyser with appropriate size standards by the Core Sequencing Facility. 
2.2.12.4 MS-MLPA results analysis 
The initial analysis of the MS-MLPA products was performed using genemapper 
software version 4.0 (Applied Biosystems). The raw data was then exported as a text 
file and the rest of the analysis described in Sections 2.2.12.4.1 - 2.2.12.4.3 was 
performed in Microsoft Excel spreadsheets templates and using an in-house 
algorithm designed by Dan Connely (Bioinformatician in our research group).  
2.2.12.4.1 Quality control 
Two types of quality control (QC) fragments are included in the MS-MLPA kit, the “Q” 
and the “D” fragments. The Q-fragments (64, 70, 76 and 82bp) are generated by the 
Q-probes in a non-ligation dependent manner. The Q-peaks areas should be smaller 
than half the area of D-peaks (below), if they were not, then the sample ligation failed 
or the DNA concentration was very low. The D-fragments (88, 92 and 96bp) are 
generated by the D-probes in a ligation dependent manner. The D-peaks areas 
should be comparable to other MLPA reference probes areas (≥40%) which mean 
that the ligation was successful, there was a sufficient amount of DNA and that they 
were properly denatured. If the 88 and the 96 D-fragments averaged areas were 
<40% of the 92 D-fragment area then denaturation was not enough. If the area of the 
92 D-fragment was <40% of the 88 and 96 D-fragments averaged areas, it indicates 
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that hybridisation was incomplete. This can result from short hybridisation time, low 
hybridisation temperature, insufficient amounts of MLPA probe mix and/or MLPA 
buffer, the use of >5ul of DNA, or the thermal cycler lid temperature was less than 
100oC. The QC tests are summarised in Table 2.6. Finally, a digestion control probe 
is included in the probe mix (Section 2.2.12.1) to test the efficiency of the digestion 
step. This probe should not give a signal upon digestion. 
Table 2.6 MS-MLPA “Q” and “D” fragments QC tests 
 
Test Description Pass* Fail* 
A DNA Concentration/Ligation Q-peaks against D-peaks ≤50% >50% 
B Denaturation 88D and 96D against 92D ≥40% <40% 
C Hybridisation 92D against 88D and 96D ≥40% <40% 
D DNA Quantity/Ligation/Denaturation D-peaks against reference peaks ≥40% <40% 
* The % reflect the ratio between the peaks areas 
2.2.12.4.2 Intra-sample data normalisation 
For the analysis of the MS-MLPA results, relative peak areas are used instead of 
absolute peak areas (generated by the ABI PRISMTM 3730 DNA Analyser). In order 
to calculate the relative peak areas, the data was normalised in an intra-sample 
fashion. This involved dividing the peak area generated from each marker probe by 
the peak area from each of the 10 reference probes in the same sample, thus 
creating 10 ratios for each of the marker probes. The median of the 10 marker 
probes ratios is considered the normalisation constant of the probe and is used for 
the methylation and copy number analyses. This normalisation was performed for the 
undigested as well as the digested samples. 
2.2.12.4.3 Methylation analysis 
The methylation status of the marker probe regions is calculated by dividing the 
normalisation constant of the probes from the digested sample by the normalisation 
constant of the probes from the corresponding undigested sample and multiplying the 
result by 100 to obtain the methylation percentage. In order to identify aberrant 
methylation, the tumour DNA methylation percentages were compared to their 
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matching normal DNA controls. A marker is considered to be methylated in the 
tumour DNA if the averaged methylation levels of all of its probes were greater by 
≥10% than the value for the normal DNA. However, at least 2 probes should indicate 
such an increase in methylation levels. This level of increase was previously shown 
to correlate with a marked decrease in mRNA expression (Cheng et al. 2008). 
Finally, a sample was classified as CIMP negative (CIMP-N) if none of the markers 
were methylated, CIMP low (CIMP-L) if 1-4 of the markers were methylated and 
CIMP high (CIMP-H) if 5 or more were methylated (Ogino et al. 2007).  
2.2.12.4.4 Sex determination and BRAF V600E mutation 
In addition to copy number and methylation analysis, the MS-MLPA kit ME042-A1 
provides X and Y chromosome specific probes which can be used to determine the 
gender of the samples. Moreover, a mutation-specific probe that binds only in the 
presence of the BRAF mutation V600E is available. 
2.2.13 DNA bisulphite treatment 
DNA bisulphite treatment results in the conversion of unmethylated cytosine residues 
to uracil with no effect on methylated cytosine (5-methylcytosine) (Ehrich et al. 2007). 
Bisulphite treatment of DNA is an essential step in many methylation studies as it is 
used prior to techniques including methylation specific PCR, real time PCR, 
sequencing and pyrosequencing. 
 
In this project, bisulphite treated DNA was used in pyrosequencing reactions to 
validate methylation positive and negative controls for MS-MLPA tests. The 
CpGenome DNA modification kit from Chemicon (Millipore, Watford) was used to 
perform DNA bisulphite treatment. All the reactions were performed according to the 
manufacturer‟s protocol. Briefly, 500 ng DNA was diluted to 10 μl in nuclease free 
water and then mixed with 97 μl of DNA modification reagent 4 (R4) mix (alkaline 
solution). The DNA/R4 mix was then incubated at 50oC for 10 min. This results in the 
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denaturation of the DNA (mild heat at an alkaline pH). 550 μl of DNA modification 
reagent 1 (R1) is then added to the samples and the mixture is incubated at 50oC for 
16 hr in the dark. R1 contains sodium bisulphite, which results in the conversion of 
unmethylated cytosine into uracil sulfonate. After 16 hr, 5 μl of DNA modification 
reagent 3 (R3) were added to the samples, followed by 750 μl of DNA modification 
reagent 2 (R2). R2/3 mix results in the binding of the DNA to micro-particulate 
carriers.  
 
Samples were then incubated at room temperature for 10 min, centrifuged at 8000 xg 
for 1 min and the supernatant was carefully discarded. The pellet was then washed 3 
times by adding 70% ethanol, vortexing and spinning at 8000 xg for 1 min. After the 
last wash, 50 μl of 20 mM NaOH/90% ethanol was added, and the tubes were 
incubated at room temperature for 5 min and then washed twice with 90% ethanol. 
This results in DNA desalting and the complete conversion of the intermediate uracil 
sulfonate into uracil (via alkaline desulfonation). After removing the supernatant, the 
samples were air dried for 20 min. The pellet was then dissolved in 20 μl 1x TE buffer 
(promega), vortexed and incubated at 60oC for 15 min. The samples were then 
centrifuged at 13000 xg for 3 min and the solution containing the bisulphite treated 
DNA transferred to new tubes. 
2.2.14 Pyrosequencing 
Pyrosequencing is a “sequencing by synthesis” method that is dependent on 
detecting pyrophosphate release during nucleotide incorporation (Brakensiek et al. 
2007). Pyrosequencing is only used for sequencing known and short DNA 
sequences, to screen for known variations (mutations or SNPs), or to quantify 
methylation levels in bisulphite treated DNA. In this project, pyrosequencing was 
used to validate the methylation status of DNA from HCT116 cells, in addition to 
methylation positive and negative controls used to test the MS-MLPA technology.  
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2.2.14.1 Pyrosequencing primer design 
Pyrosequencing primers for 2 of the methylation markers included in the MS-MLPA 
kit (NEUROG1 and CRABP1) were designed using the software PyroMark assay 
design v2.0 (Qiagen). The assay type was selected as methylation analysis (CpG). 
DNA sequences of both markers were imported into the software and the target 
regions were selected. PyroMark assay design software provided lists of 3 primers 
for each region; 2 PCR primers (one biotin labelled) and a sequencing primer. The 
genomic areas underneath the primers were then checked for SNPs using the 
diagnostic SNP check online tool provided by NGRL 
(http://ngrl.man.ac.uk/SNPCheck/SNPCheck.html, accessed April, 2010). 
2.2.14.2 Pyrosequencing PCR 
Pyrosequencing PCR was performed using hot start Taq polymerase (Qiagen). 
Standard 25 μl PCR reactions were used; each reaction contained 1-2 μl of the 
bisulphite treated DNA, 2.5 μl of 10x PCR buffer, 1.5 μl MgCl2 (25mM), 0.5 μl dNTPs, 
0.2 μl HotStart Taq and up to 25 μl deionised water. PCR cycling conditions were; 
initial denaturation step at 95ºC for 15 min, followed by 50 cycles of denaturation at 
95ºC for 20 sec, annealing at nºC for 20 sec and extension at 72ºC for 20 sec, and a 
final extension step at 72 ºC for 5 min. The annealing temperatures varied according 
to the TM of the primers (Appendix 1, Table 8). All PCR reactions were carried out 
using GeneAmp® PCR System 9200 thermocycler (Applied Biosystems). Prior to 
pyrosequencing, all the PCR products were analysed using agarose gel 
electrophoresis (Section 2.2.7) 
2.2.14.3 Pyrosequencing reaction 
The PCR products were taken to the Sheffield Children‟s hospital where the 
pyrosequencing procedures were performed. The pyro-CpG software was used to 
create the specific assay files for the reactions included in the run. Capturing master 
mixes were firstly prepared by mixing 30 μl deionised water, 38 μl binding buffer and 
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2 μl sepharose beads for each sample. The capturing mix (70 μl) was then added to 
the corresponding wells and 10 μl of the PCR products were then added to the wells. 
The plate was then sealed and transferred to a shaker and incubated for 10 min at 
1400 RPM. During this step, the biotin labelled PCR products are attached to the 
sepharose beads. During the 10 min incubation step, pyrosequencing master mix 
was prepared by mixing 0.36 μl sequencing primers (10 pmol/ μl) with 11.64 μl of the 
annealing buffer. The pyrosequencing master mix was then transferred to the 
corresponding wells of a pyrosequencing plate and the plate was placed in the 
designated position of the pyrosequencing working station (Figure 2.6). The pyrofilter 
was hydrated in deionised water and checked for blocked filters by observing the 
water levels in the wells after switching on the vacuum pump. This pyrofilter is an 
aspiration device that is used to capture the biotin labelled PCR products attached to 
the sepharose beads. After 10 min shaking, the PCR plate was unsealed and 
transferred to the designated position on the working station (Figure 2.6).  
 
The vacuum pump was switched on and the pyrofilter was used to aspirate all the 
PCR products from the wells. Any biotin labelled PCR products attached to 
sepharose beads will be captured by the filters tips and all the other PCR reagents 
will pass through. The captured biotin labelled PCR products were denatured and 
washed by immersing the pyrofilter tips (containing captured PCR products) into the 
3 successive stations (~5 sec each) of ethanol, denaturation solution and washing 
buffer. At the end of this step, washed single stranded biotin labelled DNA sequences 
are attached to the pyrofilter tips ready to be released onto the pyrosequencing plate. 
The pyrofilter was positioned on top of the pyrosequencing plate, the pump was 
switched off and the pyrofilter was then lowered into the pyrosequencing plate wells. 
A gentle shake was the used to release the biotin labelled single stranded DNA. The 
pyrofilter was transferred to the water station and the sequencing plate was 
incubated at 80oC on a hot plate for a few minutes.  
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While the plate is incubating, the pyrogold reagents were prepared. The required 
amounts of the substrate, enzyme and nucleotides (A, C, G and T) were added into 
the respective tips. While adding the reagents to the tips, air bubbles were strictly 
eliminated. The tips were checked for blockage by gently pressing the sides after 
covering the top of the tips with gloved fingers. A circular tiny drop should appear. If 
not, then the tip is blocked or there is an air bubble. After checking, tips were placed 
in the tip-holder in the correct order (Figure 2.7) and it was transferred to the 
pyrosequencer (PyroMarkTM MD) to test the dispensation. The tip-holder was placed 
in the specific chamber and dispensation was tested using a sealed plate underneath 
the tips. The sealed plate should have 6 drops after dispensation coming from the 
substrate, enzyme and the 4 nucleotides tips. After the dispensation test, the 
pyrosequencer was ready to run and the pyrosequencing plate was transferred into 
position and the reaction started. When the run was completed, the pyrosequencing 
data were analysed using the pyro-CpG software (Qiagen). 
 
The pyrofilter will be used in station 1 to aspirate the solution from the PCR plate wells. Biotin 
labelled PCR products attached to sepharose beads will be captured by the pyrofilter tips. 
The PCR products will then be denatured and washed (stations 2-4). Biotin labelled ssDNA 
will then be released into the pyrosequencing (PSQ) plate in station 5 and then the pyrofilter 
will be washed in water (station 6) (Figure adapted from http://www.pyrosequencing.com/). 
Figure 2.6 The pyrosequencer working station 
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The pyrosequencer tip holder showing the locations of the enzyme (E), substrate (S) and the 
four nucleotides. 
2.2.15 Array Comparative Genome Hybridisation 
Array comparative genome hybridisation (aCGH) is an array-based technology that is 
used to compare genomic copy number variation between two DNA samples at high 
resolution. It is widely used in cancer genetics to detect copy number changes 
acquired by tumour cells by comparing normal and tumour DNA (Pinkel and 
Albertson 2005). Figure 2.8 summarises the aCGH technology. Briefly, tumour DNA 
is usually isolated from the cancer cells and control DNA is ideally isolated from 
normal cells from the same patient if available (e.g. peripheral blood). If not available, 
commercial sex-matched pooled genomic DNA can be used. Equal amounts of the 
tumour and normal DNA are first labelled with different fluorescent dyes, mixed and 
then hybridised to an array slide. The microarray slides contain oligonucleotide 
probes referring to human genomic sequences. After hybridisation and washing, the 
array slides are then scanned and the fluorescent intensities are measured from 
each probe. The scanned images are then interpreted and quantified using feature 
extraction (FE) software. The output from the FE software is then analysed using 
copy number analysis software where the ratios of the different dyes will be 
interpreted for each genomic region. All the aCGH steps were carried out according 
to Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis version 6.0 
(Agilent Technologies UK Ltd., Wokingham). 
Figure 2.7 The pyrosequencer tip holder 
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Figure 2.8 Schematic representation of the aCGH technology 
Equal amounts of normal and tumour DNA are differentially labelled and hybridised to an 
array slide. After washing, scanning and feature extraction, the log2ratios of the normal and 
the tumour DNA signals are calculated. The dots underneath the log2ratio scale represent 
probes. Positive and negative log2ratios reflect amplifications (red probes) and deletions 
(green probes) respectively. Probes coloured in black represent stable genomic regions 
detected by log2ratios around zero. 
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2.2.15.1 Direct method 
The direct method of aCGH was used for samples for which a minimum amount of 
0.5 μg DNA was available. In this method, DNA samples were fragmented by 
restriction digestion using AluI and RsaI. The DNA samples (0.5 μg in 21 μl) were 
mixed with 5.8 μl digestion master mix which consisted of; 2 μl nuclease free water, 
2.6 μl 10x buffer C (supplied with RsaI), 0.2 μl acetylated bovine serum albumin 
(BSA) (10μg/ μl), 0.5 μl AluI (10U/ μl) and 0.5 μl RsaI (10 U/μl). The mix was then 
incubated at 37oC for 2 hr followed by 20 min at 65oC. In order to evaluate the 
completeness of digestion, the samples were then analysed on 1.5% agarose gel.  
2.2.15.2 Whole genome amplification  
When less than 0.5 μg of DNA was available, WGA was used to produce a 
representative amplification of genomic DNA (Brueck et al. 2007). In this research 
project, WGA was performed using a commercially available kit GenomePlex (Sigma 
Aldrich). The first step was DNA fragmentation; 10 μl of the DNA samples (50 ng) 
were mixed with 1 μl 10x fragmentation buffer and incubated at 95oC for exactly 4 
min. Then, the samples were immediately cooled on ice. The second step was library 
preparation; 2 μl of 1x library preparation buffer and 1 μl of library stabilisation 
solution were added to the fragmented DNA samples and incubated at 95oC for 2 
min. The samples were then cooled on ice and centrifuged briefly. Next, 1 μl of the 
library preparation enzyme was added to each sample and mixed thoroughly by 
pipetting. The samples were centrifuged briefly and incubated at 16oC for 20 min, 
24oC for 20 min, 37oC for 20 min and 75oC for 5 min in GeneAmp® PCR System 
9200 thermocycler (Applied Biosystems). The last step of the WGA protocol was 
DNA amplification; 60 μl of amplification master mix was prepared for each sample. 
Each reaction contained 7.5 μl 10x amplification master mix, 47.5 μl nuclease free 
water and 5 μl WGA DNA polymerase. The amplification master mix was then added 
to the 15 μl from the library preparation step, mixed thoroughly and amplified with the 
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following cycling conditions; initial denaturation at 95ºC for 3 min, followed by 14 
cycles of denaturation at 94ºC for 15 sec, annealing/extension at 65ºC for 5 min.  
2.2.15.2.1 Purification of WGA PCR products 
Following WGA, the PCR products were purified using the commercially available kit 
GenElute PCR clean-up (Sigma Aldrich); the 75 μl WGA products were mixed with 
375 μl binding solution and transferred to the miniprep binding column in a collection 
tube. The miniprep columns with the samples were then centrifuged at 13000 xg for 1 
min. The eluate was discarded, 0.5 ml of the wash buffer was added to the miniprep 
columns (supplied in the kit) and they were centrifuged at 13000 xg for 1 min. The 
eluate was discarded again and the miniprep columns were centrifuged at 13000 xg 
for 2 min, to remove any residual wash buffer. Next, the miniprep columns were 
transferred to a fresh collection tube and 50 μl of elution buffer was added to the 
centre of each column. The columns were incubated at room temperature for 1 min 
and finally centrifuged at 13000 xg for 1 min to recover the purified WGA products in 
the eluate. The purified products were quantified using Nanodrop as described in 
Section 2.2.2. The WGA yield (μg) was calculated by multiplying DNA concentration 
(ng/ μl) by the sample volume (50 μl) and dividing by 1000. 
2.2.15.3 Fluorescent labelling of DNA 
After the restriction digestion or WGA, the normal and tumour DNA samples were 
fluorescently labelled with cyanine 3-dUTP and cyanine 5-dUTP respectively; Firstly, 
DNA samples were mixed with 5 ng of random primers and incubated at 95oC for 3 
min followed by 5 min on ice. Subsequently, the samples were centrifuged at 6000 xg 
for 1 min and the labelling master mix was prepared; 2.0 μl nuclease free water (only 
for restriction digestion products), 10 μl 5x buffer, 5.0 μl 10x dNTP, 3.0 μl cyanine 3-
dUTP or cyanine 5-dUTP and 1.0 μl exo-klenow fragment. The labelling master mix 
was then added to 19 μl restriction digest product from Section 2.2.15.1 or 21 μl 
cleaned WGA product from Section 2.2.15.2.1 and then mixed thoroughly by 
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pipetting. The cyanine 3-dUTP mix was used for the normal DNA and the cyanine 5-
dUTP was used for the tumour DNA. The samples were then incubated at 37oC for 2 
hr, followed by 10 min at 65oC for 10 min. 
2.2.15.4 Clean-up of labelled genomic DNA 
The labelled genomic DNA was purified using microcon YM-30 filters (Fisher 
Scientific UK Ltd.). Labelled DNA samples were mixed with 430 μl of 1x TE, pH 8.0 
(Promega), transferred to YM-30 filters in a 1.5 ml microfuge tube and centrifuged at 
8000 xg for 10 min. Then, the flow-through was discarded, 480 μl of 1x TE was 
added, and the tubes were centrifuged again at 8000 xg for 10 min. Next, the YM-30 
filters were inverted into a fresh 1.5 ml microfuge tube and centrifuged at 8000 xg to 
collect the purified labelled sample. The volume of the purified eluate was measured 
and recorded. If the volume of the purified labelled DNA was >21 μl, it was returned 
to its filter, centrifuged at 8000 xg for 1 min and the flow through was discarded. Then 
the filters were re-inverted and the same steps were repeated until sample volumes 
were equal to or less than 21 μl. If the volume was <21 μl, 1x TE buffer (pH 8.0) was 
used to bring the volume up to 21 μl.  
2.2.15.5 Labelling yield and specific activity determination 
The labelling yield and the specific activity were determined using the Nanodrop. 
From the main menu of the ND-1000 software, the microarray measurement module 
was selected and the sample type was changed to DNA-50 (double-stranded DNA). 
1x TE buffer (pH 8.0) was used to set the blank reading, and then 1.5 μl of purified 
labelled DNA was used for quantitation. The absorbance was recorded at A260nm 
(DNA), A550nm (cyanine 3) and A650nm (cyanine 5). The specific activity was calculated 
with the following equation: 
Specific activity (pmol dye/ μg DNA) = pmol per  μl dye / μg per  μl DNA  
Next, equal volumes of the cyanine-3 labelled “normal” DNA was mixed with the 
cyanine-5 labelled “tumour” DNA. 
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2.2.15.6 Microarray hybridisation 
Prior to hybridisation, the combined labelled DNA samples from the previous section 
were mixed with 50 μl cot-1 DNA (1.0 mg/ml) (Invitrogen Ltd., Renfrew) (to prevent 
the hybridisation of repetitive DNA sequences), 52 μl Agilent 10x blocking agent and 
260 μl of Agilent Hi-RPM buffer, then incubated at 95oC for 3 min and at 37oC for 30 
min. Then, the samples were centrifuged at 6000 xg for 1 min prior to hybridisation 
on the microarray slides. A clean gasket slide with 4 chambers was placed in an 
Agilent SureHyb chamber base with the gasket label facing up. Then, 100 μl of 
samples prepared as above were loaded into each chamber in a “drag and dispense” 
manner. Following that, the microarray (4x44K or 4x180K) was placed with the 
Agilent labelled barcode side (active side) facing down. The microarray slides were 
handled carefully without touching the edges. The SureHyb chamber cover was then 
placed onto the array-gasket sandwiched slides and they were clamped tightly. The 
assembled chamber was then rotated vertically to spread the samples, wet the 
microarray and to check the mobility of bubbles. Next, the assembled chamber was 
placed in the rotator rack of the hybridisation oven set at a temperature of 65oC and 
rotation speed of 20 RPM. The slides were left to hybridise for 24 hr. 
2.2.15.7 Microarray washing 
Wash procedure A of the Agilent‟s protocol version 6 was used. Three separate 250 
ml slide staining dishes were used. The first 2 slide staining dishes were filled with 
wash buffer 1 at room temperature and the 3rd was filled with wash buffer 2 pre-
warmed overnight at 37oC. Slide staining dish number 2 was placed on a magnetic 
stir plate and a slide rack and a magnetic stir bar were placed inside it. Slide staining 
dish number 3 was left in a water bath set at 37oC. After the washing dishes were in 
place, the hybridisation chamber was removed from the oven and the bubbles inside 
were checked to confirm that they were still rotating freely in the array-gasket 
sandwich. Next, the clamp of the hybridisation chamber and the chamber cover were 
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removed. The array-gasket sandwich was then taken out and quickly submerged in 
wash buffer 1 (in the first slide staining dish). The sandwich was opened from the 
barcode end using clean plastic forceps. The array slide was then placed in the slide 
rack in slide staining dish number 2 for 5 min. Afterwards, slide staining dish number 
3 was taken out of the water bath and placed on a heated magnetic stir plate with a 
magnetic stir bar inside. Next, the slide rack was transferred to dish number 3 for 1 
min. The slide rack was then removed slowly and the array slide was scanned 
immediately.  
2.2.15.8 Microarray scanning 
Microarray scanning was performed using an Agilent C scanner and scanner control 
software v8.3 (Agilent). The washed slides were placed in slide holders with the 
Agilent barcode facing up. The assembled slide holders were then placed into the 
scanner carousel. For the 4x180K arrays, Agilent G3_CGH was selected with 3 μm 
resolution while for the 4x44K arrays, Agilent HD_CGH profile was selected with 5 
μm resolution. After checking the scanner status, the slides slots were selected and 
scanning was performed. 
2.2.15.9 Data extraction using feature extraction software 
The feature extraction software version 10.5.1.1 (Agilent) was used to extract the 
microarray TIFF images. The software was launched and an FE project was opened. 
Then using the “add new extraction set” icon, the .tif files of the scanned arrays were 
added. The grid template and the CGH FE protocol were automatically assigned 
depending on the scanned microarray platform. The FE project was then saved and 
the extraction was performed.  
2.2.15.10 Quality control 
In order to ensure the integrity and quality of the aCGH results, 11 QC metrics were 
closely monitored for each array (Figure 2.9). These QC metrics check the placement 
of the array GRID, the noise of the experiment determined by the Derivative Log 
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Ratio Spread (DLRS), the signal intensity and the signal background (green and red), 
the signal reproducibility of non-control replicate probes and the presence of any 
outliers. Each metric was scored as excellent, good or evaluate. “Evaluate” metrics 
are usually of low quality. Each array will have a final QC status of either pass, 
marginal or fail. Array QC metrics were closely monitored with special attention to 
DLRS values as they greatly affect reliable analysis.  
 
Figure 2.9 An example of aCGH QC report 
 75 
2.2.15.11 Data analysis 
Genomic workbench software version 5.0.14 (Agilent) was used for the main analysis 
of the aCGH microarray results. The CGH module was selected and a new 
experiment was created. Then, the results files, exported from the feature extraction 
software, were imported and the analysis performed.  
 
Several algorithms were available in the genomic workbench software v5.0 to 
perform the analysis. For defining and displaying the aberrations, 5 algorithms were 
available; circular binary segmentation (CBS), hidden Markov model (HMM), z-score 
based method, aberration detection method 1 (ADM1) and quality weighted interval 
score algorithm, also called the aberration detection method 2 (ADM2). In support for 
the aberration detection algorithms, data centring and correction algorithms were 
also available. These algorithms were used to increase the stringency of the 
aberration detection algorithms. Moreover, replicate probes and feature and 
aberration filters were also available to ensure the validity of the calls. Finally, 2 
common aberration analysis algorithms were provided; the t-test based method and 
the modified context corrected analysis algorithm. The following sections aim to 
briefly describe the concepts, limitations and advantages of the available algorithms. 
Most of the information presented is based on the CGH interactive analysis user 
guide for the Agilent genomic workbench software (v5.0).   
2.2.15.11.1 Aberration detection algorithms 
CBS and HMM are used for genome segmentation and detection of aberrant probes 
respectively. CBS identifies genomic points where the mean log2ratio scores change 
between intervals. On the other hand, aberrant probes identified by HMM can be 
collectively used to define aberrant regions. CBS and HMM are not user friendly and 
their outputs require a lot of processing and input from the operator to identify the 
aberrant regions. The latter might cause subjective calls, thus, they were not used in 
this project. The z-score based method detects aberrations by searching for genomic 
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regions enriched with probes that have log2ratios significantly different from a 
calculated baseline. The algorithm does so using a user defined sliding window of a 
fixed size. The disadvantage of the z-score algorithm is the fixed size of the sliding 
window which can limit the ability of the algorithm to identify some aberrations.  
 
ADM1 searches for any genomic regions and intervals that consistently have 
log2ratio values that are statistically significantly different from the zero log2ratio. The 
level of significance is determined by a user-defined statistical threshold which is 
recommended by Agilent to be set to a value of 6.0 for reliable results. ADM1 also 
determines the optimal size and the breakpoints of the identified aberrations. ADM2 
uses the same approach as ADM1, however, it also incorporates the quality 
information for the log2ratio values. Therefore, ADM2 deals better with lower quality 
or noisy data and is more stringent in identifying aberrations. ADM2 was the 
aberration detection method of choice in this project and its statistical threshold was 
set to 6.0 as recommended by Agilent. Another advantage of choosing ADM2 (or 
ADM1) is that the common aberration analysis algorithms (t-test based method and 
the modified context corrected analysis method) cannot deal with the outputs from 
the other aberration detection algorithms (CBS, HMM and z-score). 
2.2.15.11.2 Data centring and correcting algorithms 
Data centring and correcting algorithms were included in the analysis to increase the 
confidence in the called aberrations. 
2.2.15.11.2.1 Centralisation 
In general, the aberration detection algorithms will assume that the log2ratio values 
are centred around zero. That is, that the mean fluorescence values for the reference 
and the sample DNA are the same. This is often true for samples with stable or 
relatively stable genomes. However, for highly aberrant and unstable genomes (such 
as tumour genomes), the measured centre might deviate from the zero log2ratio and 
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the above assumption can lead to many aberrations being falsely called. 
Centralisation is an additional normalisation algorithm used to re-centre the log2ratio 
values and ensure that the zero-point value actually reflects the most common ploidy 
status of the samples. The algorithm will find a constant value for each sample based 
on its genomic status to re-normalise the log2ratios. The default centralisation 
parameters (bin size= 10 and threshold 6.0) were used as recommended by Agilent. 
The use of this centralisation algorithm was shown to increase the accuracy of the 
aberration detection algorithms (Chen et al. 2008). 
2.2.15.11.2.2 Fuzzy zero correction algorithm 
ADM1 and 2 can sometimes call large aberrations with a very low log2ratio average. 
These aberrations might be of genuinely low amplitude because of tumour 
heterogeneity. However, they could also be false aberrations caused by noise, and 
only reaching statistical significance because of the large number of probes in the 
area. This is caused by the limited ability of the ADM (1&2) algorithms to estimate 
errors over long genomic intervals. When used, the Fuzzy zero correction algorithm 
will apply a global error model to all of the aberrations called by the ADM algorithms. 
The global error model will assume two sources of noise; a local probe to probe 
noise where the error is not correlated between different probes within the same 
interval and a global noise where the error is correlated between the different probes. 
This meticulous global error estimation approach will avoid erroneous calling of large 
intervals with a high level of noise. 
2.2.15.11.3 Feature filter, aberration filter and replicate probes 
Feature filters were used to exclude non-uniform and saturated signals from the 
green and red fluorescence channels based on information from the feature 
extraction software. The default feature filter settings were used as recommended by 
Agilent. Additionally, an aberration filter was used which requires a minimum of 3 
probes for any aberration to be called. This will remove any aberrations called based 
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on deviation of 2 probes or less from the normalised zero log2ratio. Thus, the 
remaining calls will be of higher confidence. Finally, replicate probes were included in 
all of the Agilent arrays. The values of the intra-array replicate probes were combined 
during analysis to increase the statistical power for aberration detection.  
2.2.15.11.4 Common aberration analysis 
For common aberration analysis, context corrected common aberration (COCA) 
algorithm was chosen over the t-test based method. The t-test based method looks 
for commonly aberrant regions regardless of the amplification/deletion nature of the 
aberration. On the other hand, the COCA algorithm considers amplifications and 
deletions separately. It uses the aberrant regions identified by ADM2 (or ADM1) to 
construct a set of candidate intervals. Then, it will generate a statistical score 
reflecting the significance of each aberration in each sample. This significance score 
will be corrected based on the aberration status of each specific sample. This 
correction can be made in a genomic context for all the aberrations or chromosomal 
context. Because of the nature of CRC DNA in which some of the chromosomes are 
highly aberrant and others are relatively stable, a chromosomal context approach 
was applied for correction.  
 
The COCA algorithm will then test the hypothesis that each candidate aberration is 
common between any number of samples and it will generate a combined statistical 
score for each candidate. Candidate intervals will be reported as common aberrant 
regions if their combined statistical score (COCA score) was more than the 
recommended t-test p-value threshold of 0.05 and the overlap threshold of 0.9. The 
latter threshold means that for any common regions with > 90% overlap, the COCA 
algorithm will only report the one with higher statistical significance. COCA was 
previously shown to accurately identify common aberrant regions in cancer samples 
(Ben-Dor et al. 2007). 
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2.2.16 Cell lines culture 
Human cell lines were cultured in DMEM medium (Lonza, Belgium) supplemented 
with 10% foetal calf serum (FCS) and 1% pencillin-streptomycin in a 37oC incubator 
with 5% CO2. Standard sterile cell culture techniques were used to maintain the cell 
lines, which were all performed in a microbiological grade 2 safety cabinet. 
2.2.17 Western blotting 
Western blotting is a technique that can is used to detect the presence and the 
amount of specific proteins in a cell lysate. Briefly, proteins are separated according 
to size using Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE), transferred to a nitrocellulose membrane and then detected using a specific 
antibody. Western blotting was used in this project to specifically assess the NFKBIA 
and the phosphorylated RELA protein levels in cellular extracts of various cell lines 
(Section 2.1.4). 
2.2.17.1 Protein extraction 
Confluent tissue culture plates were always used for protein extraction. The DMEM 
medium was removed and the cells were washed twice with PBS. Trypsin:versene 
(1:1) mixture (Lonza) was then added to the cells and the plates were incubated for  
few minutes (time varied according to cell lines) at 37ºC. When the cells were 
completely detached, 10 ml of DMEM medium (without antibiotics) were added to the 
plate. After pipetting up and down, the cells/medium mixture was transferred to 10 ml 
sterile tubes and centrifuged at 1300 RPM for 3 min. The cell pellet was then washed 
twice with 1x PBS. After the second wash, the cell pellet was resuspended in 1 ml 1x 
PBS and transferred to 1.5 ml eppendorf tube and centrifuged for at 2100 RPM for 3 
min at 4ºC. Meanwhile, 1 ml of 1x cell lysis buffer was prepared by mixing 100 μl of 
10x cell lysis buffer (Cell Signalling), 100 μl protease inhibitor (Roche), 100 μl 
phosphatase inhibitor (Roche), 10 μl serine protease inhibitor, termed 
phenylmethanesulfonylfluoride (100mM PMSF) and 690 μl distilled water. The PBS 
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was then fully removed and ~300 μl of the freshly prepared ice-cold 1x cell lysis 
buffer were added to the tubes (the volume varied according to pellet size). After 
thoroughly pipetting the pellet up and down, the extracts were passed through a fine-
gauge needle ~30 times in order to release nuclear proteins. The tubes were 
incubated on ice for 30 min and then centrifuged at 14500 RPM for 5 min at 4ºC. The 
supernatant was then transferred to a new 1.5 ml tube and stored at -80ºC. 
2.2.17.2 Protein quantification 
Aliquots of the extracted protein samples were slowly defrosted on ice and then 
diluted in distilled water. Serial dilutions of 1 mg/ml BSA solution were also prepared 
in distilled water to be used as standards for protein quantification. The serial 
dilutions of both the samples and the BSA were then quantified using Bradford 
reagent (Bio-Rad Laboratories Ltd.) according to the manufacturer‟s instructions. 
2.2.17.3 Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis 
SDS denatures proteins and coats them in negative charges which will ensure their 
separation largely according to size during electrophoresis. SDS polyacrylamide gels 
were used to separate the protein extracts in preparation for Western blotting. 
Resolving and stacking gels were freshly prepared prior to each experiment using the 
reagents listed in Table 2.7 and Table 2.8 respectively. Tetramethylethylenediamine 
(TEMED) and 10% ammonium persulphate (APS) were only added when the gels 
were ready to be poured. The Bio-Rad mini protein gel apparatus was assembled 
according to the manufacturer‟s instructions (Bio-Rad Laboratories Ltd.) and 7 ml of 
the resolving gel was poured between the gel electrophoresis plates. Next, 200 μl of 
distilled water was carefully poured on top to eliminate air bubbles. Gels were left to 
set for ~15 min. After removing the water completely, the stacking gel was poured to 
fill the space between the plates and the well comb was inserted. The gel was ready 
to use after ~15 min. While the gel was polymerising, 20 μg of the protein samples 
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were prepared by mixing with an equal volume of 2x Leammli buffer (5% v/v ß-
mercaptoethanol) (Sigma-Aldrich) and boiling for ~3 min. 
 
The electrophoresis plates were placed in the mini protein gel apparatus and 1x SDS 
buffer was poured into the central and the outer compartments. The well combs were 
then removed and 5 μl of Precision Plus ProteinTM Standard (Bio-Rad Laboratories 
Ltd.) was added into the first well. The protein samples were then added into the 
adjacent wells and the gels were electrophoresed for ~2 hr at 100 V. 
  
 
Table 2.7 Reagents and quantities for SDS-PAGE resolving gels 
 
 Quantity (ml) 
Resolving gel 10% 12% 
Distilled water 5.30 4.00 
30% polyacrylamide 6.70 8.00 
10% SDS 0.20 0.20 
1 M Tris-Cl (pH 8.8) 7.50 7.50 
10% APS* 0.25 0.25 
TEMED 0.025 0.025 
 
 *10% APS were freshly prepared by dissolving 0.1g ammonium persulphate in 1ml distilled water.  
Table 2.8 Reagents and quantities for SDS-PAGE stacking gel 
 
 
 
 
 
 
 
 
 *10% APS were freshly prepared by dissolving 0.1 g ammonium persulphate in 1ml distilled water.  
 
Stacking gel 5% Quantity (ml) 
Distilled water 6.80 
30% polyacrylamide 1.70 
1 M Tris-Cl (pH 6.8) 1.25 
10% SDS 0.10 
10% APS* 0.125 
TEMED 0.005 
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2.2.17.4 Protein transfer 
Once electrophoresis was complete, the gel was removed from the mini protein gel 
apparatus and the stacking gel was detached. The resolving gel was then incubated 
in transfer buffer for 30 min with shaking. The protein transfer apparatus (Bio-Rad 
Laboratories Ltd.) was assembled according to the manufacturer‟s instructions. 
Whatman Nitrocellulose membrane (GE Healthcare UK Ltd., Little Chalfont) was cut 
according to the size of the gel and incubated in the transfer buffer for ~15 min. 
Sponges and 3 mm thick blotting filter papers (GE Healthcare UK Ltd.) were also 
prepared and briefly soaked in transfer buffer. The protein transfer sandwich was 
prepared by placing a wet sponge onto the cathode of the transfer apparatus, 
followed by 3 mm blotting filter paper, the gel, the nitrocellulose membrane, another 3 
mm blotting paper, the second sponge and the anode (Figure 2.10). The protein 
sandwich was placed into the transfer apparatus and it was filled with transfer buffer. 
Transfer was carried out at 200 mA for 90 min.  
 
Figure 2.10 Western-blot protein transfer sandwich 
 
The transfer apparatus was disassembled and the membrane was stained with 
Ponceau S solution (Sigma-Aldrich) to check the efficiency of the transfer. The 
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membrane was washed with 1x TBS-T and placed in blocking buffer (5% dried milk 
in 1% TBS-T) for 2 hr at room temperature to prevent non-specific binding of the 
antibody. During the blocking step, fresh dilutions of the primary mouse anti-human 
antibody (NFKBIA or p-RELA) (Cell signalling) were prepared according to the 
manufacturer‟s instructions (1:1000 in the blocking buffer). The blocking buffer was 
removed and the membrane was incubated with 10 ml of the freshly diluted primary 
antibody overnight at 4ºC. 
Next day, the membrane was washed twice for 10 min with 1x TBS-T on a shaker. 
Following that, mouse secondary antibody (Sigma-Aldrich) was added after dilution in 
10 ml blocking buffer according to the manufacturer‟s recommended concentration 
(1:1000). The membrane was incubated for 1 hr at room temperature on shaker. Two 
10 min 1X TBS-T washes were then performed and the membrane was transferred 
onto a dry and clean plastic plate. Enhanced Chemiluminescent (ECL) reagent (GE 
Healthcare UK Ltd.) was prepared by mixing an equal volume of reagent 1 and 2 and 
then added slowly to cover the membrane. The covered membrane was incubated 
for 2 min at room temperature and the ECL reagent was then poured off. The 
membrane was wrapped in a plastic film and analysed using the luminescent image 
analyser LAS-3000 (Fuji-film, Bedfordshire) according to manufacturer‟s 
recommendations. The membranes were then washed 3 times for 10 min with 1x 
TBS-T on a shaker and the incubated in blocking buffer (5% dried milk in 1% TBS-T) 
for 1 hr at room temperature and then stained with the reference protein anti-α-
tubulin antibody (Sigma-Aldrich) using the same procedure described above. 
2.2.18 siRNA transfection and NFKBIA knockdown 
Small interfering RNA (siRNA) silencing is an effective mechanism that has been 
demonstrated to downregulate gene expression, and thus protein levels, in human 
cells (Lares et al. 2010). siRNA technology was used to temporarily knockdown 
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NFKBIA proteins by transfecting cells with a pool of NFKBIA-siRNA (Fisher Scientific 
UK Ltd.,) designed to complement NFKBIA messenger RNA (mRNA) (Table 2.9). 
 
Table 2.9 NFKBIA-siRNA target sequences 
NFKBIA-siRNA on target plus smart pool sequences 
GUGCUGAUGUCAAUGCUCA 
AGGACGAGCUGCCCUAUGA 
GCUGAUGUCAACAGAGUUA 
AGUCAGAGUUCACGGAGUU 
 
Transfection of the NFKBIA-siRNA into the target cells was performed using the 
transfection reagent Lipofectamine 2000 according to the manufacturer‟s instructions 
(Invitrogen Ltd.). On the day before siRNA transfection, 2-2.5x105 target cells were 
added to a 6 well cell culture plate containing  2 ml DMEM medium (with 10% FCS 
but without antibiotics) and incubated overnight at 37oC with 5% CO2. The next day, 
NFKBIA-siRNA, “negative” siRNA (designed not to complement any known human 
m-RNA sequence) (Eurogentec S.A., Southampton) and Lipofectamine 2000 were 
prepared. For each sample, 10 μl of 20 μM NFKBIA-siRNA (or negative siRNA) stock 
was mixed with 240 μl DMEM medium (without 10% FCS or antibiotics). Also, for 
each sample, 5 μl Lipofectamine 2000 was mixed with 245 μl DMEM medium 
(without 10% FCS or antibiotics). After 5 min incubation at room temperature, the 250 
μl Lipofectamine 2000 in DMEM was gently mixed with the 250 μl NFKBIA-siRNA in 
DMEM (or “negative” siRNA). These mixtures were then incubated for 20 min at 
room temperature. Meanwhile, the plated cells were washed with 1x PBS and then 
1.5 ml DMEM medium (with 10% FCS but without antibiotics) was added to each 
well. The Lipofectamine 2000/siRNA (NFKBIA or “negative”) mix was added to the 
cells which were then incubated at 37oC with 5% CO2. siRNA knockdown efficiency 
was determined by Western blotting (Section 2.2.17).  
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2.2.19 MTT cell proliferation assay 
In order to investigate the effect of NFKBIA knockdown on CRC cell lines growth, the 
number of viable transfected cells was estimated using the 3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. The MTT assay 
reflects the number of viable cells based on the activity of dehydrogenase enzymes 
(Mosmann 1983). The MTT assay was performed according to the manufacturer‟s 
instructions (ATCC). Briefly, 100 μl of 1x104 transfected cells were plated in 96 well 
plates and incubated (24-72 hr) at 37oC with 5% CO2. Next, 10 μl of the MTT reagent 
was added to the wells and incubated for 4 hr at 37oC with 5% CO2. Then, 100 μl of 
the solubilisation reagent (10% SDS, 10mM HCl) was added and incubated overnight 
at 37oC with 5% CO2. Absorbance was then measured at 570 nm using the MTT 
module on the Multiskan FC plate spectrophotometer (Thermo Scientific). The MTT 
test was performed on 3 consecutive days following transfection of cells with 
NFKBIA-siRNA and the “negative” siRNA. 
2.2.20 Colony formation experiment 
Colony forming activity is considered a representation of cell transformation which 
reflects the malignancy of cancer cells in culture (Bredel et al. 2010). Colony 
formation test was performed to examine the effect of the NFKBIA knockdown on the 
malignant behaviour of the transfected CRC cell lines. Briefly, 100 μl of 1x104 
transfected cells were mixed with 8 ml DMEM medium (with 10% FCS but without 
antibiotics), plated in cell culture petri dishes and incubated at 37oC with 5% CO2. 
Colonies were observed up to 2 weeks and counted following staining with 0.4% 
methylene blue. The test was performed on cells transfected with NFKBIA-siRNA 
and the “negative” siRNA. 
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2.2.21 Statistical tests 
2.2.21.1 Chi-square association test 
The chi-square test ( 2) was used to compare genotype frequencies for the 6bp 
ins/del polymorphism rs3834129 (and CASP8 CNV23598) between CRC cases and 
controls. The different genotypes (Ins/Ins, Ins/Del and Del/Del) and phenotypes (such 
as cases and controls) were tabulated in a 2x3 contingency table (Table 2.10). The 
equation                             was used to calculate the 2 statistic, where O is observed 
genotype frequency and E is expected genotype frequency. Expected frequencies 
are calculated using the contingency table. For example, the expected frequency of 
cases to have an Ins/Ins genotype is calculated by: (Tcase x Tins/ins)/T (Table 2.10). To 
determine whether the 2 is significant or not, the degrees of freedom (df) of the test 
are calculated using the equation: df = (number of columns – 1) x (number of rows – 
1). The df for 2x3 contingency tables thus equals 2. The chi-square distribution table 
can then be used to obtain the p-value for the 2 statistic. P-values <0.05 are 
considered to represent a significant result. The “CHIDIST” function in Microsoft 
Excel spreadsheet template was used to automatically determine the p-values for the 
various contingency tables.  
Table 2.10 A 2x3 contingency table 
 Genotype  
Phenotype Ins/Ins Ins/Del Del/Del Total 
Case x y z Tcase 
Control a b c Tcontrol 
Total Tins/ins Tins/del Tdel/del T 
                           
2.2.21.2 Hardy Weinberg Equilibrium  
In conditions of HWE, allele and genotype frequencies remain constant in the 
population across generations. This is an indication of random mating in large 
populations in the absence of selective pressure and mutations. Under conditions of 
HWE, the genotype frequencies are given by: 
E
EO
x
2
2
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p2+2pq+q2=1 
Where p and q stand for the frequencies of the common and the rare alleles 
respectively. Therefore, the expected genotype frequencies of the population in HWE 
were calculated as follows:  
E for the homozygous common= p2 x n 
   E for the homozygous rare= q2 x n 
   E for the heterozygoutes = 2pq x n 
Where “n” is the total number of genotyped samples in each assay. 
 
Testing for HWE is an essential quality control step in association studies. Departure 
from HWE might indicate low assay quality and genotyping errors. It might also 
indicate problems with the genotyped cohort such as small sample size, the 
presence of selection or population stratification. The chi-squared test with df=1 was 
used to check for any deviations from HWE. If the P-value was <0.05, the population 
genotypes were considered to be inconsistent with HWE. 
2.2.21.3 Odds ratios 
The odds ratio (OR) is an estimate of relative risk of CRC in a subset of patients with 
a specific genotype (e.g. Ins/Del) compared to another subset with a different 
genotype (e.g. Ins/Ins). The OR was calculated by dividing the odds in one group 
(e.g. Ins/Del) by the odds in the other group (Ins/Ins). An additive model was also 
used to calculate the OR based on the assumption that the risk of CRC increases 
additively with each copy of the rare allele (Del). OR and confidence intervals applied 
in this thesis were estimated by Dr. Angela Cox using Stata (v9). 
2.2.21.4 Fisher’s exact test 
Fisher‟s exact test (2x2 contingency table) was used to examine the significance of 
association between various genetic and/or clinical variables. The test was 
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performed using an online Fisher‟s exact test calculator available on Microsoft 
research website (http://research.microsoft.com, accessed May – September, 2011) 
2.2.21.5 Mann Whitney U test 
Mann Whitney U test is applied to assess if two independent sets of observations 
have statistically similar or different values. The test was used in this project to 
compare the number of CNA between CIMP-L/N and CIMP-H samples. The Mann 
Whitney U test was calculated using an online Microsoft Excel spreadsheet template 
(www.holah.karoo.net/Mann-Whitney%20U-test.xls, accessed May 2011). 
2.2.21.6 Spearman’s correlation test 
Spearman‟s correlation test was used to examine the strength of relationship 
between two different genetic defects (variables). The Spearman correlation 
coefficient (rs) was calculated using the CORREL function available in Microsoft 
Excel spreadsheet. A negative correlation coefficient value indicates an inverse 
relationship between the two tested variables.  
2.2.22 Splice site prediction 
In order to predict the physiological relevance of the novel intronic sequence 
alterations identified in this study, online splice-site prediction tools were used to 
predict any potential effects of the sequence alterations on splicing. Five online tools 
were applied on each of the sequence alterations. Several online tools were used to 
overcome shortcomings and weaknesses in any of the tools, as recommended by 
Houdayer et al. (2008). The splice site prediction tools web addresses are listed 
below (the default parameters were maintained unless specified): 
1) Splice site prediction by neural network: 
http://fruitfly.org:9005/seq_tools/splice.html. 
2) Exonic Splicing Enhancer (ESE) Finder : 
http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi.  
Parameters used: 
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a) Matrix Library: Splice sites 
b) Matrix: 5‟ splice sites donor of human 
3) MaxEntScan: scorsplice (MES): 
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html.  
All the scoring models available on the tool were chosen. 
4) Relative Enhancer and Silencer Classification by Unanimous Enrichment 
(RESCUE-ESE): http://genes.mit.edu/burgelab/rescue-ese/. 
5) NetGene2 splice prediction: http://www.cbs.dtu.dk/services/NetGene2/ 
(All the above web tools were accessed July, 2011). 
2.2.23 Sequence nomenclature 
Throughout this study, the Human Genome Variation Society (HGVS) 
recommendations were followed for sequence nomenclature (http://www.hgvs.org/, 
accessed May, 2009). The coding DNA sequences were numbered from the 1st 
nucleotide of the start codon as the +1 position and they were prefixed with a “c”. The 
amino acid (aa) sequences were numbered from the 1st amino acid as the +1 
position, standard three letter amino acid codes were used and each aa sequence 
was prefixed with a “p”. 
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3. Caspase 8 Inherited Variants and CRC Predisposition 
3.1 Introduction 
As described in Section 1.3, CRC is a major cause of cancer related deaths 
worldwide (Parkin et al. 2005, Jemal et al. 2011). The prognosis of CRC cases is 
largely dependent on the presenting cancer stage at the time of diagnosis. More than 
90% of the patients diagnosed in Duke‟s stage A survive for ~5 years compared to 
only ~5% when diagnosed in Duke‟s stage D (de la Chapelle 2004). Therefore, early 
diagnosis of CRC can play an important role in increasing the survival of patients.  
 
CRC is divided into sporadic and hereditary cases with the latter accounting for 
~25% of the incidence (Lichtenstein et al. 2000, de la Chapelle 2004, Broderick et al. 
2007). Environmental factors, such as diet and physical activity, have a major impact 
on CRC risk (Jong et al. 2002), however, genetics also play a key role in CRC 
predisposition with an estimated contribution of ~35%, placing it 2nd among common 
cancers in terms of heritability (Lichtenstein et al. 2000). Nonetheless, highly 
penetrant and well characterised mutations are rare and account for ~5% of all CRC 
cases and ~20% of the hereditary CRC cases (Jong et al. 2002, de la Chapelle 
2004). The majority of the hereditary cases and a large proportion of the sporadic 
CRC cases are probably caused by more common, but less penetrant, genetic 
variants and polymorphisms (Broderick et al. 2007). These are generally difficult to 
identify, since linkage studies do not have enough power to detect low penetrance 
variants. Nevertheless, through the use of SNP-based genetic association studies 
(based on both, candidate genes and genome wide) with large numbers of CRC 
cases and controls, some of these less penetrant genetic variants have already been 
identified (Jong et al. 2002, de la Chapelle 2004, Broderick et al. 2007, Haiman et al. 
2007, Sun et al. 2007, Tomlinson et al. 2007, Zanke et al. 2007, Jaeger et al. 2008, 
Tenesa et al. 2008, Tomlinson et al. 2008). In general, all the identified common risk 
 91 
variants can only account for ~6% of the unknown CRC heritability (Lascorz et al. 
2010). Identifying more of these lower penetrance genetic variants will play an 
important role in increasing our knowledge of the genetic pathways involved in CRC 
development with possible applications in the clinic (de la Chapelle 2004, Lerman 
and Shields 2004). Recently, it has been suggested that some of the missing 
heritability may be accounted for by copy number variants (CNVs) (Pearson and 
Manolio 2008). CNVs are structural copy number polymorphisms; insertions, 
deletions and duplications of more than 1Kb in size that occur across the human 
genome. CNVs have been considered as a form of genetic variation and they affect 
the risk of genetic diseases (Beckmann et al. 2007). Therefore, they can provide an 
alternative strategy to identify cancer predisposing genes (Venkatachalam et al. 
2010). 
 
Apoptosis, is a fundamental biochemical pathway that plays an essential role in 
normal tissue homeostasis and differentiation, as it helps to eliminate abnormal cells 
(Reed 2000, Fadeel and Orrenius 2005). One of the main hallmarks of cancer cells is 
their ability to evade apoptosis (Hanahan and Weinberg 2000) which is usually 
acquired by disrupting apoptotic genes (Butler et al. 1999). Caspase 8 is one of the 
initiator caspases that plays a major role in activating apoptosis. Several studies 
have shown the loss of caspase 8 expression in tumours such as neuroblastoma, 
medulloblastoma and small cell lung cancer (Shivapurkar et al. 2002b, Pingoud-
Meier et al. 2003b, Stupack et al. 2006). Moreover, inactivating CASP8 mutations 
were previously reported in several cancer types such as CRC and gastric cancer 
(Shivapurkar et al. 2002b, Kim et al. 2003, Soung et al. 2005). Additionally, CASP8 
SNPs such as D203H have been shown to affect breast cancer risk (Cox et al. 2007).  
 
Recently, a large association study in a Chinese population identified a 6bp in/del 
(rs3834129) in the CASP8 promoter as a risk factor for multiple cancers including 
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CRC (Sun et al. 2007). However, these results were not confirmed in European and 
multi-ethnic American populations (Haiman et al. 2008, Pittman et al. 2008). In an 
attempt to clarify this apparent disparity, the initial aim of the work described in this 
chapter was to investigate the relationship between rs3834129 and CRC risk in a 
Caucasian population. Secondly, our lab had some preliminary data indicating an 
association between CASP8 SNPs and CRC risk (Curtin et al. manuscript in 
preparation). Therefore, we decided to try to identify relatively rare and novel 
functional SNPs in CASP8 that might affect CRC risk. This was performed by re-
sequencing the coding region, intron/exon boundaries, the promoter region and the 
3‟UTR of CASP8. Rare variants could easily be missed by GWAS, because they are 
mainly based on a tagging SNP approach which uses specific known SNPs as 
representatives of multiple other common SNPs that occur together in strong linkage 
disequilibrium. Thus, rare variants are usually poorly captured by this approach. 
Finally, we also decided to develop an assay to investigate a possible role of CASP8 
CNV23598 in CRC predisposition. At the time this project was designed, only two 
CNVs were reported to occur in CASP8; CNV23598 and CNV23081. Both CNVs 
were not validated and their frequencies were unknown. However, we decided to 
develop an assay for investigating CNV23598 mainly because of its physical 
proximity to D302H, a CASP8 variant identified by our group to affect breast cancer 
risk (Cox et al. 2007). 
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3.2 Results 
3.2.1 rs3834129 genotyping 
The SNP rs3834129 was genotyped by TaqMan assay (Section 2.2.9.1) (Figure 3.1) 
in 1193 cases and 1388 controls from the UK (Sheffield, Leeds and Dundee) and the 
USA (Utah) populations (these are described in Section 2.1.3). A summary some of 
the characteristics of the cases and controls included in the study is presented in 
Table 3.1.  
 
 
 
Figure 3.1 TaqMan genotyping 
Genotyping clusters of rs3834129 Taqman assay from a 384 well plate from the Sheffield 
population. The X and the Y axes represent fluorescent signals from VIC® and FAM
TM
 
labelled probes respectively. Blue and Red clusters represent homozygous insertion and 
homozygous deletion genotypes respectively. Green cluster represents heterozygous 
genotypes. The crosses represent undetermined samples.  
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Table 3.1 Summary of the cases and controls for rs3834129 genotyping 
  Sheffield Leeds Dundee Utah 
  Cases Controls Cases Controls Cases Controls Cases Controls 
  n (%) 
 Total 475 (100.0) 447 (100.0) 270 (100.0) 227 (100.0) 137(100.0)  365(100.0)  455 (100.0) 449 (100.0) 
Sex 
Male 264 (55.6) 221 (49.4) 153 (56.7) 131 (57.7) 85(62.0)  189 (51.8)  250 (55.0)  250 (55.7) 
Female 211 (44.4) 220 (49.2) 116 (43.0) 96 (42.3) 52(38.0)  173 (47.4)  205 (45.0) 199 (44.3) 
Unknown NA 6 (13.4) 1 (0.4) NA NA   3 (0.82) NA   NA 
Family 
History* 
None 393 (82.7) 405 (90.6) 228 (84.4) 202 (89.0)  109 (79.6) 315 (86.3)  62 (13.6)   420 (93.5) 
1 relative 69 (14.5) 36 (8.1) 37 (13.7) 24 (10.6) 26 (19.0)  45 (12.3)  264 (58.0) 25 (5.6) 
≥ 2 relatives 13 (2.7) 6 (1.3) 5 (1.9) 1 (0.4) 6 (4.4)  5 (1.4)  129 (28.4)  4 (0.9)  
Age** 
≤50 25 (5.3) 18 (4.0) 11 (4.1) 11 (4.9) 6 (4.4)  16 (4.4)   54 (11.8)  NA 
51-59 82 (17.3) 98 (21.9) 40 (14.8) 29 (12.8) 20 (14.6)   67 (18.5) 69 (15.2) NA 
60-69 127 (27.6) 171 (38.3) 94 (34.8) 85 (37.4) 51 (37.2)  143 (39.5)  134 (29.5) NA 
≥70 237(49.9) 160 (35.8) 124 (45.9) 102 (44.9) 60 (43.8)  136 (37.6)  185 (40.7) NA 
Mean (Range) 68 (30-96) 66 (26-86) 67.4 (45-89) 67.1 (45-80) 67.2 (46-80)  66.7 (45-86)  64.9 (29-91)  NA 
CRC site*** 
Proximal 122 (25.7) NA 57 (24.4) NA 22 (16.0)  NA 158 (32.6) NA 
Distal 126 (26.5) NA 81 (34.6) NA 49 (35.8)  NA 147 (30.4) NA 
Rectal 190 (40.0) NA 92 (39.3) NA 62 (45.3)  NA 115 (25.3) NA 
Unknown 37 (7.8) NA 4 (1.7) NA 4 (2.9)  NA 64 (14.1)  NA 
* Family history includes 1st degree relatives only. 
** Controls for Utah were samples collected from previous studies. All controls were cancer 
free and matched by sex and year of birth (Age will reflect the age at recruitment for previous 
studies, therefore it will not necessarily match for this study (Section 2.1.3.3). 
*** CRC site for Utah includes 29 cases with multiple primary CRC. 
 
3.2.1.1 Quality control 
In order to assess the quality of the DNA samples and the accuracy of the TaqMan 
assay and genotyping results, several quality control assessments were performed. 
The assay genotyping call rate represents the number of successfully genotyped 
samples out of the total number of samples. It gives an indication of both assay and 
sample quality. Usually, a call rate of ~95% indicates that both the assay and the 
samples are of high quality. The call rate achieved for the different genotyped 
populations was between 92-96%, as shown in Table 3.2.  In each 384 well taqman 
plate, 5-10% of the samples were duplicated. The duplicate concordance represents 
the percentage of the duplicated samples that were successfully called with the same 
genotype. A duplicate concordance of 98% represents high accuracy. An overall 
duplicate rate of 97.5% was obtained for all of the genotyped cohorts combined 
(range 95-100%) (Table 3.2). As mentioned in Section 2.2.21.2, testing for Hardy 
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Weinberg equilibrium (HWE) is an important step to investigate the quality of the 
genotyping assay. Table 3.2 summarises the p-values for the populations genotyped 
for rs3834129. The chi-squared test was performed on the control genotypes only. All 
the p-values were >0.05 suggesting that all the genotyped populations were 
consistent with HWE. In summary, the quality control analysis of the genotyping 
results indicates reasonable data quality. 
Table 3.2 Quality control results of the genotyped cohorts 
Study Group Samples (n) 
Call rate 
(%) 
Overall call rate 
(%) 
Duplicate Concordance % 
(n)* 
HWE 
 (p-value) 
Sheffield 
Cases  436  92.0 
92.3  94.7 (94) 0.507 
Controls  442  92.5 
Leeds 
Cases 262 94.7 
96.1 100.0 (41) 0.254 
Controls 226 97.8 
Dundee 
Cases 136 94.8 
94.0 97.2 (36) 0.990 
Controls 364 93.7 
Utah 
Cases 451 92.0 
93.3 100.0 (71) 0.714 
Controls 444 94.6 
 
3.2.1.2 Allelic discrimination and genotypes 
Table 3.3 represents a summary of the rs3834129 genotype counts for the cases and 
controls from the genotyped populations. Moreover, Table 3.4 shows the observed 
allele frequencies in this study, together with those from previous publications and 
dbSNP. Comparison with the known frequencies of rs3834129 shows an agreement 
between our results and the results from the European and multi-ethnic American 
populations. However, it shows substantial difference from the Asian population. 
Table 3.3 rs3834129 Genotyping results 
  Genotyping results  
  n (%)  
  Ins/Ins Ins/Del Del/Del Total 
Sheffield 
Cases 107 (26.7) 186 (46.4) 108 (26.9) 401 
Controls 119 (29.1) 197 (48.2) 93 (22.7) 409 
Leeds 
Cases 53 (21.4) 126 (50.8) 69 (27.8) 248 
Controls 58 (26.2) 102 (46.2) 61 (27.6) 221 
Dundee 
Cases 40 (31.0) 60 (46.5) 29 (22.5) 129 
Controls 80 (23.5) 171 (50.1) 90 (26.4) 341 
Utah 
Cases 107 (25.8) 210 (50.6) 98 (23.6) 415 
Controls 116 (27.6) 213 (50.7) 91 (21.7) 420 
 
Table 3.3 summarises the genotyping results for rs3834129. 
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Table 3.4 rs3834129 frequencies 
 rs3834129 allele frequencies 
Insertion Deletion 
Sheffield 0.53 0.47 
Leeds 0.49 0.51 
Dundee 0.49 0.51 
Utah 0.53 0.47 
Pittman et al. 2008 0.50 0.50 
Haiman et al. 2008  0.50-0.52 0.48-0.50 
European panel dbSNP(133) 0.452 0.548 
Sun et al. 2007 0.76 0.24 
Asian panel dbSNP(133) 0.783 0.217 
 
Pittman et al. 2008 and Haiman et al. 2008 studies were performed in European and multi-
ethnic American populations respectively. Sun et al. 2007 study was performed in a Chinese 
population. dbSNP allele frequency was obtained from the database release 133. 
3.2.1.3 Association of rs3834129 with colon cancer 
A contingency table chi-squared test (Degree of freedom (df) =2) was used to 
investigate whether there was a significant difference in the frequency of the 
genotypes between cases and controls (Section 2.2.21.1). The test was applied 
separately on the four different populations using observed and expected values 
based on the null hypothesis of no association between genotype and case status. 
The p-values for the 4 populations are summarised in Table 3.5. 
  
The odds ratios (OR) for CRC relative risk of the heterozygous and the homozygous 
deletion (the rare allele) genotypes were calculated in comparison to the 
homozygous insertion (the common reference allele) (Section 2.2.21.3). OR were 
calculated separately for the different populations and a combined OR was also 
computed for the 4 populations with adjustment for study size. Finally, an additive OR 
model assuming an increase in CRC risk with each copy of the deletion allele (allele 
dose) was calculated for each study separately and with all the studies combined. 
The calculated OR are summarised in Table 3.5. All the calculated p-values were > 
0.05 and all the estimated OR 95% confidence intervals overlapped 1.0. Therefore, 
these data provide no evidence of association between rs3834129 and CRC risk. 
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Table 3.5 Chi-squared test p-values and odds ratios 
  Odds ratios (OR) 
Study p-value* 
Heterozygous OR  
(95% CI) 
Homozygous Del OR  
(95% CI) 
Additive model OR  
(95% CI) 
Sheffield 0.369 1.050 (0.756-1.459) 1.292 (0.882-1.890) 1.134 (0.937-1.372) 
Leeds 0.429 1.352 (0.858-2.130) 1.238 (0.745-2.056) 1.105 (0.857-1.424) 
Dundee 0.234 0.702 (0.434-1.134) 0.644 (0.366-1.134) 0.797 (0.599-1.061) 
Utah 0.736 1.069 (0.773-1.479) 1.168 (0.792-1.721) 1.080 (0.890-1.310) 
Combined data** 1.040 (0.860-1.258) 1.110 (0.891-1.384) 1.053 (0.944-1.176) 
 
Table 3.5 summarises the chi-squared test p-values, and the odd ratios for the different 
populations used in rs3834129 genotyping. 
* 2x3 Chi-squared p-values testing the null hypothesis that there is no significant difference in 
genotypes frequencies between cases and controls. 
** Combined OR were adjusted for the sizes of the 4 studies based on a logistic regression 
analysis by Dr Cox. 
 
3.2.2 Caspase 8 gene sequencing 
In order to try and identify any rare and possible coding variants that might have an 
effect on caspase 8 function and CRC risk, the coding region of the CASP8 gene, the 
intron/exon boundaries, the promoter region and the 3‟UTR (Figure 3.2) were 
sequenced in the peripheral blood DNA samples of 94 random CRC cases from the 
Sheffield population sample described in Section 2.1.3.1 (Table 3.6). 
 
.
 
 
A schematic representation of CASP8 promoter region and exons sequenced in the project. 
 
  
Figure 3.2 CASP8 promoter region and exons 
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Table 3.6 Patients and tumour characteristics 
Median age (range), years                  67 (30-90) 
Gender                                                  n (%) 
  Male 51 (54.3) 
  Female 43 (45.7) 
Tumour location                                    n (%) 
  Proximal 31 (33.0) 
  Distal 27 (28.7) 
  Rectal 34 (36.2) 
  Unknown 02 (2.1) 
Duke's Stage                                          n (%) 
  A 07 (7.4) 
  B 26 (27.7) 
  C 44 (46.8) 
  D 03 (3.2) 
  Unknown 14 (14.9) 
Family history CRC                               n (%) 
  None 72 (76.6) 
  1 relative 11 (11.7) 
  ≥ 2 relatives 11 (11.7) 
Metastastatic                                         n (%) 
  Yes 07 (7.4) 
  No 83 (88.3) 
  Unknown 04 (4.3) 
Differentiation                                       n (%) 
  Well 07 (7.4) 
  Well/Moderate 53 (56.4) 
  Moderate 20 (21.3) 
  Poor 04 (4.3) 
  Unknown 07 (7.4) 
 
Table 3.6 summarises the patients and tumour characteristics of the 94 sequenced 
CRC cases. Family history was defined by 1
st
 degree relatives having CRC. 
 
3.2.2.1 Novel sequence variants 
Six novel variants were identified in the screened cohort. To date, none of these 
variants have been previously reported. All the novel variants (except c.646+25) 
were confirmed by bi-directional sequencing and are summarised in Table 3.7. 
Table 3.7 Novel sequence variants 
Variant Location Genomic position* Number of cases 
-565 G>A Promoter region 202097619 2 
c.1-8338Del115 Exon 3 202122873-202122988 1 
c.1-7982A>G Intron 3 202123228 1 
c.646+25A>G Intron 8 202137524 1 
c.1488+388DelATTA Intron 13 202151702-202151705 1 
c.1488+1163C>T Intron 13 202152480 1 
 
* Genomic positions are according to human genome build 37.2. 
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3.2.2.1.1 Promoter region variant 
The first variant was identified in the promoter region of CASP8 in two different CRC 
cases (C201 and M202) (Figure 3.3). The variant is a G to A transition at nucleotide 
position -565 (-565 G>A) from the transcription initiation site in exon 1. The CASP8 
promoter region is well characterised and the regulatory sequences have been 
previously mapped and functionally validated (Figure 3.4) (Liedtke et al. 2003). The 
novel -565 variant does not occur within any of the known functional sites.  Moreover, 
in silico analysis using the online tool PROMO for the identification of putative 
transcription factors binding sites (TFBS) did not predict the introduction of any new 
sites (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3, 
accessed July, 2011). Finally, the genomic position 202097619 was checked using 
the UCSC genome browser (http://genome.ucsc.edu, assembly Feb 2009, accessed 
July, 2011) for evolutionary conservation (across; Rhesus, Mouse, Dog, Elephant 
and Opossum) and the presence of regulatory regions assessed by DNase 
hypersensitivity clusters and histone marks. The genomic position was not highly 
conserved and it did not occur within any regulatory region. 
Bidirectional sequencing of the promoter region showing the -565 G>A variant in a wild type 
sample (A and B) and C201 (C and D). The site of the variant is marked with a red arrow. 
Figure 3.3 The novel variant -565 G>A 
  Forward sequence    Reverse 
A 
C D 
B 
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The novel variant is highlighted in pink. Nucleotides highlighted in yellow and green represent 
the 6bp ins/del (rs3834129) and STAT1 binding site respectively. Nucleotides highlighted in 
turquoise represent known SNPs.  
 
3.2.2.1.2 Exon 3 variant 
The second variant was a 115bp deletion in exon 3 (c.1-8338Del115). The variant 
was identified in one CRC case only (C536) (Figure 3.5). Exon 3 is only expressed in 
the longest isoform of CASP8 (Isoform G). c.1-8338Del115 results in an in-frame 
deletion of the first 11 amino acids (MEGGRRARVVI) of the isoform G precursor. The 
deleted 11 amino acids are not part of the known functional domains of caspase 8. 
 
In silico analysis using the database of protein domains, families and functional sites 
Prosite (http://www.expasy.ch/prosite/ accessed July, 2011) did not predict any highly 
conserved or functional domains. Nevertheless, c.1-8338Del115 genomic region was 
checked using the UCSC genome browser (http://genome.ucsc.edu, assembly Feb 
2009, accessed July, 2011) for evolutionary conservation (across; Rhesus, Mouse, 
Dog, Elephant and Opossum) and the presence of regulatory regions assessed by 
DNase hypersensitivity clusters and histone marks. The region was not highly 
conserved, however, the presence of strong DNase hypersensitivity cluster and 
histone marks were predicted in CASP8 exon3 and the surrounding region (including 
the novel variant c.1-7982A>G described in the following section). However, CASP8 
Figure 3.4 CASP8 promoter region 
Exon 1 
SP1 
NFκB 
ETS 
P53 responsive element 
GAGCTAAGTATTTTGCATGTATTAACTCATTTTGTTCTCATAATAACCTTCACATGCAGGAATCATTATA 
GCTACTTTATGAATGAGCCGAGGAAGGCACTGAGACGTTAAGTAACTTGCCCAAGGTCACGCAGCTAGTA 
AGTGGCAGAGCAAGAATTACTATGGCTTTATAAGCCTAGGAAAAAGTCTGAAAGAATCAAAATGTTAACA 
GCGGGGACCTCAAGGAAGCATTGAAGAGGCCATGGGAGAAGTTTTCACTTTGTTAAAAAATCAGTCCTTC 
AAATAAATAAATACAGTGAGGCTTCCCCAGAAGCAGATGTCACTATGCTTCCTGTACAGCCTGTGGAACT 
GTGAGCCAGTTAAACCTCTTTTCTTTATAAATTATCCAGTCTTAGGTATTTCTTTATAACAGTGCTAGGA 
TGAGCTGATACAGTTTCCTACACTGTAACCTAAGGCAATGCTTTGCACAAAGGGATGAGCCAGATTGCTT 
AGTAATTAAAACGCAAATACAAACCACAAGCATATCCATTCATGAATTGGGGGGCTGCTTTGTGTGCATA 
GATAAGGTATATTTTTTAAAAAAATTATTTTTCCAAGAAGAAAATAAACCAGTTAATAAACGACAACTCA 
CAGTGCCAGGAAGTGAGAAACAAGTGTGTGATAAACGGTGGAGAATGGGAGCACTCTCCGCAGTGGGCGG 
GAGGAGACGAGGAGGGCGTTCCCTGGGGAGTGGCAGTGGTTGGAGCAAAGGTTTGGAGGAGGTAAGTCAT 
GTGCTCTGAGTTTTTGGTTTCTGTTTCACCTTGTGTCTGAGCTGGTCTGAAGGCTGGTTGTTCAGACTGA 
GCTTCCTGCCTGCCTGTACCCCGCCAACAGCTTCAGAAGAAGGTGACTGGTGGCTGCCTGAGGAATACCA 
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exon 3 is only expressed in CASP8 isoform G, which is not a predominantly 
expressed CASP8 isoform (Scaffidi et al. 1997). 
 
 
A) Exon 3 deletion on 1.5% agarose gel (M: Hyperladder IV, 1: C536, 2: M225). B) 
Electropherogram of C536 showing c.1-8338Del115. (i and ii forward and reverse sequences 
respectively). Red arrows mark deletion breakpoints. C) CASP8 exon 3 is marked in red. c.1-
8338Del115 is highlighted in yellow and SNPs in turquoise. The underlined red nucleotides 
represent primers (italics for reverse). 
 M           1           2 
600 
500 
400 
622 
i 
ii 
GCACGTCCATGAATTGTCTGCCACATCCCTCTTCTGAATGGTTGGAAATTGGGCATCTGTTCCTTTAAAC 
AGGAAACATTTCTTGTTCGAGTGAGTCATCTCTGTTCTGCTTTAGGAGTAAAGTTTACCCTGCAGTTCCT 
TCTGTGGTGAAGTTTTCTCTTTCTCTCGGAGACCAGATTCTGCCTTTCTGCTGGAGGGAAGTGTTTTCAC 
AGGTTCTCCTCCTTTTATCTTTTGTGTTTTTTTTCAAGCCCTGCTGAATTTGCTAGTCAACTCAACAGGA 
AGTGAGGCCATGGAGGGAGGCAGAAGAGCCAGGGTGGTTATTGAAAGTAAAAGAAACTTCTTCCTGGGAG 
CCTTTCCCACCCCCTTCCCTGCTGAGCACGTGGAGTTAGGCAGGTTAGGGGACTCGGAGACTGCGATGGT 
GCCAGGAAAGGGTGGAGCGGGTGAGTGCCTGTTGCCAAGGTGGCCTCTTCAACAGGAAACCACAATATTT 
TTGTTTCTTGACTTGCTCTAGAAACAGGGCTGTGGGGGTGGGGAAGCAACTTGGATCTGCCCTTCTGAGG 
ACACCTCTGGGTGCTGCCTGGCCCAGGTCTCCTGTGTGGTTTCTCTCTGAGCCGTTGCCTCTGACTTTGC 
B 
C 
A 
Figure 3.5 CASP8 exon 3 115 bp deletion 
Size (bp) Expected size 
(bp) 
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3.2.2.1.3 Intronic variants 
Four novel intronic variants were identified; c.1-7982A>G (intron 3) in case C371 
(Figure 3.6), c.646+25A>G (intron 8) in case C109 (Figure 3.7) and 
c.1488+388DelATTA (intron 13) in control CO201 (used in the optimisation of the 
PCR conditions) (Figure 3.8) and c.1488+1163C>T (intron 13) in case C249 (Figure 
3.9). 
 
In silico analysis of the 4 intronic variants was performed using 5 different online 
splicing prediction tools as described in Section 2.2.21.4 and recommended by 
Houdayer et al. (2008). None of the tools used predicted any effect on splicing. 
Moreover, the genomic locations for the 4 intronic variants were checked using the 
UCSC genome browser (http://genome.ucsc.edu, assembly Feb 2009, accessed July 
2011) for evolutionary conservation (across; Rhesus, Mouse, Dog, Elephant and 
Opossum) and the presence of regulatory regions assessed by DNase 
hypersensitivity clusters and histone marks. In terms of evolutionary conservation, 
c.1488+1163C>T was the only variant occurring in a highly conserved position 
(Rhesus, Mouse Dog and Elephant), however, it was not predicted to be in a 
regulatory region. The rest of the genomic variants (except for intron 3 c.1-7982A>G 
as explained in the previous section) did not occur within any regulatory regions. 
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Bidirectional sequencing of intron 3 region showing the variant c.1-7982A>G in a wild type 
sample (A and B) and C371 (C and D). The site of the variant is marked with a red arrow. 
 
Reverse sequencing of intron 8 region showing the variant c.646+25A>G in a C109 (A) and a 
wild type sample (B). The site of the variant is marked with a red arrow. 
Figure 3.6 CASP8 intron 3 c.1-7982A>G 
Figure 3.7 CASP8 intron 8 c.646+25A>G 
A 
C D 
B 
  Forward sequence    Reverse sequence 
A B 
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Bidirectional sequencing of intron 13 region showing the 4bp in/del (c.1488+388DelATTA ) in 
a wild type sample (A and B) and CO201 (C and D). The breakpoints are marked with red 
arrows and the in/del sequence is marked with a horizontal red bar. 
 
Bidirectional sequencing of intron 13 region showing the variant c.1488+1163C>T in a wild 
type sample (A and B) and C249 (C and D). The site of the variant is marked with a red 
arrow. 
Figure 3.8 CASP8 intron 13 c.1488+388DelATTA 
Figure 3.9 CASP8 intron 13 c.1488+1163C>T 
Forward sequence Reverse sequence 
A 
C D 
B 
A 
C D 
B 
  Forward sequence    Reverse sequence 
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3.2.2.2 Known polymorphisms 
A summary of all the previously reported SNPs that were found in the course of this 
project is presented in Table 3.8. The frequencies of the SNPs in the sequenced 
cohort are compared to those from the European population panel (EGP-CEPH) 
available on dbSNP133 (http://www.ncbi.nlm.nih.gov/projects/SNP/). As shown in the 
table, the frequencies were similar and no major differences were observed. 
Table 3.8 Known SNPs identified and their observed/known frequencies 
SNP Reference 
Number 
CASP8 
Exon/Intron 
Alleles Known 
Frequency* 
(db SNP 133) 
Alleles Screened 
in the project (n) 
Observed 
Frequency 
rs3729647 Promoter G/C 0.548/0.452 184 0.570/0.430 
rs34224214 Promoter C/T 0.976/0.024 182 0.940/0.060 
rs3834129 Promoter AGTAAG/- 0.452/0.548 188 0.569/0.431 
rs35093568 Promoter A/G 0.977/0.023 184 0.989/0.011 
rs6747918 Promoter G/A 0.568/0.432 184 0.490/0.510 
rs36028425 Promoter A/T 0.977/0.023 106 0.915/0.085 
rs17860416 Promoter G/A 0.932/0.068 188 0.952/0.048 
rs3769823 Exon 3 G/A 0.705/0.295 188 0.680/0.320 
rs3769824 Exon 3 T/C 0.979/0.021 188 0.963/0.037 
rs2293554 Intron 5 T/G 0.952/0.048 188 0.930/0.070 
rs13401994 Intron 5 G/T 0.977/0.023 188 0.973/0.027 
rs36043647 Intron 11 T/C 0.932/0.068 188 0.936/0.064 
rs1045485 Exon 12 G/C 0.773/0.227 188 0.872/0.128 
rs1045487 Exon 12 G/A 0.977/0.023 188 0.968/0.032 
rs34750049 Intron 12 C/T 0.977/0.023 188 0.984/0.016 
rs41309820 Exon 13 C/T Unknown 42 0.976/0.024 
rs34841024 Exon 13 T/G 0.773/0.227 184 0.870/0.130 
rs3769818 Exon 13 G/A 0.750/0.250 184 0.790/0.210 
rs41309822 Exon 13 G/A Unknown 184 0.990/0.001 
rs17860428 Exon 13 G/A 0.841/0.159 182 0.841/0.159 
rs3185378 Exon 13 C/G 0.682/0.318 180 0.611/0.389 
rs2141331 Exon 13 C/T 0.932/0.068 180 0.906/0.094 
rs35419671 Exon 13 C/T 0.977/0.023 186 0.994/0.006 
rs17860432 Exon 13 G/C 0.977/0.023 184 0.935/0.065 
rs17860433 Exon 13 A/G 0.955/0.045 184 0.973/0.027 
rs1045494 Exon 13 T/C 0.977/0.023 184 0.967/0.033 
rs13113 Exon 13 A/T 0.432/0.568 186 0.414/0.586 
rs34461625 Exon 13 -/AT 0.977/0.023 186 0.973/0.027 
rs1035140 Exon 13 A/T 0.500/0.500 184 0.544/0.456 
rs35010052 Exon 13 -/A 0.955/0.045 184 0.956/0.044 
 
* Known frequencies were obtained from the EGP-CEPH European panel available on NCBI 
website (dbSNP133). 
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3.2.3 Copy number variant CNV23598 genotyping 
As of August 2009, when we started this investigation, 8410 CNV loci had been 
reported in the human genome (http://projects.tcag.ca/variation/). At the time, only 
two CNVs were present within CASP8; CNV23081 and CNV23598. Both of these 
CNVs were not independently confirmed and their frequencies were unknown. 
CNV23081 is located between intron 9 and intron 11 and CNV23598 is located in 
intron 11 downstream from CNV23081 (Figure 3.10). Because of the physical 
proximity to the D302H variant identified as a risk factor in breast cancer (Cox et al. 
2007) (Figure 3.10), we wanted to investigate the association between CNV23598 
and colorectal and breast cancer risk. To this end, we set up genotyping assays for 
CNV23598 in a set of CRC cases (n=189) and controls (n=95) from the Sheffield 
population sample (Section 2.1.3.1). We also made use of 47 carefully selected 
patients from a breast cancer study. The chosen patients included 24 cases 
homozygous for a CASP8 breast cancer risk haplotype and 23 controls homozygous 
for a CASP8 breast cancer protective haplotype (Shephard et al. 2009).  
 
Figure 3.10 CNV23081 and CNV23598 in CASP8 
A schematic representation of CASP8 promoter region and coding sequence. The 
approximate location of CNV23081 and CNV23598 is presented by coloured lines. The breast 
cancer risk variant (D302H) location is also marked. 
 
3.2.3.1 Optimisation of GAP PCR 
Gel based GAP PCR, as described in Section 2.2.6.3 was initially used to investigate 
CNV23598 in CRC cases and controls from the Sheffield population. Three primers 
were designed to amplify both insertions and deletions in a duplex PCR reaction 
(Figure 3.11). The primers were optimised initially in two separate PCR reactions to 
 107 
give single amplification products. Subsequently, the primers were combined in a 
duplex reaction at equal concentrations of each of the 3 primers. However, 
preferential amplification of the smaller deletion region resulted in a stronger product 
(Figure 3.12 A). In order to obtain equal amplification of both products, a range of 
lower concentrations of the deletion reverse primer were used until products of 
similar intensity were obtained (Figure 3.12 B). 
 
CNV23598 is highlighted in grey, exon 12 in red and SNPs in turquoise. Primers are 
highlighted in different colours as indicated. The sizes of the expected products and the 
genotypes are represented in the box.  
1450bp 
AGCCTAAATGATAGCTTACCCATCTTGTAAACTAGTTTACTAGAGAAAACAGACCAACAATAACACTCTC 
TCCTTTCTCATTTGCTTCAGGGTTTGAGAATGTTTTTAGCTGGTGGCAATAAATATTAGAAGCCTGCAGA 
ATCCAGCTACGAATATAGAGGGTTTTGCTCTTGAATTTCTGGTTCAAATTCTTTTTTTTTTTTTTTTTTT 
TTTATTGATCATTCTTGGGTGTTTCTCGCAGAGGGGGATTTGGCAGGGTCACAGGACAATAGTGGAGGGA 
AGGTCAGCAGATAAACAAGTGAACAAAGGTCTCTGGTTTTCCTAGGCAGAGGACCCTGCGGCCTTCCGCA 
GTGTTTGTGTCCCTGGGTACTTAAGATTAGGGAGTGGTGATGACTCTTAACGAGCATGCTGCCTTCAAGC 
ATCTGTTTAACAAAGCACATCTTGCACCGCCCTTAATCCATTTAACCCTGAGTGGACACAGCACATGTTT 
CAGAGAGCACAGGGTTGGGGATAAGGTCACAGATCAACAGGATCCCAAGGCAGAAGAATTTTTCTTAGTA 
CAGAACAAAATGAAAAGTCTCCCATGTCTACTTCTATCCACACAGACCCGGCAACCATCCGATTTCTCAA 
TTTTTTCCCCACCCTTCCCGCCTTTCTATTCCACAAAACCGCCATTGTCATCATGGCCCATCCCCAATGA 
GCCGCTGGGCACACCTCCCAGACGGGGTCGTGGCCGGGCAGAGGGGCTCCTCACTTCCCAGTAGGGGCGG 
CCCGGCAGAAGCGCCCCTCACCTCCCAGATGGGGCGGCTGGCCGGGCGGGGGGCTGACCCCCCCACCGCC 
CTCCCGGACGGGGCGGCTGGCCAGGCAGAGGGGCTCCTCACTTCCCAGTAGGGGCGGCCGGGCAGAGGCG 
CCCCTCACCTCCTGGATAGGGCGGCTGGCCGGGCGGGGGGCTGTTCCCCCCACCTCCCTCCCGGATGGGG 
 
TTCCCAGACGGCGTGGCGGCCGGGCAGAGGCTGCAATCTCGGCTCTTTGGGAGGCCAAGGCAGGCGGCTG 
GGAGGTGGTTGTAGCAAGCCGAGATCACGCCACTGCACTCCAGCCTGGGCACCATTGAGCACTGAGTGAA 
CGAGACTCCATCTGCAATCCCGGCACCTCGGGAGGCCGAGGCTGGCGGATCACTCGCGGTTAGGAGCTGG 
AGACCAGCCCGGCCAACACAGCGAAACCCCATCTCCACCAAAAAAAAAACGAAAACCAGTCAGGCGTGGC 
GGCGCGCGCCTGCAATCGCAGGCACTCGGCAGGCTGAGGCAGGAGAATCAGGCAGGGAGGTTGCAGTGAG 
CCGAGATGGCAGCAGTACCGTCCAGCTTTGGCTCGGCATGAGAGGGAGAGGGAGACGGGGAGAGGGAGAG 
GGAGAGGGAGACGGGGAGAGGGAGAGGGAGAGGGGTCAAATTCTTATCTATCAATGTTATGCCCACTGTG 
CTCTCCAGCTGTGGTCTGTGAATTACTGTGGTATAACGTGACTGTTCAAATTTCACTTTTCAGGGGCTTT 
GACCACGACCTTTGAAGAGCTTCATTTTGAGATCAAGCCCCACGATGACTGCACAGTAGAGCAAATCTAT 
GAGATTTTGAAAATCTACCAACTCATGGACCACAGTAACATGGACTGCTTCATCTGCTGTATCCTCTCCC 
ATGGAGACAAGGGCATCATCTATGGCACTGATGGACAGGAGGCCCCCATCTATGAGCTGACATCTCAGTT 
CACTGGTTTGAAGTGCCCTTCCCTTGCTGGAAAACCCAAAGTGTTTTTTATTCAGGCTTGTCAGGGGGAT 
AACTACCAGAAAGGTATACCTGTTGAGACTGATTCAGAGGAGCAACCCTATTTAGAAATGGATTTATCAT 
CACCTCAAACGAGATATATCCCGGATGAGGCTGACTTTCTGCTGGGGATGGCCACTGTGAATAACTGTGT 
TTCCTACCGAAACCCTGCAGAGGGAACCTGGTACATCCAGTCACTTTGCCAGAGCCTGAGAGAGCGATGT 
CCTCGGTAAGTTTTGCCTACTCAGCCCTCCTCACTGTTACACTACCTTCCCCCCCTACTCCATCACACTA 
Common forward 
Insertion reverse 
Deletion reverse 
Exon 12 
      INS/INS    INS/DEL   DEL/DEL 
567 
368 
Figure 3.11 CNV23598 GAP PCR 
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Equimolar concentrations of the 3 primers resulting in preferential amplification of the smaller 
deletion product. B) Lower concentration of reverse insertion resulting in insertion and 
deletion products of similar intensities M) Hyperladder IV, 1&2) C003 & C011 (Ins/Ins), 3&4) 
M026 & C017 (Ins/Del), 5)  C059 (Del/Del). 
 
3.2.3.2 CNV23598 testing in breast cancer cases and controls 
The optimised GAP PCR test was then used by Marina Parry (a PhD student in our 
research group) to test the 24 breast cancer cases and 23 controls. The results 
showed that 23 out of the 24 cases homozygous for the breast cancer CASP8 risk 
haplotype were also homozygous for the insertion allele. On the other hand, the 23 
controls homozygous for the protective haplotype were either heterozygotes (n=11) 
or homozygotes for the deletion allele (n=12). These results suggest a strong 
association between the insertion allele and the breast cancer risk haplotype (Table 
3.9). 
Table 3.9 CNV23598 genotypes for breast cancer cases and controls 
 Homo INS Heterozygous Homo DEL 
Cases 23 1 0 
Controls 0 11 12 
 
3.2.3.3 CNV23598 testing in CRC cases and controls 
The assay was then used to genotype 96 non-metastatic CRC cases, 96 metastatic 
CRC cases and 96 controls from the Sheffield population sample. Table 3.10 
summarises the genotyping results. 
 
  M         1        2           3          4         
600 
500 
400 
300 
  M         1        2           3          4         
600 
500 
400 
300 
A B 
Figure 3.12 CNV23598 GAP PCR optimisation 
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Table 3.10 Observed frequencies of CNV23598 
 Genotype 
 n (%) 
Total Ins/Ins Ins/Del Del/Del Total 
Non-metastatic 21 (21.9) 64 (66.7) 11 (11.5) 96 
Metastatic 10 (10.8) 58 (62.4) 25 (26.9) 93 
Controls 12 (12.6) 60 (63.2) 23 (24.2) 95 
Totals 43 182 59 284 
 
As mentioned in Section 2.2.21.2, testing for HWE is a useful step in investigating the 
quality of the genotyping assay. Therefore, the HWE test was performed on the 95 
successfully amplified controls in order to test the quality of the GAP PCR genotyping 
assay. The HWE chi-squared test p-value of 0.0063 was less than 0.05, suggesting 
that the genotyped data were inconsistent with HWE. We noticed that there was an 
excess of heterozygotes. The HWE test was then also applied to the non-metastatic 
and metastatic cases and the HWE chi-squared test p-values were 0.00065 and 
0.0068 respectively. Therefore, the tested cohort might be non-random, or the GAP 
PCR test might not be accurate. The former seems unlikely since the samples are a 
subset of cases and controls demonstrated to be consistent with HWE (Section 
3.2.1.1). It was observed that the genotype frequencies in the metastatic cases 
looked similar to the controls and both differed from the non-metastatic cases. 
However, as the populations are inconsistent with HWE, further investigations were 
carried out to confirm the validity and accuracy of the genotyping assay. 
3.2.3.4 Comparison of fluorescent GAP PCR and gel-based GAP 
PCR and DNA sequencing of PCR products 
In order to genotype a larger cohort of CRC cases for CNV23598, a high throughput 
technique was required. Fluorescent GAP PCR was optimised using a new set of 
reverse primers for the insertion and the deletion (Figure 3.13). The use of these new 
primers might also help in resolving the apparent genotyping issues described in the 
previous section. The insertion reverse was labelled with a FAMTM dye and the 
deletion reverse was labelled with a VIC® dye. The PCR products for the 3 
genotypes are shown in Figure 3.14. After optimising the fluorescent GAP PCR 
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assay, 16 CRC cases (6 homozygous insertion, 8 heterozygotes and 2 homozygous 
deletion as determined by GAP PCR, Table 3.11) were genotyped using the 
fluorescent GAP PCR and the gel based GAP PCR for comparison. Furthermore, the 
GAP PCR products were sequenced to confirm their specificity towards the correct 
region of the genome.  
 
Fluorescent GAP PCR and gel-based GAP PCR were concordant in the 16 samples. 
Moreover, the sequencing results confirmed the genotypes for all of the samples. 
Examples are shown (Figure 3.15 - Figure 3.17).  Seven of the samples with the 
insertion sequence had a longer stretch of Ts at the beginning of the CNV23598 
compared to the published sequence. This was confirmed by DNA sequencing and 
fluorescent GAP PCR (Figure 3.18). 
 
Table 3.11 The 16 samples for CNV23598 confirmation 
Sample Genotype* 
C004 Ins/Ins 
C009 Ins/Ins 
C010 Ins/Del 
C017 Ins/Ins 
C021 Ins/Ins 
C047 Ins/Ins 
C066 Ins/Del 
C069 Ins/Del 
C091 Ins/Ins 
C099 Ins/Del 
C106 Del/Del 
C111 Ins/Del 
C115 Ins/Del 
C117 Ins/Del 
C119 Del/Del 
C121 Ins/Del 
 
* CNV23598 genotypes in these samples were based on the gel-based GAP PCR results 
(Section 3.2.3.3). 
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A 
B 
C 
Insertion 
Allelic 
Ladder 
 
Deletion 
Ins/Del 
Del/Del 
Ins/Ins 
 
CNV23598 is highlighted in grey, exon 12 in red and SNPs in turquoise. Fluorescent primers 
are highlighted in different colours as indicated. The c.898+5147A/G SNP is highlighted in 
pink. The sizes of the expected products and the genotypes are represented in the box.  
 
The multiple peaks of the insertion product are caused by Taq slippage due to the stretch of 
Ts at 5‟ end of the insertion sequence (Figure 3.13).  
Figure 3.13 CNV23598 fluorescent PCR 
Figure 3.14 The 3 genotypes of CNV23598 using QF-PCR. 
1450bp 
AGCCTAAATGATAGCTTACCCATCTTGTAAACTAGTTTACTAGAGAAAACAGACCAACAATAACACTCTC 
TCCTTTCTCATTTGCTTCAGGGTTTGAGAATGTTTTTAGCTGGTGGCAATAAATATTAGAAGCCTGCAGA 
ATCCAGCTACGAATATAGAGGGTTTTGCTCTTGAATTTCTGGTTCAAATTCTTTTTTTTTTTTTTTTTTT 
TTTATTGATCATTCTTGGGTGTTTCTCGCAGAGGGGGATTTGGCAGGGTCACAGGACAATAGTGGAGGGA 
AGGTCAGCAGATAAACAAGTGAACAAAGGTCTCTGGTTTTCCTAGGCAGAGGACCCTGCGGCCTTCCGCA 
GTGTTTGTGTCCCTGGGTACTTAAGATTAGGGAGTGGTGATGACTCTTAACGAGCATGCTGCCTTCAAGC 
ATCTGTTTAACAAAGCACATCTTGCACCGCCCTTAATCCATTTAACCCTGAGTGGACACAGCACATGTTT 
CAGAGAGCACAGGGTTGGGGATAAGGTCACAGATCAACAGGATCCCAAGGCAGAAGAATTTTTCTTAGTA 
CAGAACAAAATGAAAAGTCTCCCATGTCTACTTCTATCCACACAGACCCGGCAACCATCCGATTTCTCAA 
TTTTTTCCCCACCCTTCCCGCCTTTCTATTCCACAAAACCGCCATTGTCATCATGGCCCATCCCCAATGA 
GCCGCTGGGCACACCTCCCAGACGGGGTCGTGGCCGGGCAGAGGGGCTCCTCACTTCCCAGTAGGGGCGG 
CCCGGCAGAAGCGCCCCTCACCTCCCAGATGGGGCGGCTGGCCGGGCGGGGGGCTGACCCCCCCACCGCC 
CTCCCGGACGGGGCGGCTGGCCAGGCAGAGGGGCTCCTCACTTCCCAGTAGGGGCGGCCGGGCAGAGGCG 
CCCCTCACCTCCTGGATAGGGCGGCTGGCCGGGCGGGGGGCTGTTCCCCCCACCTCCCTCCCGGATGGGG 
 
TTCCCAGACGGCGTGGCGGCCGGGCAGAGGCTGCAATCTCGGCTCTTTGGGAGGCCAAGGCAGGCGGCTG 
GGAGGTGGTTGTAGCAAGCCGAGATCACGCCACTGCACTCCAGCCTGGGCACCATTGAGCACTGAGTGAA 
CGAGACTCCATCTGCAATCCCGGCACCTCGGGAGGCCGAGGCTGGCGGATCACTCGCGGTTAGGAGCTGG 
AGACCAGCCCGGCCAACACAGCGAAACCCCATCTCCACCAAAAAAAAAACGAAAACCAGTCAGGCGTGGC 
GGCGCGCGCCTGCAATCGCAGGCACTCGGCAGGCTGAGGCAGGAGAATCAGGCAGGGAGGTTGCAGTGAG 
CCGAGATGGCAGCAGTACCGTCCAGCTTTGGCTCGGCATGAGAGGGAGAGGGAGACGGGGAGAGGGAGAG 
GGAGAGGGAGACGGGGAGAGGGAGAGGGAGAGGGGTCAAATTCTTATCTATCAATGTTATGCCCACTGTG 
CTCTCCAGCTGTGGTCTGTGAATTACTGTGGTATAACGTGACTGTTCAAATTTCACTTTTCAGGGGCTTT 
GACCACGACCTTTGAAGAGCTTCATTTTGAGATCAAGCCCCACGATGACTGCACAGTAGAGCAAATCTAT 
GAGATTTTGAAAATCTACCAACTCATGGACCACAGTAACATGGACTGCTTCATCTGCTGTATCCTCTCCC 
ATGGAGACAAGGGCATCATCTATGGCACTGATGGACAGGAGGCCCCCATCTATGAGCTGACATCTCAGTT 
CACTGGTTTGAAGTGCCCTTCCCTTGCTGGAAAACCCAAAGTGTTTTTTATTCAGGCTTGTCAGGGGGAT 
AACTACCAGAAAGGTATACCTGTTGAGACTGATTCAGAGGAGCAACCCTATTTAGAAATGGATTTATCAT 
CACCTCAAACGAGATATATCCCGGATGAGGCTGACTTTCTGCTGGGGATGGCCACTGTGAATAACTGTGT 
TTCCTACCGAAACCCTGCAGAGGGAACCTGGTACATCCAGTCACTTTGCCAGAGCCTGAGAGAGCGATGT 
CCTCGGTAAGTTTTGCCTACTCAGCCCTCCTCACTGTTACACTACCTTCCCCCCCTACTCCATCACACTA 
Common forward Fluorescent 
insertion reverse 
Fluorescent 
deletion reverse 
Exon 12 
         Ins/Ins    Ins/Del     Del/Del 
185 
152 
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DNA sequencing of sample C017 with homozygous Insertion genotype using the primers 
designed for the GAP PCR. A) Common forward, the figure indicates the start of CNV23598, 
B) Insertion reverse confirming CNV23598 sequence, C) Deletion reverse failed to generate 
PCR product. 
 
DNA sequencing of sample C119 with homozygous deletion genotype using the primers 
designed for the GAP PCR. A) Common forward, CNV23598 insertion is missing here, B) 
Insertion reverse, failed to generate a PCR product, C) Deletion reverse confirming CASP8 
exon12 sequence. The red arrow indicates the location where CNV23598 should appear if 
present. 
Figure 3.15 Homozygous insertion CNV23598 
Figure 3.16 Homozygous deletion CNV23598 
A 
B C 
Intron CNV235
A 
B C 
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DNA sequencing of a sample with heterozygous genotype using the primers designed for the 
GAP PCR. A) Common forward, the figure indicates the start of CNV23598. The double 
sequence indicates the presence of a deletion product as well. B) Insertion reverse confirming 
the CNV23598 sequence, C) Deletion reverse confirming CASP8 exon12 sequence. 
 
DNA sequencing and QF-PCR results of sample C121 showing the 22/~32 Ts at the 3‟start of 
the CNV23598. A & B represent the 22Ts repeat. CD represent ~32Ts repeat. 
Figure 3.17 Heterozygous CNV23598 
Figure 3.18 CNV23598 22T/32T alleles 
A 
B C 
Intron CNV2359
 
 
D 
B 
C 
A 
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3.2.3.5 A SNP in the insertion sequence suggests the presence of 
an apparent extra insertion allele 
An interesting event was observed while analysing the results of the heterozygous 
samples. A single heterozygous SNP c.898+5147A/G was detected in 5 of the 
heterozygous samples in the insertion sequence. The SNP was detected through the 
analysis of the sequences produced by the insertion reverse primer. The common 
forward sequence cannot be analysed downstream of the stretch of Ts at the 
beginning of the CNV23598 sequence as the DNA sequence becomes noisy due to 
Taq polymerase slippage. In order to confirm the SNP, an internal forward primer 
was designed (identical to the fluorescent insertion reverse primer, but in the forward 
direction) downstream of the stretch of Ts (Figure 3.13). The SNP was then 
confirmed by bi-directional sequencing (Figure 3.19). The presence of this SNP was 
remarkable because the heterozygous samples should in theory have one insertion 
allele and one deletion allele.  
 
The apparent extra insertion copy was also confirmed by analysing the QF-PCR 
results. Two of the heterozygous samples have shown the presence of the 2 alleles 
of the T stretch 22/32 in addition to the deletion allele (Figure 3.20). It is worth noting 
here that both of these samples had the heterozygous c.898+5147A/G SNP. 
However, the A/G SNP and the 32T allele did not associate together as 2 of the 
samples carrying the SNP had he 22T insertion allele only. These apparent extra 
insertion copies could account for the genotyped population being inconsistent with 
HWE by having too many heterozygous genotypes (Section 3.2.3.4). Table 3.12 
summarises the genotyping results of the 16 samples using GAP-PCR, fluorescent 
GAP PCR and sequencing. The table also shows the samples where 3 copies of 
CNV23598 were predicted. 
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Table 3.12 GAP-PCR, QFPCR and sequencing for CNV23598 in 16 samples 
 Genotype 
Sample GAP PCR QFPCR* Sequencing** 
C004 Ins/Ins Ins/Ins Ins/Ins 
C009 Ins/Ins Ins/Ins Ins/Ins 
C010 Ins/Del Ins/Del Ins/Ins/del 
C017 Ins/Ins Ins/Ins Ins/Ins 
C021 Ins/Ins Ins/Ins Ins/Ins 
C047 Ins/Ins Ins/Ins Ins/Ins 
C066 Ins/Del Ins/Ins/del Ins/Ins/del 
C069 Ins/Del Ins/Del Ins/Ins/del 
C091 Ins/Ins Ins/Ins Ins/Ins 
C099 Ins/Del Ins/Del Ins/Del 
C106 Del/Del Del/Del Del/Del 
C111 Ins/Del Ins/Del Ins/Del 
C115 Ins/Del Ins/Del Ins/Del 
C117 Ins/Del Ins/Ins/del Ins/Ins/del 
C119 Del/Del Del/Del Del/Del 
C121 Ins/Del Ins/Ins/del Ins/Ins/del 
 
* Ins/Ins/Del genotype with QF-PCR was based on having 2 insertion peaks of different size in addition 
to the deletion peak 
** Ins/Ins/del genotype with sequencing was based on having the c.898+5147A/G SNP in a 
heterozygous sample 
A              Forward sequence B             Reverse sequence 
Figure 3.19 Novel c.898+5147A/G identified in CNV23598 insertion sequence 
22T insertion allele 
~30T insertion allele Deletion allele 
Figure 3.20 Three copies of CNV23598 using QF-PCR 
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3.2.3.6 In silico analysis 
The CNV23598 sequence was found to be common across the genome with high 
homolog, thus, it was hypothesised that the apparent observation of 3 alleles might 
be due to non-specific amplification.. Several in silico approaches were taken to 
investigate the possibility of non-specific amplification.To begin with, the specificity of 
the GAP PCR primers (both gel-based and fluorescent) were initially checked by 
primer BLAST as described in Section 2.2.5.1 (Figure 3.21 and Figure 3.22). This 
predicted high specificity of the primers to their target sequence, suggesting that non-
specific PCR products would not be expected. Following that, the sequence 
upstream of CNV23598, up to the beginning of the common forward primer 
sequence, was checked by nucleotide BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
and BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) in order to 
confirm the specificity of the area where the common forward primer was designed. 
The results showed that this sequence is highly specific to CASP8 intron 11 (Figure 
3.23).  
 
Next, the region amplified using the common forward primer and the insertion 
reverse primer was checked by BLAST and BLAT, which resulted in several regions 
with very high homology (Figure 3.24). The high homology areas were shared only 
with CNV23598 sequence. Moreover, analysing the 15 highest hits in detail revealed 
that none of the sequences could explain the observation of the single A/G SNP or 
the extended stretch of Ts (~30) in our sequence. It is worth mentioning that 
chr4:15793565-15794093(-) had the same A/G SNP, however, it had several more 
variants in addition. Moreover, chr12:90260871-90261372(+) had the extended T 
stretch (30Ts) but with 2 more SNPs.  Additionally, none matched the upstream 
sequence in CASP8 intron 11, and so would not be predicted to amplify with these 
primers. 
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The results showed high predicted specificity of the primers to their target sequence. Note 
that the amplicon size of the common forward with the deletion reverse includes CNV23598 
sequence. 
Figure 3.21 Primer BLAST for CNV23598 gel-based GAP PCR primers 
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The results showed high predicted specificity of the primers to their target sequence. Note 
that the amplicon size of the common forward with the deletion reverse includes CNV23598 
sequence. 
Figure 3.22 Primer BLAST for CNV23598 fluorescent GAP PCR primers 
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The results confirmed the high specificity of the 66 nucleotides (upstream CNV23598 in 
CASP8 intron11) to the target sequence. 
 
 
The highest 15 hits from “BLATing” the whole region amplified by common forward and 
insertion reverse primers. 
BLAST Search Results 
Figure 3.23 BLAST and BLAT of the 66 nucleotides upstream CNV23598 
Figure 3.24 BLAT for CNV23598 amplicon 
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3.2.3.7 Testing a 3’ GAP PCR assay 
Because of the difficulty of designing more primers in the 5‟ intron 11 area upstream 
of CNV23598, it was decided to try and genotype CNV23598 from the 3‟ end. This 
would allow the use of the reverse primer in CASP8 exon12 as the common primer. 
CASP8 exon12 was checked by BLAT and BLAST and results confirmed that this 
area is unique to CASP8 (Figure 3.25). The 3‟ deletion reverse primer was designed 
in the same location as the 5‟ common forward primer and the 3‟ common reverse 
primer was designed in the same location of the 5‟deletion reverse primer (Figure 
3.26). Designing a 3‟ forward insertion primer was not easy, due to potential non-
specific products identified in primer BLAST. The primer with the lowest number of 
potential non-specific products and the maximum number of mismatches with these 
products was chosen. It had three potentially unintended targets with sizes 
significantly different from the intended target (366bp, 2343bp and 3062bp) (Figure 
3.27). The unintended targets were the results of the forward primer serving both as 
forward and reverse. Aligning the sequences of the potentially unintended products 
with the CASP8 target region using the specialised BLAST “align” 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) has shown that the unintended target regions 
were completely different from the actual target as no significant similarity was found.  
 
The primers were then used to amplify samples that were shown to be heterozygous, 
homozygous insertion and homozygous deletion (Figure 3.28). The results confirmed 
the genotypes of the samples as identified previously; however, the size of the 
insertion product was consistently larger than the expected product by ~450bp. As 
shown in Figure 3.26, the expected insertion product was 406bp but the results 
showed ~850bp insertion products (Figure 3.28). The results were confirmed using 
different samples and the PCR products were then sequenced to verify their 
specificity. DNA sequencing results confirmed the specificity of the PCR products to 
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the target area, however, two main repeat sequences at the 3‟end of the CNV23598 
were found to be expanded (Figure 3.29). This expansion of repeats could account 
for the larger PCR products obtained with the 3‟ forward insertion and the 3‟ common 
reverse primers.  
 
 
The results of BLAST and BLAT confirmed the uniqueness of CASP8 exon 12 sequence 
 
CNV23598 is highlighted in grey, exon 12 in red and SNPs in turquoise. Primers are 
highlighted in different colours as indicated. The sizes of the expected products and the 
genotypes are represented in the box. 
BLAST Search Results 
Figure 3.25 BLAST and BLAT for CASP8 exon 12  
Figure 3.26 CNV23598 3’GAP PCR 
1450bp 
AGCCTAAATGATAGCTTACCCATCTTGTAAACTAGTTTACTAGAGAAAACAGACCAACAATAACACTCTC 
TCCTTTCTCATTTGCTTCAGGGTTTGAGAATGTTTTTAGCTGGTGGCAATAAATATTAGAAGCCTGCAGA 
ATCCAGCTACGAATATAGAGGGTTTTGCTCTTGAATTTCTGGTTCAAATTCTTTTTTTTTTTTTTTTTTT 
TTTATTGATCATTCTTGGGTGTTTCTCGCAGAGGGGGATTTGGCAGGGTCACAGGACAATAGTGGAGGGA 
AGGTCAGCAGATAAACAAGTGAACAAAGGTCTCTGGTTTTCCTAGGCAGAGGACCCTGCGGCCTTCCGCA 
GTGTTTGTGTCCCTGGGTACTTAAGATTAGGGAGTGGTGATGACTCTTAACGAGCATGCTGCCTTCAAGC 
ATCTGTTTAACAAAGCACATCTTGCACCGCCCTTAATCCATTTAACCCTGAGTGGACACAGCACATGTTT 
CAGAGAGCACAGGGTTGGGGATAAGGTCACAGATCAACAGGATCCCAAGGCAGAAGAATTTTTCTTAGTA 
CAGAACAAAATGAAAAGTCTCCCATGTCTACTTCTATCCACACAGACCCGGCAACCATCCGATTTCTCAA 
TTTTTTCCCCACCCTTCCCGCCTTTCTATTCCACAAAACCGCCATTGTCATCATGGCCCATCCCCAATGA 
GCCGCTGGGCACACCTCCCAGACGGGGTCGTGGCCGGGCAGAGGGGCTCCTCACTTCCCAGTAGGGGCGG 
CCCGGCAGAAGCGCCCCTCACCTCCCAGATGGGGCGGCTGGCCGGGCGGGGGGCTGACCCCCCCACCGCC 
CTCCCGGACGGGGCGGCTGGCCAGGCAGAGGGGCTCCTCACTTCCCAGTAGGGGCGGCCGGGCAGAGGCG 
CCCCTCACCTCCTGGATAGGGCGGCTGGCCGGGCGGGGGGCTGTTCCCCCCACCTCCCTCCCGGATGGGG 
 
TTCCCAGACGGCGTGGCGGCCGGGCAGAGGCTGCAATCTCGGCTCTTTGGGAGGCCAAGGCAGGCGGCTG 
GGAGGTGGTTGTAGCAAGCCGAGATCACGCCACTGCACTCCAGCCTGGGCACCATTGAGCACTGAGTGAA 
CGAGACTCCATCTGCAATCCCGGCACCTCGGGAGGCCGAGGCTGGCGGATCACTCGCGGTTAGGAGCTGG 
AGACCAGCCCGGCCAACACAGCGAAACCCCATCTCCACCAAAAAAAAAACGAAAACCAGTCAGGCGTGGC 
GGCGCGCGCCTGCAATCGCAGGCACTCGGCAGGCTGAGGCAGGAGAATCAGGCAGGGAGGTTGCAGTGAG 
CCGAGATGGCAGCAGTACCGTCCAGCTTTGGCTCGGCATGAGAGGGAGAGGGAGACGGGGAGAGGGAGAG 
GGAGAGGGAGACGGGGAGAGGGAGAGGGAGAGGGGTCAAATTCTTATCTATCAATGTTATGCCCACTGTG 
CTCTCCAGCTGTGGTCTGTGAATTACTGTGGTATAACGTGACTGTTCAAATTTCACTTTTCAGGGGCTTT 
GACCACGACCTTTGAAGAGCTTCATTTTGAGATCAAGCCCCACGATGACTGCACAGTAGAGCAAATCTAT 
GAGATTTTGAAAATCTACCAACTCATGGACCACAGTAACATGGACTGCTTCATCTGCTGTATCCTCTCCC 
ATGGAGACAAGGGCATCATCTATGGCACTGATGGACAGGAGGCCCCCATCTATGAGCTGACATCTCAGTT 
CACTGGTTTGAAGTGCCCTTCCCTTGCTGGAAAACCCAAAGTGTTTTTTATTCAGGCTTGTCAGGGGGAT 
AACTACCAGAAAGGTATACCTGTTGAGACTGATTCAGAGGAGCAACCCTATTTAGAAATGGATTTATCAT 
CACCTCAAACGAGATATATCCCGGATGAGGCTGACTTTCTGCTGGGGATGGCCACTGTGAATAACTGTGT 
TTCCTACCGAAACCCTGCAGAGGGAACCTGGTACATCCAGTCACTTTGCCAGAGCCTGAGAGAGCGATGT 
CCTCGGTAAGTTTTGCCTACTCAGCCCTCCTCACTGTTACACTACCTTCCCCCCCTACTCCATCACACTA 
 
3’Forward 
Deletion 
3’Forward 
insertion 
3’Common 
reverse Exon 12 
      INS/INS    INS/DEL   DEL/DEL 
406 
368 
 122 
These non-specific targets are the products of the forward primer only acting in both 
directions. All the sizes differ significantly from the expected size of the specific target and 
they have several mismatches with the primer in both directions. 
 
Genotyping CNV23598 from the 3‟end. The genotypes of the samples were confirmed. 
Different conditions (A, B and C) were used and they all gave specific products. The size of 
the deletion product was as expected (368bp). The size of the insertion product was 
consistently larger (~850bp) than expected (406bp). M: Hyperladder IV Samples 1-
homozygous insertion, 2&3- heterozygous and 4- homozygous deletion. 
Figure 3.27 Potential unintended products with the 3’ insertion forward primer 
Figure 3.28 CNV23598 3’ GAP PCR gel electrophoresis 
  M     A               B              C 
 1       2       3       4                  1       2       3       4              1       2       3       4 
600 
500 
400 
300 
700 
800 
900 
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Sequencing results from the 3‟ forward insertion & 3‟ common reverse primers showing an 
expansion of two main repeat sequences B &C. A) The target area with the two repeat 
sequences B & C highlighted in turquoise and yellow respectively D) The sequence of the 
expansion that was analysable by sequencing and it contains repeats of B&C sequences; 
BBCBCBCGGGAGACCBCCBCC. E and F represent the sequencing results of the 3‟ common 
reverse primer. The sequences confirm the specificity of the PCR products. 
Figure 3.29 Repeat sequences at 5’ end of CNV23598 
D 
Exon 12 
Reverse primer sequencing results 
B C 
Forward primer sequencing results 
E 
F 
Intron 11 CNV23598 
Exon 12 
GGAGGTGGTTGTAGCAAGCCGAGATCACGCCACTGCACTCCAGCCTGGGCACCATTGAGCACTGAGTGAA 
CGAGACTCCATCTGCAATCCCGGCACCTCGGGAGGCCGAGGCTGGCGGATCACTCGCGGTTAGGAGCTGG 
AGACCAGCCCGGCCAACACAGCGAAACCCCATCTCCACCAAAAAAAAAACGAAAACCAGTCAGGCGTGGC 
GGCGCGCGCCTGCAATCGCAGGCACTCGGCAGGCTGAGGCAGGAGAATCAGGCAGGGAGGTTGCAGTGAG 
CCGAGATGGCAGCAGTACCGTCCAGCTTTGGCTCGGCATGAGAGGGAGAGGGAGACGGGGAGAGGGAGAG 
GGAGAGGGAGACGGGGAGAGGGAGAGGGAGAGGGGTCAAATTCTTATCTATCAATGTTATGCCCACTGTG 
CTCTCCAGCTGTGGTCTGTGAATTACTGTGGTATAACGTGACTGTTCAAATTTCACTTTTCAGGGGCTTT 
GACCACGACCTTTGAAGAGCTTCATTTTGAGATCAAGCCCCACGATGACTGCACAGTAGAGCAAATCTAT 
GAGATTTTGAAAATCTACCAACTCATGGACCACAGTAACATGGACTGCTTCATCTGCTGTATCCTCTCCC 
ATGGAGACAAGGGCATCATCTATGGCACTGATGGACAGGAGGCCCCCATCTATGAGCTGACATCTCAGTT 
CACTGGTTTGAAGTGCCCTTCCCTTGCTGGAAAACCCAAAGTGTTTTTTATTCAGGCTTGTCAGGGGGAT 
CACCTCAAACGAGATATATCCCGGATGAGGCTGACTTTCTGCTGGGGATGGCCACTGTGAATAACTGTGT 
 
A 
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3.2.3.8 Long range PCR CASP8 exon11- exon12 
The size of the region of CASP8 between exon11 and 12 (including CNV23598) is 
8491bp. In order to try and solve the problems of genotyping CNV23598, we decided 
to amplify the whole region by long range PCR and then sequence with internal 
primers. Phusion Taq polymerase have been successfully used in our lab to amplify 
PCR products up to 10Kb in size, however, several attempts using different DNA 
samples, primers and PCR conditions failed completely to give any specific products.  
3.3 Discussion 
As mentioned earlier, our lab had some preliminary data indicating an association 
between CASP8 SNPs and CRC risk. In order to further investigate the potential role 
of inherited CASP8 variants in affecting CRC risk, the following was performed; 
firstly, rs3834129 (an ins/del variant in the promoter region of CASP8 previously 
implicated in CRC risk) (Sun et al. 2007) was genotyped in 1193 CRC cases and 
1388 controls from Sheffield, Leeds, Dundee and Utah. Secondly, the CASP8 coding 
region, in addition to intron/exon boundaries, the promoter region and 3‟UTR were 
sequenced in 94 CRC cases from the Sheffield cohort.  
 
The SNP rs3834129 was genotyped using TaqMan assays. Several QC 
assessments were performed to validate the TaqMan assay and the genotyping data. 
In summary, the QC measures indicated a reasonable quality of the genotyping 
results. Chi-square association test was then performed and the results have shown 
that there was no significant difference in genotype frequencies between cases and 
controls. These results contradict the previous results from the Chinese population 
(Sun et al. 2007) which showed an association between rs3834129 and multiple 
cancer risks including CRC. However, the results are in concordance with the 
published data on the European and multi-ethnic American populations which found 
no effect of rs3834129 on CRC risk (Haiman et al. 2008, Pittman et al. 2008). Based 
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on the size of the analysed cohort, we had ~98% power (α=0.05) to detect an effect 
of similar size (OR=0.75/ copy of deletion allele) as described by Sun and 
colleagues. Possible explanations for the discrepancy between our results (and the 
European and the American studies) in comparison to the original study in the 
Chinese population could be due to different frequencies and effects of genetic and 
environmental modifier factors between the different populations, or due to the initial 
association being a false positive. Despite the lack of association overall, rs3834129 
genotyping results are currently being used in a more in depth analysis of CASP8 
inherited variants and CRC risk. This further analysis is being performed both to fine 
map associations and to investigate various subgroups of CRC cases (Curtin et al. 
manuscript in preparation).  
 
CASP8 sequencing was performed to try and identify rare coding variants that might 
affect CRC risk. Association studies are usually performed using a “tagging SNP” 
approach which depends on common and known SNPs. Therefore, rare or unknown 
SNPs could have been easily missed. Sequencing 94 cases yields an 85% 
probability of identifying variants with a minor allele frequency (MAF) of 0.01. Normal 
DNA extracted from the peripheral blood of 94 CRC cases from the Sheffield 
population was sequenced and six novel variants were identified. The first variant (-
565 G>A) was within the promoter region of CASP8, however, it did not affect any of 
the known functional sequences identified in that area. Moreover, in silico analysis 
did not predict the introduction of any transcription factors binding sites or the 
presence of any regulatory regions. The genomic location was not conserved across 
5 mammalian species. Therefore, it was not predicted to have an effect on CASP8 
function. The second variant was identified only in one case and was a 115 bp 
deletion in exon 3 (c.1-8338Del115). Despite this region having a potential regulatory 
role, as predicted by the presence of DNase cluster region and histone marks which 
could reflect transcriptional enhancers and promoters (Crawford et al. 2006), the 
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following observations led to the prediction that it was unlikely to be functionally 
important. Firstly, CASP8 has 8 different isoforms and exon 3 is only expressed in 
the G isoform precursor. The deletion results in an in-frame deletion of the first 11 
amino acids of isoform G precursor which is not part of the mature protein. 
Additionally, the deleted 11 amino acids are not part of the known conserved 
functional domains of CASP8 protein. Furthermore, in silico analysis of the 11 amino 
acids sequence using the database of protein domains, families and functional sites 
Prosite (http://www.expasy.ch/prosite/, accessed July, 2011) did not predict any 
highly conserved and functional domains. Finally, isoform G is not one of the 
predominantly expressed CASP8 isoforms and it is not detected at the protein level 
(Scaffidi et al. 1997). Therefore, this variant did not seem a suitable candidate for 
further investigation at this stage. The four other variants were intronic, and were not 
predicted to have an effect on CASP8 mRNA splicing using 5 different online splice 
sites prediction tools. Apart from the intron 3 variant c.1-7982A>G, none of the 
variants were predicted to be in a region with a potential regulatory role. However, 
the variant c.1-7982A>G was in the same region as the exon 3 115 bp deletion and it 
was not predicted to be functionally important for the same reasons discussed above.  
 
CNVs were recently shown to play an important role in several human inherited 
diseases and cancer (Beckmann et al. 2007). Moreover, they have been used 
successfully to predict cancer related genes (Venkatachalam et al. 2010). Although 
the above results do not suggest a role for CASP8 inherited variants in CRC risk, we 
decided to investigate the role of CNV23598, reported on the database of genomic 
variants, because of its physical proximity to the known breast cancer D302H risk 
variant and due to its unknown frequency.  
 
The genotyping results of 47 selected breast cancer cases and controls suggested a 
strong association between the insertion allele and the CASP8 risk haplotype. 
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However, when 288 CRC cases and controls were investigated, the genotype 
frequencies differed markedly from HWE with excess heterozygotes. Several 
molecular techniques (Gel-based and fluorescent GAP PCR, in addition to DNA 
sequencing) were used in an attempt to validate the genotyping results. The 
combined results showed some differences from the published reference sequence, 
and suggested the presence of multiple insertion copies of CNV23598. DNA 
sequencing results and the use of in silico tools indicated that the genotyping assays 
were specific to the target region. Multi-allelic CNVs are known to occur in the human 
genome, which could explain the presence of the 3rd copy (McCarroll and Altshuler 
2007). Moreover, reported CNVs in the genomic databases usually lack specificity at 
their breakpoints. Several more CNVs were recently reported on the database of 
genomic variants which overlap CNV23598, but with variable breakpoints at both 
ends. This could explain some of the difficulties encountered in the genotyping 
experiments. Thus, our attempts to accurately genotype CNV23598 using 
conventional molecular techniques have so far failed. The 47 breast cancer samples 
described in this project were recently sequenced using a 2nd generation sequencing 
platform as part of a different project. The analysis of these data may reveal the 
exact sequence of the CNV flanking regions and resolve some of the inconclusive 
observations for the data. 
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4. Colorectal Cancer Molecular Classification 
4.1 Introduction 
As described in section 1.3.5, recent studies on CRC have shown that the disease is 
highly heterogeneous from a molecular point of view and should no longer be 
considered as one disease (Cheng et al. 2008, Derks et al. 2008, Issa 2008, Ogino 
and Goel 2008). There are at least three different subtypes that develop through 
different pathways of genetic and epigenetic instabilities (MSI, CIN and CIMP) and 
mutations in key cancer genes such as APC, TP53, KRAS, BRAF and PIK3CA 
(Figure 1.5). MSI, CIN and CIMP are not entirely mutually exclusive and associations 
between these genomic instabilities and mutations in the cancer driver genes define 
the different CRC molecular subtypes.  
4.1.1 Associations of molecular events and CRC subtypes 
MSI-H was previously shown to be associated with CIMP-H (including MLH1 
methylation) (Weisenberger et al. 2006). MSI-H and CIMP-H tumours were both 
shown to be associated with mutations in BRAF (V600E) and PIK3CA (exons 9 and 
20) (Hawkins et al. 2002, Kambara et al. 2004, Weisenberger et al. 2006, Shen et al. 
2007, Abubaker et al. 2008, Nosho et al. 2008). However, the association between 
MSI-H and PIK3CA mutations is controversial and was suggested to occur as a 
result of MSI-H association with CIMP-H (Nosho et al. 2008). MSI-H was also shown 
to be inversely correlated with CIN and KRAS and TP53 mutations (Samowitz et al. 
2001b, Ogino and Goel 2008). In general, CIMP tumours (whether H or L, MSI or 
MSS) were found to associate with BRAF/KRAS mutant status (Samowitz et al. 
2005, Ogino et al. 2006b, Weisenberger et al. 2006). CIMP-H was found to be 
inversely correlated with TP53 mutations and CIN (or significantly associated with 
low levels of CIN) (Hawkins et al. 2002, Goel et al. 2007, Cheng et al. 2008). CIN 
was found to be associated with TP53 mutations (Chang et al. 2006). Mutations in 
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KRAS and BRAF oncogenes are mainly mutually exclusive as they both play roles in 
activating the proliferative MAP Kinase (MAPK) signalling pathway. However, 
although rare, concomitant KRAS/BRAF mutations were shown to have a synergistic 
effect and were associated with advanced CRC (Oliveira et al. 2007). 
 
Based on these molecular associations, several CRC molecular classification 
systems were proposed with various molecular subtypes (Jass 2007, Issa 2008, 
Ogino and Goel 2008). The 3 main subtypes include the MSI-H/CIMP-H pathway 
which accounts for 10-20% of sporadic CRC cases (Chang et al. 2006, 
Weisenberger et al. 2006, Shen et al. 2007), the CIN/MSS pathway which accounts 
for 50-70% of sporadic CRC cases (Eshleman et al. 1998, Chang et al. 2006, Issa 
2008) and the CIMP-L/MSS/chromosomally stable pathway which accounts for 10-
30% of sporadic CRC cases (Shen et al. 2007, Issa 2008, Ogino and Goel 2008). In 
addition to their distinct molecular characteristics, these CRC molecular subtypes are 
known to associate with different clinical and pathological features. (Chang et al. 
2006, Ogino et al. 2006b, Shen et al. 2007, Issa 2008, Ogino et al. 2009). Molecular 
classification has potential applications in both the clinic and in research. The main 
goal of molecular classification is to discover molecular biomarkers that can be used 
to predict prognosis and survival, or to predict treatment response and efficacy and 
help in the development of targeted cancer therapies (Issa 2008, Ogino and Goel 
2008). Moreover, classifying CRC into different molecular subtypes can help in 
designing more structured studies. For example, studies that have identified 
associations between certain polymorphisms and specific subtypes of CRC could be 
missed if CRC was considered a single disorder (Karpinski et al. 2010, Slattery et al. 
2011, Whiffin et al. 2011). 
 
At the beginning of this project, several studies had attempted to establish a 
molecular classification for sporadic CRC (Chang et al. 2006, Shen et al. 2007, 
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Cheng et al. 2008, Derks et al. 2008). The studies used different techniques to 
identify CIN, including conventional and BAC CGH, DNA ploidy analysis by flow 
cytometry and SNP arrays. Additionally, CIMP was investigated with different panels 
of CpG island methylation markers and using different technologies, not all of which 
were quantitative. MSI testing has been more standardised, however, it was mainly 
performed using the old NCI consensus panel (Section 1.3.3.2.2). 
 
The main limitation of CRC molecular classification studies was the lack of uniformity 
and standardisation in investigating and defining the molecular characteristics, 
especially global events such as CIMP and CIN (Issa 2008, Ogino and Goel 2008). 
This makes it a major challenge to compare results from different studies (Ogino and 
Goel 2008). The aims of the work described in this chapter were; firstly, to investigate 
MSI using a panel of 5 mononucleotide microsatellite markers according to the 
revised NCI criteria on MSI testing (Bacher et al. 2004, Umar et al. 2004). This panel 
was shown to be more accurate in MSI testing compared to the old NCI panel 
(Murphy et al. 2006). Secondly, to identify the common mutations in the key genes 
APC, TP53, KRAS, BRAF and PIK3CA. Thirdly, to investigate CIMP using a panel of 
8 methylation markers that were selected from different CIMP studies and have been 
validated in a large independent population based study (Ogino et al. 2006a, 
Weisenberger et al. 2006, Ogino et al. 2007) This panel was shown to give an 
accurate and specific estimation of the genomic status of CIMP (Ogino et al. 2007). 
Fourthly, to characterise CIN using high resolution genome-wide array CGH. This 
systematic approach was used to provide very detailed information on the molecular 
subtypes, in order to investigate new associations.  At the beginning of this project, a 
total of 67 paired “normal” and tumour DNA samples were assembled; 50 samples 
from the Sheffield population and 17 from the Sheffield tissue bank as described in 
Section 2.1.3.4. Samples were chosen based on the availability of both normal and 
tumour DNA (or tissue). 
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4.2 Results 
4.2.1 DNA quality 
DNA extraction was performed as described in Section 2.2.1. As described in Section 
2.2.2 and Section 2.2.3, samples included in the molecular classification study were 
checked for several quality measures; DNA concentration/quantity, 260/280 ratio 
(ideal ratio: 1.8-2.0), 260/230 ratio (ideal ratio: 1.8-2.2) and degree of DNA 
fragmentation. The latter is shown in Figure 4.1. Samples were selected if their DNA 
concentration was more than 50 ng/µl and if more than 2.5 µg DNA was available 
with acceptable 260/280 and 260/230 ratios. The 2.5 µg DNA quantity limit was the 
minimum amount required to perform all the molecular tests described in the 
following sections. Samples with very low 260/230 were rescued through sodium 
acetate/ethanol precipitation as described in Section 2.2.4. Samples were only 
included if their DNA was of high molecular weight. A total of 67 paired DNA samples 
(134 normal and tumour DNA samples) described above were checked for these 
quality measures. Out of the 50 Sheffield population samples, 10 did not qualify for 
inclusion. However, all of the 17 tissue bank samples were included. A total of 57 
samples were carried forward to the next step. 
 
 
 
Lane F represents an example of a sample with fragmented DNA (circled) in comparison to 
samples with high molecular weight DNA (in rectangle). Fragmented DNA samples were 
excluded from the study. M: Hyperladder I. 
Figure 4.1 DNA fragmentation test on agarose gel  
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4.2.2 Matching tumour and normal DNA test 
After sample quality validation, the next step of the molecular classification was to 
confirm that the normal and tumour DNA samples matched (i.e. were from the same 
patient). This confirmation step was done by comparing two highly polymorphic 
pentanucleotide markers, termed penta C and penta D. These markers were 
included in the MSI analysis kit (Section 4.2.3), thus, the matching test was 
performed as part of the MSI test. Two main reasons lie behind the choice of penta C 
and penta D to demonstrate any sample mix-up; firstly, the combined probability that 
penta C and penta D (based on their allele frequency) will both randomly match 
between two unrelated individuals is 0.2-0.6% (depending on the population), 
secondly, penta-nucleotide markers are stable in mismatch repair deficient cells 
(Bacher et al. 2004). In total, 57 pairs of matching normal and tumour DNA were 
tested using the MSI analysis kit. Comparing penta C and penta D data, 3 pairs of 
samples, 2 from the Sheffield population (CA147 and CA182) and 1 from Sheffield 
tissue bank sample set (CA945), were not matched and thus were excluded from the 
study. An example of a mismatched pair of DNA samples is given in Figure 4.2. 
 
 
 
Matching           Non-matching 
 
 
 
Normal 
 
 
 
Sample A             Sample B 
Penta 
Penta 
Figure 4.2 Matching normal and tumour DNA test 
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4.2.3 Microsatellite instability analysis 
The MSI status of the matching “normal” and tumour DNA samples was determined 
using the commercially available QFPCR kit: MSI Analysis System Version 1.2 Kit 
(Section 2.2.8). The kit includes 5 quasimonomorphic mononucleotide microsatellite 
markers; BAT-25, BAT-26, NR-21, NR-24 and MONO-27, and the two highly 
polymorphic pentanucleotide markers penta C and penta D (Figure 4.3). The MSI 
markers were considered unstable if they exhibit a change in size in the tumour DNA 
compared to the paired normal DNA. The samples were classified to have high MSI 
(MSI-H) if they showed instability in two or more of the 5 mononucleotide markers, 
low MSI (MSI-L) if they showed instability in one of the markers, and MSS if none of 
the markers showed instability (Murphy et al. 2006).  
 
Panel A represents a normal MSS sample. Panel B represents an MSI-H sample. Marked 
with coloured arrows are the size aberrations of the quasimonomorphic mononucleotide 
markers. For a sample to be considered MSI-H, two or more markers should show size 
aberration. Penta C and D are pentanucleotide markers used to verify that the matching 
normal/tumour DNA samples were from the same patient. The MSI-H sample presented is a 
mix of DNA from MSI-H HCT-116 and MSS normal sample, hence, the several penta C and 
penta D peaks.   
NR BAT 
BAT 
NR 
MONO 
Penta 
Penta 
Allelic 
A 
B 
Figure 4.3 MSI analysis system v2.1 
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4.2.3.1 MSI kit sensitivity testing 
In order to evaluate the sensitivity of the MSI kit, serial dilutions of MSI-H DNA were 
mixed with MSS normal DNA (10%, 30% and 50% MSI-H). The MSI-H DNA was 
extracted from HCT-116 cells which carry a homozygous MLH1 mutation (c.755C>A) 
and is known to exhibit MSI-H (http://www.sanger.ac.uk/genetics/CGP/CellLines/). 
The mixed DNA samples were then tested using the MSI kit. As shown in Figure 4.4, 
microsatellite markers showing instabilities were still detected (with careful 
examination) at a level of 10% of the total DNA.  
 
MSI kit sensitivity testing was performed using serial dilutions of MSI-H DNA mixed with MSS 
DNA. A) 10% dilution, B) 30% dilution and C) 50% dilution, the MSI-H status was still 
detectable at the 10% dilution with careful examination 
 
A 
B 
C 
Figure 4.4 MSI kit sensitivity testing 
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4.2.3.2 MSI results 
Two of the tested CRC samples (n=57) were found to be MSI-H (Figure 4.5). The 
first MSI positive sample, CA945, was determined to have high levels of MSI (Figure 
4.5 A), however, it is one of the samples that were considered to be contaminated in 
Section 4.2.2 as it had 3 alleles of both penta C and penta D. Comparing the patterns 
of the extra alleles with all the other DNA samples analysed within the same run 
excluded contamination at the MSI test level. The pattern was also compared to the 
samples extracted during the same run and it also excluded contamination on the 
DNA extraction level. Repeating the MSI test confirmed the presence of the extra 
alleles. The second MSI positive sample, CA008, had very low levels of MSI 
instability. According to the sensitivity test, this sample contained 10% or less MSI 
positive DNA. Therefore, it was either a heterogeneous tumour DNA sample, or the 
tumour sample was highly contaminated with normal DNA. A new cut from the 
tumour tissue has shown that the tumour is actually highly interspersed with normal 
cells. Therefore, CA008 and CA945 were excluded from further examination and the 
remaining cases were considered to be MSS.  
 
In summary, 4 samples were excluded at the MSI testing stage (including the 
matching “normal” and tumour DNA test) for either being non-matching (CA147, 
CA182 and CA945) or being highly interspersed with normal DNA (CA008). 
Therefore, out of the 57 paired DNA samples with sufficient amounts, 53 MSS cases 
were further characterised; 38 samples from the Sheffield population and 15 from the 
Sheffield tissue bank cohort. The clinical and pathological characteristics of these 
samples are summarised in Table 4.1. 
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Represents the 2 MSI samples identified in the project.  A) CA945 has high levels of MSI 
(marked by red arrows), however, penta C and D are indicating DNA contamination (Extra 
alleles marked by red circles). B) CA008 has low levels of MSI ~10% or less (marked by red 
arrows) high normal DNA presence. 
  
N008 
T008 
B 
N945 
T945 
A 
Figure 4.5 MSI positive cases 
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Table 4.1 Patient details and tumour characteristics of the paired samples 
  
Sheffield population     Tissue Bank  
Median age (range)/years                    67 (51-87) 76 (41-90) 
Gender  (n (%))   
  Male 21 (55.3) 8 (53.0) 
  Female 17 (44.7) 7 (47.0) 
Tumour location (n(%))   
  Proximal 8 (21.1) 11 (73.3) 
  Distal 10 (26.3) 1 (6.7) 
  Rectal 20 (52.6) 3 (20.0) 
Duke's Stage  (n(%))   
  A 2 (5.3) 2 (13.3) 
  B 11 (28.9) 3 (20.0) 
  C 22 (57.9) 9 (60.0) 
  D 1 (2.6) 0 (0.0) 
  Unknown 2 (5.3) 1 (6.7) 
Family history CRC (n(%))* 
NA 
  None 26 (68.4) 
  1 relative 9 (23.7) 
  ≥ 2 relatives 3 (7.9) 
Metastastatic  (n(%)) 
NA 
  Yes 10 (26.3) 
  No 26 (68.4) 
  Unknown 2 (5.3) 
Differentiation  (n(%))     
  Well/Moderate 11 (28.9) 1 (6.7) 
  Moderate 24 (63.2) 8 (53.3) 
  Poor 2 (5.3) 5 (33.3) 
  Unknown 1 (2.6) 1 (6.7) 
Survival   
NA 
  Alive 13 (34.2) 
  Dead 24 (63.2) 
  Unknown 1 (2.6) 
Median survival (range)/years         2.54 (0.08-7.58) NA 
 
* Family history includes first degree relatives only 
4.2.4 Mutations in APC, TP53, KRAS, BRAF and PIK3CA 
The next step of the CRC molecular classification was to determine the mutational 
status of APC, TP53, KRAS, BRAF and PIK3CA genes, which are known to play a 
key role in the development of sporadic CRC through the different molecular 
pathways (Figure 1.5). Somatic mutations were investigated in the 53 matching 
normal/tumour DNA samples that passed the quality and MSI testing. 
4.2.4.1  APC gene mutation cluster region sequencing 
Inactivating mutations in the TSG APC are one of the earliest genetic events that 
initiate CRC development (Kinzler and Vogelstein 1996, Kohler et al. 2008). Somatic 
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APC mutations were previously shown to occur in 34-70% of sporadic CRC cases 
(Miyaki et al. 1994, Luchtenborg et al. 2004). The vast majority of the APC somatic 
mutations occur in the mutation cluster region (MCR) in exon 15 (Miyoshi et al. 1992, 
Luchtenborg et al. 2004). The MCR and its surrounding region (codons 1265-1560) 
in APC exon 15 were sequenced in the screened cohort. Of the 53 cases, 29 (54.7%) 
had previously reported somatic mutations in the MCR (Table 4.2). All the mutations 
were only found in the tumour DNA (not present in normal DNA) and they were all 
confirmed by bi-directional sequencing. Moreover, all the somatic mutations were 
either frameshift (71%) or nonsense (29%) and they were predicted to result in 
truncated APC protein. This pattern of mutations agrees with previously published 
data (Beroud and Soussi 1996). None of the cases were found to carry more than 
one mutation.  
 
APC deletion results were available through the aCGH data (Section 4.2.6). Out of 
the 53 cases analysed by aCGH, 9 cases were shown to have deletions in the APC 
region, 3 of these samples did not have a somatic mutation in the MCR (Table 4.2). 
Therefore, a total of 32 cases (60.4%) had at least 1 genetic defect in the APC gene. 
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Table 4.2 APC somatic mutations 
Sample Mutation Codon Type APC deletions (aCGH) 
CA828 c.3871C>T 1291 Nonsense Del 
CA206 c.3883G>T 1295 Nonsense None 
CA096 c.3970C>T 1303 Nonsense None 
CA037 c.3916G>T 1306 Nonsense None 
CA104 c.3916G>T 1306 Nonsense None 
CA218 c.3927_3931del5 1309 Frame shift None 
CA045 c.3933_3934ins1 1312 Frame shift None 
CA085 c.3964G>T 1322 Nonsense None 
CA097 c.3982C>T 1328 Nonsense None 
CA249 c.4033G>T 1345 Nonsense Del 
CA098 c.4037C>G 1346 Nonsense None 
CA079 c.4054_4062dup7 1354 Frame shift Del 
CA138 c.4127_4128del2 1376 Frame shift None 
CA150 c.4216C>T 1406 Nonsense None 
CA244 c.4271del1 1424 Frame shift Del 
CA080 c.4271_4280del10 1424 Frame shift None 
CA184 c.4303A>T 1435 Nonsense None 
CA023 c.4328_4329insC 1443 Frame shift None 
CA078 c.4342del1 1448 Frame shift None 
CA109 c.4350C>T 1450 Nonsense None 
CA153 c.4350C>T 1450 Nonsense None 
CA741 c.4350C>T 1450 Nonsense Del 
CA795 c.4391_4394delAGAG 1464 Frame shift None 
CA863 c.4391_4394delAGAG 1464 Frame shift Del 
CA221 c.4415del1 1472 Frame shift None 
CA112 c.4421del1 1474 Frame shift None 
CA088 c.4582_4603del22 1528 Frame shift None 
CA114 c.4666_4667ins1 1554 Frame shift None 
CA208 c.4666_4667ins1 1554 Frame shift None 
CA213 None N/A N/A Del 
CA142 None N/A N/A Del 
CA158 None N/A N/A Del 
 
Table 4.2 summarises all the somatic mutations and genomic deletions (Section 4.2.6) that 
were identified in APC in the screened cohort. The mutations are in order of location. Twenty 
one cases did not have any APC defects. 
4.2.4.2 TP53 gene sequencing 
Mutations in TP53 represent the most common genetic alteration in human cancers. 
According to the International Agency for Research on Cancer (IARC) TP53 
database, CRC has the 2nd highest level of TP53 mutations (43.3%) (http://www-
p53.iarc.fr/index.html, accessed June, 2011). Mutations in TP53 are spread across 
the gene, however, most mutations occur in the region between exon 4 and exon 9 
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(>98% according to IARC TP53 database). TP53 exons 4-9 and their exon/intron 
boundaries were sequenced in this study. Previously reported somatic TP53 
mutations were identified in 49% (n=26) of the screened cohort (Table 4.3). One 
case, CA208, carried 2 somatic mutations, thus, the number of the identified 
mutations was 27 (Table 4.3). Most of these somatic mutations were missense 
(70.4%) and the rest were nonsense (14.8%), frameshift (11.1%) and splice site 
(3.7%). This pattern of TP53 mutations agrees with the published data (http://www-
p53.iarc.fr/index.html, accessed June, 2011). Moreover, most of these mutations 
occurred in exons 7 and 8 (~63%) which also agrees with the published figures.  
 
Throughout the sequenced regions of TP53, 7 polymorphic SNPs were identified. 
These SNPs enabled basic LOH analysis by comparison of variable alleles between 
the tumour and the normal DNA (Figure 4.6). Out of the 53 screened cases, 27 cases 
(51%) were informative (i.e. had at least 2 polymorphic SNPs) and the LOH status 
was therefore determined. For the rest of the cases (49%, n=26), there were fewer 
than 2 polymorphic SNPs, therefore, they were considered uninformative and their 
LOH status was undetermined. Out of the 27 informative cases, 16 cases (30.2% of 
the total cases) showed evidence of TP53 LOH. Interestingly, one of the CRC cases 
(CA045) had a germline mutation (c.935C>G) in TP53 exon 9 (Figure 4.7). 
Surprisingly, this mutation was on the allele that showed LOH (Figure 4.7 and Figure 
4.8). The sample also had a somatic mutation (c.524G>A) in exon 5 on the other 
allele (Figure 4.9). Interestingly, patient CA045 was not diagnosed with CRC at an 
early age (80 years); however, she had three 1st degree relatives with cancer.  
 
TP53 deletion information was also available through the analysis of the aCGH data 
(Section 4.2.6). Out of the 53 cases analysed by aCGH, 17 carried TP53 deletions. 
Comparing the aCGH results with the 27 LOH informative cases showed that 22 
cases were concordant and 5 were not (CA79, CA86, CA249, CA271 and CA828). 
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These 5 discordant samples were shown to have LOH by SNP analysis, however, 
they were found to be diploid by aCGH analysis. This result can be explained by 
mono-allelic inheritance from the parental cancerous cell or gene conversion events. 
In summary, 31 cases (~58.5%) had at least one defect in TP53 (Table 4.3). 
Table 4.3 TP53 somatic mutations 
Sample Mutation Exon Codon Type Amino acid change Deletion/LOH 
CA088 c.250del1 4 84 Frame shift N/A Del 
CA206 c.455-456ins1 5 152 Frame shift N/A LOH 
CA045 c.524G>A 5 175 Missense p.R175H Del/LOH 
CA098 c.524G>A 5 175 Missense p.R175H Del 
CA249 c.524G>A 5 175 Missense p.R175H LOH 
CA828 c.524G>A 5 175 Missense p.R175H LOH 
CA090 c.559+1G>T i5-intron NA Splice site N/A None 
CA863 c.586C>T 6 196 Nonsense N/A Del/LOH 
CA053 c.592G>T 6 198 Nonsense N/A Del/LOH 
CA097 c.637C>T 6 213 Nonsense N/A Del/LOH 
CA158 c.722C>G 7 241 Missense p.S241C None 
CA142 c.725G>T 7 242 Missense p.C242F None 
CA208 c.730G>A 7 244 Missense p.G244S None 
CA632 c.733G>A 7 245 Missense p.G245S Del/LOH 
CA104 c.733G>A 7 245 Missense p.G245S Del/LOH 
CA218 c.733G>A 7 245 Missense p.G245S Del/LOH 
CA213 c.751A>C 7 251 Missense p.I251L None 
CA223 c.811G>A 8 271 Missense p.E271K Del 
CA086 c.818G>A 8 273 Missense p.R273H LOH 
CA244 c.817C>T 8 273 Missense p.R273C Del/LOH 
CA153 c.844C>G 8 282 Missense p.R282G None 
CA079 c.844C>T 8 282 Missense p.R282W LOH 
CA184 c.844C>T 8 282 Missense p.R282W Del 
CA208 c.844C>T 8 282 Missense p.R282W None 
CA271 c.844C>T 8 282 Missense p.R282W LOH 
CA1120 c.847_859del13 8 283 Frame shift N/A None 
CA085 c.916C>T 8 306 Nonsense N/A None 
CA114 None N/A N/A N/A N/A Del/LOH 
CA201 None N/A N/A N/A N/A Del 
CA203 None N/A N/A N/A N/A Del 
CA214 None N/A N/A N/A N/A Del 
CA221 None N/A N/A N/A N/A Del/LOH 
 
Table 4.3 summarises all the somatic mutations, LOH and genomic deletions (Section 4.2.6) 
that were identified in TP53 in the screened cohort. The mutations are in order of location. 
Thirty one had at least 1 defect in TP53 (1 case with 2 somatic mutations, 18 cases with a 
somatic mutation and LOH/deletion, 5 cases with LOH/deletion only and 7 cases with a 
somatic mutation without LOH/deletion or LOH status undetermined). 
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Samples were analysed for using polymorphic SNPs comparison between normal and tumour 
DNA. The SNPs are marked with red arrows. As seen in the figure, the heterozygous SNPs in 
the normal DNA appear homozygous in the tumour DNA due to loss of one of the alleles. 
Traces of the normal DNA can be seen in the tumour DNA. 
 
 
 
Bidirectional sequencing of CA045 TP53 exon 9 region showing the germline mutation 
c.935C>G in the normal DNA (A and B) and tumour DNA (C and D). As seen in the figure, the 
tumour DNA was considered wild-type at this position, however, traces of the germline 
mutation can be seen in the tumour DNA.  
  
Figure 4.6 LOH analysis 
Figure 4.7 TP53 germline mutation c.935C>G in CA045 
Normal DNA 
Tumour DNA 
A 
C D 
B 
  Forward sequence    Reverse sequence 
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Bidirectional sequencing of CA045 TP53 showing 2 different heterozygous SNPs in the 
normal DNA (A and B) and the tumour DNA (C and D). As seen in the figures, the 2 SNPs 
indicate LOH in the tumour DNA. 
 
 
Bidirectional sequencing of CA045 TP53 exon 5 region showing the somatic mutation 
c.524G>A in the tumour DNA (C and D). The normal DNA did not show any evidence of 
mutation at this position (A and B). 
 
 
 
Figure 4.8 TP53 LOH in CA045 
Figure 4.9 TP53 somatic mutation c.524G>A in CA045 
A 
C D 
B 
A 
C D 
B 
  Forward sequence    Reverse sequence 
 144 
4.2.4.3 KRAS exon 1 sequencing 
KRAS oncogene activation by somatic mutations has been shown to occur in 30-60% 
of CRC cases (Brink et al. 2003). Approximately, 95% of these mutations occur in 
exon 1 (codons 12 & 13) and ~5% in exon 2 (codon 61). Therefore, KRAS exon 1 
was sequenced in our 53 CRC cases. Previously published somatic mutations were 
found in 36% (n=19) of the sequenced samples (Table 4.4). As expected, most of the 
mutations (84%, n=16) were in codon 12. All the mutations were only found in the 
tumour DNA (not present in normal DNA) and they were all confirmed by bi-
directional sequencing. 
Table 4.4 KRAS somatic mutations 
Sample Mutation Codon Type Amino acid change 
CA037 c.35G>T 12 Missense p.G12V 
CA046 c.35G>A 12 Missense p.G12D 
CA080 c.35G>A 12 Missense p.G12D 
CA086 c.35G>A 12 Missense p.G12D 
CA088 c.35G>T 12 Missense p.G12V 
CA097 c.34G>T 12 Missense p.G12V 
CA104 c.35G>T 12 Missense p.G12V 
CA107 c.35G>A 12 Missense p.G12D 
CA109 c.35G>T 12 Missense p.G12V 
CA114 c.38G>A 13 Missense p.G13D 
CA135 c.38G>A 13 Missense p.G13D 
CA138 c.35G>C 12 Missense p.G12A 
CA153 c.34G>T 12 Missense p.G12V 
CA201 c.35G>T 12 Missense p.G12V 
CA208 c.35G>T 12 Missense p.G12V 
CA249 c.35G>T 12 Missense p.G12V 
CA632 c.38G>A 13 Missense p.G13D 
CA824 c.35G>C 12 Missense p.G12A 
CA1350 c.34G>T 12 Missense p.G12V 
 
Table 4.4 summarises all the somatic mutations that were identified in KRAS in the screened 
cohort. The samples are in numerical order. 
4.2.4.4 BRAF exon 15 sequencing 
Activating mutations in the BRAF oncogene were previously shown to be involved in 
the development of a wide range of human cancers including CRC (Davies et al. 
2002). However, BRAF somatic mutations are relatively rare (~12%) in CRC. 
Nonetheless, they usually tend to cluster within the MSI-H pathway where they were 
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observed with a frequency of 40-50% compared to ~5% only in MSS CRC (Oliveira 
et al. 2007, Shen et al. 2007).  Most of the BRAF mutations occur in exons 11 and 
15. Approximately 80% of these mutations occur in the mutational hotspot in exon 15 
specifying amino acid V600. Therefore, exon 15 was sequenced and somatic 
mutations in BRAF were identified in 2 cases (3.8%) (Table 4.5). One of the 
mutations was in the hotspot codon encoding V600E. The second mutation is a 
relatively rare, but known, mutation (N581S). All the mutations were only found in 
tumour DNA (not present in normal DNA) and they were confirmed by bi-directional 
sequencing.  
Table 4.5 BRAF somatic mutations 
Sample Mutation Codon Type Amino acid change 
CA208 c.1742A>G 581 Missense p.N581S 
CA271 c.1799T>A 600 Missense p.V600E 
 
Table 4.5 summarises all the somatic mutations that were identified in BRAF in the screened 
cohort. The samples are in numerical order. 
 
4.2.4.5 PIK3CA exons 9 and 20 sequencing 
Activating mutations in the PIK3CA oncogene were previously shown to play an 
important role in the development of several human cancers including CRC (Samuels 
et al. 2004). Somatic PIK3CA mutations were reported in ~13-30% of sporadic CRC 
cases with mutational hotspots in exons 9 and 20 (~80% of the mutations) (Samuels 
et al. 2004, Ikenoue et al. 2005, Velho et al. 2005). Therefore, exons 9 and 20 were 
sequenced in this study and previously identified somatic mutations were found in 6 
cases (11.3%) (Table 4.6), consistently, most of which (n=5) were in exon 9, as 
previously reported (Samuels et al. 2004). All the mutations were only found in 
tumour DNA (not present in normal DNA) and they were confirmed by bi-directional 
sequencing. 
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Table 4.6 PIK3CA somatic mutations 
 
Table 4.6 summarises all the somatic mutations that were identified in PIK3CA in the 
screened cohort. The mutations are in order of genomic location. 
 
4.2.5 CpG island methylator phenotype 
As described in section 1.3.3.3, CpG island methylator phenotype (CIMP) occurs in 
20-40% of CRC cases and plays an essential role in sporadic CRC development 
(Weisenberger et al. 2006, Ogino et al. 2007, Goel and Shin 2008). The MS-MLPA 
kit ME042-A1 (MRC-Holland) was used to determine the methylation status of the 53 
normal/tumour paired DNA samples (Section 2.2.12). Eight methylation markers 
were included in the kit (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, 
RUNX3 and SOCS1), however, SOCS1 was excluded from the analysis because 
only one probe was available. As described in section 2.2.12.4.3, no CIMP (CIMP-N) 
was defined as an absence of any methylated markers, CIMP low (CIMP-L) as the 
presence of 1-4 methylated markers and CIMP high (CIMP-H) as 5 or more (Ogino et 
al. 2007, Barault et al. 2008). During our study, the ME042-A1 MS-MLPA kit was still 
under development by MRC-Holland and not commercially available. Therefore, it 
was decided to attempt to validate the kit in-house. 
4.2.5.1 Pyrosequencing, MS-MLPA and testing methylation 
controls 
In order to validate the MS-MLPA kit, a commercially available universally methylated 
DNA (UMD) (CpGenome) and HCT116 cell line DNA were used as positive controls. 
In theory, UMD should give ~100% methylation in all of the markers; on the other 
hand, HCT116 cells which are MSI-H and CIMP-H, have positive and negative 
Sample PIK3CA Exon Codon Type Amino acid change 
CA023 c.1633G>A 9 545 Missense p.E545K 
CA046 c.1633G>A 9 545 Missense p.E545K 
CA107 c.1633G>A 9 545 Missense p.E545K 
CA153 c.1633G>A 9 545 Missense p.E545K 
CA795 c.1633G>A 9 545 Missense p.E545K 
CA109 c.3140A>G 20 1047 Missense p.H1047R 
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markers corresponding to various levels of methylation (Hinoue et al. 2009). One 
normal DNA sample from case CA037 was also used as negative control. As the 
gold standard technique for DNA methylation studies, pyrosequencing was used to 
test the positive and negative controls for three of the markers (MLH1, NEUROG1 
and CRABP1), which are available in the MS-MLPA kit. MLH1 primers were 
purchased from Qiagen, while NEUROG1 and CRABP1 primers were designed as 
described in Section 2.2.14.1, and obtained from Applied Bio-systems. The primers 
were designed to target areas previously investigated in CIMP studies (Ogino et al. 
2007). The PyroMark assay design software (v2.0) assigns quality measures for the 
designed primers and assays as high, medium or low. Both CRABP1 and NEUROG1 
designs scored “high” on the quality measures.  
 
Following bisulphite treatment, UMD, HCT116 and CA037 DNA samples were 
analysed by pyrosequencing (“pyrosequenced”) to confirm their methylation status. 
As described in Section 2.2.13, DNA bisulphite treatment results in the conversion of 
unmethylated cytosines into uracil with no effect on methylated cytosines. Therefore, 
all cytosines that are not followed by guanines should, in theory, be fully converted 
into uracil following bisulphite treatment, regardless of the methylation status of the 
sample. Uracil nucleotides will subsequently be replaced by thymidines during 
pyrosequencing. Therefore, a cytosine that is not followed by a guanine is usually 
selected as a marker to measure the bisulphite treatment quality (Figure 4.10). High 
quality bisulphite treatment should result in a thymdine instead of cytosine peak at 
the position indicated. Likewise, unmethylated cytosines followed by guanines (CpG) 
will also be converted into uracil and thus appear as thymidines in the pyrogram 
(Figure 4.11 A). On the other hand, methylated cytosines followed by guanines 
(CpG) will be protected and will remain as cytosines in the final pyrogram (Figure 
4.11 B). A ratio of the thymidines to cytosines at each CpG position will reflect the 
methylation level of the DNA. Usually, several CpGs are used to test the methylation 
 148 
of a specific marker or gene. An average of these CpGs represents the methylation 
level of the marker. 
 
  
A pyrogram representing an unmethylated cytosine (highlighted in a light yellow box) followed 
by adenine. The cytosine was fully converted into thymidine as indicated by the red arrow. 
Highlighted in light blue box, a 50% methylated CpG. 
 
 
Shaded in light blue, cytosine nucleotides of the target CpGs. The small boxes on top of each 
CpG represent the calculated methylation percentage at each location. Blue coloured boxes 
indicate high pyrosequencing quality. A) Unmethylated sample, B) Highly methylated sample. 
 
The 3 methylation controls (UMD, HCT116 and CA037) were bisulphite treated and 
then pyrosequenced to confirm their methylation status. The methylation levels of the 
3 controls were as expected (Table 4.7). The controls were then tested using the MS-
MLPA kit. As described in Section 2.2.12 and, as summarised in Figure 2.5, the 
Figure 4.10 Pyrogram showing a bisulphite treatment control 
A B 
Figure 4.11 Unmethylated and methylated pyrograms 
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methylation sensitive enzyme HhaI is used in the MS-MLPA digestion/ligation step. In 
the case of a methylated DNA sample, the MS-MLPA probes will ligate to methylated 
DNA sequences and will be protected against digestion. Thus, these regions will be 
amplified in the PCR step, and produce a signal during capillary electrophoresis 
appearing as peaks when analysed by the genemapper software (Figure 4.12 B).  
 
In the case of an unmethylated DNA sample, MS-MLPA probes will ligate to 
unmethylated DNA sequences, and hence, they will be digested by HhaI. 
Consequently, they will fail to amplify and no peaks will be identified (Figure 4.12 C). 
The ratio between methylation sensitive peak areas and reference peak areas 
represents the methylation level. This is calculated using a Microsoft Excel based 
spreadsheet and in-house algorithm described in Section 2.2.12.4. The final 
quantitative estimates of the methylation levels are presented as barcharts (Figure 
4.13). Table 4.7 summarises both the pyrosequencing and the MS-MLPA results for 
UMD, HCT116 and CA037. As demonstrated in the table, there is very good 
concordance between pyrosequencing and MS-MLPA in determining the methylation 
levels of these controls. The results of the controls were confirmed twice by 
pyrosequencing.  
Table 4.7 Positive & negative controls using pyrosequencing & MS-MLPA 
 Methylation levels (%) 
 Pyrosequencing MS-MLPA 
Sample MLH1 NEUROG1 CRABP1 MLH1 NEUROG1 CRABP1 
CA037 14.5 7.0 5.4 0.5 9.3 4.4 
HCT116 11.5 96.3 94.6 0.4 100.0 95.9 
UMD 96.3 89.5 94.4 94.9 97.2 95.1 
No of CpGs* 4 8 7 3 6 4 
*Number of CpGs analysed for each marker, the methylation levels of the markers are determined by 
averaging the CpGs for each marker. 
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Peaks highlighted in light red boxes are the products of methylation sensitive probes. Peaks 
in between them represent the products of the reference probes. Peaks marked by the 
horizontal red arrow are the products of the QC metrics and sex determining probes. Peak 
marked by the vertical red arrow is the digestion control probe. This peak should disappear in 
digested samples. Peak marked by the red circle is the BRAF V600E mutation specific peak. 
This peak will appear only in the case of the mutation. A) Non-digested N212 DNA sample B) 
Methylated T271 DNA sample with BRAF V600E mutation C) Unmethylated N212 sample 
A 
B 
C 
 
Figure 4.12 MS-MLPA genemapper peaks 
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A) Methylated sample T271, B) Unmethylated sample N271 
 
  
A 
B 
Figure 4.13 Barcharts showing MS-MLPA calculated methylation levels 
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4.2.5.2 MS-MLPA quantification test 
After confirming the specificity of the MS-MLPA kit, its ability to produce quantifiable 
data was tested. MS-MLPA as technology was previously described to be semi-
quantitative (Jeuken et al. 2007). In order to test the quantification of the MS-MLPA 
ME042-A1 kit, serial dilutions of the UMD were used. CIMP negative DNA from the 
tested sample CA037 was used to do serially dilute the UMD (75%, 50% and 25% 
UMD). The results of the serial dilution are shown in Table 4.8 and they indicate the 
ability of the MS-MLPA kit to quantify the methylation levels of the indicated DNA 
samples. 
Table 4.8 MS-MLPA ME042-A1 quantification test 
UMD serial 
dilution 
CIMP markers and average methylation levels (%) 
IGF2 RUNX3 NEUROG1 MLH1 CDKN2A CRABP1 CACNA1G 
100% 101.02 99.70 97.21 94.90 93.87 95.13 107.17 
75% 75.55 79.67 80.77 72.74 69.54 76.37 65.68 
50% 50.24 54.64 54.93 48.04 48.00 53.88 51.94 
25% 35.91 31.88 38.62 30.51 32.17 35.50 35.40 
 
4.2.5.3 MS-MLPA reproducibility 
Finally, the reproducibly of the MS-MLPA kit was tested by performing duplicate 
experiments. As its methylation status is known, HCT116 DNA was duplicated within 
both the same run and in separate runs. However, patient DNA samples had their 
methylation levels tested by MS-MLPA and these were then repeated in different 
runs, to confirm the findings and to further test the reproducibility of the MS-MLPA kit. 
In total, HCT116 DNA was tested 5 times and 4 case DNA samples (2 CIMP-H, 1 
CIMP-L and 1 CIMP-N) were analysed twice. The results of these duplications are 
summarised in Table 4.9. 
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Table 4.9 MS-MLPA reproducibility tests 
 Methylation Levels (%) 
 CACNA1G CDKN2A CRABP1 IGF2 MLH1 NEUROG1 RUNX3 
T080-1 1.6 1.3 3.4 29.9 1.0 5.7 1.7 
T080-2 2.1 1.6 3.9 25.7 1.0 5.2 1.8 
T184-1 7.6 1.8 10.9 50.0 0.4 46.1 2.5 
T184-2 9.3 1.9 11.0 51.0 1.3 45.7 2.4 
T114-1 2.1 24.7 25.5 60.3 0.0 52.2 23.7 
T114-2 1.9 31.1 31.1 68.9 1.8 60.0 24.9 
T271-1 34.3 17.0 28.6 58.7 18.3 49.7 51.0 
T271-2 32.0 19.3 28.4 59.4 21.9 50.4 62.2 
HCT116-1 95.7 38.3 95.9 100.0 0.4 100.0 4.0 
HCT116-2a 88.6 41.6 98.1 100.0 0.7 100.0 6.1 
HCT116-2b 89.8 35.8 99.0 100.0 2.1 100.0 5.9 
HCT116-3a 77.5 37.2 92.0 100.0 2.1 97.1 7.7 
HCT116-3b 85.2 41.1 100.0 99.2 1.1 100.0 5.6 
 
Table 4.9 summarises the results of the repeated samples. All the case samples were 
repeated in different runs. HCT116 was either duplicated within the same run (a and b) or 
repeated in different runs as well. 
4.2.5.4 CpG island methylator phenotype results 
After validating the performance of the MS-MLPA kit, it was used to determine the 
methylation levels in the paired tumour and normal DNA cohort. Two main issues 
were identified in the methylation testing of the MS-MLPA kit and were reported back 
to MRC-Holland. Firstly, there was only one probe for SOCS1, therefore it was not 
included in the analysis. Secondly, RUNX3 probe 1 had high methylation levels in the 
normal DNA, thus it was not included in the analysis of RUNX3 methylation. As a 
final validation step, 3 more cases were confirmed using pyrosequencing. Paired 
DNA samples from 2 CIMP-H cases (CA114 and CA223) and a CIMP-L case 
(CA090) were used. Table 4.10 summarises the results of these 3 paired samples 
using both pyrosequencing and MS-MLPA.  
 
As described in Section 2.2.12.4.4, sex determination probes and a specific BRAF 
V600E mutation probe (associated with CIMP-H) are part of the MS-MLPA ME042-
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A1 kit. It is noteworthy here that there was a full concordance between the sex 
prediction of in the MS-MLPA assay and the recorded sex of each case. Moreover, 
the mutation status of the only BRAF V600E positive sample CA271 (Table 4.5) was 
also confirmed by the MS-MLPA assay (Figure 4.12 B).  
 
It is noteworthy that all the MS-MLPA tests included in CIMP analysis had excellent 
QC metrics results (MS-MLPA QC-results were described in Section 2.2.12.4.1). The 
QC-tests results for all the samples are summarised in Appendix 5. Finally, out of the 
53 tested samples, 6 (11.3%) were defined as CIMP-H, 41 (77.4%) as CIMP-L and 6 
were defined as CIMP-N (11.3%) (Table 4.11). 
  
Table 4.10 Random samples analysed using pyrosequencing and MS-MLPA 
 Methylation levels (%) 
 Pyrosequencing MS-MLPA 
Sample MLH1 NEUROG1 CRABP1 MLH1 NEUROG1 CRABP1 
N090 11.8 9.5 5.7 1.2 7.6 4.4 
T090 12.5 31.0 38.3 1.2 19.8 20.4 
N114 13.8 6.9 6.7 1.2 11.7 3.7 
T114 13.3 45.6 54.0 0.0 52.2 23.7 
N223 15.3 7.5 5.4 0.6 10.0 3.8 
T223 10.8 52.5 57.0 0.7 48.3 50.8 
No of CpGs 4 8 7 3 6 4 
 
Table 4.10 summarises the reproducibility test performed on 3 paired cases. Normal DNA for 
the 3 samples was used to represent CIMP-N. T090 was used to represent CIMP-L and T114 
and T223 were used to represent CIMP-H. 
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Table 4.11 Summary of the final CIMP status for all of the 53 samples 
Sample CACNA1G CDKN2A CRABP1 IGF2 MLH1 NEUROG1 RUNX3 Result 
CA271 31.93 15.36 23.60 47.61 17.46 41.08 50.63 CIMP-H 
CA088 31.73 45.90 38.66 56.54 0.44 56.66 39.00 CIMP-H 
CA223 36.41 13.84 46.95 66.65 0.09 38.32 57.81 CIMP-H 
CA109 0.05 11.48 33.55 51.76 0.57 44.09 19.56 CIMP-H 
CA114 0.16 23.50 21.79 50.35 -1.21 40.51 22.64 CIMP-H 
CA138 -0.02 19.97 33.84 40.84 -0.47 33.77 32.93 CIMP-H 
CA795 0.36 12.56 6.86 20.92 0.13 25.86 23.12 CIMP-L 
CA085 3.63 0.77 18.16 33.39 0.24 42.82 1.34 CIMP-L 
CA086 0.99 0.77 17.61 57.23 10.30 40.03 13.33 CIMP-L 
CA090 -0.22 34.34 15.99 52.70 0.02 12.17 2.60 CIMP-L 
CA046 0.70 14.22 0.96 15.01 -0.23 12.62 1.88 CIMP-L 
CA150 12.90 2.12 6.60 23.68 6.66 12.82 28.14 CIMP-L 
CA244 -0.55 7.15 8.44 37.50 0.16 13.99 13.70 CIMP-L 
CA249 0.35 10.09 12.82 45.25 -0.20 31.05 0.80 CIMP-L 
CA023 1.06 5.89 6.59 16.07 0.94 12.30 0.08 CIMP-L 
CA045 0.13 8.39 0.42 39.23 0.00 18.22 2.10 CIMP-L 
CA053 1.91 0.44 -1.79 39.63 0.68 27.15 2.71 CIMP-L 
CA083 -0.31 0.78 -0.55 45.26 9.87 36.73 0.65 CIMP-L 
CA097 -0.74 -0.15 1.41 33.28 9.10 25.86 8.47 CIMP-L 
CA104 0.98 -0.16 1.20 43.49 0.12 27.88 0.48 CIMP-L 
CA107 -0.66 5.65 -2.94 40.73 0.19 32.66 -0.63 CIMP-L 
CA135 -0.12 7.84 -0.07 35.97 0.57 17.68 2.15 CIMP-L 
CA153 -1.10 13.72 3.27 45.75 -1.07 37.25 5.84 CIMP-L 
CA167 3.00 0.86 2.36 22.87 0.53 4.92 2.64 CIMP-L 
CA184 4.64 -0.28 7.34 43.57 -0.53 36.38 1.46 CIMP-L 
CA201 -1.26 -1.13 -1.44 31.91 -0.37 18.74 0.93 CIMP-L 
CA202 -0.33 1.91 -0.42 19.56 -0.92 13.69 0.48 CIMP-L 
CA203 -0.33 0.14 1.54 37.34 0.28 15.23 -0.47 CIMP-L 
CA206 -1.11 3.48 -0.35 23.23 16.00 37.45 1.59 CIMP-L 
CA208 0.50 -0.52 -1.68 46.73 -1.43 19.90 1.33 CIMP-L 
CA213 0.51 -0.28 0.79 41.90 14.11 9.46 2.68 CIMP-L 
CA214 0.62 2.61 -1.35 15.93 0.82 17.51 0.20 CIMP-L 
CA037 -0.49 1.26 -0.48 23.03 1.03 -0.42 1.13 CIMP-L 
CA218 -0.54 0.01 -2.23 41.98 -0.08 1.01 3.19 CIMP-L 
CA632 0.11 -0.89 -2.75 12.76 -0.35 75.08 -0.04 CIMP-L 
CA741 -0.63 -0.56 12.99 9.43 0.17 -3.78 -0.57 CIMP-L 
CA824 4.36 0.70 5.87 12.20 1.11 3.92 -2.07 CIMP-L 
CA828 2.90 9.80 -0.56 31.80 0.18 25.29 -2.09 CIMP-L 
CA863 -0.40 -0.51 -3.12 29.40 -0.48 25.09 -2.76 CIMP-L 
CA110 0.56 1.32 1.63 15.04 1.24 3.25 2.79 CIMP-L 
CA112 -0.30 -0.82 5.17 14.14 -0.19 -1.80 1.30 CIMP-L 
CA1120 -0.02 0.11 -2.29 3.21 0.36 33.59 0.18 CIMP-L 
CA1350 -0.09 0.26 8.58 55.24 -0.54 1.69 -1.67 CIMP-L 
CA016 1.26 -0.36 6.68 5.59 8.67 11.99 3.80 CIMP-L 
CA080 0.32 -0.71 -0.62 22.06 -0.24 -2.08 1.04 CIMP-L 
CA098 -1.95 0.29 -2.37 51.57 -0.03 15.50 1.14 CIMP-L 
CA142 -1.52 6.39 24.01 18.09 1.00 -7.36 1.53 CIMP-L 
CA79 -0.54 -0.34 0.24 16.69 -0.32 2.56 -1.82 CIMP-N 
CA122 0.63 -7.70 -0.48 -6.04 0.46 4.44 -0.78 CIMP-N 
CA158 0.29 -1.69 8.22 0.10 0.24 -2.70 -2.19 CIMP-N 
CA212 0.87 0.28 -0.59 10.19 0.39 -1.43 2.75 CIMP-N 
CA221 -1.28 8.41 -3.96 4.77 0.27 4.55 -0.09 CIMP-N 
CA248 0.71 1.42 0.52 9.72 0.13 3.26 2.02 CIMP-N 
 
 
Table 4.11 summarises the methylation status of all the markers and the final methylation 
status for all of the samples. Red boxes represent methylated markers, green boxes 
represent unmethylated markers. A Result red box represents CIMP-H, orange box represent 
CIMP-L and green box represents CIMP-N samples respectively. The values in the boxes 
represent the difference in percentage between the tumour and normal DNA methylation 
levels. Samples are arranged according to their final methylation status. 
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4.2.6 Chromosomal instability 
As described in section 1.3.3.1, chromosomal instability (CIN) is the most common 
form of genomic instability in CRC, and it accounts for between 65-85% of the cases 
(Pino and Chung 2010, Migliore et al. 2011). CIN is mainly characterised by 
numerical chromosomal abnormalities (aneuploidy) and structural amplifications and 
deletions (Pino and Chung 2010). Genome wide aCGH was the method used in this 
project to investigate CIN. Array CGH steps and protocol were performed according 
to the manufacturer‟s recommendations as described in Section 2.2.15. In this study, 
CIN was defined as a continuous variable of aberrations and samples were 
considered chromosomally unstable by the presence of significant amplifications or 
deletions in one or more region of any chromosome (Cheng et al. 2008). 
4.2.6.1 Array comparative genome hybridisation platforms 
A wide range of Agilent aCGH formats with differing resolutions are commercially 
available. After considering the cost of the arrays, their throughput, DNA requirement 
and resolution, two array formats were plausible; the whole genome 4x44K and 
4x180K. The 4x refers to the number of arrays per slide and the 44K and 180K refers 
to the number of distinct biological features covered by the array probes (42494 and 
170334 features). In terms of sample throughput and amount of DNA required, both 
formats were identical. In terms of resolution, the 180K platform provides an average 
resolution of ~13Kb based on the overall median probe spacing (11Kb in the Refseq 
genes). On the other hand, the 44K platform has an overall median probe spacing of 
43Kb (24Kb in Refseq genes). The advantages of using the 44K platform are the 
lower cost and potentially lower background signals. On the other hand, the 
advantages of using the 180K platform are the higher resolution, which might help in 
detecting smaller aberrations. Moreover, with higher probe density, the 180K platform 
would be expected to provide higher confidence in detecting chromosomal 
abnormalities in mosaic and heterogeneous tumour DNA samples.  
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The minimum DNA input required for both arrays is 0.5 µg. Unfortunately, this 
amount of DNA is not available for all the tumour DNA samples included in the study. 
Therefore, whole genome amplification (WGA) might be necessary for some of the 
samples. Reviewing the literature, several publications (including Agilent‟s technical 
note) described the use of WGA DNA on aCGH with consistent and reproducible 
results (Brueck et al. 2007, Pugh et al. 2008). Nevertheless, other publications have 
shown that the use of WGA DNA on aCGH will result in the introduction of spurious 
aberrations (Talseth-Palmer et al. 2008). 
4.2.6.2 Array CGH Quality control metrics results 
As described in Section 2.2.15.10, the QC metrics of the CGH arrays are closely 
monitored to ensure high quality results. The genomic workbench software used in 
the analysis of the aCGH data combine the 11 QC metrics together and assigns a 
final GC status of either pass, marginal, fail or not applicable. All the CGH arrays 
included in the analysis of this study had a final QC status of pass. 
4.2.6.3 Array comparative hybridisation and whole genome 
amplification 
In order to decide upon the best platform to use (44K or 180K), and determine 
whether WGA affects the integrity of the results, a comparison aCGH test was 
performed. The test included 2 DNA samples, with and without WGA, on both array 
formats (Figure 4.14). Some of the QC metrics of the arrays were in the evaluate 
range, however, the total QC metrics score was pass and the experiment was 
considered valid for comparative purposes.  
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A schematic representation of the aCGH/WGA test, CA037 and CA184 were run twice on 
each array, both without and without WGA. 
 
To summarise the findings, one of the test samples was classified as chromosomally 
stable (CA037) and the other as unstable (CA184). CA037 results were identical with 
and without WGA. For the unstable CA184 sample, the direct unamplified DNA 
experiment was analysed first. The results of the unstable sample on both the 44K 
and the 180K platforms were highly comparable (Figure 4.15). In total, 7 aberrations 
were called on the 44K platform and 12 aberrations on the 180K platform. The 
aberrations on the 44K platform were all detected on the 180K platform. The missed 
aberrations by the 44K platform were on chrY (p and q arms), chr8p arm, chr18p arm 
and a small deletion on chr13. Figure 4.15 represents one of the relatively large 
aberrations (chr8p) missed on the 44K platform. As illustrated in the Figure, the chr8p 
probes on the 44K platform showed a clear shift towards the negative log2ratio, 
however, they did not reach the statistical significance to call a deletion. Thus, the 
fact that the 44K platform missed this aberration might be explained by tumour 
heterogeneity and/or the presence of normal DNA in the sample, in addition to the 
lower probe frequency in comparison to the 180K platform.  
 
4x180K 
CA037 
CA037 
WGA 
 
CA184 
CA184 
WGA 
4x44K 
CA037 
CA037 
WGA 
CA184 
 
CA184 
WGA 
Figure 4.14 aCGH and WGA 
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The results of this experiment confirmed the ability of the 180K platform to detect 
more aberrations, especially in heterogeneous tumour DNA. Analysing the WGA test 
results confirmed the advantage of using the 180K platform. As mentioned earlier, 7 
aberrations were detected on the 44K platform using unamplified DNA. The results of 
the WGA DNA on the 44K platform showed only 2 aberrations; the chr8q 
amplification and an extra focal amplification on chr7. In contrast, the results for the 
WGA DNA on the 180K platform were much more consistent with those of the 
unamplified DNA (Figure 4.17). All of the 12 aberrations detected on the 180K array 
of the unamplified DNA were detected on the 180K array of the WGA DNA. However, 
an extra focal deletion on chr17 was noted (Figure 4.17). Therefore, using the 180K 
platform will allow the use of WGA DNA when required. 
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A summary of the genomic aberrations called using both 44K and 180K platforms with the CA184 DNA samples. Solid lines represent aberrations. 
Transparent lines represent the amplitude of each aberration. Blue and red refer to 44K and 180K respectively. 
Figure 4.15 CA184 44K vs 180K test 
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A closer look at chromosome 8. Probes (represented by small crosses) coloured in black 
represent genomic regions with a log2ratio around zero, probes coloured in red and green 
represent amplifications (log2ratio ≥ 0.5) and deletions (log2ratio ≤ -0.5) respectively. As 
shown in the Figure, chromosome 8 long arm was called as an amplification on the 2 
platforms (marked by red arrows). However, because of the probe density the result appear 
with higher confidence on the 180K. On the other hand, chromosome 8 short arm was only 
recognised to be deleted using the 180K format (marked by the green arrow). On the 44K 
platform, the software did not consider chromosome 8 short arm to be deleted. However, 
although it is visually clear (marked by pink box), that the area has a deletion, the probe 
density was not enough for a confident call. 
 
Figure 4.16 CA184 Chromosome 8 
180K 44K X 
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A summary of the genomic aberrations called on the 180K platform using the CA184 unamplified and WGA DNA samples. Solid lines represent aberrations. Transparent lines 
represent the amplitude of each aberration. Red and blue refer to unamplified and WGA respectively. The red arrow points to the extra “spurious” aberration detected in the 
WGA DNA. 
Figure 4.17 CA184 180K platform unamplified vs WGA DNA 
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4.2.6.4 aCGH reproducibility test 
In order to confirm the specificity and reproducibility of the aCGH technology, 2 extra 
duplicate experiments were performed. Samples CA080 and CA090 were analysed 
twice, using both 44K and 180K platforms. The quality of this experiment was very 
high, since the 4 arrays passed all the QC metrics. The results of the duplicate 
experiments are shown in Figure 4.18 and Figure 4.19. CA080 had 27 aberrations 
called using the 44K platform and 38 aberrations called using the 180K platform. All 
27 aberrations called using the 44K platform were successfully called based on the 
180K platform (Figure 4.18). All the extra aberrations called using the 180K platform 
were small in size, except the amplification on chr12p and the y-chromosome 
deletion. However, these were of low amplitude.  
 
Sample CA090 had 39 aberrations called using the 44K platform and 64 using the 
180K platform. Out of the 39 called using the 44K array, 38 were also identified with 
the 180K array (97.4%) (Figure 4.19). All the other aberrations that were called by 
the 180K, but not the 44K, were relatively small in size except the amplification on 
chr8q. Figure 4.20 demonstrates an up-close look at one of the large aberrations that 
was missed by the 44K platform; chr8q from the CA090 duplicate experiment. The 
probes on the 44K show a shift towards the positive log2ratio area, however, it was 
not statistically significant and so not called as an amplification. It is also noteworthy 
that even on the 180K platform the chr8q amplification was of low amplitude. Figure 
4.21 represents a close-up look on a highly concordant result on chr20 from the 
CA090 experiment. Chr20 had several high amplitude amplifications and deletions of 
variable sizes and all of them were successfully called on both platforms. The 
experiments in this section and Section 4.2.6.3 confirm the reproducibility of the 
aCGH technology and the advantage of using a higher resolution array in detecting 
small aberrations and those of low amplitude caused by tumour heterogeneity. 
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Figure 4.18 CA080 aCGH duplicate experiment 
A summary of the genomic aberrations called on both 44K and 180K platforms using the CA080 DNA samples. Solid lines represent aberrations. Transparent lines represent 
the amplitude of each aberration. Blue and red refer to 44K and 180K respectively. 
 165 
 
Figure 4.19 CA090 aCGH duplicate experiment 
A summary of the genomic aberrations called on both 44K and 180K platforms using the CA090 DNA samples. Solid lines represent aberrations. Transparent lines represent 
the amplitude of each aberration. Blue and red refer to 44K and 180K respectively. 
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Solid lines represent aberrations and transparent boxes represent aberration amplitude. A) 
CA090 chr8 on the 44K platform, B) CA90 chr8 on the 180K platform, red and green probes 
represent amplified and deleted regions respectively 
 
Solid lines represent aberrations and transparent boxes represent aberration amplitude. A) 
CA090 chr20 on the 44K platform B) CA090 chr20 on the 180K platform C) both platforms, 
red and green probes represent amplified and deleted regions respectively. 
Figure 4.20 CA090 Chromosome 8 
Figure 4.21 CA090 Chromosome 20 
A C B 
A B 
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4.2.6.5 Chromosomal instability results 
So far, there is no clear definition of CIN in CRC. For the purposes of molecular 
classification as mentioned earlier, CIN was defined as a continuous variable of 
aberrations and samples were considered chromosomally unstable based on the 
presence of one or more significant amplifications or deletions in one or more of the 
chromosomal regions (Cheng et al. 2008). Array CGH was successfully performed 
on the 53 cases and they all passed the QC metrics analysis. Six of the samples 
were analysed on a 44K platform (CA037, CA112, CA114, CA213, CA214 and 
CA218) and the remaining 47 samples were analysed on the 180K platform. 
Samples CA138, CA202, CA203, CA212 and CA249 required WGA prior to their 
aCGH experiments. 
 
All the samples investigated in the project were analysed using the genomic 
workbench software v5.0 and the same set of settings (except CA824 and CA1120). 
Copy number aberrations (CNA) were detected using the ADM2 algorithm with a 
threshold set to 6.0 and the use of centralisation and fuzzy zero correction. Default 
feature and aberration filters were applied and intra array probe replicates were 
combined as described earlier. CA824 and CA1120 were analysed using the same 
settings, but with ADM1 (instead of ADM2). These 2 arrays had very good QC-
metrics (11/11), however, ADM2 failed to call any CNA for unapparent reasons. 
Visual inspection of the aCGH data has shown clear CNA which were successfully 
called by ADM1. Agilent bioinformatics support recommended the use of ADM1 for 
these 2 samples. Out of the 53 cases, 5 (CA023, CA037, CA046, CA110, and 
CA248) were considered to be be chromosomally stable (i.e. no CNA). The rest 
(n=48, 91%) were considered chromosomally unstable. Table 4.12 summarises the 
number of aberrations (deletions and amplifications) for all of the chromosomally 
unstable samples. 
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Samples CA824, CA1120 and CA184 aCGH data was used only to determine their 
overall CIN status (all chromosomally unstable). However, they were excluded from 
any detailed chromosomal aberration analysis. CA824 and CA1120 were excluded 
because they were analysed using ADM1 and CA184 was excluded for having high 
DLRS ratio (Section 2.2.15.10).  
Table 4.12 Aberrations summary per sample 
Sample Aberrations Amp Del CIMP  TP53 Gender Survival/years Dukes Stage Tumour Location 
CA112 1 1 0 CIMP-L WT Female 2.92 C1 Distal 
CA795 2 2 0 CIMP-L WT Female NA C Proximal 
CA1120 2 1 1 CIMP-L Mt Male NA C Proximal 
CA086 3 2 1 CIMP-L Mt Female 0.92 C1 Distal 
CA016 4 3 1 CIMP-L WT Female NA B Proximal 
CA150 5 0 5 CIMP-L WT Male NA C Distal 
CA83 10 9 1 CIMP-L WT Male NA Unknown Distal 
CA184 12 2 10 CIMP-L Mt Male 6.50 C1 Distal 
CA135 14 3 11 CIMP-L WT Female 2.83 B Distal 
CA167 14 6 8 CIMP-L WT Male Alive C1 Distal 
CA218 14 8 6 CIMP-L Mt Female Alive C1 Distal 
CA109 18 10 8 CIMP-H WT Male 1.00 C2 Proximal 
CA122 18 17 1 CIMP-N WT Female NA C Proximal 
CA632 18 2 16 CIMP-L Mt Female NA C Proximal 
CA824 21 12 9 CIMP-L WT Female NA C Distal 
CA201 23 14 9 CIMP-L WT Female 2.50 B Distal 
CA138 24 8 16 CIMP-H WT Male 0.58 C1 Distal 
CA212 29 0 29 CIMP-N WT Female NA C1 Proximal 
CA202 33 25 8 CIMP-L WT Male Alive A Distal 
CA213 33 7 26 CIMP-L Mt Female Alive C2 Distal 
CA208 35 19 16 CIMP-L Mt Female 0.08 C1 Distal 
CA104 37 17 20 CIMP-L Mt Female 0.58 C2 Distal 
CA080 38 27 11 CIMP-L WT Male Alive B Distal 
CA221 39 17 22 CIMP-N WT Male 0.75 B Distal 
CA085 43 20 23 CIMP-L Mt Male NA B Proximal 
CA097 43 17 26 CIMP-L Mt Male 3.33 Unknown Distal 
CA088 45 13 32 CIMP-H Mt Female 0.83 C1 Proximal 
CA206 50 34 16 CIMP-L Mt Female 3.25 B Distal 
CA249 61 33 28 CIMP-L Mt Male 7.25 B Distal 
CA090 63 26 37 CIMP-L Mt Female 7.58 B Distal 
CA271 66 47 19 CIMP-H Mt Male Alive C1 Proximal 
CA741 66 35 31 CIMP-L WT Female NA C Proximal 
CA203 67 21 46 CIMP-L WT Female 5.75 B Proximal 
CA079 71 19 52 CIMP-N Mt Male 0.42 C1 Distal 
CA114 74 13 61 CIMP-H WT Male 2.58 C1 Distal 
CA223 76 53 23 CIMP-H Mt Male 0.67 C2 Proximal 
CA214 86 12 74 CIMP-L WT Male Alive B Distal 
CA158 87 31 56 CIMP-N Mt Female NA Unknown Proximal 
CA053 88 49 39 CIMP-L Mt Female Alive B Distal 
CA098 93 38 55 CIMP-L Mt Male 4.75 B Distal 
CA1350 94 85 9 CIMP-L WT Female NA B Distal 
CA107 110 91 19 CIMP-L WT Male 1.58 D Distal 
CA863 114 61 53 CIMP-L Mt Male NA A Proximal 
CA153 150 100 50 CIMP-L Mt Male NA C Proximal 
CA142 219 171 48 CIMP-L Mt Female 4.75 C1 Proximal 
CA828 248 152 96 CIMP-L Mt Male NA A Distal 
CA45 260 120 140 CIMP-L Mt Female 5.75 C1 Distal 
CA244 411 116 295 CIMP-L Mt Male Alive C1 Distal 
 
Table 4.12 summarises the number of aberrations/ sample including the type of the aberration 
(Amplification or deletion). TP53 mutation status, gender, survival years and tumour stage are 
also summarised. 
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4.2.6.5.1 Copy number aberrations: summary and patterns 
A total of 3097 CNA were identified in the 45 chromosomally unstable samples (apart 
from CA824 and CA184) (Table 4.12). The number of CNA per sample ranged from 
1-411, with an average of 68.8 per sample. CNA ranged in size from 0.0136Mb-
147.4767Mb (mean: 14.7627Mb, median: 2.2910Mb). Out of the 3097 CNA 
identified, 1554 were amplifications, ranging in size from 0.0136Mb-147.4767Mb 
(mean: 17.5479Mb, median: 3.2727Mb). There were also 1543 deletions, ranging in 
size from 0.0245Mb-145.1558 (mean: 11.9577Mb, median: 1.5526Mb). An overview 
of the pattern and frequencies of these CNA is presented in Figure 4.22. A summary 
of the CNA identified in the 40 samples analysed using the 180K arrays is presented 
in Figure 4.23. In the 45 CIN cases, the most common amplifications were within chr 
20q (73.3%, n=33), 13 (57.8%, n=26), 8q (53.3%, n=24), 7 (51.1%, n=23) and X 
(51.1%, n=23) and the most common deletions were within chr 18 (55.6%, n=25), 8p 
(51.1%, n=23) and 17p (51.1%, n=23). Some of these regions contain key CRC 
driver genes, such as MYC at 8q, SMAD4 at 18q and TP53 at 17p. 
 
Figure 4.22 Patterns of CNA in the studied cohort. 
Red represents amplifications and green represents deletions. The y-axis of the red and 
green bars reflects frequency. The figure represents the 40 CIN cases analysed by the 180K 
format. 
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Figure 4.23 CNA identified in 40 chromosomally unstable cases (180K) 
Representation of the entire CNA identified in 40 chromosomally unstable cases analysed 
using the 180K platform. Red represents amplification and green represents deletion. Dotted 
lines mark centromeres. Molecular and clinical features in order from top; PIK3CA, APC, 
TP53, KRAS and BRAF mutation status (blue and white represents mutant and WT 
respectively), CIMP (red, orange and green represent CIMP-H, CIMP-L and CIMP-N 
respectively), patient‟s sex (pink and grey represent female and male respectively) and 
tumour location (yellow and cyan represent proximal and distal respectively).   
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4.2.7 Associations of molecular events 
4.2.7.1 CIMP status and molecular and clinical features 
Two-tailed Fisher‟s exact test was used to test whether the published associations 
between the different molecular events and tumour/patient characteristics could be 
seen in our data. A summary of the molecular and clinical characteristics of the cases 
in relation to their CIMP status is summarised in Table 4.13. CIMP-H was found to 
associate with mutations in KRAS and BRAF in comparison to CIMP-L/N (p-value = 
0.024) and the only sample with the BRAF V600E mutation was CIMP-H (the only 
sample with methylation in all of the markers). However, no association was found 
between CIMP status and PIK3CA mutations (p-value = 0.5323), patient‟s gender (p-
value = 0.1959) and tumour location (p-value = 0.6687). Moreover, none of the 
CIMP-N (n=6) cases had any mutations in KRAS, BRAF or PIK3CA. Compared to 
CIMP-H/N, CIMP-L tumours seemed to be more common among samples from the 
distal colon, but the results did not reach statistical significance (p-value = 0.09). 
Figure 4.24 represents the CIMP status in relation to the molecular and clinical 
features of the 53 patients. 
Table 4.13 CIMP status and molecular and clinical features 
  
CIMP status 
  
n (%) 
  
CIMP-H CIMP-L CIMP-N 
  
6 (100.0) 41 (100.0) 6 (100.0) 
KRAS/BRAF 
Mutant 5 (83.3) 15 (36.6) 0 (0.0) 
WT 1 (16.7) 26 (63.4) 6 (100.0) 
PIK3CA 
Mutant 1 (16.7) 5 (12.2) 0 (0.0) 
WT 5 (83.3) 36 (87.8) 6 (100.0) 
TP53 
Mutant 3 (50.0) 21 (51.2) 2 (33.3) 
WT 3 (50.0) 20 (48.8) 4 (66.7) 
APC 
Mutant 4 (66.7) 21 (51.2) 2 (33.3) 
WT 2 (33.3) 20 (48.8) 4 (66.7) 
Tumour 
Location 
Proximal 4 (66.7) 12 (29.3) 3 (50.0) 
Distal 2 (33.3) 29 (70.7) 3 (50.0) 
Gender 
Male 5 (83.3) 20 (48.8) 3 (50.0) 
Female 1 (16.7) 21 (51.2) 3 (50.0) 
CIN 
CIN+ 6 (100.0) 37 (90.2) 5 (83.3) 
CIN- 0 (0.0) 4 (9.8) 1 (16.7) 
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Figure 4.24 CIMP and molecular and clinical features 
 
4.2.7.2 CIMP and CIN 
CIMP-H samples were previously shown to be inversely correlated with CIN (Goel et 
al. 2007) or correlated with a low degree of CIN when compared with CIMP-L/N 
cases (Cheng et al. 2008). Table 4.14 summarises the range of chromosomal 
aberrations in CIMP-H and CIMP-L/N samples. CIMP-H and CIMP-L/N were not 
found to be significantly different in-terms of the number of chromosomal aberrations 
(Mann Whitney U-test, p-value = 0.88) (Figure 4.25).  
 
Although the overall CNA frequency was not significantly different between CIMP-H 
and CIMP-L/N, there were some differences in the frequency of some of the broad 
and common CNA. The main differences were observed in amplifications within 13q 
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(33.3% CIMP-H, 61.5% CIMP-L/N), 20q (33.3% CIMP-H, 79.5% CIMP-L/N), chrX 
(16.7% CIMP-H, 56.4% CIMP-L/N) and chr7 (83.3% CIMP-H, 46.2% CIMP-L/N) and 
deletions in 8p (83.3% CIMP-H, 46.2% CIMP-L/N). However, both CIMP-H and 
CIMP-L/N tumours exhibited similar frequencies of amplifications within 8q (66.7% 
CIMP-H, 51.3 CIMP-L/N), and deletions in chr18 (66.7% CIMP-H, 53.8% CIMP-L/N) 
and 17p (66.7% CIMP-H and 48.7% CIMP-L/N). 
 
 
Table 4.14 CIN and CIMP 
 Copy number aberrations (CIN) 
 
No. of samples No. of Aberrations (range) Mean Median 
CIMP-H 6 18-76 50.50 55.50 
CIMP-L/N 39 1-411 71.64 43.00 
 
 
Figure 4.25 CIMP status and chromosomal aberrations 
Box plot and whisker charts representing the range and mean of chromosomal aberrations in 
CIMP-L/N cases compared to CIMP-H cases. 
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4.2.7.3 CIN and molecular and clinical features 
A summary of the molecular and clinical characteristics of the 53 cases in relation to 
CIN status is presented in Table 4.15. Chromosomally stable samples did not have 
any TP53 mutations while CIN samples had high frequency (54.2%), however, this 
difference was borderline statistically significant (p-value = 0.051). Moreover, CIN 
samples had relatively lower PIK3CA mutation frequency, but this was not 
statistically significant (p-value = 0.093). No associations were found with patient‟s 
gender (p-value = 0.356), or tumour location (p-value = 0.613) or mutations in KRAS 
(p-value = 1.000), BRAF (p-value = 1.000), or APC (p-value = 0.669). 
 
Table 4.15 CIN status and molecular and clinical features 
  
CIN status 
 
  
n (%) 
 
  
CIN positive CIN negative 
 
  
48 (100.0) 5 (100.0) p-value 
KRAS 
Mutant 17 (35.4) 2 (40.0) 
1.000 
WT 31 (64.6) 3 (60.0) 
BRAF 
Mutant 2 (4.2) 0 (0.0) 
1.000 
WT 46 (95.8) 5 (100.0) 
PIK3CA 
Mutant 4 (8.3) 2 (40.0) 
0.093 
WT 44 (91.7) 3 (60.0) 
TP53 
Mutant 26 (54.2) 0 (0.0) 
0.051 
WT 22 (45.8) 5 (100.0) 
APC 
Mutant 25 (52.1) 2 (40.0) 
0.669 
WT 23 (47.9) 3 (60.0) 
Tumour Location 
Proximal 17 (35.4) 2 (40.0) 
1.000 
Distal 31 (64.6) 3 (60.0) 
Gender 
Male 24 (50.0) 4 (80.0) 
0.355 
Female 24 (50.0) 1 (20.0) 
 
4.2.8 Molecular classification of the tested samples 
All the tested samples were MSS, therefore, none of them will fit within the MSI-H 
pathway. Out of the 5 chromosomally stable samples, 4 were CIMP-L. Table 4.14 
summarises the molecular characteristics of the 4 chromosomally stable/CIMP-L 
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samples. These samples can fit within the heterogeneous CIMP-L subtype described 
in Section 1.3.5.1.3.  
Table 4.16 Molecular and clinical features of the CIN negative samples 
Sample ID BRAF KRAS TP53 APC PIK3CA Location Gender Age 
CA023 WT WT WT Mut Mut Proximal Male 79 
CA037 WT Mut WT Mut WT Distal Male 57 
CA046 WT Mut WT WT Mut Distal Female 65 
CA110 WT WT WT WT WT Proximal Male 78 
 
One of the chromosomally stable samples (CA248) was also CIMP-N (and MSS). 
Therefore, CA248 fits within the chromosomally stable, CIMP-N, MSS subtype 
described in Section 1.3.5.1. Sample CA248 is referred to in the following section. 
The remainder of the samples were identified as chromosomally unstable. Six of 
these samples were also CIMP-H. The 6 CIMP-H samples did not differ from the rest 
of the CIN samples in terms of frequency of aberrations. A summary of the molecular 
and clinical features of all the CIN positive samples stratified according to their CIMP 
status (CIMP-H and CIMP-L/N) is presented in Table 4.17. Two tailed Fisher‟s exact 
test was used to test for differences between the 2 groups (CIN/CIMP-H and 
CIN/CIMP-L/N). Neither groups had any significant difference in terms of tumour 
location (p-value = 0.167), patient‟s gender (p-value = 0.188), or mutations in 
PIK3CA (p-value = 0.425), TP53 (p-value = 1.000) and APC (p-value = 0.668). 
However, the CIN/CIMP-L/N had significantly fewer KRAS/BRAF mutations (p-value 
= 0.022). In summary, the analysed cohort can be divided into 3 molecular 
subgroups; chromosomally stable CIMP-L/MSS (11.9%), CIN/CIMP-H/MSS (14.3%) 
and CIN/MSS subgroup (71.6%), in addition to CA248 which did not show any form 
of genomic instability. Figure 4.26 represents the 3 molecular subtypes identified in 
the screened samples. 
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Table 4.17 CIN positive samples and CIMP status 
CIN positive samples 
CIMP status 
 
n (%) 
 
CIMP-H CIMP-L/N 
 
6 (100.0) 42 (100.0) p-value 
KRAS/BRAF 
Mutant 5 (83.3) 13 (31.0) 
0.022 
WT 1 (16.7) 29 (69.0) 
PIK3CA 
Mutant 1 (16.7) 3 (7.1) 
0.425 
WT 5 (83.3) 39 (92.9) 
TP53 
Mutant 3 (50.0) 23 (54.8) 
1.000 
WT 3 (50.0) 19 (45.2) 
APC 
Mutant 4 (66.7) 21 (50.0) 
0.668 
WT 2 (33.3) 21 (50.0) 
Tumour Location 
Proximal 4 (66.7) 13 (31.0) 
0.167 
Distal 2 (33.3) 29 (69.0) 
Gender 
Male 5 (83.3) 19 (45.2) 
0.188 
Female 1 (16.7) 23 (54.8) 
 
 
Figure 4.26 The molecular subtypes identified in the screened cohort 
* Mutations details, in addition to CIMP and CIN are summarised in Appendix 6. 
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4.2.9 Molecular characteristics & CRC phenotype (extreme cases) 
One of the investigated samples (CA248) was shown to be MSS, chromosomally 
stable and with CIMP-N. This subset of CRC was previously reported at a similar low 
frequency (Cheng et al. 2008). However, surprisingly, the patient (CA248) did not 
even have any of the common somatic key mutations discussed above. The patient 
was diagnosed with CRC in the year 2002 at the age of 65 without any family history 
of cancer. The cancer had very good prognosis, it responded well to treatment, and 
cancer registry records of March 2011 show that the patient was still alive at this 
time.  
 
On the other hand, one of the cases (CA208) had 5 somatic mutations; APC, BRAF 
and KRAS, in addition to 2 somatic mutations in TP53. Moreover, the tumour was 
chromosomally unstable with CIMP low (but MSS). The patient did not have any 
family history of cancer, but she was diagnosed with CRC at the age of 51 and died 
within 1 month of diagnosis due to aggressive cancer progression. The aggressive 
CRC behaviour and the bad prognosis might be explained by the complex molecular 
characteristics of the tumour. 
4.3 Discussion 
As described earlier, molecular classification of CRC can play an important role in 
research and in the clinic. Towards the beginning of the project, 4 main studies were 
published on the molecular classification of CRC (Chang et al. 2006, Shen et al. 
2007, Cheng et al. 2008, Derks et al. 2008). One of the drawbacks of these initial 
studies was the lack of standardisation, especially when analysing CIN and CIMP, 
which makes it very difficult to compare the findings. The initial aim of this project 
was to try and classify our CRC samples using more standardised methods and 
marker panels.  
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4.3.1 Quality measures and MSI testing 
A thorough molecular characterisation was performed on our samples. The matched 
normal/tumour DNA samples were verified as coming from the same patient. MSI 
analysis was the first step of our classification, and a relatively new marker panel was 
used. This panel was developed according to the revised NCI recommendations on 
MSI testing (Bacher et al. 2004). Two samples out of 57 were shown to be MSI-H, 
however, they were excluded from further study because of contamination with a 
different DNA sample in sample CA945, and because of high levels of normal DNA in 
sample CA008. The remaining samples were all considered to be MSS. Because of 
the size of our sample, the expected number of MSI-H cases was ~6-9 based on a 
known MSI frequency of ~10-15% of sporadic CRC. The frequency of MSI-H in our 
samples (n=2, 3.6%) was below the expected. This could be due to sampling 
variation (i.e. chance), or due to limitations in the detection technique. We 
determined the sensitivity of the MSI detection kit by testing a serial dilution of MSI-H 
DNA extracted from HCT-116 cell line DNA. HCT-116 cells are classified as the MSI-
H/CIMP-H subtype. The analysis showed the ability of the kit to detect MSI down to 
10% dilution (assuming careful examination). Logically, therefore, only MSI-H 
tumours with a very high level of normal DNA contamination would have been 
missed by this assay. Thus, we considered the remaining cases as MSS. 
4.3.2 Sporadic CRC driver mutations 
The paired cohort DNA samples were tested for the most common mutations of the 
key CRC driver genes; APC, TP53, KRAS, BRAF and PIK3CA. The frequencies of 
the mutations found, especially BRAF (3.8%) and PIK3CA (11.3%), are consistent 
with the MSS nature of our cohort. Mutations in both genes were previously shown to 
cluster with MSI-H samples and the frequencies of mutations in both genes in our 
cohort were below those expected for a sporadic CRC cohort (Weisenberger et al. 
2006, Abubaker et al. 2008). In contrast, the frequency and pattern of APC (54.7%), 
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TP53 (49%) and KRAS (36%) mutations were within the expected range for sporadic 
CRC. These mutations are more common in sporadic CRC than BRAF and PIK3CA 
and they have a wider range of mutations.  
4.3.3 CpG island methylator phenotype and MS-MLPA 
The samples were screened for CIMP using a set of 7 methylation markers 
(CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1 and RUNX3), which had 
been shown in a previous large study to specifically and accurately estimate the 
genomic CIMP status. MS-MLPA was used to estimate CIMP (Ogino et al. 2007). 
None of the studies in CRC have previously used MS-MLPA and the kit used 
(ME042-A1) was still under-development by MRC-Holland. The performance and 
accuracy of the kit was tested and the results confirm the ability of the MS-MLPA kit 
to accurately estimate methylation levels. In summary, out of the 53 tested samples, 
6 (11.3%) were defined as CIMP-H, 41 (77.4%) as CIMP-L and 6 (11.3%) were 
defined as CIMP-N. The CIMP-H frequency was less than expected, (~20%), for 
sporadic CRC (Cheng et al. 2008). However, this can be explained by the MSS 
nature of the analysed cohort. CIMP-H and MSI-H are known to strongly associate 
together in sporadic CRC (Weisenberger et al. 2006). The absence of KRAS, BRAF 
and PIK3CA mutations from the CIMP-N subgroup confirms the existence of CIMP-L 
as an independent subgroup of CIMP with a distinct biological background (Ogino 
and Goel 2008).  
4.3.4 Chromosomal instability and array CGH 
Finally, CIN was investigated in the samples using aCGH. High-resolution genome 
wide aCGH platforms were used and their intrinsic reproducibility was confirmed. Our 
samples exhibit a high frequency of CIN (90.1%, n=48), which is higher than 
expected for sporadic CRC samples (65-85%) (Pino and Chung 2010, Migliore et al. 
2011). CIN samples had a higher frequency of TP53 mutations (p-value = 0.051) and 
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none of the chromosomally stable samples had mutations in TP53 which agree with 
previously published data (Chang et al. 2006).  
 
The overall pattern of identified broad CNA, amplifications within chromosomes 20q 
(73.3%, n=33), 13 (57.8%, n=26), 8q (53.3%, n=24), 7 (51.1%, n=23) and X (51.1%, 
n=23) and deletions within chromosomes 18 (55.6%, n=25), 8p (51.1%, n=23) and 
17p (51.1%, n=23), strongly agree with published data (Hermsen et al. 2002, 
Lassmann et al. 2007, Poulogiannis et al. 2010a) 
4.3.5 Molecular associations and CRC subtypes 
In summary, 3 CRC molecular subtypes were observed in our cohort (Figure 4.26). 
Chromosomally stable/CIMP-L characterised by lower levels of CIMP, MSS and 
absence of chromosomal aberrations and TP53 mutations. The 2nd subtype was the 
CIN subtype characterised by CIN, MSS, TP53 mutations and distal tumours. The 3rd 
subtype was characterised by high levels of CIMP, CIN, MSS and KRAS and BRAF 
mutations. These results clearly confirm the molecular heterogeneity of sporadic 
CRC. Statistical analyses have also confirmed previous correlations between CIMP-
H and KRAS/BRAF mutations. Finally, the known association between TP53 
mutations and CIN was also confirmed.  
 
Interestingly, our CIMP-H samples were neither mutually exclusive with CIN nor 
correlated with low degree of CIN, as previously reported (Goel et al. 2007, Cheng et 
al. 2008). CIMP-H samples were characterised with CIN and they were not 
statistically different from other CIN samples (CIMP-L/N) (Mann Whitney U-test, p-
value = 0.88). This could be the result of sample size, however, the previous study 
that has shown a mutual exclusive relationship between CIMP-H and CIN employed 
LOH analysis to define CIN (Goel et al. 2007). LOH analysis is known to 
underestimate CIN and result in false negative chromosomally stable cases (Ogino 
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and Goel 2008). On the other hand, the cases in the study that established the 
association between CIMP-H and lower degree of chromosomal aberrations were 
mainly CIMP-H/MSI-H cases (Cheng et al. 2008). MSI and CIN have a well-
established mutually exclusive relationship (Ogino and Goel 2008). Therefore, the 
association between CIMP-H and the lower degree of CIN in this study could well be 
MSI dependent. Close examination of the data from the study by Cheng and 
colleagues has confirmed this suggestion. Four of the 60 investigated cases (6.67%) 
were CIMP-H/MSS samples and they had more chromosomal aberrations than 
CIMP-H/MSI-H samples. In fact, one case with the highest number of chromosomal 
aberrations was a CIMP-H/MSS sample. In their conclusion, the authors did suggest 
that the association between CIMP-H and low degree of CIN could reflect the inverse 
relationship between CIN and MSI and they anticipated the possible existence of the 
CIN/CIMP-H subset (Cheng et al. 2008). Nevertheless, a CIN/CIMP-H/MSS subtype 
has not been proposed by any of the current CRC molecular classification systems 
(Jass 2007, Issa 2008, Ogino and Goel 2008). Based on our data and the suggestion 
made by Cheng and colleagues, we propose the existence of a novel CIMP-H/MSS 
CRC subtype with high levels of CIN. However, this subtype needs to be confirmed in 
a larger sample size with more CIMP-H/MSS samples.  
 
Although the frequency of the CNA was similar across chromosomally unstable 
samples regardless of CIMP status, there were some differences in terms of common 
broad CNA patterns. Amplifications within 13q, 20q and chrX were less frequent in 
the CIMP-H samples. However, chr7 amplifications and 8p deletions were less 
common in the CIMP-L/N samples. Similar differences in the frequencies of 
amplifications within 13q and 20q were recently observed between CIN/MSS tumours 
and the rare CIN/MSI-H tumours (Poulogiannis et al. 2010a). These observations 
indicate that 13q and 20q amplifications play an important and specific role in the 
samples developing primarily through the CIN pathway. In contrast, CIMP-H and 
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CIMP-L/N chromosomally unstable samples had similar frequencies of 8q 
amplifications and 18q and 17p deletions. Likewise, MSI-H and MSS chromosomally 
unstable samples showed the same pattern for 8q amplifications (Poulogiannis et al. 
2010a). This might indicate that 8q aberrations might play a role in the development 
of CRC in general.  
 
Also, MS-MLPA technology was shown to be useful for testing CIMP. This will be 
essential if this molecular classification is to become of use in the clinical setting. 
Commonly used methylation techniques for determining CIMP are time consuming 
and they cannot be multiplexed. Moreover, they are all bisulphite treatment 
dependent, which in addition to requiring large amounts of DNA, introduces more 
variability. All the markers required for CIMP testing in CRC were multiplexed in a 
single MS-MLPA test that requires a small amount of DNA (as low as 50ng) without 
bisulphite treatment.  
 
Finally, two of the investigated samples, CA248 and CA208 demonstrate the 
opposite ends of the CRC molecular background. CA248 did not have any defects in 
the investigated molecular characteristics, the patient was diagnosed at the age of 
62, and had a very good survival. On the other hand CA208 had 5 somatic mutations 
in APC, TP53 (2 mutations), KRAS and BRAF, in addition to, CIMP-L and CIN. The 
patient was diagnosed with CRC at the age of 51 and died within 1 month due to 
cancer progression. These 2 extreme cases demonstrate the prognostic value of 
molecular characterisation. 
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5. Focal Minimal Common Regions in Microsatellite Stable 
Colorectal Cancer 
5.1 Introduction  
Three main genomic instabilities are thought to drive CRC development; CIN, MSI 
and CIMP (Migliore et al. 2011). CIN is the most common and is associated with 65-
85% of CRC cases (Derks et al. 2008, Issa 2008, Pino and Chung 2010, Migliore et 
al. 2011). Tumours that develop through the CIN pathway are characterised by 
frequent numerical and/or structural gains and losses of chromosomal segments or 
whole chromosomes (Rajagopalan et al. 2003). CIN is thought to drive CRC 
development through the amplification of oncogenes and the deletion of TSG (Kozma 
et al. 1994, Ozakyol et al. 2006, Tanaka et al. 2006, Martin et al. 2007, Ogino and 
Goel 2008, Migliore et al. 2011). This view is supported by the strong association 
reported between copy number abnormalities of cancer-related genes and their 
expression levels in CRC samples (Tsafrir et al. 2006, Sheffer et al. 2009, Brosens et 
al. 2010). 
 
Although most of the chromosomal aberrations arise in a random fashion, some are 
recurrent and are commonly found in different colorectal tumours and other types of 
cancer (Martin et al. 2007, Beroukhim et al. 2010, Brosens et al. 2010). These 
common aberrations were probably selected for during tumour development for 
providing a survival advantage. Recurrent CNA provide the tumour with a way of 
targeting TSG and oncogenes to acquire one or more of the cancer hallmarks and 
drive tumourigenesis (Martin et al. 2007). Several common chromosomal 
abnormalities have been identified through conventional cytogenetic techniques, 
such as metaphase CGH and fluorescent in situ hybridisation (FISH), and are 
thought to drive CRC development (Hermsen et al. 2002, Diep et al. 2006, Lassmann 
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et al. 2007).  These chromosomal defects include gains of 8q, 13q and 20q and 
losses of 18q, 5q, 8p, 17q (Hermsen et al. 2002, Lassmann et al. 2007). However, 
due to their large size, identification of specific driver genes within these regions is 
usually challenging (Carvalho et al. 2009, Brosens et al. 2010).  
 
Recent developments in the technologies used to define CIN, primarily array based 
methods, and advances in the computational algorithms used to interpret the results, 
have resulted in the acquisition of genome-wide information with high resolution 
(down to a few Kb) (Beroukhim et al. 2010, Brosens et al. 2010). This, in turn, has led 
to the identification of common focal chromosomal CNA. These focal CNA are 
usually smaller than 3Mb in size and thus contain a relatively small number of genes, 
hence simplifying the identification of driver genes (Brosens et al. 2010). Recently, 
focal CNA have led to the identification of several novel cancer driver genes with 
potential therapeutic and prognostic value in several cancer types including CRC 
(Andersen et al. 2010, Beroukhim et al. 2010, Bredel et al. 2010, Brosens et al. 2010, 
Poulogiannis et al. 2010a, Poulogiannis et al. 2010b, Veeriah et al. 2010, Dyrso et al. 
2011). Nonetheless, the picture is far from complete and many of these recurrent 
CNA and their target genes are yet to be identified (Andersen et al. 2010). 
 
Around 90.1% (n=48) of the 53 sporadic CRC cases investigated in this study were 
characterised by CIN and were MSS (Section 4.2.6.5). Only six of these CIN samples 
(~16%) were found to be CIMP-H. Therefore, CIN was considered the main form of 
genomic instability and a major driving force for CRC development amongst this 
cohort. The aims of the work described in this chapter were as follows. Firstly, 
identify the common CNA in the 45 CIN samples. Secondly, define the focal and 
highly recurrent minimal common regions (MCR) of the CNA and thirdly, identify any 
novel putative CRC driver genes located within these regions. A final aim was to 
confirm the aberrations in some of the candidate driver genes using qPCR.  
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5.2 Results 
5.2.1 Focal amplifications and deletions 
The aCGH data described in section 4.2.6 was used in the analysis performed in the 
following sections. Out of the 3097 CNA identified in the 45 chromosomally unstable 
samples, 1689 aberrations were focal (<3.0Mb) ranging in size from 0.0136Mb up to 
2.9992Mb (mean: 0.9518Mb, median: 0.7058Mb). The focal aberrations consisted of 
746 amplifications with a size range of 0.0136Mb-2.9897Mb (mean: 1.0882Mb, 
median: 0.9148Mb) and 943 deletions, with a size range of 0.02450Mb-2.9992Mb 
(mean: 0.8438Mb, median: 0.5747Mb).  
5.2.2 Minimal common regions 
The presence of several CNA arising at the same region in different samples allows 
definition of so-called “minimal common regions” (MCR). Figure 5.1 represents the 
concept of delimiting MCR by the combined analysis of several samples. The first 
step towards defining these MCR in the analysed cohort was attempted by using the 
context corrected common aberration (COCA) algorithm. 
 
Chromosome 10 aCGH data from 4 different cases, probes coloured in black represent 
genomic regions with a log2ratio around zero, probes coloured in red and green represent 
amplifications (log2ratio ≥ 0.5) and deletions (log2ratio ≤ -0.5) respectively. The 4 samples had 
amplifications of variable sizes. Combined analysis of the data delimits the minimal common 
region of amplification in the 4 cases. The MCR is marked by transparent red box. 
Figure 5.1 Delimiting an MCR from four different samples 
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5.2.2.1 Context corrected common aberration analysis results 
In order to identify recurrent CNA, COCA analysis was performed as described in 
Section 2.2.15.11.4. COCA employs several steps. Firstly, the software considers all 
the aberrations reported by the ADM2 as candidate regions. Secondly, it assigns a 
score for each of these candidate regions. This score is based on the ADM2 results 
and the amplitude of the aberration, thus, it reflects the potential significance of each 
aberration in each sample. Finally, the hypothesis that a specific aberration is a 
common aberration in a certain number of samples is tested and each common 
aberration assigned a p-value and a final COCA score (-log10 of the p-value), which 
reflects the significance of the recurrent CNA.  
 
When applied to the ADM2 results from the 45 cases, COCA identified 357 recurrent 
deletions and 286 recurrent amplifications. A graphical summary of the common CNA 
is presented in Figure 5.2. 
 
 
Figure 5.2 Heat map of common aberrations identified by COCA 
Red represents amplifications, green represents deletions, the intensity of the colour reflects 
the frequency and the width of the bars reflects COCA score. 
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5.2.3 Focal minimal common regions 
Some of the small common CNA occur within larger aberrant regions. In some of the 
cases, the COCA report summarises the large common aberrations encompassing 
the smaller ones, in other words, maximum rather than minimum common regions. 
Moreover, based on the amplitude and the size of the aberration from different 
samples, COCA separates a single common aberrant region into several (Figure 5.3 
A). Therefore, the data output from COCA needed further analysis in order to 
accurately define the MCR.  
 
The MCR were defined by applying an algorithmic approach that scanned the 
common regions identified by COCA output and recalculated the predicted MCR 
when necessary. The algorithm was designed by Wei-Yu Lin (Post-Doctoral 
researcher in our group) and delimits the MCR using aberration breakpoints in that 
region. The genomic location at the start of the aberration lying furthest downstream 
(the maximum “start” of the common aberrations in the area) was subtracted from the 
genomic location at the most upstream end of another aberration (the minimum “end” 
of the common aberrations in the area) (Figure 5.3 B).  
 
All of the MCR identified by this algorithm were checked manually and aberrations 
that played a role in defining the size of the MCR, referred to as size determining 
events (SDE), were summarised (Figure 5.3B). Next, the MCR were filtered by size 
and only those with a size of 3Mbs or less were retained. These focal MCR (FMCR) 
were then filtered by frequency and any FMCR occurring in less than 10% of the 
cases were excluded from further analysis. The final step was to filter according to 
SDE, and FMCR were only kept when defined at least by 2 SDE (Figure 5.4). In 
order to increase the stringency of defining the significant FMCR, the minimum 
accepted COCA score was increased to ~2.0 (p-value of 0.01). These criteria 
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resulted in a list containing 64 deletions and 32 amplifications (Table 5.1 and Table 
5.2). 
 
 
Figure 5.3 Recurrent CNA area on chr20p (MACROD2 gene region) 
A) COCA output identifies several common aberrations in the presented area. B) The 
coloured lines represent different deletions in the area. The green transparent box represents 
the MCR identified by the in-house algorithm. Green arrows mark all the SDE in that area. 
The green circles mark the genomic locations of the maximum start and the minimum end of 
the 2 SDE that defined the MCR size. 
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Coloured horizontal lines represent aberrations. SDE are marked by horizontal green arrows 
and vertical transparent green boxes represent MCR. A) An MCR identified by 1 SDE, B) An 
MCR identified by 5 SDE. 
 
5.2.3.1 Summary of focal minimal common regions 
The 64 deleted FMCR ranged in size between 0.03-2.64Mb (median: 0.42Mb, mean: 
0.62Mb) and contained a total of 714 known genes with a range of 0-69 genes 
deleted per region (median: 4 genes, mean: 11 genes) (Table 5.1). The 32 amplified 
FMCR ranged between 0.03-1.96Mb in size (median: 0.83Mb, mean: 0.85Mb) and 
contained a total of 288 known genes with a range of 0-34 genes amplified per region 
(median: 3 genes, mean: 9 genes) (Table 5.2). It should be emphasised that for 
amplified FMCR, genes were only included in this count if they were fully contained 
within an FMCR. However, in the case of deleted FMCR, partially affected genes 
overlapping the size of delineation were included. Subsequently, deleted and 
amplified FMCR sets were checked for well-known cancer genes. To this end, the 
genes within the deleted and amplified FMCR were cross-checked against the 
complete gene list from the cancer gene census project 
Figure 5.4 Size determining events 
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(http://www.sanger.ac.uk/genetics/CGP/Census/, accessed August, 2011), and the 
CRC and breast cancer driver genes identified in a relatively recent high throughput 
re-sequencing study (Wood et al. 2007). This analysis indicated the presence of 25 
“cancer genes” located within the deleted FMCR (~3.5% of the total number of 
deleted genes) and 11 “cancer genes” within the amplified FMCR (~3.8% of the total 
number of amplified genes). 
 
The occurrence of a cancer gene within an FMCR does not necessarily imply that it 
is a driver gene within that area. For some “cancer genes”, the type of FMCR 
(deleted or amplified) was not consistent with the known gene function, an example 
being the deletion of the known oncogene NRAS (Table 5.1). However, the gene 
function and the type of the FMCR were often consistent with expectation, examples 
include deletions of MAP2K4 and CDKN2C (Table 5.1) and amplification of FGFR1 
(Table 5.2). Perhaps, most importantly, the classical SMAD4 tumour suppressor 
deletion and oncogenic MYC amplification were both observed within deleted and 
amplified FMCR respectively. The frequency of both SMAD4 deletions and MYC 
amplifications in the 45 chromosomally unstable cases was high at ~53% (Table 5.1 
and Table 5.2). 
Table 5.1 Deleted FMCR 
Chromosomal  
location 
Start End Size (Mb) Recurrence (%) SDE Genes Cancer genes 
1p36.33 1479210 1851002 0.37 20.00 3 12 MLLT11, ARNT 
1p36.11-p35.3 26462948 28551543 2.09 24.44 4 46 ARID1A 
1p34.3 36375018 36734648 0.36 22.22 3 10 THRAP3 
1p33 49486071 50272200 0.79 22.22 3 1   
1p33-p32.3 50698666 51354770 0.66 20.00 2 2 CDKN2C 
1p31.1 78062885 78218246 0.16 20.00 2 3   
1p21.1 102307656 103278518 0.97 20.00 2 1 COL11A1 
1p13.2 112844021 115479162 2.64 17.78 2 29 NRAS, TRIM33 
1q21.2-q21.3 147644631 149711565 2.07 11.11 3 69   
1q31.3 196799738 196948778 0.15 13.33 2 1   
2p14 69914199 70385803 0.47 11.11 4 10   
2q33.1 197546654 198133273 0.59 13.33 4 6   
2q33.1 201432284 201850246 0.42 17.78 6 9   
2q37.1 232634311 232902204 0.27 11.11 2 1   
3p14.3 57521404 57652691 0.13 24.44 4 3   
3p14.2 60078018 61195823 1.12 31.11 7 1 FHIT 
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3q21.3 129834187 130497580 0.66 13.33 2 11 RPN1, CNBP 
3q26.1 163997028 164101976 0.10 17.78 2 0   
3q26.31 176177125 176426607 0.25 13.33 3 1   
4q22.1 91340468 92674544 1.33 33.33 8 2   
4q35.1 185447304 186062400 0.62 31.11 3 5   
5q12.1 59145099 59183979 0.04 22.22 2 1   
5q13.2 68438765 68906238 0.47 24.44 2 14   
5q35.1-q35.2 172069779 172570325 0.50 17.78 3 7   
6p22.1 26141996 26381758 0.24 15.56 2 26   
6p21.33-p21.32 31388886 32258223 0.87 13.33 3 63   
6p21.31 35536901 35954862 0.42 11.11 2 11 FANCE 
6q21 111214198 111443834 0.23 15.56 2 4   
6q26 162357125 163049854 0.69 22.22 7 1   
7q22.1 99307476 101900781 2.59 17.78 5 68 CUX1 
7q22.2 105680893 105712574 0.03 11.11 3 1   
8p22 16198781 16863085 0.66 48.89 2 0   
8p11.23 39431213 39480174 0.05 22.22 3 0   
8q11.21 48247963 48556480 0.31 13.33 4 1   
8q24.3 145103393 145715756 0.61 13.33 3 36 RECQL4 
9q21.13 73537301 74412105 0.87 17.78 3 7   
9q22.2 91117607 91411397 0.29 22.22 2 5   
10q23.32-q23.33 94363548 94454268 0.09 22.22 3 2   
11p15.4 3712771 3873442 0.16 15.56 3 4 NUP98 
11p15.4 9172449 9363610 0.19 22.22 5 3   
11p11.2 47337056 47964454 0.63 11.11 4 14   
11p11.2-p11.12 48215588 50164184 1.95 13.33 5 9   
11q13.1 63705254 63872837 0.17 15.56 2 17   
12p13.31 6314214 6963027 0.65 11.11 4 37 ZNF384, ATN1 
12q14.2 63277389 63368109 0.09 20.00 4 1   
12q24.31 122199734 122593396 0.39 17.78 5 8   
14q12 23615376 23888497 0.27 24.44 3 28   
14q13.2 34108596 34950339 0.84 28.89 5 9   
15q21.3 53286334 53506655 0.22 28.89 2 4   
15q26.1 88098779 89290699 1.19 31.11 4 20   
15q26.1 91163633 91270553 0.11 28.89 3 1 BLM, CRTC3, IDH2 
16p13.3-p13.2 6132536 7018275 0.89 24.44 7 1   
17p13.1 8743396 8866516 0.12 46.67 2 1   
17p13.1-p12 10957541 12400968 1.44 48.89 5 3 MAP2K4 
18p11.21 11759039 12046289 0.29 42.22 2 4   
18q12.2 32736160 32823241 0.09 51.11 2 1   
18q21.2 46648889 46859053 0.21 53.33 3 3 SMAD4 
19p13.3 909095 1223851 0.31 20.00 4 16 STK11 
19q13.11 17936643 18549005 0.61 20.00 2 21 ELL 
20p12.1 14376202 16071135 1.69 37.78 10 1   
21q22.11 33554005 33651205 0.10 28.89 7 3   
22q13.1 37647505 38597446 0.95 26.67 3 18 PDGFB 
22q13.33 48580338 49052472 0.47 26.67 3 16   
Xq25 122938369 123237260 0.30 15.56 3 1   
 
Table 5.1 summarises the deleted FMCR identified in the 45 chromosomally unstable 
samples. FMCR are arranged by genomic location (hg18 assembly). Genes within the FMCR 
were determined according to the UCSC genome browser (http://genome.ucsc.edu/, 
accessed August, 2011). “Cancer genes” are derived from the cancer gene census and Wood 
et al. 2007. 
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Table 5.2 Amplified FMCR 
Chromosomal  
location 
Start End Size (Mb) Recurrence (%) SDE Genes Cancer genes 
1p36.32 2412144 3630036 1.22 26.67 7 11 PRDM16, TNFRSF14 
1p36.13 17783440 18947883 1.16 17.78 4 4 PAX7 
1p35.1-p34.3 33866043 34889487 1.02 15.56 4 2   
1p34.3 36881028 37535891 0.65 20.00 5 1   
1q21.3 150753997 150969016 0.22 22.22 5 19   
1q21.3-q22 153171645 153567906 0.40 20.00 4 29 MUC1, THBS3 
1q32.1 203312447 205274691 1.96 15.56 2 34 ELK4, SLC45A3 
2p13.2-13.1 72867953 73995941 1.13 17.78 3 16   
2q11.2 96118572 97026741 0.91 15.56 3 21 CNNM4 
2q14.2 120835644 121713081 0.88 15.56 3 1   
2q21.2 132747027 132833787 0.09 17.78 2 0   
2q33.1 199239915 200062504 0.82 15.56 2 1   
2q35 218354227 218556081 0.20 20.00 5 1   
3p25.3 10406898 10978905 0.57 15.56 2 1   
5p15.33 131946 1578616 1.45 26.67 2 22 SLC6A3 
6p21.2-p21.1 39059270 40756937 1.70 24.44 2 9   
7p22.3-p22.2 1262920 2812963 1.55 46.67 2 18   
7p22.1-p21.3 7033162 7829887 0.80 48.89 5 4   
8p12-p11.23 38303146 39234126 0.93 15.56 5 7 FGFR1 
8q23.3 113827791 114547454 0.72 51.11 4 0   
8q24.21 128331769 128940144 0.61 53.33 2 1 MYC 
10q22.3 78238542 79084656 0.85 20.00 4 1   
10q26.3 133770546 135084977 1.31 15.56 3 22   
11p15.5-p15.4 916837 2837148 1.92 33.33 10 31   
12p13.32-p13.31 4282429 5364999 1.08 40.00 4 12   
14q11.2 21680489 21935641 0.26 20.00 3 0   
15q21.3-q22.1 55517770 56143371 0.63 11.11 2 2   
15q24.1 72478743 72569181 0.09 17.78 2 2   
16p13.3 738567 1229020 0.49 28.89 4 13   
17q11.2-q12 28205256 29488626 1.28 28.89 3 2   
22q11.21 18517833 18686313 0.17 20.00 4 1   
22q13.31 44865639 44898001 0.03 17.78 3 0   
 
Table 5.2 summarises the amplified FMCR identified in the 45 chromosomally unstable 
samples. FMCR are arranged by genomic location (hg18 assembly). Genes within the FMCR 
were determined according to the UCSC genome browser (http://genome.ucsc.edu/, 
accessed August, 2011). “Cancer genes” are derived from cancer gene census and Wood et 
al. 2007. 
 
5.2.3.2 FMCR and published focal aberrations in CRC 
In order to further validate our panel of deleted and amplified FMCR, they were 
compared to previously identified focal aberrations in CRC samples. Common 
chromosomal aberrations identified in four recent studies on CRC were used for the 
comparison (Martin et al. 2007, Leary et al. 2008, Andersen et al. 2010, Brosens et 
al. 2010). A summary of the technologies used in identifying the chromosomal 
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aberrations, the platforms and the resolutions, in addition to the number of primary 
CRC cases and CRC cell lines included in each study is presented in Table 5.3. 
Table 5.3 Previously published studies on focal aberrations in CRC 
 Martin et al. 2007 Leary et al. 2008 Brosens et al. 2010 Andersen et al. 2010 
Technology aCGH SNP array aCGH SNP array 
Platform Agilent 1AV2 SNP6.0 Agilent 44K SNP6.0 
Resolution ~55Kb ~30-50Kb ~43Kb ~30-50kb 
CRC Cases 42 36 38 33 
CRC cell lines 37 NA NA 40 
Adenomas NA NA NA 40 
 
In order to perform a valid comparison, only focal aberrations ≤3Mb in size were 
included. The combined total of focal aberrations identified in these studies was 187 
amplifications and 189 deletions. The published focal aberrations from each study 
were compared to identify any levels of similarity. The 4 studies had 10 overlapping 
focal deletions (5.3%) and 29 overlapping focal amplifications (15.5%). The published 
aberrations were then compared to the FMCR identified in our study. In total, 27 
overlapped focal deletions (42.2% of our identified deleted FMCR) and 11 
overlapped focal amplifications (34.4% of our identified amplified FMCR) were 
observed.  
 
The common overlapping areas between our FMCR and the published focal 
aberrations were investigated in order to check whether they were biologically 
significant. This was performed by examining if the overlapped regions contained the 
known cancer genes. Four of the overlapped FMCR carried established cancer 
genes (MYC, FGFR1, SMAD4 and MAP2K4). The overlapped regions were smaller 
in all cases compared to identified FMCR, and they all contained these cancer 
genes. Interesting examples were FGFR1 regions, where an overlap between our 
identified amplification FMCR of 931Kb (containing 7 genes) (Table 5.2), and a 
published focal amplification of 1475Kb resulted in a delimited region of 145Kb that 
contained only 2 genes, one of which was FGFR1.  
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5.2.3.3 FMCR and published CNA across several cancer types 
A large somatic CNA study was recently performed in 26 different cancer types, 
including CRC (Beroukhim et al. 2010). The study identified a list of the 20 most 
common somatic deletions and amplifications across the analysed cancer types. 
Moreover, a candidate driver gene was also selected for each of the common 
aberrations (Table 5.4).  
 
A comparison between our FMCR and the most common regions in the above study 
revealed an overlap with five of the deletion areas (25%) and 3 of the amplification 
areas (15%). All the candidate genes identified by Beroukhim and colleagues in their 
study were contained within the overlapping areas from our FMCR. 
Table 5.4 Candidate driver genes of the most common cancer CNA 
Deletion Amplification 
Chromosome Gene Chromosome Gene 
1p DFFB 1p MYCL1 
2q LRP1B 1q MCL1 
2q BOK 3q PRKC1 
3p FHIT 5p TERT 
4q TMSL3 7p EGFR 
4q FAT1 8p FGFR1 
5q PLK2 8p IKBKB 
6q PARK2 8q MYC 
7q TRB 11q CCND1 
8p CSMD1 12p KRAS 
9p PTPRD 12q CDK4 
9p CDKN2A/B 12q HMGA2 
10q PTEN 12q MDM2 
12p ETV6 12q CCT2 
13q RB1 14q NKX2-1 
16p A2BP1 15q IGF1R 
16q WWOX 17q ERBB2 
19q PPAP2C 19q CCNE1 
20p MACROD2 22q CRKL 
22q PPM1F Xq IRAK1 
 
Table 5.4 summarises the candidate driver genes identified across 26 different cancer types. 
Genes in bold were also found in the FMCR identified in this study (Beroukhim et al. 2010). 
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5.2.3.4 FMCR and pathway analysis 
In order to search for any specific patterns or pathways affected by the genes within 
the deleted or amplified FMCR, the Database for Annotation, Visualisation, and 
Integrated Discovery (DAVID) v6.7 was used (http://david.abcc.ncifcrf.gov/, accessed 
August, 2011). DAVID is a high throughput data mining software that can be used to 
analyse large gene lists (Huang da et al. 2009). DAVID performs enrichment analysis 
(based on biological annotations for the target genes) to identify any biological 
pathways that are statistically significantly over-represented in the analysed gene list  
(Huang da et al. 2009). The identified genes within the deleted and the amplified 
FMCR were analysed separately.  
5.2.3.4.1 Deleted FMCR pathway analysis 
For the deleted regions, the most enriched cancer-related pathway was Apoptosis (p-
value = 0.014) (Figure 5.5). Ten apoptotic genes (CASP3, CASP8, CASP10, CFLAR 
NFKBIA, BAD, PIK3R2, PIK3R5, TNFRSF1A and TNF) were found to be within the 
deleted FMCR. Seven of these genes have pro-apoptotic roles and 3 are anti-
apoptotic (Table 5.5).  
Table 5.5 Deleted apoptotic genes 
Proapoptotic Antiapoptotic 
Gene Frequency% (n)* Gene Frequency% (n)* 
CASP3 31.1 (14) PIK3R5 46.7 (21) 
NFKBIA 28.9 (13) PIK3R2 20.0 (9) 
CASP8 17.8 (8) CFLAR 17.8 (8) 
CASP10 17.8 (8)   
BAD 15.6 (7)   
TNF 13.3 (6)     
TNFRSF1A 11.1 (5)     
* Frequency out of the 45 chromosomally unstable tumours 
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Figure 5.5 Apoptotic genes in the deleted FMCR (DAVID output) 
DAVID output showing the apoptosis signalling pathway with deleted genes marked by a red star. 
 
Another cancer related pathway that was found to be enriched within deleted FMCR 
was the P53 signalling pathway (p-value = 0.079). In addition to the apoptotic genes 
CASP8 and CASP10, 5 more genes from this pathway were also deleted; CCNB1, 
GADD45G, SERPINE1, SESN2 and SFN, all of which have reported anti-survival 
functions (Figure 5.6). 
Table 5.6 Deleted P53 pathway genes 
Gene Frequency% (n)* 
CCNB1 24.4 (11) 
SESN2 24.4 (11) 
SFN 24.4 (11) 
GADD45G 20.0 (9) 
SERPINE1 15.6 (7) 
* Frequency out of the 45 chromosomally unstable tumours 
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Figure 5.6 P53 signalling pathway and the deleted FMCR (DAVID output) 
DAVID output showing the P53 signalling pathway, with deleted genes marked by a red star. 
 
5.2.3.4.2 Amplified FMCR pathway analysis 
For amplified FMCR, the oncogenic MAPK signalling pathway was the only 
statistically significantly over-represented pathway (p-value = 0.032) (Figure 5.7). 
Nine genes in the MAPK pathway (CACNA1H, DUSP2, DUSP8, FGF23, FGF6, 
FGFR1, NTF3, ELK4, MAPKAPK2 and MYC) were found to be within the amplified 
FMCR. Seven of these genes are already known to promote growth and survival 
(Table 5.7).  
Table 5.7 Amplified MAPK genes 
Pro-survival Anti-survival 
Gene Frequency % (n) Gene Frequency % (n) 
MYC 53.3 (24) DUSP8 33.3 (15) 
FGF23 40.0 (18) DUSP2  15.6 (7) 
FGF6 40.0 (18)     
MAPKAPK2 15.6 (7)     
ELK4 15.6 (7)     
CACNA1H 28.9 (13)     
FGFR1 15.6 (7)     
* Frequency out of the 45 chromosomally unstable tumours 
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DAVID output showing the MAPK signalling pathway with amplified genes marked by a red star. 
5.2.3.5 Candidate FMCR and genes 
In order to reduce our list of FMCR and identify strong candidate driver genes for 
follow up studies, the FMCR criteria described in Section 5.2.3 were made more 
stringent. Firstly, candidate FMCR were defined by 4 SDE, instead of 2 (i.e. ~10% of 
the chromosomally unstable samples had targeted CNA in the region). Secondly, 
instead of defining “focal” by size only, a candidate FMCR was considered if it had a 
maximum of 12 genes in the aberrant area (i.e. ≤3.0Mb and ≤12 genes). This 
modification was introduced to help focus the search for candidate driver genes. The 
more stringent FMCR definition reduced the number of candidate FMCR to 17 
deletions (Table 5.8) and 11 amplifications (Table 5.9). The deleted regions had a 
size range of 0.09-1.95Mb (mean: 0.74Mb, median: 0.59Mb) and the total number of 
genes in these areas was 71 with a range of 1-10 genes (median: 3, mean: 4.2) 
(Table 5.8). The amplified regions had a size range of 0.17-1.22Mb (mean: 0.80Mb, 
Figure 5.7 MAPK pathway defects 
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median: 0.85Mb) and a total of 44 genes with a range of 0-12 (mean: 4, median: 2) 
(Table 5.9). 
Table 5.8 Shortlist of deleted FMCR 
Chromosomal  
location 
Start End Size (Mb) Recurrence (%) SDE Genes Candidate genes 
2p14 69914199 70385803 0.47 11.11 4 10 GMCL1, MAD1,  PCBP1 
2q33.1 197546654 198133273 0.59 13.33 4 6   
2q33.1 201432284 201850246 0.42 17.78 6 9 CASP8, CASP10 
3p14.3 57521404 57652691 0.13 24.44 4 3   
3p14.2 60078018 61195823 1.12 31.11 7 1 FHIT 
4q22.1 91340468 92674544 1.33 33.33 8 2 TMSL3 
6q26 162357125 163049854 0.69 22.22 7 1 PARK2 
8q11.21 48247963 48556480 0.31 13.33 4 1   
11p15.4 9172449 9363610 0.19 22.22 5 3   
11p11.2-p11.12 48215588 50164184 1.95 13.33 5 9 FOLH1 
12q14.2 63277389 63368109 0.09 20.00 4 1   
12q24.31 122199734 122593396 0.39 17.78 5 8 CDK2AP1 
14q13.2 34108596 34950339 0.84 28.89 5 9 NFKBIA 
16p13.3-p13.2 6132536 7018275 0.89 24.44 7 1 A2PB1 
17p13.1-p12 10957541 12400968 1.44 48.89 5 3 MAP2K4 
20p12.1 14376202 16071135 1.69 37.78 10 1 MACROD2 
21q22.11 33554005 33651205 0.10 28.89 7 3 IFNAR1, IFNAR2 
 
Table 5.9 Shortlist of amplified FMCR 
Chromosomal  
location 
Start End Size (Mb) Recurrence (%) SDE Genes Candidate genes 
1p36.32 2412144 3630036 1.22 26.67 7 11 PRDM16 
1p36.13 17783440 18947883 1.16 17.78 4 4 PAX7 
1p35.1-p34.3 33866043 34889487 1.02 15.56 4 2   
1p34.3 36881028 37535891 0.65 20.00 5 1   
2q35 218354227 218556081 0.20 20.00 5 1 TNS1 
7p22.1-p21.3 7033162 7829887 0.80 48.89 5 4 RPA3 
8p12-p11.23 38303146 39234126 0.93 15.56 5 7 FGFR1 
8q23.3 113827791 114547454 0.72 51.11 4 0 NA 
10q22.3 78238542 79084656 0.85 20.00 4 1 KCNMA1 
12p13.32-p13.31 4282429 5364999 1.08 40.00 4 12 FGF23, FGF6 
22q11.21 18517833 18686313 0.17 20.00 4 1   
 
5.2.3.5.1 Deleted FMCR 
In total 71 genes were affected by the 17 deleted FMCR. Sixteen of these genes 
(~22.5%) were cancer-related with known or potential anti-tumourigenesis activity 
(Table 5.8). Five of these genes (FHIT, TMSL3, PARK2, A2BP1 and MACROD2) 
were within the 20 most common deleted CNA in CRC and various other cancer 
types (Section 5.2.3.3) (Beroukhim et al. 2010). PARK2 is an interesting example as 
it was initially identified as a candidate TSG in glioblastoma multiforme (GBM) and 
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CRC through focal MCR (Veeriah et al. 2010) and in vitro and in vivo experiments 
have subsequently confirmed its anti-tumour activity in CRC (Poulogiannis et al. 
2010b). MAP2K4 was also reported to be commonly deleted in CRC (Leary et al. 
2008). None of the other genes have previously been reported to be deleted in CRC. 
The following sections briefly describe the candidate genes identified in the deleted 
FMCR. 
5.2.3.5.1.1 2p14 
This region contained 3 candidate CRC TSG; GMCL1, MAD1 and PCBP1. Germ 
cell-less homolog 1 (GMCL1) was previously proposed as a TSG as it was shown to 
increase the transcriptional activity of P53 (Masuhara et al. 2003). MAD1 (encoding 
MAX dimerization protein 1), also known as MXD1, was shown to have anti-tumour 
activity and its protein was shown to be under-expressed in several human cancers 
including CRC (Gunes et al. 2000, Toaldo et al. 2010). Finally, PolyC-RNA-binding 
protein 1 (PCBP1) was shown to inhibit the oncogenic kinase AKT in CRC (Wang et 
al. 2010). 
5.2.3.5.1.2 2q33.1 
Deletion of this region has been previously implicated in several cancers, including 
gastric and lung cancer and neuroblastoma (Otsuka et al. 1996, Nishizuka et al. 
1998, Teitz et al. 2000, Takita et al. 2001, Shivapurkar et al. 2002a, Geelen et al. 
2004). The region contains the well characterised pro-apoptotic genes CASP8 and 
CASP10 (Zhang et al. 2004). CASP8 inactivating mutations were previously reported 
in ~5% of advanced CRC cases (Kim et al. 2003). 
5.2.3.5.1.3 11p11.2-p11.12 
Folate hydrolase gene (FOLH1) was considered the candidate driver gene in this 
deleted FMCR. FOLH1 plays a role in folic acid absorption by hydrolysing folate 
bound to polygultamate. Lower levels of folic acid are thought to increase the risk of 
 201 
CRC and to affect the efficiency of some chemotherapeutic agents (Giovannucci et 
al. 1995, DeVos et al. 2008, Sadahiro et al. 2010, Porcelli et al. 2011).     
5.2.3.5.1.4 12q24.31 
This region contains a candidate TSG which encodes the cell cycle regulator protein 
cdk2-associating protein1 (CDK2AP1). CDK2AP1 was recently shown to have anti-
metastatic activities in squamous cell carcinoma and prostate cancer (Zolochevska 
and Figueiredo 2010a, Zolochevska and Figueiredo 2010b). 
5.2.3.5.2 14q13.2 
NFKBIA (encoding nuclear factor of κ-light polypeptide gene enhancer in B-cells 
inhibitor-α) is the candidate TSG in this region. NFKBIA was recently reported to be 
deleted in GBM (Bredel et al. 2010). Over-expression of NFKBIA in GBM cell lines 
had anti-growth, anti-survival and anti-metastatic activities (Bredel et al. 2010). 
Moreover, inhibiting NFKBIA expression in lung cancer cell lines was shown to 
induce resistance to chemotherapeutic agents (Bivona et al. 2011). Interestingly, 
NFKBIA SNPs were also previously associated with CRC risk (Gao et al. 2007).  
5.2.3.5.2.1 21q22.11 
Interferon receptors genes (IFNAR1 and 2) were predicted to be TSG because their 
protein levels were shown to be downregulated in bladder cancer, and correlated 
with advanced stages and resistance to chemotherapy (Zhang et al. 2010).  
5.2.3.5.3 Amplified FMCR 
In total, 44 genes were within the amplified FMCR. Eight (18.2%) of these genes 
were known or predicted to have oncogenic activities (Table 5.9). FGFR1 was within 
the 20 most common amplified CNA in CRC and various other cancer types (Section 
5.2.3.3). FGF6 and FGF23 were previously reported to be amplified in CRC (Sheffer 
et al. 2009). The rest of the genes were not previously reported to be amplified in 
CRC. The following sections briefly describe the candidate genes in the amplified 
FMCR. 
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5.2.3.5.3.1 1p36.32 
PR domain-containing 16 gene (PRDM16) is a known oncogene implicated in acute 
myeloid leukaemia (AML) and osteosarcoma (Man et al. 2004, Shing et al. 2007) 
5.2.3.5.3.2 1p36.13 
This region contains the transcription factor paired box gene 7 (PAX7). PAX7 is 
known to play an important role in alveolar rhabdomyosarcoma by forming a fusion 
protein with forkhead in rhabdomyosarcoma gene (FKHR) (Barr et al. 1996). PAX7 is 
amplified in 20% of the alveolar rhabdomyosarcoma cases with the fusion gene (Barr 
et al. 1996). 
5.2.3.5.3.3 2q35 
Tensin 1 gene (TNS1) is the only gene in this region. TNS1 overexpression in vitro 
was previously shown to significantly promote cell migration in fibroblasts (Chen et al. 
2002). 
5.2.3.5.3.4 7p22.1-p21.3 
Replication protein A3 gene (RPA3) located in this area was recently shown to be 
amplified in metastatic melanoma (focal MCR) and to play an essential role in tumour 
invasion (Kabbarah et al. 2010).  
5.2.3.5.3.5 10q22.3 
Large conductance calcium-activated potassium channel alpha subunit gene 
(KCNMA1), the only gene in this area, was previously shown to be amplified in 
prostate cancer cases and overexpressed in metastatic breast cancer (Bloch et al. 
2007, Khaitan et al. 2009). Functional KCNMA1 assays confirmed a role in cancer 
cell growth and invasion in vitro (Bloch et al. 2007, Khaitan et al. 2009). 
5.2.3.6 FMCR confirmation using TaqMan copy number assays 
The reproducibility of the aCGH experiments (Section 4.2.6.4) was confirmed by 
performing duplicate experiments. In order to check the accuracy of the aCGH 
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platforms in detecting these focal aberrations, TaqMan copy number assays (qPCR) 
were used (Section 2.2.9.2). Three candidate genes (PARK2, NFKBIA and 
KCNMA1) that occur within the shortlisted FMCR, were chosen to be verified by 
qPCR. PARK2 and NFKBIA reside within deleted FMCR (6q26 and 14q13.2 
respectively) (Table 5.8) and KCNMA1 resides within an amplified FMCR (10q22.3) 
(Table 5.9). PARK2 was chosen because deletions in this gene were recently 
observed (and also confirmed) to occur in CRC and other cancers (Beroukhim et al. 
2010, Poulogiannis et al. 2010b, Veeriah et al. 2010). NFKBIA (deleted) and 
KCNMA1 (amplified) were selected because they are novel and potentially 
interesting aberrations in CRC (Sections 5.2.3.5.2 and 5.2.3.5.3.5).  
5.2.3.6.1 qPCR design 
Pre-designed TaqMan copy number assays were chosen from the ABI website 
(www.appliedbiosystems.com, accessed April, 2011). A specific assay was chosen 
for each of the 3 genes. Figure 5.8 - Figure 5.10 represent the locations of the 
PARK2, KCNMA1 and NFKBIA probes that are available on the Agilent 180K array 
platform. Additionally, the locations of the ABI TaqMan probes that were selected for 
the confirmatory qPCR experiments are shown. As described in Section 2.2.9.2, 
TaqMan copy number assays require a reference assay for relative copy number 
quantification. Two pre-designed and optimised copy number reference assays were 
available from ABI (TERT and RNAP). In order for the TaqMan copy number assays 
to be accurate, the reference probes should align to a diploid area of the genome. 
The genomic ploidy status of PARK2, KCNMA1, NFKBIA and the 2 reference assays 
according to aCGH results are shown in Table 5.10. 
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Figure 5.8 PARK2 FMCR area and TaqMan copy number assay 
The FMCR area of PARK2 on the genomic workbench software (Hg18). The aberrations 
appear as coloured lines, the green dots present deleted probes and the transparent green 
box represents the area shown in panel B. B) PARK2 from the UCSC genome browser 
(Hg19) showing the Agilent probe locations from different platforms. The 180K array probes 
are marked by the box. The red star shows the approximate location of the TaqMan copy 
number probe. The CNVs located in the area are also shown. 
 
 205 
 
Figure 5.9 KCNMA1 FMCR area and TaqMan copy number assay 
A) The FMCR area of KCNMA1 on the genomic workbench software (Hg18). The aberrations 
appear as coloured lines, the red dots present amplified probes and the transparent red box 
represents the area shown in panel B. B) KCNMA1 from the UCSC genome browser (Hg19) 
showing the Agilent probes locations from different platforms. The 180K array probes are 
marked by the box. The red star shows the approximate location of the TaqMan copy number 
probe. The CNVs located in the area are also shown. 
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Figure 5.10 NFKBIA FMCR area and TaqMan copy number assay 
A) The FMCR area of NFKBIA on the genomic workbench software (Hg18). The aberrations 
appear as coloured lines, the green dots present deleted probes and the transparent green 
box represents the area shown in panel B. B) NFKBIA from the UCSC genome browser 
(Hg19) showing the Agilent probes locations from different platforms. The 180K array probes 
are marked by the box. The red star shows the approximate location of the TaqMan copy 
number probe. 
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Table 5.10 Genomic status of PARK2, NFKBIA, KCNMA1, TERT & RPPH1 
 
Target Genes Reference genes 
Sample PARK2  NFKBIA KCNMA1  TERT RPPH1 
T045           
T053           
T079           
T080           
T088           
T090           
T097           
T098           
T107           
T114           
T142           
T158           
T203           
T206           
T208           
T213           
T214           
T221           
T223           
T244           
T249           
T828           
T863           
T1350           
 
Table 5.10 depicts the samples with PARK2 and NFKBIA deletions or KCNMA1 
amplifications. The table also summarises the genomic ploidy status of the reference genes 
TERT and RPPH1 according to the aCGH results in the same CRC cases. Green, red and 
white boxes represent deletion, amplification and normal status respectively.  
 
5.2.3.6.2 Assessment of PARK2 deletion by qPCR 
In total, 10 tumour DNA samples (22.2%) had deletions across the PARK2 gene area 
(Table 5.10). T249 and T828 could not be confirmed because the genomic status of 
both TERT and RPPH1 (the reference assays) was not diploid (Table 5.10). Also, 
T90 could not be confirmed, because its focal deletion was outside the area covered 
by the TaqMan probe. For the rest of the deleted samples, the genomic status of 
either the reference assay TERT or RPPH1 was diploid. Copy number TaqMan 
assays steps were carried out according to the manufacturer‟s recommendations as 
described in Section 2.2.9.2.  
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Tumour DNA samples that required confirmation were T097, T114, T206, T142, 
T221, T223 and T1350. qPCR was performed on each tumour DNA sample and its 
normal control DNA pair in 4 replicates, and the findings are reported in Figure 5.11. 
PARK2 deletions were confirmed in all of the tumour DNA samples except for T97 
and T1350 (Figure 5.11). Table 5.11 summarises the calculated copy number ranges 
and their equivalent estimated copy number according to the Copy Caller software 
v1.0. Both T097 and T1350 calculated copy number was 1.67 and N097 and N1350 
calculated copy numbers were 2.00, thus the results indicate a clear reduction in the 
copy number. However, as their calculated copy number was >1.5, the estimated 
copy number was 2. A closer look at the aCGH results of PARK2 area in T097 and 
T1350 could explain the qPCR results (Figure 5.12). As shown in the Figure, T097 
and T1350 clear focal deletions targeting PARK2. However, the deletions seem to be 
of low amplitude (indicated by low log2ratio) in comparison, for example, to T142. 
 
Finally, all normal samples had a calculated copy number value very close to 2.0, 
except N142 which had a calculated copy number of 2.41. This might be caused by 
the CNVs in the area as shown above in Figure 5.8. 
 
Table 5.11 Calculated and estimated copy numbers 
Copy number 
Calculated  Estimated  
<0.5 0 
≥0.5-<1.5 1 
≥1.5-<2.5 2 
≥2.5-<3.5 3 
Table 5.11 summarises the calculated copy number ranges and their equivalent estimated 
copy number according to the copy caller software. 
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Figure 5.11 PARK2 QPCR results 
The Bars reflect the calculated copy number of the samples. The error bars represent the 
standard deviation based of 4 replicates within the same experiment. The colours of the bars 
reflect the estimated copy number. 
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Chromosome 6 aCGH data from T097, T142 and T1350, probes coloured in black represent 
genomic regions with a log2ratio around zero, probes coloured in red and green represent 
amplifications (log2ratio ≥ 0.5) and deletions (log2ratio ≤ -0.5) respectively. Closer look at 
PARK2 show focal deletions with variable amplitudes (reflected by the log2ratio values). 
 
5.2.3.6.3 Assessment of KCNMA1 amplification by qPCR 
In total, 9 tumour DNA samples (20.0%) had amplifications in KCNMA1 (Table 5.10). 
T45 could not be confirmed because the genomic status of both TERT and RPPH1 
(the reference assays) was not diploid. Unfortunately, T107 and T863 could not be 
confirmed due to insufficient amounts of remaining DNA. For the rest of the samples, 
T079, T142, T206, T208, T213 and T1350, qPCR tests were performed as 
described. Paired normal DNA samples were also tested. The results are 
summarised in Figure 5.13. As shown in the Figure, qPCR confirmed KCNMA1 
Figure 5.12 T097, T142 and T1350 PARK2 aCGH results 
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amplifications in all of the tested tumour DNA samples. T208 calculated copy number 
(15.58) was very high, which is reflected in the aCGH results showing very high 
amplitude amplification (Figure 5.14).   
 
 
 
Figure 5.13 KCNMA1 qPCR results 
The Bars reflect the calculated copy number of the samples. The error bars represent the 
standard deviation based of 4 replicates within the same experiment. The colours of the bars 
reflect the estimated copy number. 
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Chromosome 10 aCGH data from T208, probes coloured in black represent genomic regions 
with a log2ratio around zero, probes coloured in red and green represent amplifications 
(log2ratio ≥ 0.5) and deletions (log2ratio ≤ -0.5) respectively. Very high log2ratio in KCNMA1 
area reflecting high amplitude amplification. 
 
5.2.3.6.4 Assessment of NFKBIA deletion by qPCR 
In total, 13 samples had deletions across the NFKBIA area. However, only 7 were 
available for confirmation. T045, T080, T158, T249 and T828 could not be confirmed 
because the genomic status of both TERT and RPPH1 (the reference assays) was 
not diploid (Table 5.10). Moreover, T107 could not be confirmed due to insufficient 
amounts of remaining DNA. For the rest of the samples, T079, T088, T098, T114, 
T203, T214 and T244, qPCR testing was performed as described, earlier and the 
results of the tumour and normal DNA pairs are summarised in Figure 5.15. As 
shown in the figure, NFKBIA deletions were confirmed in all of the samples, with the 
exception of T244 (Figure 5.15). Close inspection of the aCGH data representing the 
NFKBIA area in T244 could potentially explain the results (Figure 5.16). As shown in 
the Figure, T244 had a focal deletion targeting NFKBIA. However, the deletion was of 
very low amplitude (indicated by a low log2ratio) in comparison to, for example T203. 
Figure 5.14 T208 KCNMA1 aCGH results 
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The Bars reflect the calculated copy number of the samples. The error bars represent the 
standard deviation based of 4 replicates within the same experiment. The colours of the bars 
reflect the estimated copy number. 
 
Figure 5.15 NFKBIA QPCR results 
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Chromosome 14 aCGH data from T244 and T203, probes coloured in black represent 
genomic regions with a log2ratio around zero, probes coloured in red and green represent 
amplifications (log2ratio ≥ 0.5) and deletions (log2ratio ≤ -0.5) respectively. Closer look at 
NFKBIA show focal deletions with variable amplitudes (reflected by the log2ratio values). 
5.2.3.7 Candidate FMCR and survival 
In order to begin to assess the clinical significance of the above candidate deleted 
and amplified FMCR, a survival analysis was performed by Dr Angela Cox. This 
preliminary analysis was only performed for chromosomally unstable cases from the 
Sheffield population sample set (n=33) as the survival follow up data was not 
available for the cases from the Sheffield Royal Hallamshire Tissue bank sample set 
Figure 5.16 T244 and T203 NFKBIA aCGH results 
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(Section 2.1.3.4). The analysis suggested an association between KCNMA1 
amplification and poor prognosis (p=0.05) (Figure 5.17). There was no relationship 
between any of the other candidate FMCR and survival (p>0.05). 
 
Figure 5.17 KCNMA1 amplification and survival 
Kaplan-Meier survival analysis estimated a worse survival of CRC cases with KCNMA1 
amplification (red line) in comparison to CRC cases without KCNMA1 amplification (blue line). 
 
It was noticed that the aCGH data showed that 2 of the 7 cases with KCNMA1 
amplification were focal and of high amplitude (T079 and T208) (Figure 5.18). The 
estimated copy number for these samples based on the aCGH results was >5 and 
this was quantitatively confirmed by qPCR (Figure 5.13). These 2 patients were 
diagnosed with CRC before 55 years of age and both died within 5 months of 
diagnosis due to CRC progression (Table 5.12). None of the remaining cases with 
survival information had a similar age of onset (<55 years) combined with a survival 
of less than 5 months. 
Table 5.12 CA079 and CA208 KCNMA1 amplification and survival 
 KCNMA1 amplification   
 aCGH log2ratio* QPCR ** Age at diagnosis Survival (months) 
CA79 1.67 5 54 5 
CA208 2.85 16 51 1 
* Maximum log2ratio value in the KCNMA1 area. 
** Estimated copy number. 
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Chromosome 10 aCGH data from T079 and T208, probes coloured in black represent 
genomic regions with a log2ratio around zero, probes coloured in red and green represent 
amplifications (log2ratio ≥ 0.5) and deletions (log2ratio ≤ -0.5) respectively. Very high log2ratio 
in KCNMA1 area reflecting high amplitude amplification. 
 
5.2.3.8 MicroRNA aberrations and KCNMA1 and NFKBIA 
The term microRNA (miRNA) refers to a group of small noncoding RNAs that 
regulate gene expression (Cummins et al. 2006). miRNAs were recently shown to 
play an important role in cancer development by altering the expression of both 
oncogenes and TSG (Schee et al. 2010). Several microRNAs are implicated in the 
development and progression of CRC (Arndt et al. 2009, Balaguer et al. 2010, Liu et 
al. 2010, Liu and Chen 2010). Deregulation of miRNA expression in CRC can result 
from altered methylation or chromosomal aberrations affecting miRNA genes 
(Diosdado et al. 2009, Balaguer et al. 2010, Liu and Chen 2010).  
5.2.3.8.1 KCNMA1 and microRNA211 
Recently, miR211 was shown to target and down-regulate KCNMA1 expression 
(Mazar et al. 2010). Under-expression of miR211 was shown to play a role in 
Figure 5.18 T079 and T208 focal KCNMA1 amplification 
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melanoma development and was directly associated with overexpression of 
KCNMA1 (Mazar et al. 2010). MiR211 gene (MIR211) is located on the long arm of 
chromosome 15 and it was found to be deleted in ~24.4% (n=11) of the investigated 
CRC cases. Table 5.13 summarises the CRC cases with KCNMA1 amplifications 
and/or MIR211 deletions. As shown in the table, KCNMA1 amplifications and MIR211 
deletions show a statistically significant mutual exclusive relationship (Spearman 
correlation test, p-value = 7.3x10-5, rs = -0.80). 
Table 5.13 KCNMA1 amplifications and MIR211 deletions  
Sample KCNMA1 Amp MIR211 Del 
T045 
  
T053 
  
T079 
  
T088 
  
T097 
  
T098 
  
T107 
  
T142 
  
T206 
  
T208 
  
T213 
  
T214 
  
T244 
  
T249 
  
T158 
  
T741 
  
T863 
  
T1350 
  
 
Table 5.13 compares the CRC samples with KCNMA1 amplifications (red) and/or MIR211 
deletions (green). The defects were shown to have a statistically significant inverse 
correlation (Spearman correlation test, p-value = 7.3x10
-5
, rs = -0.80). 
 
5.2.3.8.2 NFKBIA and miR301a 
Recently, miR301a was reported to down-regulate NF-ĸB repressing factor (NKRF) 
resulting in NF-ĸB activation (Lu et al. 2011). The miR301a gene (MIR301A) is 
located on the long arm of chromosome 17 and it was found to be amplified in 22.2% 
(n=10) of the investigated CRC cases. Table 5.14 summarises the CRC cases with 
NFKBIA deletions and/or MIR301A amplifications. As shown in the table, NFKBIA 
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deletions and MIR301A amplifications show a statistically significant mutual exclusive 
relationship (Spearman correlation test, p-value = 2.3x10-4, rs = -0.73) 
Table 5.14 NFKBIA deletions and MIR301A amplifications 
Sample NFKBIA Del MIR301A Amp 
T045   
T079   
T080   
T088   
T098   
T107   
T114   
T142 
  
T153 
  
T158   
T203   
T206 
  
T214   
T221 
  
T244   
T249   
T741 
  
T828   
T863 
  
T1350 
  
 
Table 5.14 compares the CRC samples with NFKBIA deletions (green) and/or MIR301A 
amplifications (red). The defects were shown to have a statistically significant inverse 
correlation (Spearman correlation test, p-value = 2.3x10-4, rs = -0.73). 
 
5.3  Discussion 
As described previously, CIN is the most common form of genomic instability in CRC 
and is characterised by gains and losses of chromosomal segments or whole 
chromosomes (Sheffer et al. 2009, Migliore et al. 2011). CIN can drive cancer 
development by targeting TSG and oncogenes, many of which have not yet been 
identified (Brosens et al. 2010). Recently, the use of high resolution techniques such 
as SNP arrays and array CGH has prompted the identification of novel cancer driver 
genes in CRC and other cancer types (Bredel et al. 2010, Veeriah et al. 2010). As 
detailed, CIN was the main form of genomic instability found in our cohort (90.1%, 
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n=48), and the aim of the work described in this chapter was to identify novel CRC 
driver genes affected by recurrent focal chromosomal aberrations. 
5.3.1 Common aberration analysis 
Statistically significant recurrent CNA were detected using the COCA algorithm. An 
in-house algorithm was then used to define FMCR based on the COCA output. 
FMCR were stringently defined as aberrant regions smaller than 3Mb in size, 
occurring in more than 10% of the cases with at least 2 SDE and a COCA score >2 
(p-value = 0.01). Overall, 64 deleted and 32 amplified FMCR were identified 
according to these criteria. These focal aberrations were validated by comparison to 
recently published data in CRC from 4 different studies (Martin et al. 2007, Leary et 
al. 2008, Andersen et al. 2010, Brosens et al. 2010). Our FMCR have shown more 
overlap with the published focal aberrations when compared to the other 4 studies 
(Section 5.2.3.2). The overlapped regions helped in further delimiting the identified 
FMCR affecting well known cancer genes.  
 
To further validate our FMCR, they were compared with the lists of the 20 most 
significant and recurrent focal deletions and amplifications identified across 26 
different types of cancer including CRC (Section 5.2.3.3) (Beroukhim et al. 2010). A 
25% (n=5) and 15% (n=3) overlap was identified between our deleted and amplified 
FMCR respectively. In general, comparison with the literature demonstrated the 
ability of the analyses methods and algorithms we have used to identify some the 
most commonly reported focal aberrations in CRC and other tumour types. 
 
Pathway analysis using the online database DAVID revealed 3 significantly enriched 
cancer related pathways amongst the genes affected by the FMCR. For deleted 
FMCR genes, the most significantly enriched cancer-related signalling pathways 
were apoptosis and P53. Ten apoptotic genes were commonly deleted in our 
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samples. Seven of these genes (CASP3, CASP8, CASP10, NFKBIA, CAPN1, BAD, 
TNF and TNFRSF1A) are pro-apoptotic and 3 are anti-apoptotic (PIK3R2, PIK3R5 
and CFLAR). It is noteworthy that the deleted anti-apoptotic gene, CFLAR occurs 
within the same FMCR as the pro-apoptotic genes CASP8 and CASP10. Moreover, 
PIK3R5 is located 1.2Mb downstream of TP53 and 81% (n=17) of the deletions are 
common between the 2 genes. For the P53 signalling pathway, all the deleted genes 
(n=5) are known to have anti-tumourigenetic activities. It is notable that TP53 was 
also deleted in 37.8% (n=17) of the cases, but it was not identified within an FMCR. 
These results indicate that the deleted FMCR might play an important role in tumour 
survival through disabling apoptosis and/or the P53 signalling pathway. 
 
The most significantly enriched pathway for the amplified FMCR genes was the 
oncogenic MAPK pathway, with 9 genes being commonly affected. Seven of these 
genes (CACNA1H, FGF23, FGF6, FGFR1, MAPKAPK2, ELK4 and MYC), are known 
or predicted to have oncogenic activities by promoting tumour growth and survival. It 
is noteworthy that one of the amplified anti-survival genes (DUSP8) occurred within 
the same FMCR with the oncogenic growth promoting gene IGF2. These results 
confirm that focal deletions and amplifications specifically target tumour suppressor 
and oncogenic pathways respectively.  
5.3.2 Candidate CRC driver genes 
In total, the identified FMCR contained 1002 genes. In order to identify a set of 
candidate genes, the FMCR were further shortlisted by increased stringency of their 
definition. Candidate FMCR were selected to have a maximum of 12 genes and they 
should be defined by at least 4 SDE. Based on the added criteria, shortlists of 17 
deletions and 9 amplifications were identified.  
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The 17 candidate deleted FMCR harboured 71 genes, 16 (24.6%) of which are 
thought to be cancer-related. Consistently, 6 of these genes (FHIT, TMSL3, PARK2, 
A2BP1, MACROD2 and MAP2K4) were recently reported to be deleted in CRC and 
other cancers (Leary et al. 2008, Andersen et al. 2010, Beroukhim et al. 2010, 
Veeriah et al. 2010). The remaining genes (GMCL1, MAD1, PCBP1, CASP8, 
CASP10, FOLH1, CDK2AP1, NFKBIA, IFNAR1 and IFNAR2) were not previously 
reported to be deleted in CRC and the literature suggests potential role as TSG. 
Nonetheless, MAD1 and CASP8 were previously reported to be under-expressed 
(MAD1) and inactivated by somatic mutations (CASP8) in CRC patients (Gunes et al. 
2000, Kim et al. 2003). PCBP1 was recently shown to be under-expressed in CRC 
cell lines (Wang et al. 2010). Our data support a tumour suppressor role of these 
genes in CRC and suggest deletions as a novel mechanism of functional inactivation. 
Our data also propose GMCL1, FOLH1, CDK2AP1, NFKBIA, IFNAR1 and IFNAR2 
as novel candidate CRC TSG. 
 
The 11 candidate amplified FMCR harboured 44 genes, 8 (18.2%) of which were 
cancer related with predicted oncogenic functions (PRDM16, PAX7, TNS1, RPA3, 
FGFR1, KCNMA1, FGF23 and FGF6). FGFR1, FGF23 and FGF6 were previously 
reported to be amplified in CRC and other cancer types (Sheffer et al. 2009, 
Beroukhim et al. 2010). Based on the literature, the remaining genes are proposed 
as novel candidate CRC oncogenes.  
 
Importantly, copy number TaqMan assays specific for the well-established deleted 
PARK2 gene and the novel NFKBIA deletion and KCNMA1 amplification confirmed 
the accuracy of the aCGH data. 
 222 
5.3.3 Candidate FMCR and survival  
Survival analysis suggested an association between KCNMA1 high amplitude 
amplifications and poor prognosis (Table 5.12). In addition to confirming its 
oncogenic potential, these results also suggest that KCNMA1 amplification could be 
used as a potential prognostic marker. However, the results are based on a small 
sample size and should be confirmed in a larger sample before firm conclusions can 
be drawn.  
5.3.4 MicroRNA aberrations and KCNMA1 and NFKBIA 
Selective pressure in tumour cells usually requires one mechanism to achieve a 
certain tumorigenic advantage (Issa 2008, Rinkenbaugh and Baldwin 2011). This can 
be seen in known mutually exclusive relationships found in CRC, including BRAF 
V600E and KRAS mutations (Davies et al. 2002). KRAS and BRAF both regulate the 
MAPK signalling pathway (Nagasaka et al. 2004). Activating mutations in KRAS and 
the BRAF V600E mutation are known to constitutively activate the MAPK pathway, 
thus, their co-existence in the same tumour is extremely rare (Yuen et al. 2002, 
Kumar et al. 2009). Statistically significant inverse relationships were observed 
between KCNMA1 amplifications and MIR211 deletions and NFKBIA deletions and 
MIR301A amplifications. These inverse correlations support the role of miR211 in 
activating KCNMA1 and the role of both NFKBIA and miR301A in regulating NF-ĸB. 
Moreover, these observations support the oncogenic role of KCNMA1 amplifications 
and NFKBIA deletions.  
 
In summary, our results supported the hypothesis that recurrent focal aberrations 
selectively target cancer-related genes. Moreover, focal deletions and amplifications 
were clearly established to affect known TSG and oncogenes respectively. Several 
novel candidate CRC driver genes were also proposed with potential prognostic and 
therapeutic value in the future. 
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6. NFKBIA, a Tumour Suppressor in CRC 
6.1 Introduction  
Nuclear factor of ĸ-light polypeptide chain (NF-ĸB) is a transcription factor that plays 
an important role in promoting cell proliferation and survival (Sethi et al. 2007, Bredel 
et al. 2010). NF-ĸB is comprised of dimers of 5 subunits: RelA (p65), RelB, c-Rel, 
p50 and p52 (Lu et al. 2011, Rinkenbaugh and Baldwin 2011). The most abundant 
form of NF-ĸB heterodimers is RelA-p50 (Kojima et al. 2004, Ma et al. 2011). Under 
basal conditions, NF-ĸB dimers remain inactive in the cytoplasm by the binding of 
inhibitors of ĸB (IĸB) proteins (Karin et al. 2002).  
 
NF-ĸB activation occurs through 2 main pathways; the canonical classical pathway 
and the alternative pathway (Inoue et al. 2007). Both pathways result in the 
translocation of NF-ĸB dimers into the nucleus and the subsequent transactivation of 
their target genes (Bonizzi and Karin 2004, Inoue et al. 2007). NF-ĸB targets include 
immunoregulatory, inflammatory, anti-apoptotic and cell proliferative genes (Wang et 
al. 1996, Karin et al. 2002, Pikarsky et al. 2004, Jeyasuria et al. 2011). 
Proinflammatory cytokines, such as the tumour necrosis factor (TNF) family are 
important activators of the NF-ĸB pathway (Wang et al. 1996, Karin et al. 2002). 
Aberrant activation of NF-ĸB is known to play an oncogenic role in the development 
of several cancer types including, pancreatic and prostate cancer, Hodgkin 
lymphoma, GBM and CRC (Krappmann et al. 1999, Lind et al. 2001, Suh et al. 2002, 
Kojima et al. 2004, Inoue et al. 2007, Meylan et al. 2009, Basseres et al. 2010, 
Bredel et al. 2010, Lu et al. 2011). Aberrant NF-ĸB activation is relevant for the 
prognosis and survival of cancer patients, in addition to treatment efficiency (Camp et 
al. 2004, Izzo et al. 2006, Scartozzi et al. 2007). Subsequently, the NF-ĸB pathway 
and its regulatory proteins are now considered as potential targets for novel cancer 
therapeutic strategies (Inoue et al. 2007, Rinkenbaugh and Baldwin 2011). 
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Somatic aberrations affecting NF-ĸB regulatory genes and microRNAs are 
responsible for the inappropriate activation of the pathway in several cancer types 
(Cabannes et al. 1999, Krappmann et al. 1999, Nishikori 2005, Lu et al. 2011). 
Inactivating mutations in NFKBIA, encoding NF-ĸB inhibitor alpha, were previously 
shown to play a role in Hodgkin lymphoma (Cabannes et al. 1999). Recently, 
heterozygous NFKBIA deletions were reported in ~25% of GBM cases (Bredel et al. 
2010). Moreover, siRNA knockdown of NFKBIA was shown to result in increased 
levels of the activated phosphorylated RelA in lung cancer cell lines (Bivona et al. 
2011).  
 
NFKBIA was predicted to be the driver gene in one of the candidate deleted FMCR 
identified in this project (Section 5.2.3.5.2). The aCGH data and the log2ratio values 
for this deletion FMCR were of relatively low amplitude, suggesting a heterozygous 
deletion, which agrees with the findings reported in GBM (Bredel et al. 2010). 
Moreover, the frequency of the deletions was 28.9%, also similar to that in GBM 
(Table 5.8). Therefore, as proof of concept experiments, preliminary functional 
studies investigating the role of NFKBIA deletions in CRC development were 
performed. The two major aims of these experiments described in this chapter were 
as follows. Firstly, to examine NFKBIA protein expression levels in a panel of CRC 
cell lines, in particular to observe whether any CRC cell lines contained reduced 
levels of NFKBIA. Two GBM cell lines, U87 and SNB19, were included as controls, 
because NFKBIA is known to be underexpressed in GBM (Bredel et al. 2010). 
Finally, two non-tumour derived cell lines, MRC5-SV2 and HEK293, were also 
employed. Secondly, to investigate the effect of NFKBIA depletion on NF-ĸB 
activation and malignant behaviour in culture, by performing NFKBIA knockdown, 
using NFKBIA-siRNA, in CRC cell lines expressing high levels of NFKBIA. 
Subsequently, these cell lines were used to perform clonogenic assays. 
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6.2 Results 
6.2.1 NFKBIA in CRC cell lines 
Western blotting (Section 2.2.17) was performed on cellular extracts from 6 CRC cell 
lines, HCT116, CACO2, SW620, SW480, COLO205 and HT29, in addition to 2 GBM 
cell lines, U87 and SNB19, and 2 non-tumour derived cell lines, MRC5-SV2 and 
HEK293. These results are presented in Figure 6.1. Remarkably, NFKBIA protein 
was expressed at lower levels in 3 of the 6 CRC cell lines (CACO2, SW480 and 
COLO205). The other 3 cell lines (HCT116, SW620 and HT29) had similar or 
increased levels of NFKBIA compared to the non-tumour cell lines. SNB19 (GBM) 
had low levels of NFKBIA (similar to CACO2 and SW480) and U87 (GBM) had 
similar levels to HT29. These experiments were repeated 3 times using 2 
independent cellular extracts. 
 
Figure 6.1 NFKBIA protein expression 
Western blot showing NFKBIA protein levels in CRC, GBM and control cell lines. An alpha-
tubulin antibody was used to confirm loading equal amounts of cellular extracts from each cell 
line. 
 
6.2.2 NFKBIA and phosphorylated NF-ĸB 
In order to examine the effect of NFKBIA deletions on NF-ĸB activation and tumour 
behaviour, NFKBIA-siRNAs were transfected into 3 CRC cell lines (HCT116, SW620 
and HT29) that had relatively increased levels of NFKBIA. siRNA experiments were 
performed as described in Section 2.2.18. For each cell line, a negative control was 
performed by treating the cells with “negative” siRNA designed not to complement 
any known human mRNA sequence. Western blotting with NFKBIA and p-RELA 
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antibodies was performed on cellular extracts taken 24 and 48 hr after transfection of 
CRC cell lines with NFKBIA-siRNA. Figure 6.2 summarises the Western blotting 
findings. As indicated, a marked reduction in NFKBIA expression was confirmed in 
HCT116 and SW620 cells. However, the effect appeared of short duration, because 
the NFKBIA levels were lower 24 hr after transfection when compared to 48 hr. 
Additionally, p-RELA levels were very low, but detectable, in all of the 3 cell lines 
regardless of siRNA treatment and NFKBIA expression. The Western blot was 
performed twice on 2 separate siRNA transfections. 
 
Figure 6.2 NFKBIA siRNA experiment 
HCT116, SW620 and HT29 cells were transfected with NFKBIA-siRNA and “negative” siRNA 
(Neg). Protein extraction was performed 24hrs and 48hrs after NFKBIA- siRNA transfection. 
For the negative controls, protein extraction was performed 48hrs post transfection with 
“negative” siRNA. Western blotting was then performed using NFKBIA and p-RELA 
antibodies. p-RELA positive control extract (HeLa cells treated with TNF-α) was also included.  
 
 
6.2.3 Effects of NFKBIA knockdown in cell culture 
The effects of NFKBIA protein depletion were evaluated by observing tumour cell 
proliferation and colony formation in HCT116 and SW620 cells transfected with 
NFKBIA-siRNA and “negative” siRNA. 
  
HCT116 and SW620 cell proliferation was measured via the MTT assay (Section 
2.2.19). The MTT test was performed on 3 consecutive days following treatment of 
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both cell lines with NFKBIA-siRNA and the “negative” control siRNA. The results are 
summarised in Figure 6.3. 
 
Figure 6.3 MTT assay results 
Cell proliferation was inferred spectrophotometrically via the MTT assay. The growth levels 
were calculated relative to day 1 negative control for each cell line. The error bars represent 
the standard deviation of 4 replicates within the same experiment. The above results are 
based on a single experiment.    
 
Colony forming ability of tumour cells in culture is known to reflect their malignancy 
(Bredel et al. 2010). The colony formation test was performed as described in 
Section 2.2.20. HCT116 and SW620 colonies were counted 9 and 13 days post 
siRNA transfection respectively. As for the MTT assay (above), “negative” siRNA 
controls were also included. Five replicates were performed for each cell line and 
treatment. Figure 6.4 shows the colony formation results for 2 replicates of HCT116 
cells treated with NFKBIA- siRNA and “negative” siRNA. Figure 6.5 summarises the 
colony counts from the 5 replicates for both cell lines and treatments.    
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Figure 6.4 Colony formation test in HCT116 (2 replicates) 
The 4 petri dishes represent 2 replicates for colony formation test for HCT116 cells treated 
with NFKBIA-specific siRNA and negative siRNA. 
 
Figure 6.5 Colony formation test results 
Colony counts for each cell line were based on 5 replicates. P-values were calculated using 
unpaired t-test (two tailed). 
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6.3 Discussion 
The novel candidate CRC TSG NFKBIA was further investigated and its protein was 
found to be relatively under-expressed in 3 of the 6 CRC cell lines investigated. 
NFKBIA-siRNA transfection was used to deplete NFKBIA protein in the CRC cell 
lines with higher levels of NFKBIA (HCT116, SW620 and HT29). Lower levels of 
NFKBIA proteins were detected in HCT116 and SW620 cell lines after siRNA 
treatment (Figure 6.2). We were unable to determine whether the lower levels of 
NFKBIA protein affect the levels p-RELA, as previously suggested (Bivona et al. 
2011). The levels of p-RELA were very low in all CRC cell lines tested regardless of 
NFKBIA levels. In contrast, p-RELA levels were higher in lung cancer cell lines, and 
an increase in level was observed with depletion of NFKBIA (Bivona et al. 2011). 
 
Knockdown of NFKBIA was also investigated for any potential effect on CRC cell line 
malignant behaviour as measured by cell growth and colony formation. Following 
transfection with NFKBIA-siRNA and “negative” siRNA control, lower levels of 
NFKBIA increased cell proliferation and the ability to form colonies in both HCT116 
and SW620. However, the effect seems to be more evident in HCT116, which could 
potentially be due to the lower levels of NFKBIA observed in HCT116 following 
siRNA transfection (Figure 6.2). These results agree with the effect of NFKBIA re-
expression in GBM cell lines (Bredel et al. 2010). In their study, Bredel and 
colleagues achieved NFKBIA overexpression in 2 GBM cell lines which resulted in 
decrease in cell proliferation and the ability to form colonies in culture and increased 
sensitivity to the chemotherapeutic agent Temozolomide (Bredel et al. 2010). As a 
proof of concept, these experiments support the predicted tumour suppressor role of 
NFKBIA in CRC. Nevertheless, these represent preliminary results that need to be 
repeated and confirmed. 
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7. Discussion and Conclusions 
7.1 CASP8 inherited variants and CRC risk 
Cancer in is considered a genetic disease, as both germline and somatic genetic 
factors play an essential part in its predisposition, initiation and development. CRC is 
considered the 2nd highest amongst common cancers, behind prostate, in terms of 
inherited susceptibility, with an estimated genetic contribution of ~35% (Lichtenstein 
et al. 2000). Highly and moderately penetrant genetic factors are rare in CRC and 
account for ~5-7% of the total CRC cases. The rest of the heritability is predicted to 
be caused by less penetrant but more common genetic factors (Broderick et al. 2007, 
Lascorz et al. 2010). Several low penetrant and common CRC risk variants were 
identified through genome wide and candidate genes association studies, however, 
so far they only account for ~6% of CRC heritability (Lascorz et al. 2010). Thus, most 
of the inherited susceptibility for CRC remains unknown.   
 
Caspase 8 is an initiator caspase that plays an important role in activating apoptosis 
(Grenet et al. 1999). Loss of caspase 8 protein function through acquired mutations, 
deletions or silencing of CASP8 gene has been shown to play a role in the 
development of several cancer types including CRC (Teitz et al. 2000, Kim et al. 
2003, Pingoud-Meier et al. 2003b, Soung et al. 2005, Stupack et al. 2006). Moreover, 
CASP8 inherited variants were shown to affect the risk of several cancer types 
including lung and breast cancer (Son et al. 2006, Cox et al. 2007). A somewhat 
controversial association between an inherited 6bp in/del variant in the CASP8 
promoter and CRC risk had been proposed at the beginning of this project (Sun et al. 
2007, Haiman et al. 2008, Pittman et al. 2008). Moreover, preliminary data from our 
laboratory indicated a possible association between some CASP8 SNPs and CRC 
risk (Curtin et al. manuscript in preparation). The aims of the work described in 
chapter 3 were to investigate the controversial role of the rs3834129 CASP8 
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promoter variant and CRC risk, to identify novel coding CASP8 variants that can 
affect CRC risk, and to develop an assay to investigate a possible role of CASP8 
CNV23598 in CRC and breast cancer predisposition.  
7.1.1 Summary and conclusions 
The CASP8 promoter in/del rs3834129 was genotyped in 1193 CRC cases and 1388 
controls. The cases and controls were from the UK (Sheffield, Leeds and Dundee) 
and USA (Utah). Association analysis was performed on the 4 sample sets 
separately and combined, and the results did not indicate any significant association 
between rs3834129 genotypes and CRC risk (p-value > 0.05). This conclusion was 
in agreement with the published data on the European and multi-ethnic American 
populations (Haiman et al. 2008, Pittman et al. 2008), however, it contradicted the 
original results showing association in the Chinese populations (Sun et al. 2007). The 
disparity between the original study in the Chinese population and our results (in 
addition to the results from the European and American populations) could be due to 
different effects of genetic and environmental modifier factors between the different 
populations, or due to the initial association being a false positive. Nevertheless, the 
rs3834129 data is being included in a more comprehensive analysis of SNPs in the 
CASP8 gene region and their potential role in CRC risk (Curtin et al. manuscript in 
preparation). This study aims to fine map the region and examine any possible 
associations with CRC susceptibility in various subgroups of the cases. The results 
do suggest a possible association between CASP8 SNPs and female early onset 
CRC (Curtin et al. manuscript in preparation).   
 
The CASP8 promoter region, exons, intron/exon boundaries and 3‟ UTR were 
sequenced in 94 CRC cases from the Sheffield population sample set. The 
sequencing results revealed the presence of 6 (relatively rare and) novel variants 
with minimum allele frequencies of 0.005 to 0.01. To date, none of these variants 
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have been previously reported. In silico analysis was performed and the results did 
not predict any functional impact of these variants on caspase 8. Nonetheless, the 
115 bp deletion in CASP8 exon 3 (c.1-8338Del115) and the variant in CASP8 intron 
3 (c.1-1982A>G) occurred within a region with a possible regulatory role assessed by 
the presence of DNase hypersensitivity clusters which could reflect the presence of 
transcriptional enhancers and promoters (Crawford et al. 2006). However, this region 
is expressed as part of the precursor of the non-predominantly expressed CASP8 
isoform-G which is not detected on protein level (Scaffidi et al. 1997). Therefore, 
none of the variants warranted further investigation at this stage. But, if the results of 
the fine mapping by Curtin and colleagues suggest that either of these two variants 
(c.1-8338Del115 and c.1-1982A>G) occur on CRC associated risk haplotypes, they 
may merit further investigation to examine possible effects on expression of CASP8 
isoform transcripts. 
 
CASP8 CNV23598 was genotyped in 284 CRC cases and controls (Sheffield sample 
set) and 47 breast cancer cases and controls enriched for CASP8 risk and protective 
haplotypes respectively. The initial genotyping results indicated differences in 
CNV23598 allele frequencies for CRC and breast cases and controls. However, the 
CRC control and case genotype frequencies were inconsistent with HWE, which 
might indicate genotyping errors. Several molecular techniques confirmed the 
genotyping results. However, they indicated the presence of multiple CNV23598 
insertion copies in addition to differences from the published insertion sequence at 
both breakpoints. A few more CNVs with variable lengths were recently reported 
around the CNV23598 region which could explain some of the genotyping issues 
(http://projects.tcag.ca/variation/, accessed August, 2011). CASP8 region is currently 
being fully investigated using a second generation sequencing platform in the 47 
breast cancer cases and controls as part of a different project. The sequencing 
results might help in further elucidating the reasons behind the questionable results 
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for CNV23598. In conclusion, our results do not provide evidence that CASP8 
inherited variants have any significant effect on CRC risk overall. Although more 
detailed investigation including subgroup analysis is underway. Finally, we have 
shown that CNV23598 has a very complex architecture that may only be resolved by 
advanced molecular techniques (such as 2nd generation sequencing). 
7.2 Molecular classification of CRC 
Sporadic CRC is highly heterogeneous from a molecular point was shown to develop 
through multiple pathways of genomic instabilities (MSI, CIMP and CIN), and somatic 
mutations in key driver genes (APC, TP53, KRAS, BRAF and PIK3CA) (Cheng et al. 
2008, Derks et al. 2008). Molecular classification of sporadic CRC has potential 
applications in research and in the clinic. It can help in understanding the underlying 
mechanisms of CRC development, identify new molecular targets and pave the way 
for personalised cancer care (Choong and Tsafnat 2011, Pritchard and Grady 2011). 
One of the main drawbacks in the field is the lack of standardisation in investigating 
and defining the molecular characteristics, especially the global genomic instabilities 
CIMP and CIN (Cheng et al. 2008, Derks et al. 2008, Ogino and Goel 2008). The 
main aim of the work described in chapter 4 was to classify a cohort of matching 
CRC patients using a more standardised approach.    
7.2.1 Summary and conclusions 
A thorough molecular characterisation was performed on 53 CRC cases with 
matching tumour and normal DNA samples. MSI was defined with a panel of 5 
mononucleotide microsatellite markers according to the revised NCI criteria for MSI 
testing (Bacher et al. 2004, Umar et al. 2004). CIMP was investigated using a semi-
quantitative MS-MLPA technology based on a set of 7 CpG markers previously 
verified in 3 independent studies (Ogino et al. 2006a, Weisenberger et al. 2006, 
Ogino et al. 2007). CIN was investigated using a high resolution genome wide array 
CGH technology and defined as recently recommended by Cheng and colleagues 
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(Cheng et al. 2008). DNA Sequencing was used to identify the most common 
mutations in APC, TP53, KRAS, BRAF and PIK3CA. All the investigated samples 
were shown to be MSS. Three molecular subtypes were identified within the 
investigated cohort, chromosomally stable/CIMP-L subtype (~7.7%), chromosomally 
unstable/CIMP-L/N subtype (78.8%) and a novel chromosomally unstable/CIMP-H 
subtype (11.5%). The latter may be a novel subtype missed in previous studies due 
to technical limitations in defining CIN, or due to the association of CIMP-H with MSI-
H which has an established inverse correlation with CIN (Goel et al. 2007, Cheng et 
al. 2008). The existence of CIN/CIMP-H/MSS as a distinct molecular subtype from 
CIN/CIMP-L/N/MSS is supported by the different patterns of broad common CNA and 
BRAF/KRAS mutations. Nevertheless, these results need to be confirmed 
independently in a larger cohort.  
7.3 Focal chromosomal aberrations and CRC 
Chromosomal instability is the most common form of genomic instability in CRC and 
it is known to drive CRC development by affecting TSG and oncogenes (Martin et al. 
2007, Brosens et al. 2010). CIN is usually characterised by a large number of 
chromosomal aberrations that affect a wide range of genes (Rajagopalan et al. 
2003). Most of the key driver genes affected by chromosomal abnormalities are yet 
to be identified (Brosens et al. 2010). The aim of the work described in chapter 5 was 
to investigate the genes affected by common focal chromosomal aberrations in order 
to identify novel candidate driver genes. 
7.3.1 Summary and conclusions 
Array CGH was successfully performed on 53 CRC cases. Common aberration 
analysis was performed on the 45 cases that had high values for QC metrics and 
showed chromosomal instability. Chromosomal aberrations were identified using 
strict algorithms and definitions. Frequencies of the most common broad CNA 
including amplifications within chromosomes 20q, 13, 8q, 7 and X and deletions 
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within chromosomes 18, 8p and 17p strongly agree with published data (Hermsen et 
al. 2002, Lassmann et al. 2007, Poulogiannis et al. 2010a). Context corrected 
common aberration analysis combined with an in-house developed algorithm were 
used to identify FMCR. Sixty-four deleted and 32 amplified FMCR were identified. 
Deleted FMCR contained established TSG such as SMAD4 and CDKN2C, and 
amplified FMCR contained established oncogenes such as MYC and FGFR1. 
Comparison with previously published data in CRC and other cancer types (Martin et 
al. 2007, Leary et al. 2008, Andersen et al. 2010, Beroukhim et al. 2010, Brosens et 
al. 2010) have shown enrichment within our FMCR of some of the most commonly 
reported focal aberrations which supported the efficiency of the used algorithms. 
 
Pathway analysis using the online database DAVID revealed that genes within 
cancer related pathways were commonly affected by the identified FMCR. The anti-
survival apoptosis and P53 pathways were affected by deleted FMCR and the 
oncogenic MAPK pathway was affected by amplified FMCR. The enrichment of 
apoptotic genes within the deleted FMCR supports the correlation between genomic 
instability and defective apoptosis (Zhivotovsky and Kroemer 2004). More stringent 
definitions were used to further shortlist the identified FMCR into 17 deletions and 11 
amplifications. Cancer related genes were enriched in the deleted (~22.5% of the 
total number of genes) and the amplified (~18.2% of the total number of genes) 
candidate FMCR. In total 6 novel candidate CRC TSG (GMCL1, FOLH1, CDK2AP1, 
NFKBIA, IFNAR1 and IFNAR2) and 5 novel candidate CRC oncogenes (PRDM16, 
PAX7, TNS1, RPA3, KCNMA1) were proposed. Survival analysis suggested that 
high amplitude amplifications of KCNMA1 may be associated with poor survival. 
None of the other candidate FMCR/genes was significantly associated with patient 
survival. NFKBIA deletions were previously associated with poor survival of GBM 
patients but this was not observed in our cohort. Out of the 45 samples included in 
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the common aberration analysis, survival data was only available for 33, which limits 
the power to detect any statistically significant association.  
 
The microRNA miR211 was recently reported to target KCNMA1. Underexpression of 
miR211 was shown to have oncogenic effects in melanoma, through abnormal 
activation of KCNMA1 (Mazar et al. 2010). A statistically significant inverse 
correlation was observed between MIR211 deletions and KCNMA1 amplification in 
our samples. Similarly, miR301a was recently reported to activate NF-ĸB in 
pancreatic cancer (Lu et al. 2011). A statistically significant inverse correlation was 
observed between miR301a amplifications and NFKBIA deletions in our samples. 
These results support the notion that the above mutually exclusive defects function in 
the same oncogenic pathways. 
 
NFKBIA, one of the identified candidate TSG, was selected for further analysis in a 
proof of concept experiment. NFKBIA protein was shown to be relatively under-
expressed in 3 of the 6 CRC cell lines investigated (SW480, CACO2 and COLO205). 
NFKBIA-siRNA experiments were performed to deplete NFKBIA protein in CRC cell 
lines HCT116, SW620 and HT29 in which NFKBIA is relatively expressed at normal 
to high levels. This was achieved significantly in HCT116 and SW620, however, the 
effect appeared to be of relatively short duration as the NFKBIA levels were lower 24 
hr after transfection compared to 48 hr.  Preliminary results from growth and colony 
formation experiments indicated a survival advantage of NFKBIA underexpression in 
the investigated cell lines which was consistent with what was recently shown in 
GBM cell lines (Bredel et al. 2010). 
7.4 Study limitations 
The CRC molecular classification experiment was limited by a relatively small sample 
size and the absence of MSI-H cases. The main limiting factor is the high cost 
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associated with the detailed examination of the molecular characteristics, especially 
when using high throughput technologies such as array CGH. Other molecular 
classification studies that included high throughput technologies as part of their 
analysis were also confined to a similar sample size of 60-70 cases (Cheng et al. 
2008, Derks et al. 2008). Multi-centre collaborative studies with large CRC cohorts 
will thus be essential to achieve more comprehensive molecular classification results. 
The Cancer Genome Atlas project (TCGA) led by NCI and the National Human 
Genome Research Institute (NHGRI) is performing a comprehensive genomic 
characterisation of ~20-25 cancer types including CRC. TCGA aims to characterise 
~500 cases for each cancer type. The characterisation involves genome wide copy 
number, methylation, gene expression and microRNA profiling, in addition to whole 
exon sequencing (http://cancergenome.nih.gov/, accessed September, 2011). The 
results of this project should provide, in the near future, much more detailed genomic 
information for CRC and other cancer types. 
 
Another main limitation of this project was the lack of CRC tumour and normal RNA 
samples. Messenger RNA would have been very useful, especially in investigating 
the expression levels of the proposed candidate driver genes. Although a strong 
association was previously established between copy number aberrations and mRNA 
expression levels, it is not always the case (Tsafrir et al. 2006, Sheffer et al. 2009, 
Brosens et al. 2010). If mRNA was available, a direct comparison of copy number 
aberrations and expression levels could have been undertaken for the candidate 
driver genes. Moreover, investigating mRNA expression levels is also essential as 
part of the molecular classification, especially given the recently proposed 
transcriptome instability in CRC (Sveen et al. 2011). MicroRNA samples would have 
been also useful in the project for several reasons, including confirmation of the 
expression levels of miR211 and miR301a in relation to their copy number 
aberrations and KCNMA1 and NFKBIA levels respectively.  
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7.5 Future work 
Thorough analysis of CASP8 tag SNPs in CRC is in progress which may suggest 
further SNPs for follow up studies. Analysis of the second generation sequencing 
data encompassing CASP8 CNV23598 in the 47 breast cancer samples might reveal 
the exact sequence of the area flanking CNV23598 which can allow more accurate 
genotyping and further investigation of a potential role of CNV23598 in CRC and 
breast cancer risk. 
 
Further investigation and validation of the chromosomally unstable CIMP-H/MSS 
pathway is required. A larger sample set would allow confirmation of this molecular 
subtype. It would also allow us to examine any clinical associations of this subtype. 
 
Recent studies have shown that cancer related microRNA genes are targeted by 
chromosomal defects in several cancer types including CRC (Zhang et al. 2006, 
Diosdado et al. 2009). Further analysis of the aCGH data is required to investigate 
the presence of microRNA genes within the identified FMCR which can potentially be 
used to identify novel cancer related microRNAs. 
 
Preliminary functional studies results have supported the predicted role of NFKBIA as 
a TSG in CRC. However, these studies should be replicated. The siRNA experiments 
suffer from having only a short-term effect on NFKBIA protein expression. This could 
affect the scale and reproducibility of the results. An alternative approach to 
investigate the role of NFKBIA in CRC would be to overexpress NFKBIA in cell lines 
such as, CACO2, SW480 and COLO205, where NFKBIA was shown to be 
underexpressed. Stable transfection and overexpression of NFKBIA in these cell 
lines may provide a better model for determining the role of NFKBIA as a TSG in 
CRC. This model will also be more suitable to conduct more experiments and 
investigate the effect of NFKBIA on resistance to chemotherapeutic agents. It is also 
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important to examine NFKBIA copy number in the same cell lines in order to 
elucidate whether heterozygous deletions of the gene were also responsible for lower 
expression levels. 
 
NF-ĸB is known to be constitutively activated in several cancer types including CRC, 
however, the mechanisms behind this are mainly unknown (Kojima et al. 2004, Lu et 
al. 2011, Rinkenbaugh and Baldwin 2011). NFKBIA deletions were predicted to 
promote tumourigenesis in GBM through the aberrant activation of NF-ĸB (Bredel et 
al. 2010), however, NF-ĸB activation was not investigated. For potential clinical and 
therapeutic studies, it is necessary to understand the mode of action of NFKBIA 
deletions and to confirm its effect on NF-ĸB activation. In lung cancer cell lines 
NFKBIA-siRNA were shown to affect p-RELA (activated NF-ĸB subunit) levels 
(Bivona et al. 2011). However, we could not establish this in our tested CRC cell 
lines, because the levels of p-RELA were very low using Western blot. Considering 
that NF-ĸB was previously shown to be constitutively active in CRC (Kojima et al. 
2004). There might be a technical reason for not detecting p-RELA. When activated, 
RELA is translocated to the nucleus and phosphorylated. Our protein extraction 
procedure involved passing the protein extracts through a fine-gauge needle ~30 
times in order to release nuclear proteins. It is possible that this procedure was not 
sufficient. Another approach will be to try including a sonication step in the protein 
extraction protocol to try to release nuclear proteins more efficiently. 
Immunohistochemical staining of p-RELA was previously shown to be effective in 
determining NF-ĸB activity in CRC samples (Kojima et al. 2004). Therefore, this 
method could also be used to investigate NF-ĸB levels in the CRC cell lines. 
 
Functional studies (similar to the NFKBIA experiments) will be required to validate 
the other proposed candidate driver genes. Protein expression levels of the 
candidate CRC driver genes could be investigated in a panel of CRC cell lines, and 
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based on the results of these experiments, further functional studies can be 
performed to investigate the role of the promising genes in CRC development. The 
possible association between KCNMA1 and CRC prognosis should be examined in a 
large CRC cohort. This could be achieved relatively cheaply and quickly using a 
panel of TaqMan probes for the KCNMA1 gene. Validating this association is 
important to propose KCNMA1 as a prognostic marker and as a possible therapeutic 
target in CRC.  
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APPENDICES 
Appendix 1. Primers Sequences 
Table 1 CASP8 Primers 
 
Primer Primer Sequence 5'-3' Length GC % Tm º C 
CASP8-promoter Forward TCAAGCTGTCTGCAGTCAGCAG 22 54.5 62.00 
CASP8-promoter Reverse CTCATACCAGTGTACAGGGAAC 22 50.0 60.25 
CASP8-exon3F CATCCCTCTTCTGAATGGTTGG 22 50.0 60.25 
CASP8-exon3R CAGAGAGAAACCACACAGGAG 21 52.4 59.80 
CASP8-exon4F GAAGCTTTAGAAGGCACTCTGC 22 50.0 60.25 
CASP8-exon4R AGAGGGACTGCTACCTCTTAC 21 52.4 59.80 
CASP8-exon5F AGAGGGAACTTGTCTGGTGTTC 22 50.0 60.25 
CASP8-exon5R ACCCAAGGCACTACTGTCTTTC 22 50.0 60.25 
CASP8-exon6F GGGGAGAACACTATTCAACCAG 22 50.0 60.25 
CASP8-exon6R AATGGTAAGTGGTCACCCTAGC 22 50.0 60.25 
CASP8-exon7F TAGACTTCTGTGTCACCACACC 22 50.0 60.25 
CASP8-exon7R CACATCTGTAACACTCGTGCTG 22 50.0 60.25 
CASP8-exon8/9F ATGGAATCGCTTCCCTAGTAGC 22 50.0 60.25 
CASP8-exon8/9R TGCATGTGGTAGAAGGCTGTG 21 52.4 59.80 
CASP8-exon10F TGCTTGCAGAATCTCTCTGGC 21 52.4 59.80 
CASP8-exon10R TCCAGTATCTTCATCTCGGGTC 22 50.0 60.25 
CASP8-exon11F GGTCCTGTGTGAAGGAAATAGG 22 50.0 60.25 
CASP8-exon11R TGCACTTAACAGCCCAACCTG 21 52.4 59.80 
CASP8-exon12Fn CAATGTTATGCCCACTGTGCTC 22 50.0 60.25 
CASP8-exon12R TGACCTGGGAAATGCAGCTATG 22 50.0 60.25 
CASP8-exon13F GCAGATGCGATGTCAATTCGAG 22 50.0 60.25 
CASP8-exon13R TGCTTCTCAGACCTTTGCCATG 22 50.0 60.25 
Promoter-seqF1 TACAAGCTGCTGGCAGTCATG 21 52.4 59.80 
Promoter-seqF2 TTATGAATGAGCCGAGGAAGGC 22 50.0 60.25 
Promoter-seqF3 AACGACAACTCACAGTGCCAG 21 52.4 59.80 
Promoter-seqF4 GCAGAGCTGGGATTTGAATCC 21 52.4 59.80 
Exon13-seqF1 GTAGGTCTTGGTTTCGCACC 20 55.0 59.35 
Exon13-seqF2 GTAGAGACAGGGTTTCACTGTG 22 50.0 60.25 
Exon13-seqF3 GATTGCTTGAACCCAAGAGGTC 22 50.0 60.25 
Promoter-seqR1 GGATTCAAATCCCAGCTCTGC 21 52.4 59.80 
Promoter-seqR2 TTCCTGGCACTGTGAGTTGTC 21 52.4 59.80 
Promoter-seqR3 TTAACGTCTCAGTGCCTTCCTC 22 50.0 60.25 
Exon13-seqR1 AGTGCAGCGGTGTGAACATG 21 55.0 59.35 
Exon13-seqR2 GCCTGTAATCCCAGCACTTTG 22 52.4 59.80 
CASP8-exon10Fseq AAGTGATCTGCCCATCTTGGC 22 52.4 59.80 
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Table 2 KRAS Primers 
Primer Primer Sequence 5'-3' Length GC% Tm º C 
KRAS-exon1F ACGATACACGTCTGCAGTCAAC 22 50.0 60.30 
KRAS-exon1R GCACAGAGAGTGAACATCATGG 22 50.0 60.30 
 
Table 3 BRAF Primers 
Primer Primer Sequence 5'-3' Length GC% Tm º C 
BRAF-exon15F CCAGGAGTGCCAAGAGAATATC 22 50.0 60.30 
BRAF-exon15R AGTAACTCAGCAGCATCTCAGG 22 50.0 60.30 
 
Table 4 TP53 Primers 
Primer Sequence 5'-3' Length GC% Tm 
o 
C 
TP53-exon4F ACGTTCTGGTAAGGACAAGGG 21 52.4 59.8 
TP53-exon4R GACAGGAGTCAGAGATCACAC 21 52.4 59.8 
TP53-exon5/6F AAAGCTCCTGAGGTGTAGACG 21 52.4 59.8 
TP53-exon5/6R GGGAGGTCAAATAAGCAGCAG 21 52.4 59.8 
TP53-exon7F AAAAGGCCTCCCCTGCTTGC 20 60.0 61.4 
TP53-exon7R TGATGAGAGGTGGATGGGTAG 21 52.4 59.8 
TP53-exon8/9F AGCTTAGGCTCCAGAAAGGAC 21 52.4 59.8 
TP53-exon8/9R AGTTAGCTACAACCAGGAGCC 21 52.4 59.8 
TP53-exon10F GTCAGCTGTATAGGTACTTGAAG 22 43.5 58.9 
TP53-exon10R TGACCATGAAGGCAGGATGAG 21 52.4 59.8 
 
Table 5 APC Primers 
Primer Primer Sequence 5'-3' Length GC% Tm º C 
APCMCRf GTTCTGCACAGAGTAGAAGTGG 22 50.0 60.3 
APCMCRr GTGATGACTTTGTTGGCATGGC 22 50.0 60.3 
APCMCReqf CTCCGTTCAGAGTGAACCATG 21 52.4 59.8 
APCMCReqr CATGGTTCACTCTGAACGGAG 21 52.4 59.8 
 
Table 6 PIK3CA Primers 
Primer Primer Sequence 5'-3' Length GC% Tm º C 
PIK3CAexon9F CAGTTACTATTCTGTGACTGGTG 23 43.5 58.9 
PIK3CAexon9R TGCTGAGATCAGCCAAATTCAG 22 45.5 58.4 
PIK3CAexon20F TTGCTCCAAACTGACCAAACTG 22 45.5 58.4 
PIK3CAexon20R TGCAATTCCTATGCAATCGGTC 22 45.5 58.4 
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Table 7 CNV23598 primers 
Primer Primer Sequence 5'-3' Length GC% Tm º C 
Common forward TAGAAGCCTGCAGAATCCAGC 21 52.4 59.80 
Insertion reverse GGATGGGCCATGATGACAATG 21 52.4 59.80 
Deletion reverse GAGATGTCAGCTCATAGATGGG 22 50.0 60.30 
Fluorescent insertion reverse  CCTCCACTATTGTCCTGTGAC 21 52.4 59.80 
Fluorescent deletion reverse GAAGCTCTTCAAAGGTCGTGG 21 52.4 59.80 
A/G SNP confirmation forward GTCACAGGACAATAGTGGAGG 21 52.4 59.80 
Forward deletion TAGAAGCCTGCAGAATCCAGC 21 52.4 59.80 
New insertion forward AGCAGTACCGTCCAGCTTTG 20 55.0 59.35 
Common reverse GAGATGTCAGCTCATAGATGGG 22 50.0 60.30 
 
 
Table 8 Pyrosequencing Primers 
Primer Primer Sequence 5'-3' Length GC% Tm º C 
CRABP1F GGTGGATGTTTTGATGTAGAATTGA 25 45.6 58.5 
CRABP1R* B-ACCCAAACCTATAATACACCCTAC 24 52.4 59.8 
CRABP1seq ATGTTTTGATGTAGAATTGATT 22 52.4 59.8 
NEUROG1F AGGGAGTTTTTAGGTAGTGAAATAGAG 27 52.4 59.8 
NEUROG1R* B-ACTCCAAATACCCTCCAAATTTC 23 52.4 59.8 
NEUROG1seq AGGTAGTGAAATAGAGG 17 52.4 59.8 
 
* Biotin labelled primers 
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Appendix 2. MS-MLPA probes- ME042-A1 Kit 
Expected Length (nt) Observed Length (nt) Probe Hha1 Site Chromosomal Position 
130 126.53 Reference-1 
 
8q24 
141 137.56 IGF2-1 + 11p15.5 
148 144.28 RUNX3-1 + 1p36.11 
160 157.41 Reference-2 
 
10q26.13 
166 163.43 NEUROG1-1 + 5q31.1 
171 168.62 IGF2-2 + 11p15.5 
176 174.37 MLH1-1 + 3p22.2 
183 180.19 CDKN2A-1 + 9p21.3 
190 186.61 Reference-3 
 
2p22.3 
195 192.25 CDKN2A-2 + 9p21.3 
202 198.64 NEUROG1-2 + 5q31.1 
207 204.83 CRABP1-1 + 15q25.1 
211 209.75 NEUROG1-3 + 5q31.1 
218 216.23 CACNA1G-1 + 17q21.33 
226 222.54 Reference-4 
 
6q24.3 
232 231.49 CDKN2A-3 + 9p21.3 
246 244.33 CACNA1G-2 + 17q21.33 
256 253.54 RUNX3-2 + 1p36.11 
265 263.01 CRABP1-2 + 15q25.1 
273 271.02 CACNA1G-3 + 17q21.33 
282 279.24 NEUROG1-4 + 5q31.1 
292 289.93 Reference-5 
 
19q13.13 
310 307.46 CRABP1-3 + 15q25.1 
319 316.51 CRABP1-4 + 15q25.1 
327 323.89 Reference-6 
 
14q22.1 
335 333.95 CDKN2A-4 + 9p21.3 
346 343.48 RUNX3-3 + 1p36.11 
355 352.02 MLH1-2 + 3p22.1 
364 361.49 NEUROG1-5 + 5q31.1 
372 370.27 RUNX3-4 + 1p36.11 
382 380 Reference-7 
 
10q22 
389 387.21 NEUROG1-6 + 5q31.1 
399 397.54 SOCS1 + 16p13.13 
409 407.50 BRAF V600E 
 
7q34 
418 416.03 IGF2-3 + 11p15.5 
427 424.84 Reference-8 
 
12p13.31 
436 432.9 Digestion + 17q23.2 
463 461.53 MLH1-3 + 3p22.1 
472 471.41 Reference-9 
 
22q12.3 
481 479.71 Reference-10 
 
3p25.3 
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Appendix 4. DNA Size Standards 
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Appendix 5. MS-MLPA QC metrics 
Table 1 Normal DNA QC metrics results 
Sample DNA Conc./Ligation Denaturation Hybridisation DNA Quant./Lig./Denat. Sample DNA Conc./Ligation Denaturation Hybridisation DNA Quant./Lig./Denat. 
N016 9.52 140.06 71.40 42.35 N016D 4.80 145.17 68.88 40.54 
N023 9.96 131.67 75.95 41.08 N023D 6.60 114.78 87.12 39.31 
N037 10.08 139.13 71.87 77.18 N037D 7.89 182.57 54.77 60.14 
N045 7.35 142.18 70.34 108.03 N045D 7.70 194.89 51.31 99.66 
N046 5.97 115.54 86.55 118.86 N046D 12.34 199.51 50.12 99.60 
N053 6.95 130.13 76.84 61.62 N053D 4.24 126.96 78.77 66.41 
N079 4.67 100.63 99.37 85.17 N079D 7.31 147.68 67.72 75.21 
N080-1 12.97 151.53 66.00 111.94 N080D-1 13.53 184.42 54.22 82.48 
N080-2 17.91 182.17 54.89 91.58 N080D-2 13.53 184.42 54.22 82.48 
N083 6.04 126.26 79.20 81.32 N083D 6.80 136.81 73.09 76.26 
N085 7.27 157.17 63.63 40.74 N085D 5.47 139.20 71.84 42.17 
N086 8.67 85.28 117.26 106.67 N086D 9.82 106.98 93.48 84.75 
N088 11.35 164.84 60.67 73.52 N088D 4.74 155.36 64.37 68.38 
N090 12.74 166.19 60.17 74.42 N090D 10.74 138.10 72.41 81.37 
N097 16.92 54.12 184.79 121.63 N097D 7.47 101.12 98.90 101.06 
N098 11.25 85.00 117.65 104.81 N098D 13.24 157.38 63.54 85.54 
N104 6.57 77.02 129.83 97.35 N104D 7.71 83.36 119.96 107.90 
N107 5.53 105.52 94.77 102.08 N107D 5.35 132.10 75.70 100.75 
N109 3.96 161.16 62.05 211.57 N109D 2.64 228.37 43.79 157.55 
N110 5.73 125.38 79.76 144.09 N110D 10.55 103.46 96.66 83.95 
N112 16.04 166.63 60.01 123.25 N112D 13.53 184.42 54.22 82.48 
N114-1 5.80 108.74 91.97 139.06 N114D-1 12.51 190.10 52.60 117.18 
N114-2 5.65 89.53 111.69 354.06 N114D-2 6.98 141.24 70.80 113.93 
N122 7.15 144.96 68.98 42.77 N122D 3.92 144.38 69.26 46.37 
N135 9.75 104.33 95.85 142.43 N135D 10.36 146.24 68.38 94.13 
N138 3.35 89.30 111.99 112.22 N138D 3.67 131.65 75.96 94.68 
N142 6.73 93.23 107.26 84.29 N142D 8.60 136.65 73.18 73.23 
N150 10.83 161.50 61.92 48.57 N150D 4.29 158.80 62.97 59.12 
N153 7.56 108.93 91.80 55.86 N153D 4.96 153.25 65.25 58.55 
N158 7.64 158.61 63.05 51.19 N158D 6.43 123.97 80.67 49.80 
N167 6.84 81.16 123.22 131.58 N167D 5.22 128.31 77.93 91.25 
N184-1 8.01 160.69 62.23 71.75 N184D-1 7.05 171.02 58.47 68.83 
N184-2 9.95 154.78 64.61 83.96 N184D-2 8.55 117.68 84.98 113.56 
N201 4.68 132.05 75.73 111.96 N201D 5.84 181.32 55.15 102.37 
N202 7.00 121.34 82.41 151.41 N202D 9.51 183.30 54.56 114.36 
N203 6.46 111.54 89.66 115.66 N203D 7.49 98.86 101.15 99.35 
N206 3.65 101.87 98.16 118.28 N206D 5.26 131.24 76.20 101.33 
 264 
N208 5.40 140.36 71.25 89.42 N208D 6.51 158.17 63.22 84.76 
N212 6.82 180.46 55.41 80.75 N212D 5.95 176.08 56.79 76.59 
N213 12.01 136.65 73.18 87.88 N213D 5.26 136.73 73.14 83.24 
N214 8.33 160.39 62.35 174.09 N214D 13.71 158.25 63.19 124.56 
N218 8.74 136.08 73.49 101.40 N218D 9.33 160.34 62.37 91.77 
N221-1 6.70 104.97 95.27 84.39 N221D-1 11.74 124.92 80.05 62.65 
N221-2 6.70 104.97 95.27 84.39 N221D-2 11.74 124.92 80.05 62.65 
N223 4.17 97.04 103.06 125.69 N223D 10.04 158.93 62.92 91.90 
N244 5.40 126.45 79.08 68.59 N244D 1.43 154.85 64.58 68.74 
N248 10.35 116.44 85.88 70.72 N248D 3.56 148.44 67.37 64.81 
N249 6.55 138.33 72.29 63.38 N249D 5.80 149.24 67.01 62.27 
N271-1 7.37 118.69 84.25 76.08 N271D-1 4.03 143.64 69.62 57.95 
N271-2 7.56 188.23 53.13 93.03 N271D-2 5.75 108.67 92.02 97.88 
N632 7.38 139.80 71.53 46.01 N632D 7.26 131.21 76.21 45.85 
N741 5.05 124.06 80.61 53.83 N741D 8.53 105.44 94.84 74.49 
N795 6.39 90.31 110.74 52.38 N795D 8.42 132.44 75.51 47.09 
N824 9.17 152.41 65.61 39.09 N824D 7.86 141.96 70.44 37.32 
N828 8.11 73.92 135.29 56.41 N828D 6.95 130.08 76.87 43.55 
N863 3.10 85.32 117.20 64.40 N863D 2.72 133.94 74.66 63.53 
N1120 32.07 73.89 135.34 74.81 N1120D 4.10 137.57 72.69 54.59 
N1350 10.59 150.13 66.61 63.31 N1350D 6.41 127.17 78.63 55.50 
 
Table 2 Tumour DNA QC metrics results 
Sample DNA Conc./Ligation Denaturation Hybridisation DNA Quant./Lig./Denat. Sample DNA Conc./Ligation Denaturation Hybridisation DNA Quant./Lig./Denat. 
T016 29.31 164.88 60.65 43.43 T016D 29.31 164.88 60.65 43.43 
T023 6.97 227.34 43.99 60.83 T023D 6.97 227.34 43.99 60.83 
T037 27.51 173.41 57.67 60.51 T037D 14.58 174.70 57.24 53.00 
T045 18.11 125.55 79.65 91.61 T045D 22.62 178.67 55.97 84.46 
T046 9.39 107.76 92.80 94.20 T046D 8.18 164.90 60.64 79.22 
T053 8.17 125.71 79.55 73.51 T053D 7.99 131.81 75.87 67.90 
T079 7.68 102.69 97.38 87.89 T079D 8.81 135.05 74.05 66.24 
T080-1 8.76 86.86 115.12 130.53 T080D-1 7.23 119.79 83.48 69.04 
T080-2 8.91 163.32 61.23 92.06 T080D-2 7.23 119.79 83.48 69.04 
T083 12.96 151.92 65.83 78.44 T083D 8.06 131.37 76.12 72.12 
T085 7.76 190.48 52.50 48.62 T085D 6.03 171.63 58.27 49.51 
T086 8.96 104.62 95.59 98.70 T086D 13.04 88.21 113.36 78.13 
T088 11.28 142.66 70.10 68.40 T088D 11.55 136.03 73.52 63.68 
T090 10.05 212.56 47.04 111.62 T090D 10.97 184.65 54.16 92.28 
T097 12.30 79.04 126.52 91.44 T097D 9.57 94.63 105.68 80.01 
T098 13.66 78.86 126.80 97.36 T098D 12.17 146.19 68.41 98.67 
T104 8.18 104.05 96.11 145.31 T104D 5.18 123.06 81.26 154.05 
T107 18.09 64.90 154.07 80.96 T107D 18.35 99.35 100.66 81.02 
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T109 12.63 54.74 182.69 89.34 T109D 12.15 77.69 128.72 82.06 
T110 7.72 89.35 111.93 100.89 T110D 6.71 128.42 77.87 93.35 
T112 24.47 174.30 57.37 109.36 T112D 5.80 111.91 89.35 69.78 
T114-1 18.38 164.98 60.61 94.30 T114D-1 19.97 170.10 58.79 121.15 
T114-2 12.73 134.37 74.42 72.35 T114D-2 9.94 109.26 91.52 76.93 
T122 5.50 134.86 74.15 53.89 T122D 7.99 146.93 68.06 45.75 
T135 24.37 36.11 276.90 197.46 T135D 14.59 138.29 72.31 96.89 
T138 12.18 70.85 141.15 86.44 T138D 10.63 83.11 120.32 75.47 
T142 7.31 195.00 51.28 150.67 T142D 5.37 147.09 67.98 154.77 
T150 5.57 159.42 62.73 54.46 T150D 7.14 166.51 60.06 59.14 
T153 6.64 121.86 82.06 60.14 T153D 3.67 114.86 87.07 55.10 
T158 7.81 156.36 63.96 50.92 T158D 9.34 142.19 70.33 51.61 
T167 5.22 79.79 125.33 100.53 T167D 12.50 105.15 95.10 76.89 
T184-1 12.33 115.61 86.50 63.75 T184D-1 11.53 154.32 64.80 64.12 
T184-2 7.32 165.99 60.24 65.60 T184D-2 4.34 139.41 71.73 81.72 
T201 16.63 92.99 107.54 93.03 T201D 35.45 119.76 83.50 76.30 
T202 6.60 78.09 128.06 96.88 T202D 6.29 100.18 99.82 78.99 
T203 13.91 70.21 142.43 97.90 T203D 9.96 103.26 96.84 88.44 
T206 19.06 97.90 102.15 90.66 T206D 16.78 108.05 92.55 70.33 
T208 9.54 154.68 64.65 70.94 T208D 9.80 162.99 61.35 75.80 
T212 7.98 132.81 75.29 58.14 T212D 5.62 140.48 71.19 60.97 
T213 34.13 89.37 111.89 67.32 T213D 24.30 127.39 78.50 67.41 
T214 4.96 92.15 108.51 101.58 T214D 6.60 129.67 77.12 94.04 
T218 18.27 109.72 91.14 88.56 T218D 14.01 128.48 77.83 102.69 
T221-1 14.16 107.42 93.09 60.30 T221D-1 11.99 121.46 82.33 66.60 
T221-2 14.16 107.42 93.09 60.30 T221D-2 11.99 121.46 82.33 66.60 
T223 14.06 127.61 78.37 124.12 T223D 13.58 141.16 70.84 104.44 
T244 9.87 112.38 88.98 68.30 T244D 5.63 88.16 113.44 56.22 
T248 10.51 116.52 85.82 65.44 T248D 10.52 147.38 67.85 60.91 
T249 12.33 124.49 80.33 62.77 T249D 10.63 124.87 80.08 70.27 
T271-1 9.08 143.73 69.58 72.71 T271D-1 8.33 226.34 44.18 76.60 
T271-2 9.53 69.90 143.07 177.49 T271D-2 6.92 170.41 58.68 82.63 
T632 14.02 144.95 68.99 51.06 T632D 4.54 143.21 69.83 49.30 
T741 8.35 150.88 66.28 46.23 T741D 7.02 161.54 61.90 53.20 
T795 5.72 144.58 69.17 51.44 T795D 3.60 119.00 84.04 54.82 
T824 6.88 119.93 83.38 53.52 T824D 7.29 132.11 75.70 49.15 
T828 8.05 222.22 45.00 50.61 T828D 7.79 146.47 68.28 58.43 
T863 5.53 118.77 84.20 42.50 T863D 8.83 131.84 75.85 48.89 
T1120 9.10 184.01 54.34 57.16 T1120D 4.00 149.01 67.11 58.85 
T1350 8.09 139.67 71.60 51.01 T1350D 6.15 154.51 64.72 49.22 
 
The QC metrics are described in section 2.3.4.2.1. A suffix of D represents digested DNA samples. Cells highlighted in red represent failed QC metrics.
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Appendix 6. Molecular characteristics of the 53 CRC cases 
Sample CIMP CIN APC MCR TP53 KRAS BRAF PIK3CA 
CA016 CIMP-L 4 WT WT WT WT WT 
CA023 CIMP-L 0 c.4328_4329insC WT WT WT c.1633G>A 
CA037 CIMP-L 0 c.3916G>T WT c.35G>T WT WT 
CA045 CIMP-L 260 c.3933_3934insT c.524G>A WT WT WT 
CA046 CIMP-L 0 WT WT c.35G>A WT c.1633G>A 
CA053 CIMP-L 88 WT c.592G>T WT WT WT 
CA079 CIMP-N 71 c.4054_4062dup7 c.844C>T WT WT WT 
CA080 CIMP-L 38 c.4271_4280del10 WT c.35G>A WT WT 
CA083 CIMP-L 10 WT WT WT WT WT 
CA085 CIMP-L 43 c.3964G>T c.916C>T WT WT WT 
CA086 CIMP-L 3 WT c.818G>A c.35G>A WT WT 
CA088 CIMP-H 45 c.4582_4603del22 c.220del1 c.35G>T WT WT 
CA090 CIMP-L 63 WT c.559+1G>T WT WT WT 
CA097 CIMP-L 43 c.3982C>T c.637C>T c.34G>T WT WT 
CA098 CIMP-L 93 c.4037C>G c.524G>A WT WT WT 
CA104 CIMP-L 37 c.3916G>T c.734G>A c.35G>T WT WT 
CA107 CIMP-L 110 WT WT c.35G>A WT c.1633G>A 
CA109 CIMP-H 18 c.4350C>T WT c.35G>T WT c.3140A>G 
CA110 CIMP-L 0 WT WT WT WT WT 
CA112 CIMP-L 1 c.4421delC WT WT WT WT 
CA114 CIMP-H 74 c.4666_4667insA WT c.38G>A WT WT 
CA122 CIMP-N 18 WT WT WT WT WT 
CA135 CIMP-L 14 WT WT c.38G>A WT WT 
CA138 CIMP-H 24 c.4127_4128delAT WT c.35G>C WT WT 
CA142 CIMP-L 219 WT c.725G>T WT WT WT 
CA150 CIMP-L 5 c.4216C>T WT WT WT WT 
CA153 CIMP-L 150 c.4350C>T c.844C>G c.34G>T WT c.1633G>A 
CA158 CIMP-N 87 WT c.722C>G WT WT WT 
CA167 CIMP-L 14 WT WT WT WT WT 
CA184 CIMP-L 12 c.4303A>T c.844C>T WT WT WT 
CA201 CIMP-L 23 WT WT c.35G>T WT WT 
CA202 CIMP-L 33 WT WT WT WT WT 
CA203 CIMP-L 67 WT WT WT WT WT 
CA206 CIMP-L 50 c.3883G>T c.455-456ins1 WT WT WT 
CA208 CIMP-L 35 c.4666_4667insA c.730G>A & c.844C>T c.35G>T A1742G WT 
CA212 CIMP-N 29 WT WT WT WT WT 
CA213 CIMP-L 33 WT c.751A>C WT WT WT 
CA214 CIMP-L 86 WT WT WT WT WT 
CA218 CIMP-L 14 c.3927_3931del5 c.734G>A WT WT WT 
CA221 CIMP-N 39 c.4415delT WT WT WT WT 
CA223 CIMP-H 76 WT c.811G>A WT WT WT 
CA244 CIMP-L 411 c.4271delC c.817C>T WT WT WT 
CA248 CIMP-N 0 WT WT WT WT WT 
CA249 CIMP-L 61 c.4033G>T c.524G>A c.35G>T WT WT 
CA271 CIMP-H 66 WT c.844C>T WT T1796A WT 
CA632 CIMP-L 18 WT c.733G>A c.38G>A WT WT 
CA741 CIMP-L 66 c.4350C>T WT WT WT WT 
CA795 CIMP-L 2 c.4391_4394delAGAG WT WT WT c.1633G>A 
CA824 CIMP-L 21 WT WT c.35G>C WT WT 
CA828 CIMP-L 248 c.3871C>T c.524G>A WT WT WT 
CA863 CIMP-L 114 c.4391_4394delAGAG c.586C>T WT WT WT 
CA1120 CIMP-L 2 WT c.847_859del13 WT WT WT 
CA1350 CIMP-L 94 WT WT c.34G>T WT WT 
 
